




May 18 (Mon) ~ 23 (Sat), 2020 www.biokorea.org

PROGRAM E-BOOK

BIO KOREA Organizing Committee












Contents





V	T	D	N
1		N	U

WELCOME MESSAGE · · · · · · · · · · · · · · · · · · ·	03
BIO KOREA 2020 Overview	05
BIO KOREA 2020 at a Glance	06
E-CONFERENCE	
Overview · · · · · · · · · · · · · · · · · · ·	07
Program · · · · · · · · · · · · · · · · · · ·	30
ONLINE BUSINESS FORUM WITH PARTNERING	
Overview ·····	32
List of Partnering Companies	33
VIRTUAL EXHIBITION	
Overview · · · · · · · · · · · · · · · · · · ·	40
List of Exhibitors	41
Introduction of Exhibitors	48
INVEST FAIR / JOB FAIR	
Invest Fair · · · · · · · · · · · · · · · · · · ·	238
Job Fair · · · · · · · · · · · · · · · · · · ·	242

2006년부터 대한민국 보건산업의 글로벌 위상 증진과 지속적인 성장을 위하여 노력해 온 BIO KOREA가 15번째 문을 열게 되었습니다. 매년 세계적인 석학과 비즈니스 전문가들의 참가를 통해 명실공히 대한민국 대표 바이오헬스 국제컨벤션으로 입지를 다지며, 지난 14년간 대한민국 보건산업과 함께 성장해 왔습니다.

금번 BIO KOREA 2020은 예년과 달리 코로나 19의 세계적 대유행(팬데믹) 으로 온라인 개최라는 새로운 도전장을 내밀었습니다.

실질적인 비즈니스 교류 및 투자기회를 제공하는 BIO KOREA를 코로나 19로 어려운 시기에 온라인 플랫폼으로 활용하여 기업들의 활발한 비즈니스 교류를 이어나가길 바랍니다.

올해는 『데이터시대 시작, 바이오산업의 변화』라는 주제로 산업관계자들에게 최신 정보 및 비즈니스 기회를 제공하는 다양한 프로 그램을 준비했습니다.

BIO KOREA가 국내 최대 규모의 기술거래시장으로 자리잡고 대한민국이 바이오 헬스 강국으로 거듭나는 또 하나의 기폭제가 되길 기대하며 앞으로도 우리나라 보건산업의 눈부신 발전 및 글로벌 선도국가로 거듭날 수 있도록 최선을 다하겠습니다.

BIO KOREA에 보내주신 관심과 성원에 감사드리며, 온라인 진행이라는 새로운 형태에도 불구하고 본 행사의 준비를 위해 도움을 주신 관계기관 및 관계자 여러분께 다시 한 번 감사의 말씀을 드립니다.

함께하는 모든 분들의 건승을 기대합니다.



권 덕 철 한국보건산업진흥원장 BIO KOREA 공동주최기관



이 시 종 충청북도지사 BIO KOREA 공동주최기관

It is a great pleasure to host the 15th BIO KOREA International convention and welcome bio industry experts around the globe to BIO KOREA 2020. Since 2006, BIO KOREA international Convention has been providing wonderful opportunities for world- renowned scholars, researchers and business experts to exchange invaluable information and the latest resources on biotechnology and healthcare industry every year.

Unlike previous BIO KOREA International Convention, we have proceeded in taking a new challenge of holding the event online due to COVID-19's global pandemic state.

We hope for an active business change to take place using BIO KOREA's online platform which aims to provide practical business exchange and investment opportunities, whilst being under a difficult situation with COVID-19.

BIO KOREA 2020 has prepared various programs for global health industry professionals with a slogan, "A new paradigm in the Age of Data Science".

With the anticipation of BIO KOREA making its stance as the largest national technology trade market and Korea's transformation of becoming a nation with remarkable strength in bio-health field, we will continue to do our utmost to ensure extraordinary progress in Korean bio industry and become a global lead boasting expertise among all.

We would like to extend our sincere gratitude to you for your continuous support and enthusiastic involvement. We very much wish you a productive and rewarding time at the BIO KOREA 2020, sharing in-depth knowledge and expertise, broadening professional networks and friendships, and exploring potential business partnership opportunities and supports with one another.

Yours sincerely,



Kwon, Deok-cheol
President of Korea Health Industry Development Institute
Co-Chairman of BIO KOREA Organizing Committee



Lee, Si-Jong
Governor of Chungcheongbuk-do
Co-Chairman of BIO KOREA Organizing Committee



TITLE BIO KOREA 2020 International Convention

DATE May 18(Mon) ~ May 23(Sat), 2020

POINT OF ACCESS BIO KOREA website (www.biokorea.org)

HOSTED BY Korea Health Industry Development Institute (KHIDI), Chungcheongbuk-do

ORGANIZED BY BIO KOREA Organizing Committee

PROGRAM e-Conference, Business Forum, Virtual Exhibition, Invest Fair, Job Fair

The 15th BIO KOREA,

Welcome to BIO KOREA 2020 International Convention held online for the first time. The 15th BIO KOREA, one of the most comprehensive bio technology events, will be held from May 18th to May 23rd, 2020.

BIO KOREA is the best platform to share the current information and cutting-edge trends of the global biopharma industry where researchers, scholars, and enterprises gather to discuss future courses for international collaboration, developments, and innovative revolutions.

Taking its first step in 2006, annually held BIO KOREA has become the most influential and well-known bio event in Asia, providing a great opportunity for both domestic and foreign investors to meet fast-growing bio companies and leading research institutions based in Korea.

This year's online hosting of BIO KOREA will demonstrate such components in a whole new perspective by providing all of its contents online through various means at the forefront of present technologies, including the utilization of virtual reality and 3D modeling in Virtual Exhibition, Online Business Forum, e-Conference offering discussions and exchange of expertise on diverse range of agendas, Invest Fair and Job Fair.

We greatly appreciate your contribution to BIO KOREA 2020 and hope this event delivers an experience beyond your expectations and past practices.

Meet the present and future of global bio industry at BIO KOREA 2020!

	5/18	5/19	5/20	5/21	5/22	5/23
andard Time	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
COVID-19 Special Session	KEYNOTE Jerome Kim, Director General, International Vaccine Institute	Trends on Diagnostic Kit for COVID-19	COVID-19'S R&D Trends of Therapeutics	Vaccine Development & Collaboration for COVID-19		
	Therapeutic Antibody	Vaccine	Alzheimer's Disease	Regenerative Medicine		
Therapeutics	S1 From Target Antibody Discovery to Preclinical, Current Innovations in Antibody Industry	S1 Vaccine Bioprocessing Technology; Today and Tomorrow	Recent Research Trends on Neurodegenerative Diseases Therapy	S1 Current Status of Regenerative Medicine Industry in Korea		
	ADC(Antibody-drug Conjugate) R&D and Commercialization Strategy			Trends in Global S2 Regenerative Medicine Industry		
	Artificial Intelligence (AI)	Future Technology I	Future Technology II	Patients Generated Healthcare Data		
Data	S1 Digital Healthcare Transformation	Innovation of Digital Pathology and Companion	Electroceutical : Could Electrical Pulses Replace Traditional	Digital Healthcare Industry and Regulatory Trends		
Technology	S2 Al for Medicine	Diagostics Current Status and	Medicines? The Research Trend	A Case Study on the	Open videos ca	an be accessed
	S3 Smart Healthcare Future	S2 Challenges for the Industrialization of Digital Therapeutics	of 3D Organoids and Applications in Drug Discovery	S2 Use of PGHD in the Development of Digital Healthcare Service		-,
	Cosmetic	Technology Licensing	Intellectual Property			
	K-Beauty and Bio Convergence Forum	Collaboration for	Trade Secret Compliance for			
	Pharmaceutical	Innovation	Biopharmaceutical			
Industrial Information	\$1 2020 Insight Online Seminar		moustly			
	Medical Device		Regulatory and IP			
	Medical Device Industry All-Cycle S1 Market Penetration Comprehensive Presentation		S2 Compliance in the Field of Biosimilars and Biobetters			
Partnering		Oı	nline Business Vide	o Meeting		
Company			Company Presentation (2	24 hours)		
Presentation	-					_
	Latest	technologies and p	products of bio indu	ustry presented in a	a virtual space	
Morning	COVID-19 Special	Anticancer Drug	Degenerative Neurodisease /	Artificial Intelligence /	Healthcare /	
		•				
						-
11:10	SCM Lifescience	GC Cell	ARIBIO		35,03	
11:35	ImmuneMed		Neuroventi			
Afternoon	Stem Cell / Microbiome	Healthcare / Medical I	Platform New Drug Development I	Platform New Drug Development II	Bio New Drug Development	
I	Biosolution	Osstem Implant	OliX Pharmaceuticals	Inventage Lab	Rznomics	-
13:30	Diosolution	·				
	Opening (OS COVID-19 Special Session Therapeutics Data Convergence Technology Partnering Company Presentation Morning 10:20 10:45 11:10 11:35	Opening Remarks Video (09:00~09:10) COVID-19 Special Session Therapeutics Therapeutic Antibody From Target Antibody From Target Antibody Discovery to Preclinical, Current Innovations in Antibody Industry ADC(Antibody-drug Conjugate) R&D and Commercialization Strategy Artificial Intelligence (AI) Data Convergence Technology Al for Medicine S1 Digital Healthcare Transformation Convergence Forum Pharmaceutical Industrial Information Information Industrial Information Medical Device Industry All-Cycle Market Penetration Comprehensive Presentation Partnering COVID-19 Special Session 10:20 Celltrion 10:45 Solgent (EDGC) 11:10 SCM Lifescience 11:35 ImmuneMed Afternoon Statey Afternoon Statey Covident States Afternoon Statey Covident States Afternoon States Afternoon States Covident States Afternoon States States Afternoon States Afternoon States Afternoon States Afternoon States Afternoon Aftern	Opening Remarks Video (09:00-09:10) COVID-19 Special Session	COVID-19 Special Session Serone Remarks Video (09:00-09:10) COVID-19 Special Session Serone Remarks Video (09:00-09:10) COVID-19 Special Session Serone Remarks Video (09:00-09:10) COVID-19 Serone Remarks Video (19:00-09:10) COVID-19 Sease Recent Research (19:00-09:10) Sease (19:00-09:10)	Country Coun	Course Course Company





E-CONFERENCE

Overview · · · · · · · · · · · · · · · · · · ·	. 08



DATE May 18(Mon) ~ May 23(Sat), 2020

POINT OF ACCESS www.biokorea.org

OFFICIAL LANGUAGES English, Korean

KEYWORDS

Coronavirus (COVID-19)

Therapeutic Antibody

Regenerative Medicine

Patients Generated Healthcare Data

Technology Licensing

Medical Device

Pharmaceutical

Alzheimer's Disease

Vaccine

Future Technology

Artificial Intelligence (AI)

• Intellectual Property

Cosmetics

Covering a wide range of agendas related to the global Bio & Pharmaceutical industry, BIO KOREA International Convention has become a major platform for businesses and exchange of expertise in Korea, where prominent global CEOs and related scholars gather together to discuss and share information with close views. This year, BIO KOREA 2020 e-Conference consists of 24 sessions discussing numerous essential issues in the industry including: COVID-19, Alzheimer's Disease, Therapeutic Antibody, Vaccine, Regenerative Medicine, Future Technology, Patients Generated Healthcare Data (PGHD), Artificial Intelligence, Technology Licensing, Intellectual Property, Medical Device, Cosmetics, and Pharmaceutical.

For deeper insights on these subjects undergoing intense study, visit BIO KOREA 2020's e-Conference, accessible via BIO KOREA's website.



COVID-19 Special Session

Keynote Speech

Keynote Speech

Global Cooperation in COVID-19 Vaccine Development
 Jerome Kim, Director General, International Vaccine Institute (IVI)

COVID-19 Special Session

Session 01

Trends on Diagnostic Kit for COVID-19

As the novel Coronavirus(COVID-19) intensifies, stakeholders are racing against time to develop diagnostic kits to faster detect the pandemic case. For timely and appropriate quarantine and clinical management, early and rapid identification is essential. This session will introduce the development status of diagnostic kits for COVID-19 and share the export cases.

Speakers

- Development of COVID-19 Diagnostic Kit
 Chae Seung Lim, Professor, Dept. of Laboratory Medicine, Korea University Guro Hospital
- Case of Successful Development & Sales, COVID-19 Diagnosis Kit: Sugentech COVID-19 Serology Tests Jung-Eun Lee, Vice President, Sugentech Inc.
- Bioneer's COVID-19 Molecular Diagnostics Development and Export Cases
 Han-Oh Park, Ph.D / CEO, BIONEER Corporation

Panel Discussion: COVID-19 Diagnostic Kit Development Prospect and Main Issues

- Chair
 Chae Seung Lim, Professor, Dept. of Laboratory Medicine, Korea University Guro Hospital
- Panelists Jung-Eun Lee, Vice President, Sugentech Inc.
 Han-Oh Park, Ph.D / CEO, BIONEER Corporation

COVID-19 Special Session

Session 02

COVID-19's R&D Trends of Therapeutics

COVID-19 originated from Wuhan, a city in China's Hubei province and spread quickly all over the world. WHO(World Health Organization) declared COVID-19 a global pandemic on March 11th, 2020. Vaccines and therapeutics against COVID-19 will be the key to overcome pandemic phenomenon. Most well-known global pharmaceutical companies such as Gilead Science, Novartis, Pfizer have embarked on developing therapeutics and vaccines for COVID-19.

This session will cover global R&D trends of therapeutics against COVID-19 and precautions of preclinical and clinical trials to develop COVID-19 pipelines, sharing the case of R&D for COVID-19's therapeutics from Korean companies. It will encourage the development of COVID-19's therapeutics and contribute to the advancement of Korean healthcare industry.

Speakers

- Overview of COVID-19 and Development of Therapeutics
 James Jungkue Lee, CEO, Bridge Biotherapeutics
- Development of Antivirals against COVID-19: Global Challenges for Outbreak Control Meehyein Kim, Ph.D, Korea Research Institute of Chemical Technology
- Development of Antiviral Drug Candidates against SARS-CoV-2 Seungtaek Kim, Ph.D, Zoonotic Virus Laboratory, Institut Pasteur Korea
- Stem Cell Treatment for SARS-CoV2 Induced Diseases(COVID-19) Sun Uk Song, Vice president, SCM Lifescience
- Improved Cell-Permeable Nuclear Import Inhibitor (iCP-NI) Suppresses Severe Acute Inflammation to Cure COVID-19

 Dae Woong Cho, CEO, Cellivery Therapeutics, Inc.
- RNAi Therapeutics Against COVID-19
 Dongki Lee, CEO, OliX Pharmaceuticals, Inc.

Panel Discussion: COVID-19 Therapeutics Development Prospect and Main Issues

Chair
 BG Rhee, President, SCM Lifescience

Panelists
 James Jungkue Lee, CEO, Bridge Biotherapeutics

Meehyein Kim, Ph.D, Korea Research Institute of Chemical Technology Seungtaek Kim, Ph.D, Zoonotic Virus Laboratory, Institut Pasteur Korea

Sun Uk Song, Vice President, SCM Lifescience Dongki Lee, CEO, OliX Pharmaceuticals, Inc. Dae Woong Cho, CEO, Cellivery Therapeutics, Inc.

COVID-19 Special Session

Session 03

Vaccine Development & Collaboration for COVID-19

Amid the impact of the novel Coronavirus(COVID-19), stakeholders are scrambling to develop a vaccine for COVID-19. In this process, pharma, biotech, research institutes, and universities around the globe are working together to develop a vaccine and identify new therapeutics to treat the symptoms of the pandemic. This session will introduce the status of vaccine development of COVID-19 as well as cases of sharing quality trial data collected at South Korea to worldwide. Also, sharing global collaboration cases countering COVID-19.

Speakers

- COVID-19 Vaccine Development and International Collaboration Manki Song, Ph.D, International Vaccine Institute (IVI)
- Induction of Global Research Collaboration Platform on COVID-19 and Its Implication Yeun Sook Rho, Director, Health Insurance Review & Assessment Service
- Merck COVID-19 Global Collaboration Case Sharing: Interferon beta 1a (Rebif[®]) as a Potential Therapy in the Management of COVID-19 Infection

Pierre-Yves Berclaz, Senior Vice President / Head of Global Medical Affairs Neurology and Immunology, EMD Serono, Inc.

GSK Response to the COVID-19 Pandemic
 Bruce Mungall, Medical Director, GSK Korea Vaccine

Alzheimer's Disease

Recent Research Trends on Neurodegenerative Diseases Therapy

Identifying various causes of neurodegenerative disease and development of innovative therapies

Alzheimer's Disease is a neurodegenerative disease where the patient's memory and recognition abilities gradually decline, and takes up the majority of dementia cases. Many researches have taken place since its introduction through Alois Alzheimer's thesis in 1907, only 5 FDA-approved drugs are available, all with limited effects such as symptom relief or set back its progress, the needs for a fundamental cure is very high. Despite repeated failures in clinical trial, numerous new drugs based on various theories are being developed. Wide-ranged changes are expected within the industry, including spotlighting of combined treatment approaches due to heterogeneous features of Alzheimer's Disease. This session discusses mutual cooperation models through sharing of academia and industry trends, along with development cases of venture businesses and pharmaceuticals.

- Overview of Biomarkers and Therapies in Alzheimer's Disease
 Sun Ah Park, MD/Ph.D, Dept. of Anatomy and Dep. of Neurology, Ajou University School of Medicine
- Interplay between Neuroinflammation and Synucleinopathy Propagation
 Seung-Jae Lee, Professor, Dept. of Medicine, Seoul National University College of Medicine / Newramedy
- Introduction of National Dementia R&D Initiative
 Eun-young Jung, Director, Div. of Health Research and Development, Ministry of Health and Welfare
- A New Paradigm in Drug Development for Alzheimer's Disease Global Trend & Case Study Sanghoon Park, Ph.D / Head of R&D Strategy, Amyloid Solution Inc.
- Alzheimer's Disease Mechanisms and Emerging Roads to Novel Mitotherapeutics
 Soon Ha Kim, CEO, Mitolmmune Therapeutics Inc.
- The Molecular Origins of Alzheimer's Disease: When Does It Start and What Strategies for Primary Prevention? Colin Masters, Professor, Medicine, Dentistry and Health Sciences, The University of Melbourne

Therapeutic Antibody

Session 01

From Target Antibody Discovery to Preclinical, Current Innovations in Antibody Industry

Emerging trends and new technologies in antibody discovery & development

If we were to select a single class of drug which is leading the current pharma industry without a doubt, it would be an antibody. In the case of cancer and auto-immune diseases which are two largest therapeutic areas in terms of sales, antibodies have already become a major therapy. Even though Keytruda and Humira have provided better opportunities and lives to patients, the pharma industry is still searching for better therapeutics. New trends and technological innovations are rapidly changing the process of antibody development more than ever. In this session, "From target discovery to preclinical, Current innovations in antibody industry" We have invited five companies who will share their innovative work in this antibody industry to provide us some guidance to develop better antibody therapeutics.

Speakers

- Deeptech-driven Solutions for Therapeutic Antibody Development Anne Poupon, Ph.D / CTO, MAbSilico
- Rationally Guided Discovery and Development of Novel Therapeutic Antibody Programs: HMBD-001 (Anti-HER3) and HMBD-002 (Anti-VISTA)

Piers Ingram, Ph.D / CEO, Hummingbird Bioscience

Namita Gandhi, Ph.D / Head of Transitional Biology, Hummingbird Bioscience

- Multi Immune Modulating Bispecific Antibody for Autoimmune Disease
 Chungmin Lee, Ph.D, Biopharmaceutical Research Center, HK inno.N Corp.
- Anti-TFPI Antibody as a Hemophilia Therapy
 Min Jung Kim, Team Leader, R&D Center, GC Pharma

Therapeutic Antibody

Session 02

ADC (Antibody-drug Conjugate) R&D and Commercialization Strategy

Connecting specialists of antibodies, drugs, and linkers to collaborate and apply in ADC development

Developing ADCs require advanced technologies that include cancer cell-specific antibodies, drugs with low side effects, and linkers that connect them. Currently, there are only 7 FDA-approved ADCs: Mylotarg (Gemtuzumab ozogamicin), Adcetris (Brentuximab vedotin), Kadcyla (Trastuzumab emtansine), Besponsa (Inotuzumab ozogamicin), Lumoxiti(moxetumomab pasudotox), Polivy (polatuzumab vedotin), and Enhertu (trastuzumab deruxtecan). This suggests a high degree of difficulty in developing ADCs. We would like to suggest strategies for the successful development and commercialization of ADCs on each component, antibodies, drugs, and linkers.

- ABL202: ROR1-targeting antibody-drug conjugate for treating TNBC and CLL Jinwon Jung, Principal Research Scientist, R&D Center, ABL Bio
- New Self-Immolative Linker for Phenolic Payload Conjugation
 Tae Kyo Park, CEO, IntoCell
- Novel ADC Warhead and ADC Platform
 Mary Do, Ph.D / Senior Scientist, R&D, pH Pharma

Vaccine

Vaccine Bioprocessing Technology; Today and Tomorrow

Vaccine CMC/CDMO related process technology

Currently there are challenges to develop the manufacturing process for vaccines because there is no manufacturing template and few tools for the purpose of vaccine in the market. The vaccine development is directly linked with process technology development, which requires the expertise in process technology including new technology of higher efficiency purification platforms. In this session, the latest vaccine process technology trend, and local & global development experiences will be shared. In Session I, global vaccine process technology trends, cutting edge technology for process intensification to be applied from upstream to downstream, and key challenges for vaccine process development and CMC will be spoken with international speakers. In session II, Korean vaccine developers' vaccine process technology development cases and public-private partnership case will be presented.

- Development & Manufacturing of Vaccines at Pandemic Speed
 Anissa Boumlic-Courtade, Ph.D / Head, Global Vaccine Segment, EMEA, Merck KGaA
- Rapid Biosafety Testing for Vaccine Products
 Kathy Remington, Technical Consultant, Development Services, Merck BioReliance[®] Biosafety Testing Service
- Development of Cell Culture-based Influenza Vaccine: Key of Vaccine Effectiveness Yongwook Park, Chief, Bio1 Team, SK bioscience
- Development of Recombinant Vaccine using Vaccine Adjuvant
 Jung Sun Yum, Executive Director, CHA Vaccine Institute
- Development of 2nd Generation Varicella Vaccine (MAV/06 strain)
 Jaewoo Lee, Vice President, Corporate Development, GC Pharma

Regenerative Medicine

Session 01

Current Status of Regenerative Medicine Industry in Korea

Regenerative medicine (RM) in the globe is entering a new era of prosperity along with the commercial development of many 2nd generation products of gene therapies and immune cell therapies like chimeric antigen receptor-modified T cell (CAR-T). Korea is still somewhat away from market approval of these advanced RM therapies but many biotech companies and startups have recently started research and development to catch up with the global leader in the field. The first session will introduce these recent activities of Korean RM companies and sketch a prospect of the industry in the near future. A special highlight will be on the new RM legislation that will be enacted at the end of this August in its goal, main agenda, current process and expected impact on the regulatory innovation and promotion of industry envisioned by the Korea government.

- Prospects of Korea Regenerative Medicine Industry
 Bryan Choi, Ph.D / Secretary General, CARM(Council for Advanced Regenerative Medicine)
- The New Act on the Safety and Support of Advanced Regenerative Medicine and Advanced Biopharmaceuticals; its Implications and Prospects
 Eun-young Jung, Director, Div. of Health Research and Development, Ministry of Health and Welfare

Regenerative Medicine

Session 02

Trends in Global Regenerative Medicine Industry

This session will prospect the future of the global RM industry and medical innovations lead by it through recent trends in technology and product development. In addition, the activities of the Center for Commercialization of RM (CCRM) Australia and the current status of Japan RM could be a good benchmark to make a master plan for RM by the Korea government. CCRM Australia established by the support of the Australia government and in collaboration with CCRM in Canada is playing a leading role in supporting the RM industry in Australia. Japan has launched a new RM Act in 2014 and made an innovation in the regulatory process of and patient access to RM therapies in Japan. Now they have 6~7 years of experience after the new Act and its effect on their RM industry could be a good case study. The last talk of the session will deal with the current hot spot in the RM area, immune cell therapy about the recent development and key considerations in the IND approval for clinical application.

- Recent Trends in Regenerative Medicine Technology Development with Global Perspective Silvio Tiziani, CEO, CCRM Australia
- Regenerative Medicine in Japan
 Andrew Fleury, Vice President, CJ Partners
- Regulation on Immune Cell Therapy Saeheum Song, Ph.D, Cure Therapeutics

Future Technology

Session 01

Electroceutical: Could electrical pulses replace traditional medicines?

Recent R&D and Commercialization Trends in Neurostimulation Technologies

Electroceutical, a compound word made with 'electronics' and 'pharmaceutical' refers to electronic devices used to treat illnesses by modulating the electronic signals occurring in the brain and nerves. Trends in various technology developments and its commercialization status will be discussed; grain-sized bio-electronic implants used to treat rheumatoid arthritis in which Google's Verily and GSK have invested \$800M, and recently FDA-approved wrist watch-like essential tremor treatment device are few examples.

- High-Definition Transcranial Direct Current Stimulation (HD-tDCS):
 Low-power, Targeted, and Non-invasive Electroceuticals for CNS Diseases
 Marom Bikson, Professor, Biomedical Engineering, City University of New York
- Frontiers in Pain/Migraine Neuroimaging and Neuromodulation
 Alex F. DaSilva, Director, Headache & Orofacial Pain Effort, University of Michigan
- Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS):
 Parameters Optimization and Potential Applications
 Roberta Sclocco, Ph.D, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School
- Updates and Perspectives on Electroceuticals in South Korea Kiwon Lee, Founder / CEO, Ybrain Inc.

Future Technology Session 02

The Research Trend of 3D Organoids and Applications in Drug Discovery

3D cell culture technologies are now well accepted by the scientific community as a means of recapitulating the in vivo environment and behaviors of cells which are more physiologically relevant. Organoids are in vitro-derived 3D cell aggregates from primary tissue or stem cells that are capable of self-renewal, self-organization and exhibit organ functionality. Recently, tumor organoids have shown to predict how well patients respond to cancer therapy to aid in personalized medicine development and be used as anti-cancer drug screening. This seminar will introduce an overview of available advanced technologies for 3D organoid generation and the applications of organoids in various research especially in drug discovery for cancer and neurodegenerative disease.

- The Research Trend and Applications of 3D Organoids

 Mun-Keat Chong, Head, Commercial Marketing Cell Biology, Alliances and Academia, Asia Pacific, Merck Pte. Ltd, Singapore
- Identification of Novel Therapeutic Targets and Hits from Multicellular Tumor Spheroids for HCC Therapy Haeng Ran Seo, Ph.D / Team Leader, Cancer Biology, Institut Pasteur Korea
- Organoid Medicine: Strategies for Commercialization
 Jongman Yoo, Ph.D / CEO, ORGANOIDSCIENCES Ltd.

Future Technology Session 03

Innovation of Digital Pathology and Companion Diagnostics

The Future Perspective Data-Driven Healthcare and Companion Diagnostics

Innovative convergence technologies are being used for the accurate diagnosis of the disease and the selection of a suitable treatment. For example, NGS panel tests can provide prediction for the response of immunotherapy, and AI technology can analyze the severity of cancer or suggest clinical implications that derived from conventional pathology. Moreover, we would like to discuss innovative examples such as a holographic optics and ultra-compact laser scanning microscopy to be able to clarify clinical unmet needs in diagnostics.

- Quantitative Phase Imaging and Artificial Intelligence: Label-free 3D Imaging and Analysis of Individual Live Cells YongKeun(Paul) Park, Professor / Co-founder & CTO, KAIST Physics / Tomocube Inc.
- Panel Sequencing-based Prediction of Immunotherapy Response
 Woong-Yang Park, Head, Genomic Institute, Samsung Medical Center
- Al-based Cancer Diagnosis in the Era of Digital Pathology Sunwoo Kim, CEO, Deep Bio
- Fluorescence Confocal Endomicroscope for Real Time Tissue Biopsy : cCeLL™
 Kyungmin Hwang, CEO, VPIX Medical

Future Technology

Session 04

Current Status and Challenges for the Industrialization of Digital Therapeutics

Digital Therapeutics was mentioned as one of the five technologies to represent 2020 announced at CES in January 2020, and began to draw attention. ICT technology has been used for diagnosis, after care, and monitoring, but it is now expanding as a Medication Replacement and Medication Complement. We would like to look at various product development and technology development cases, and review and discuss the direction of future of Digital Therapeutics and issues to consider for its activation.

- How Digital Therapeutics becomes Business
 Seongji Kang, CEO, Welt Corporation
- Digital Therapeutics: Opportunities and Challenges
 Jinwoo Kim, Professor / CEO, Yonsei University / HAII(Human AI Interaction)

Patients Generated Healthcare Data

Session 01

Digital Healthcare Industry and Regulatory Trends Based on PGHD

Recently, medical service needs have changed from disease treatment to prevention and management concepts. The importance and value of PGHD (Patients Generated Health Data) in rapidly changing digital healthcare environments are expected to continue to increase. In this session, we would like to look at the current and global regulatory trends of PGHD-based industries.

Speakers

- Digital Healthcare Trends; HW Technology
 Kichang Nam, Associate Professor, Dept. of Medical Engineering, College of Medicine, Dongguk University
- Digital Healthcare Software Trend Focusing on PGHD Platform Youngin Kim, M.D. / Country Manager, Noom Korea / Japan
- PGHD-based Digital Healthcare Industry and Regulatory Trends
 Gyuha Ryu, Professor, Dept. of Medical Device Management & Research, Sungkyunkwan Univ. School of Medicine

Patients Generated Healthcare Data

Session 02

A Case Study on the Use of PGHD in the Development of Digital Healthcare Service

The use of Patients Generated Health Data (PGHD) in the digital healthcare industry is gaining attention as a new opportunity and challenge. In this session, we will share various practical applications of PGHD research and infrastructure construction cases. Through this, we will examine the industrial value of PGHD and explore ways to improve the responsiveness of the data-based digital healthcare industry.

- Personal Health Records (PHR) & Patient-Generated Health Data (PGHD): Perspective & Experience
 Jae-Ho Lee, Professor, Dept. of Emergency Medicine/Information Medicine, Asan Medical Center
- P-HIS: Significance in Utilizing Patient-Generated Health Data (PGHD)
 Sangheon Lee, Leader / Professor, P-HIS Development Group / Dept. of Physical Medicine & Rehabilitation,
 Korea University College of Medicine
- Introduction to PGHD-based Digital Healthcare Infrastructure and Implementation Dongbum Kim, Director, ICT Convergence Lab., LifeSemantics Corporation

Artificial Intelligence

Session 01

Digital Healthcare Transformation

Recently, there has been growing interest in social phenomena from a healthcare perspective, such as aging population, increasing interest in health care and rising medical costs. The paradigm of healthcare is changing, with technological advances in the fourth industrial revolution gaining attention as a solution to this social phenomenon. With regard to the "Digital Health Care Transformation," this session explore the application of information and communication technology to the medical field and the collection and utilization of healthcare big data as the basis.

Speakers

- Health Avatar: Crypto-Al Platform for Personal & Private Health Big Data
 Ju Han Kim, Professor, Institute of Endemic Diseases, Seoul National University College of Medicine
- Introducing the Precision Medicine Hospital Information System (P-HIS)
 Sangheon Lee, Professor, Rehabilitation Medicine, Korea University College of Medicine

Artificial Intelligence

Session 02

Al for Medicine

In terms of changing the healthcare paradigm, artificial intelligence plays a key role in improving the overall quality of medical care, including diagnosis, treatment, prevention and management, based on the merit of learning a large number of data efficiently. In this session, we want to identify various cases in which artificial intelligence technology is being used in healthcare.

- Accelerating Drug Discovery with AI: De Novo Drug Design and Protein-Ligand Binding Affinity
 Jaeyoung Kim, Executive Director, Korean AI Center for Drug Development, KPBMA
- Dr. Answer: Al Meets Healthcare
 Young-Hak Kim, Professor, Div. of Cardiology / Dept. of Information Medicine, Health Innovation Big Data Center,
 Asan Medical Center, Ulsan University College of Medicine
- SYNTHIA[™] Retrosynthetic Software: Novel and in silico Pathway Design Validated at the Bench Lindsey Rickershauser, Ph.D / Technical Application Scientist, Cheminformatics, EMD Millipore

Artificial Intelligence

Session 03

Smart Healthcare Future

It is preparing for a future where smart healthcare is applied to the entire hospital as well as each space, such as an operating room and emergency room, at medical sites. In this session, we want to share the future of the healthcare industry, which has been evolving through the integration of high-tech technologies based on big data and artificial intelligence.

- Smart Hospital Through Connected Care & Health Informatics
 Donghee Kim, Country GM, Philips Korea
- Al-based Smart Emergency Medical System
 Hyuk-Jae Chang, Professor, Dept. of Medical Information, Yonsei Medical Center, Severance Hospital
- Surgical Robot and Artificial Intelligence
 Jaesoon Choi, Professor, Dept. of Biomedical Engineering, Ulsan University College of Medicine
- Strategies for Vitalizing the Use of Personal Health Record through My-healthway Kun-Ho Yoon, Professor, Dept. of Medical Informatics, Catholic University of Korea

Technology Licensing

Session

Collaboration for Innovation

In new drug development, open innovation that highly contributes to the advances in healthcare is actively carried out in various forms. In this session two companies share their successful cases they have experienced and introduce the direction of open innovation they pursue in the future.

South Korea's proprietary biotech and pharma industry is a thriving new frontier. Going global is inevitable for Korean biotech/biopharma companies, especially early stage companies seeking to accelerate product development and commercialization. For the last couple of years, more and more Korean companies collaborated with international life sciences companies. There are successes and failures. Experience in negotiating and structuring deals, knowledge of the regulatory regime and intellectual property laws in different countries, mindset, leadership, even cultural differences can impact deal-making.

- Daewoong Open Collaboration: Cooperation, Win-Win-Win and Opportunities
 Jong Sang Ryu, Ph.D / Executive Director, C&D Center, Daewoong Pharmaceuticals
- Accelerating Innovation and Capturing Value in the Asia Pacific Stephen Lee, Director, J&J Asia Pacific Innovation Center
- Top Principles for Successful Partnering with Global Life Sciences Companies
 Josh Hofheimer, Partner, Sidley
- Top 10 IP, Regulatory, and Compliance Issues Peter Choi, Partner, Sidley

Intellectual Property

Session 01

Trade Secret Compliance for Biopharmaceutical Industry

Recently, there has been an increase in disputes over leakage of technology in the biotech industry. In order to prevent disputes regarding technology leakage, biotech companies effectively manage their technology in order to maximize legal protection. This session will focus on trade secret compliance for biopharmaceutical industry.

- Legal Risk Management on Introduction of Cloud Computing System Hyeong Joo Lim, Partner, Yulchon LLC
- IP Compliance Issues for Collaboration of Biotech Companies and Educational Institutions Chiho Choi, Head, Korea Institute of Science and Technology (KIST)

Intellectual Property

Session 02

Regulatory and IP Compliance in the Field of Biosimilars and Biobetters

Many biotech companies are preparing to enter foreign markets. For a successful overseas expansion, biotech companies need information on each country's regulations for biopharmaceuticals. This session will discuss the regulations and IP compliance issues that biotech companies need to know for successful entry into foreign markets.

Speakers

- Biosimilars and Biobetters IP and Regulatory Issues (Part 1: US)
 Huiya Wu, Partner, Goodwin Procter LLP
 Robert Cerwinski, Partner, Goodwin Procter LLP
- Optimizing and Structuring Global Collaboration and Licensing Transactions Recent Trends
 Kristopher D. Brown, Partner, Goodwin Procter LLP
- Biosimilars and Biobetters IP and Regulatory Issues (Part 2: Europe)
 Dominic Adair, Partner, Bristows LLP
- Overview of the Amended Personal Information Protection Act and the Impact on Artificial Intelligence in Healthcare Data

Sang Tae Jeong, Partner, Yulchon LLC

Medical Device

Medical Device Industry All-Cycle Market Penetration Comprehensive Presentation

- Introduction of Government Medical Device Industry Promotion Plan, Comprehensive Support Center and Promotion projects
- Introduction of Medical Devices Approval, New Health Technology Assessment and Reimbursement System of Korea
- * The seminar doesn't provide foreign language interpreting service

- Introduction of Government Medical Device Industry Promotion Plan
 Ji-won Nam, Deputy Director, Div. of Health Industry Promotion, Ministry of Health and Welfare
- Medical Devices Approval System in Korea
 SeungHwan Jung, Deputy Director, Div. of High-Tech Medical Devices, National Institute of Food and Drug Safety Evaluation
- In Vitro Diagnostic Medical Devices Approval System in Korea

 Young-Wook Ahn, Deputy Director, Div. of In Vitro Diagnostic Devices, National Institute of Food and Drug Safety Evaluation
- In Vitro Diagnostic Medical Devices Approval System in
 Young-Wook Ahn, Deputy Director, Div. of In Vitro Diagnostic Devices, National Institute of Food and Drug Safety Evaluation
- Medical Device Reimbursement System of Korea
 Sook-hee Lee, Deputy Director, Medical Technology Assessment Division, Health Insurance Review & Assessment Service (HIRA)
- New Health Technology Assessment System
 Jin Ho Kim, Team Director, External Affairs Team, National Evidence-based Healthcare Collaborating Agency (NECA)
- Introduction of Financial Services of Korea Eximbank for Bio/Healthcare Industry
 Su-Hyeong Jin, Senior Loan Officer, Service Industry Finance Department, Korea Eximbank
- Customs Counselling Services for Traders
 Ji Hyoung Choi, Assistant Director, Incheon Import & Export Business, Incheon Main Customs

Cosmetics

K-Beauty and Bio Convergence Forum

- Introduce the latest Policy and R&D in Cosmetics industry
- Current situation of Bio convergence Cosmetics
- Introduction of Genetic-Based Customized Cosmetics Research
- New technology in beauty-tech industry

- Current Status and Policy Direction of the Cosmetics Industry

 Mi-Hee Kim, Team Leader, Beauty-Cosmetics Industry Team, Korea Health Industry Development Institute (KHIDI)
- Next Generation Ceramides
 Chang-Seo Park, Ph.D / CTO, LCS Biotech Co., Ltd.
- Skin Type Genetics & Solution

 Kyung-Won Hong, Director, Healthcare R&D Department, Theragen Etex Bio Co., Ltd.
- New Technology in Beauty-tech Industry
 Yong Joon Choe, Founder / CEO, Lulu Lab

Pharmaceutical

2020 Insight Online Seminar

Current Status of Global Pharmaceutical industry and Marketing Strategy

This session focuses on strengthening the capabilities of domestic pharmaceutical companies to develop new drugs and enter into foreign markets. In this session,, we will analyze and introduce the current status of the pharmaceutical industry in global pharmaceutical expert's perspective amid the wide spread of COVID-19 and provide pharmaceutical guidelines for GMP and global marketing strategy to enable domestic companies to utilize the risks as an opportunity to penetrate into global markets.

- Principles of Business Development in Medical Devices, Life Sciences and Pharmaceuticals; a European Perspective Lee Taylor, Principal Consultant, Bio&Pharma Industry Global Team, Korea Health Industry Development Institute (KHIDI)
- Reforms in Saudi Arabia; Healthcare Opportunities & Challenges
 Kemal Hatip, Principal Consultant, Bio&Pharma Industry Global Team, Korea Health Industry Development Institute (KHIDI)
- Middle East Business Opportunities; GMP & Registration Obstacles
 Mahmoud Al Qawasmeh, Principal Consultant, Bio&Pharma Industry Global Team, Korea Health Industry Development Institute (KHIDI)
- Current Trend of Healthcare Industry in China and Opportunity for Korea
 Feng Tao, Principal Consultant, Bio&Pharma Industry Global Team, Korea Health Industry Development Institute (KHIDI)





ONLINE BUSINESS FORUM WITH PARTNERING

Overview ·····	32
List of Partnering Companies	33



DATE May 18(Mon) ~ May 23(Sat), 2020

POINT OF ACCESS BIO KOREA website (www.biokorea.org)

PARTICIPANTS Diverse affiliations from bio industry, research institutes, academia,

and interested individuals from all over the world are expected to

take part

OFFICIAL LANGUAGES English, Korean

Bio industry, the core engine of economic growth for future generations!

The global bio industry has had an average annual growth of 10% for the past 20 years. The number of bio-related businesses has increased by about 7 times, multiplying the overall value of bio-industry and playing a pivotal role in global economic growth.

Bio industry is directly related to many challenges of humanity in fields such as medicine, healthcare, agriculture and environment. Widely considered as a high-value added industry of the future, bio industry is expected to receive increased government funding, resulting in its diversification and further growth. Bio industry will aid in a virtuous circle of economic growth and technology advancements. BIO KOREA 2020's Online Business Forum with Partnering will be the place to discover the latest trends of biotechnology for the future grow of your company.

Numerous companies are expected to showcase their advanced technologies at BIO KOREA 2020. Bio companies armed with superior products and technologies will seek potential business partners and exchange information at partnering meetings, and build strategic business relationships through 1:1 online meeting with the aim of collaborating on multi-scale projects.

Celebrating its 15th anniversary, BIO KOREA 2020 Business Forum consists of Online Partnering and Company Presentation where corporations with advanced technologies can meet with research institutions and other bio business leaders to share knowledge, encourage further innovation in bio-industry, and interconnect with future business/ research partners.



0	
360biolabs	Australia
A	
AbbVie	United States of America
Able designs Co., Ltd	Republic of Korea
AceBiome	Republic of Korea
acromion GmbH	Germany
AEVA BIOTECH SRL	Italy
AGERA BioTech	Republic of Korea
Agilex Biolabs	Australia
AI DOT	Republic of Korea
AIRLab	Republic of Korea
ALIA THERAPEUTICS S.R.L.	Italy
All That Nature	Republic of Korea
AMYLOID SOLUTION	Republic of Korea
anyair	Republic of Korea
APAC Health Pty Ltd	Australia
Aptamer Sciences, Inc.	Republic of Korea
Aragen Bioscience, Inc	United States of America
ARAMHUVIS CO., LTD.	Republic of Korea
Arbor Pharmaceuticals	United States of America
ArcaEir	Republic of Korea
Arche Investment	Republic of Korea
Asgento	Germany
Australian Trade and Investment Commission	Republic of Korea
AVIXGEN	Republic of Korea

В	
BAREUN.CO., LTD	Republic of Korea
Bentleys RDI	Australia
BIO KOREA	Republic of Korea
BIOCOMPLETE	Republic of Korea
biolamp, Inc.	Republic of Korea
Biomat srl	Italy
Bio-Medical Science Co. Ltd.	Republic of Korea
BioWave W	Republic of Korea
Bioway Inc.	Republic of Korea
BioWin	Belgium
BIP FOCUS	Australia
BL&H USA	United States of America
BLIRT	Poland
Boehringer Ingelheim Japan	Japan
BREATHINGS Co., Ltd.	Republic of Korea
Bristol Myers Squibb Korea	- 111 611
	Republic of Korea
Bristol-Myers Squibb K.K.	Japan
	<u>'</u>
Bristol-Myers Squibb K.K.	Japan
Bristol-Myers Squibb K.K. BS Care Co., Ltd.	Japan Republic of Korea
Bristol-Myers Squibb K.K. BS Care Co., Ltd. BSL	Japan Republic of Korea Republic of Korea
Bristol-Myers Squibb K.K. BS Care Co., Ltd. BSL BUKWANG PHARMCEUTICAL CO., LTD.	Japan Republic of Korea Republic of Korea Republic of Korea
Bristol-Myers Squibb K.K. BS Care Co., Ltd. BSL BUKWANG PHARMCEUTICAL CO., LTD. Business Consulting	Japan Republic of Korea Republic of Korea Republic of Korea
Bristol-Myers Squibb K.K. BS Care Co., Ltd. BSL BUKWANG PHARMCEUTICAL CO., LTD. Business Consulting C	Japan Republic of Korea Republic of Korea Republic of Korea Republic of Korea

CELLTRION, INC.	Republic of Korea
Cellumed co., Ltd.	Republic of Korea
CEO	Republic of Korea
CHAYON Laboratories, Inc.	Republic of Korea
ChongKunDang Pharm	Republic of Korea
CIBIO - UNIVERSITY OF TRENTO	Italy
CJ PARTNERS Inc.	Japan
Claripi Inc.	Republic of Korea
Clinical Network Services	United Kingdom
CMAX Clinical Research	Australia
CookPlay Co., Ltd	Republic of Korea
CoSec Corporate Services	Australia
CSIRO	Australia
CTI Clinical Trial and Consulting Services	United States of America
Custommyskin	Republic of Korea
Cyclolab	Hungary
D	
DAE HWA PHARMACEUTICAL CO., LTD.	Republic of Korea
DAE HWA PHARMACEUTICAL CO., LTD. Daejeon Technopark	Republic of Korea
Daejeon Technopark	Republic of Korea
Daejeon Technopark Daiwha Corp., Ltd	Republic of Korea
Daejeon Technopark Daiwha Corp., Ltd DARAE STRATEGY & BUSINESS CENTER	Republic of Korea Republic of Korea Republic of Korea
Daejeon Technopark Daiwha Corp., Ltd DARAE STRATEGY & BUSINESS CENTER DEEVO	Republic of Korea Republic of Korea Republic of Korea Republic of Korea
Daejeon Technopark Daiwha Corp., Ltd DARAE STRATEGY & BUSINESS CENTER DEEVO DN Venture Partners LLP	Republic of Korea Republic of Korea Republic of Korea Republic of Korea Singapore
Daejeon Technopark Daiwha Corp., Ltd DARAE STRATEGY & BUSINESS CENTER DEEVO DN Venture Partners LLP Dongguk University Medical Center	Republic of Korea Republic of Korea Republic of Korea Republic of Korea Singapore Republic of Korea

Dxome Co. Ltd.	Republic of Korea
Е	
E&S Healthcare Co., Ltd.	Republic of Korea
E&VenturePartners	Republic of Korea
Economic Development Partnership of North Carolina, Korea Office	Republic of Korea
Eli Lilly	Japan
ENDOVISION CO., Ltd	Republic of Korea
ENSL	Republic of Korea
EROP Co., Ltd	Republic of Korea
Eurofins Discovery	United States of America
Eutilex	Republic of Korea
EverEx	Republic of Korea
F	
F. Hoffmann-La Roche Ltd	Japan
Fundación MEDINA	Spain
G2GBIO	Republic of Korea
Gachon Univ.	Republic of Korea
Gador	Chile
Gencurix	Republic of Korea
Geneuintech	Republic of Korea
Genome & Company	Republic of Korea
Genopharm Inc.	Republic of Korea
GEORGE CLINICAL	Australia
GIMHAE Industry Promotion& Bio-medical Foundation	Republic of Korea
Glaceum Incorporation	Republic of Korea
GOS	Republic of Korea

Н	
HAHO MEDI	Republic of Korea
HAII (Human AI Interaction)	Republic of Korea
Haim bio Co., Ltd.	Republic of Korea
Hana Pharm. Co., Ltd.	Republic of Korea
HANKYUL Co., Ltd.	Republic of Korea
Hanmi Pharmaceuticals	Republic of Korea
HanwoolTPC	Republic of Korea
HapInScience Inc.	Republic of Korea
HARBOUR BIOMED	China
HBOTmedical Co., Ltd.	Republic of Korea
HEALCERION	Republic of Korea
HEALING SOUND	Republic of Korea
Health Advances LLC	United States of America
Health Advances Ltd.	Hong Kong
HEM Inc.	Republic of Korea
HI MEDICAL	Republic of Korea
HIMSS LTD.	Republic of Korea
Hub Innovazione Trentino Fondazione	Italy
HUCASYSTEM Inc.	Republic of Korea
Hugel, Inc.	Republic of Korea
Human Metabolome Technologies, Inc.	Japan
Hummingbird Bioscience	Singapore
HyangZone	Republic of Korea
Hyoil Corporation	Republic of Korea
HYUNDAI PHARM. CORP.	Republic of Korea

Hyundai Venture Investment Corp	Republic of Korea
I .	
ונו	Republic of Korea
іКооВ	Republic of Korea
ILDONG PHARMACEUTICAL CO., LTD	Republic of Korea
ILIAS Biologics Inc.	Republic of Korea
IMDPHARM., LTD.	Republic of Korea
IMEDITEC	Republic of Korea
IMMAGINA BIOTECHNOLOGY S.R.L.	Italy
ImmuneMed Inc.	Republic of Korea
ImmuneOncia	Republic of Korea
ImmunoMax Co., Ltd.	Republic of Korea
ImmunXperts	Belgium
INBODY	Republic of Korea
infomeditech	Republic of Korea
inno.N	Republic of Korea
IntoCell, Inc.	Republic of Korea
Intralinks, Inc.	Republic of Korea
Intrinsik Corp.	Canada
Intro Global	Republic of Korea
Inventage Lab Inc.	Republic of Korea
Inventera Pharmaceuticals Inc.	Republic of Korea
ISU ABXIS Co., Ltd.	Republic of Korea
J	
J&J Asia Pacific Innovation Center	Hong Kong
Jakob And Partners India Pvt. Ltd.	India

JEIOS Inc.	Republic of Korea
JNBIO	Republic of Korea
JSR /KBI/SELEXIS	Japan
Jubilant Biosys Itd	India
J-WELL Co., Ltd.	Republic of Korea
K	
Kairos Bioconsulting	Republic of Korea
KAIST/Tomocube	Republic of Korea
Kanaph Therapeutics	Republic of Korea
KBBIO	Republic of Korea
KBI Biopharma	United States of America
KEIMYUNG UNIVERSITY	Republic of Korea
kherb	Republic of Korea
KHIDI (Korea Health Industry Development Institute)	Republic of Korea
Kogene biotech	Republic of Korea
koibig	Republic of Korea
KOLON LIFE SCIENCE, INC.	Republic of Korea
Korea Otsuka Pharmaceutical Co., Ltd.	Republic of Korea
KOREA UNITED PHARM, INC.	Republic of Korea
KOREA UNIVERSITY GURO HOSPITAL HBIC	Republic of Korea
Korean Health Industry Development Institute	United Kingdom
KS medical Inc.	Republic of Korea
L	
LABnPEOPLE	Republic of Korea
LAMEDITECH.Co., Ltd.	Republic of Korea
LegoChem Biosciences	Republic of Korea

Lemonex Inc.	Republic of Korea
LG Chem Life Sciences Company	Republic of Korea
Liberi Group	Netherlands
LJHBIO. Co., Ltd.	Republic of Korea
Lonza Biologics	China
Looxid Labs Inc.	Republic of Korea
LTOP	Republic of Korea
Luina Bio	Australia
Lumebio	Republic of Korea
M	
MAbSilico	France
MDimune Inc.	Republic of Korea
MEDI HUB. CO., LTD.	Republic of Korea
Medtronic	Republic of Korea
medysapiens	Republic of Korea
Medytox Venture Investment	Republic of Korea
MEGATHERAPEUTICS	Republic of Korea
MEINNTECH CO., LTD.	Republic of Korea
MercachemSyncom	Netherlands
MERCK	China
Mirabellsoft	Republic of Korea
MONORAMA	Republic of Korea
MSmedi	Republic of Korea
Multilex	Republic of Korea
N	
Nbios	Republic of Korea

Neuroscience Trials Australia	Australia
Nippon Boehringer Ingelheim Co., Ltd.	Japan
NLO	Netherlands
Novelty Nobility Inc.	Republic of Korea
NOVOTECH	Republic of Korea
Nucleus Network Pty Ltd	Australia
nunaps	Republic of Korea
0	
Olive. Co.	Republic of Korea
Oncodesign	France
Optyr	Republic of Korea
Ortho-Heal Co., Ltd	Republic of Korea
OTI Korea Co., Ltd.	Republic of Korea
Ovizio Imaging Systems	Belgium
P	
Paean Biotechnology	Republic of Korea
Patheon by THERMO FISHER SCIENTIFIC	Republic of Korea
PaxGenBio Co., Ltd	Republic of Korea
PDC*line pharma SA	Belgium
PDXen Biosystems Co.	Republic of Korea
Pfizer	China
pH Pharma	Republic of Korea
PharmCADD Co., Ltd.	Republic of Korea
PINOTBIO, Inc.	Republic of Korea
pmcc	Republic of Korea
Premier Research	Republic of Korea

PrimeMediLab	Republic of Korea
Proxihealthcare	Republic of Korea
Q	
Q-Gen Cell Therapeutics	Australia
R	
RecensMedical, Inc.	Republic of Korea
Retrogenix Limited	United Kingdom
Rznomics.INC	Republic of Korea
S	
SAMSUNG BIOLOGICS	Republic of Korea
SAMSUNG ELECTRONICS	Republic of Korea
SAMYANG BIOPHARMACEUTICALS CORPORATION	Republic of Korea
SANOFI	Republic of Korea
SANOFI	Japan
SANOFI Sanoosa Pty Ltd	Japan Australia
Sanoosa Pty Ltd	Australia
Sanoosa Pty Ltd SBA Ltd	Australia United Kingdom
Sanoosa Pty Ltd SBA Ltd SDS	Australia United Kingdom Republic of Korea
Sanoosa Pty Ltd SBA Ltd SDS Seoul Biohub	Australia United Kingdom Republic of Korea Republic of Korea
Sanoosa Pty Ltd SBA Ltd SDS Seoul Biohub SERVIER	Australia United Kingdom Republic of Korea Republic of Korea France
Sanoosa Pty Ltd SBA Ltd SDS Seoul Biohub SERVIER SevenPointOne	Australia United Kingdom Republic of Korea Republic of Korea France Republic of Korea
Sanoosa Pty Ltd SBA Ltd SDS Seoul Biohub SERVIER SevenPointOne SGhealthcare	Australia United Kingdom Republic of Korea Republic of Korea France Republic of Korea Republic of Korea
Sanoosa Pty Ltd SBA Ltd SDS Seoul Biohub SERVIER SevenPointOne SGhealthcare Shaperon	Australia United Kingdom Republic of Korea Republic of Korea France Republic of Korea Republic of Korea Republic of Korea
Sanoosa Pty Ltd SBA Ltd SDS Seoul Biohub SERVIER SevenPointOne SGhealthcare Shaperon shinwoo medison	Australia United Kingdom Republic of Korea Republic of Korea France Republic of Korea
Sanoosa Pty Ltd SBA Ltd SDS Seoul Biohub SERVIER SevenPointOne SGhealthcare Shaperon shinwoo medison SI Solution, Inc.	Australia United Kingdom Republic of Korea Republic of Korea France Republic of Korea

Smartooth korea	Republic of Korea
SOUSEIKAI Global Clinical Research Center	Japan
Southern Oncology Clinical Research Unit (SOCRU)	Australia
Southern Star Research	Australia
St Vincent's Hospital Melbourne	Australia
Strategic Transactions Advisory AG	Switzerland
Sumitomo Dainippon Pharma	Japan
Т	
Technical Trend Company	Republic of Korea
THE WAVE TALK	Republic of Korea
T-MAX	Republic of Korea
Tov&Banah	Republic of Korea
Trentino Sviluppo S.p.A.	Italy
TRICEP	Australia
trifermed	Spain

U	
UL GmbH Korea	Republic of Korea
W	
waki	Republic of Korea
WellC	Republic of Korea
WONJU MEDICAL INDUSTRY TECHNO VALLEY	Republic of Korea
Woori Investment Bank	Republic of Korea
WuXi AppTec	Republic of Korea
Υ	
YBSOFT CO., LTD.	Republic of Korea
YJTECH LTD	Republic of Korea
Yonsei University Health System	Republic of Korea
Yoon & Yang (IP) LLC	Republic of Korea
YSBio Co., Ltd.	Republic of Korea
YUHAN CORPORATION	Republic of Korea





VIRTUAL EXHIBITION

Overview · · · · · · · · · · · · · · · · · · ·	40
List of Exhibitors	41
Introduction of Exhibitors	48



DATE May 18(Mon) ~ May 23(Sat), 2020

POINT OF ACCESS BIO KOREA website (www.biokorea.org)

BIO KOREA 2020 Virtual Exhibition consists of a virtual area made up of numerous zones where relevant Exhibitor spaces are designated to. Companies and institutions participating in BIO KOREA 2020's online Virtual Exhibition will utilize VR contents which will assist attendees in exploring products/technologies beyond time and space.

EXHIBITION CATEGORIES



Pharma & Biotech



Medical Devices



Cosmetics



CMO & CRO



Business Consulting



Hospitals



Bio Clusters



Medical Institutes



Academia

EXHIBITING ORGANIZATIONS

- K-Healthcare start-ups
- COVID-19 Special Pavilion
- Healthcare Technology Licensing Office
- Korea Doctor Preneur
- Bio clusters
- New Excellent Technology Pavilion

- Korea Innovative Pharmaceutical Companies
- Hospital/Medical Institutes
- Hospital-based Business Innovation Center
- Domestic/International Pharmaceutical Companies
- National Pavilions

EXHIBITION HOURS -

*based on Korean Standard Time

24-hour operation throughout BIO KOREA convention period (ends at 6p.m. on May 23)

1drop Inc.	p.48	Bentleys R and D Services	p.62
360biolabs	p.48	BERTIS inc.	p.63
3E Co., Ltd.	p.49	BIO Asia-Taiwan (Taiwan Bio Industry Organization)	p.63
ABLBio,Inc.	p.49	BIO HK2020 (Hong Kong Biotechnology Organization)	p.64
AccuGene, Inc	p.50	Bio Ink Solution, Inc.	p.64
Agerabiotech	p.50	BioActs BM&S	p.65
Agilex	p.51	BIOCORE.CO., LTD	p.65
Ahram Biosystems, Inc.	p.51	Bio-Medical Science Co. Ltd.	p.66
AI DOT	p.52	Bioneer Corporation	p.66
AIRLab	p.52	BIORCHESTRA Co., Ltd.	p.67
Ajou University Hospital	p.53	Biosensorlab	p.67
Ajou University Hospital HBIC	p.53	BioSewoom Inc.	p.68
Ajou University Medical Center	p.54	BioSpectrum, Inc.	p.68
Alteogen, Inc.	p.54	Biot Korea	p.69
Amicogenpharma Inc	p.55	BIOTOXTECH CO., Ltd	p.69
AMOREPACIFIC	p.55	Bioway	p.70
Anyair	p.56	BioZentech Co., Ltd.	p.70
Aptamer Sciences, Inc.	p.56	Blue Beaker	p.71
Aram Huvis Co., Ltd.	p.57	Boryung pharmaceuticals Co., Ltd.	p.71
Arcaeir	p.57	BS CARE	p.72
Asan Medical Center	p.58	BUKWANG PHARMCEUTICAL CO., LTD.	p.72
ASKO Co., Ltd	p.58	CAIMI Co., Ltd.	p.73
AstraZeneca Korea	p.59	CaltecBio Co., Ltd.	p.73
Atommerce	p.59	Cancer Rop Co., Ltd.	p.74
Ausbiotech	p.60	CartiPrime Co., Ltd.	p.74
Australian Trade and Investment Commission	p.60	CAT Beam Tech	p.75
Awesomepia Co. Ltd.	p.61	Catholic Kwandong University University - Industry	r 75
Bang & Ock Consulting Co., Ltd.	p.61	Cooperation Foundation	p.75
BC WORLD PHARM. CO., LTD.	p.62	CBH Inc.	p.76

Cellengene	p.76	Customedi	p.91
Cellivery Therapeutics, INC.	p.77	Daegu-Gyeongbuk Medical Innovation Foundation	p.91
Celltrion	p.77	DAEHWA Pharm	p.92
Celvertics Co., Ltd.	p.78	Daejeon Technopark	p.92
CGBIO	p.78	Daewon Pharm.Co., Ltd.	p.93
CHA Bundang Medical Center	p.79	Daewoong Pharmaceutical Company Ltd	p.94
CHAYON Laboratories, Inc.	p.79	Daiwha Corp., Ltd	p.94
CHEM.I.NET, Lrd	p.80	Dankook University Cheonan Campus Industry Academic Cooperation Foundation	p.95
Chonnam National Unversity Hospital	p.80	Datasee Co., Ltd.	p.95
Chonnam National Unversity Hospital HBIC	p.81	DEEVO	p.96
Chungbuk National University Industry-University Cooperation Foundation Dean	p.81	DNBIO Pharm, Inc.	p.96
CiSTEM Co., Ltd.	p.82	DONG-A UNIVERSITY	p.97
CKD Pharmaceutical Corp.	p.82	Dongguk University Medical Center	p.97
ClariPI Inc	p.83	Dongguk University Medical Center HBIC	p.98
Clips	p.83	Dowgene Co., Ltd	p.98
CMAX	p.84	Dr. daddy Co., Ltd.	p.99
CMLAB	p.84	DR.PROLAB	p.99
Coagulant Therapeutics Coporation	p.85	DS MAREF (DAESUNG MAREF CO., LTD.)	p.100
Coreline	p.85	Dxome Co., Ltd.	p.100
Corestem, Inc	p.86	E&S Healthcare Co., Ltd.	p.101
COSCALdebio	p.86	EBO	p.101
Cosec Corporate Services	p.87	Ecoderm Co., Ltd.	p.102
COSMAX,INC	p.87	Edenlux	p.102
COVID-19 SPECIAL PAVILION	p.88	Edisbiotech Co., Ltd.	p.103
CrystalGenomics, Inc.	p.88	ELI Frontier	p.103
CSIRO	p.89	ENTEROENOMICS	p.104
Curigin	p.89	EROP Co, Ltd	p.104
Curocell.Inc.	p.90	Everex	p.105
Custom my skin	p.90	EvidNet Co., Ltd.	p.105

Ewha University-Industry Collaboration	p.106	HANDOK.Inc.	p.120
E-wireligner Co., Ltd.	p.106	HANDOKMEDICAL	p.120
Ex Lumina Therapeutics & Technology	p.107	Hankyul healthcare	p.121
EXOPERT	p.107	Hanlim Medical Equipment Co., Ltd	p.121
Eye Bio Korea Co., Ltd.	p.108	HANLIM PHARM. CO., LTD.	p.122
Finemedix Co., Ltd	p.108	Hanmi Pharmaceutical Co., Ltd.	p.122
Forest running	p.109	Hanwool TPC Co., LTD	p.123
Foundation for Industry Cooperation.	. 400	HAPPY FARM	p.123
University of Ulsan	p.109	HBOTmedical Co., Ltd.	p.124
Freevis inc	p.110	Healcerion Co., Ltd	p.124
Gachon University Gil Medical Center	p.110	HEALING SOUND	p.125
Gachon University Gil Medical Center	p.111	Healthcare Technology Licensing Office	p.125
GC Pharma	p.111	Hedgehog Co., Ltd.	p.126
Genematrix	p.112	Helixmith Co., Ltd	p.126
Genesystem Co., Ltd.	p.112	Hi Medical	p.127
Geneunitech	p.113	HK inno.N Corporation	p.127
Genexine, Inc.	p.113	Hospital-based Business Innovation Center	p.128
Geninus Co., Ltd.	p.114	HuBDIC	p.128
Genome & Company	p.114	HUINNO	p.129
Genome Opinion Co., Ltd.	p.115	Huniverse Global Co., Ltd.	p.129
George Clinical	p.115	Huons co., Ltd	p.130
GGulb co.	p.116	Hutom Co., Ltd.	p.130
GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION(GIBF)	p.116	HUWANT Inc.	p.131
Gilon	p.117	HYOIL Corporation	p.131
Glaceum Incorporation	p.117	HysensBio Co., Ltd.	p.132
Goodplayground Co., Ltd.	p.118	HYUNDAI Pharm. Co., Ltd	p.132
GOS	p.118	ועו	p.133
HAHO MEDI	p.119	I-key co., Ltd.	p.133
HANBITMD	p.119	lKoob	p.134

ILDONG PHARMACEUTICAL CO., LTD	p.134	Jeju National University Industry-Academic	n 147
IMEDICOM Co., Ltd.	p.135	Cooperation Foundation	p.147
ImmuneMed Inc.	p.135	JEONBUK National University Industrial	n 1/10
Immunoforge Co., Ltd.	p.136	Cooperation Foundation	p.148
Immunomax	p.136	JINWOO BIO	p.148
InBody Co., Ltd	p.137	JLK, Inc	p.149
INCELL BIO	p.137	JNBIO	p.149
Industrial-Academic Cooperation Foundation of	p.138	JSK BIOMED	p.150
Daegu Catholic University	p00	JSR Medical Co., Ltd.	p.150
Industry-Academic Cooperation Foundation	p.138	Juvic	p.151
Industry-Academic Cooperation Foundation		JW Pharmaceutical	p.151
Kyung Hee University	p.139	J-WELL Co., Ltd.	p.152
Industry-Academic Cooperation Foundation,	p.139	K- Herb	p.152
Keimyung University		KANGBUK SAMSUNG HOSPITAL	p.153
Infomeditech	p.140	Kangwon National University-Industry Cooperation Foundation	p.153
Inha University Research and Business Foundation	p.140	KH Medical	p.154
Inje university Busan Paik hospital	p.141	K-Healthcare start-ups	p.154
Innoway Co., Ltd.	p.141	Kim-Cell-Engine Co., Ltd.	p.155
INOBONE CO., LTD.	p.142	KogeneBiotech Co., Ltd.	p.155
Institut Pasteur Korea	p.142	KOIBIG	p.156
Intoborn	p.143	KOLMAR KOREA	p.156
iNtRON Biotechnology	p.143	KONKUK UNIVERSITY INDUSTRIAL	n 156
ionebio inc.	p.144	COOPERATION CORP.	p.156
ISU ABXIS CO., LTD.	p.144	Korea Doctor Preneur	p.157
IT'S HANBUL	p.145	Korea Drug Development Fund	p.158
Itsnuh	p.145	Korea Innovative Pharmaceutical Company	p.158
IVIM Technology, Inc.	p.146	Korea Institute of Oriental Medicine	p.159
Janssen Korea	p.146	Korea Otsuka	p.159
JEIOS, Inc	p.147	KOREA UNITED PHARM	p.160

Korea University Guro Hospital	p.160	Mirabellsoft	p.175
Korea University HBIC	p.161	MONORAMA	p.175
Korea University Medicine	p.162	MTEG	p.176
Korea University Medicine Research and Business Foundation	p.162	MTPConnect	p.176
KPIND Co., Ltd	p.163	Myo-Tec-Sci Co., Ltd.	p.177
Kuhnil Pharmaceutical Co., Ltd	p.163	NanoFocusRay	p.177
Kyungpook National University Hospital	p.164	National Cancer Center	p.178
Industry-Academic Cooperation Foundation	ρ.164	Neo-Gene-Pharm Co., Ltd.	p.178
LabGenomics Co., Ltd	p.164	NeogenTC Co, Ltd.	p.179
LABnPEOPLE	p.165	Neuro Venti	p.179
LAMEDITECH	p.165	New Excellent Technology Exhibition	p.180
LG Chem, Ltd.	p.166	NF Co., Ltd	p.180
Lifecore Instrument Inc.	p.166	Ngenebio	p.181
LISTEM CORPORATION	p.167	Novotech	p.181
Looxid Labs Inc.	p.167	NSW State Government	p.182
LTOP	p.168	Nucleus Network	p.182
Luina Bio	p.168	Oculight Co., Ltd.	p.183
Lunit Inc	p.169	Olix Pharamceuticals, INC.	p.183
M&B Meditech Co., Ltd.	p.169	Optyr	p.184
MD Healthcare	p.170	Orapharm	p.184
MEDIANA Co., Ltd	p.170	Orbitree	p.185
Medical IP Co., Ltd.	p.171	ORGAMEDI	p.186
MEDICAL STANDARD Co., Ltd	p.171	ORGANOID SCIENCES	p.186
Medicosbiotech	p.172	Ortho-heal Co., Ltd.	p.187
MEDIMAXKOREA ENGINEERING Co., Ltd	p.172	Osong Medical Innovation Foundation	p.187
Medytox Inc.	p.173	OTI Korea Co., Ltd.	p.188
MEINNTECH	p.173	Otologics	p.188
Microt Co., Ltd.	p.174	OTOS Co., Ltd	p.189
Minds Al Co., Ltd.	p.174	PAEAN Biotechnology Inc.	p.189

Paprica Lab	p.190	Sapien Med Co., Ltd.(설립예정)	p.204
PAUSE Co., Ltd.	p.190	Scientia Clinical Research (SCR)	p.205
PaxGen	p.191	SCM Lifescience Co., LTtd.	p.205
PCL Inc.	p.191	SDS	p.206
PDXen Biosystems Co.	p.192	SELJIN Co., Ltd.	p.206
Pensees	p.192	SEOUL Biohub	p.207
Phantomics Inc	p.193	SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL	p.207
Pharam Research Products	p.193	Seoul National University Hospital	p.208
PHARMBIO KOREA INC.	p.194	Seoul National University Hospital Biomedical	n 200
Pharmicell Co., Ltd.	p.194	Research Institute	p.208
Plarit Co., Ltd	p.195	SEWON CELLONTECH CO., LTD.	p.209
Plcoskin Co., Ltd.	p.195	SGhealthcare	p.209
Premier Research	p.196	SHIN POONG PHARM.CO., LTD.	p.210
PrimeMediLab	p.196	Shinwoo medison	p.210
Pusan National University Hospital	p.197	SI SOLUTION	p.211
Q-Gen Cell Therapeutics	p.197	SK Chemicals Co., Ltd.	p.211
Quantamatrix, Inc.	p.198	SKIMSBIO Co., Ltd.	p.212
Rapha Korea	p.198	Small Machines Co. Ltd.	p.212
Regeneus	p.199	Smartooth korea	p.213
Retrogenix Limited	p.199	SN BIOLOGICS	p.213
RevoSketch Inc.	p.200	SolGent	p.214
Royal Medical Co., Ltd	p.200	South Australia	p.214
S&E Bio Co., Ltd	p.201	Southern Oncology Clinical Research Unit	p.215
Samjin Pharmaceutical Co., Ltd.	p.201	Southern Star Research	p.215
Samsung Electronics Co., Ltd	p.202	ST PHARM	p.216
Samsung Medical Center	p.202	ST1	p.217
SAMSUNG MEDISON Co., Ltd	p.203	St Vincent's Hospital Melbourne	p.217
Samyang Biopharmaceuticals Corporation	p.203	Sullab	p.218
Sanofi-avenetis Korea	p.204	SWEXO biotechnology	p.218

Taejoon Pharmaceutical Co., Ltd.	p.219	WELLYSIS	p.228
Technical Trend company	p.219	Wiregene Co., Ltd.	p.228
TECHVILLAGE	p.220	WonderBio Inc.	p.229
TEGO SCIENCE	p.220	Wonju Medical Industry Technovalley	p.229
Theracan Co., Ltd.	p.221	WOOYOUNG MEDICAL	p.230
Thermo Fisher Scientific, Pharma Services	p.221	WOSEM Co., Ltd	p.230
THK Co., Ltd.	p.222	WuXi AppTec	p.231
Translational Research Initiative for Cellular Engineering and Printing (TRICEP)	p.222	Xaimed Co., Ltd.	p.231
	μ.ΖΖΖ	Y S Bio Co., Ltd.	p.232
Tribell lab	p.223	YBSOFT CO., LTD.	p.232
Trichogen Co., Ltd.	p.223	YD Diagnostics	p.233
UFU Health	p.224	Yeungnam University Creative Business Center	p.233
VIC State Government	p.224	YJTECH. LTD	p.234
VIVA INNOVATION	p.225	Yonsei University Health System	p.234
VUNO	p.225	Yonsei University Health System (Healthcare)	p.235
WA Government WALSIH	p.226	YoungMedical Co., Ltd.	p.235
WellC	p.226	YUHAN CORPORATION	p.236
WELLPEP	p.227	YUHAN KIMBERLY PROFESSIONAL	p.236

COVID-19 SPECIAL PAVILION



Australian Trade and Investment Commission



1drop Inc.

㈜원드롭

COUNTRY Republic of Korea

CEO Joowon Rhee 이주원

URL www.1drop.co.kr

E-mail shkim@1drop.co.kr

360biolabs

COUNTRY Australia

CEO Ms Angela Luttick
URL www.360biolabs.com
E-mail a.luttick@360biolabs.com

EXHIBIT CLASSIFICATION

1copy™ COVID-19 qPCR Multi Kit 1copy™ COVID-19 qPCR Multi Kit

COMPANY & PRODUCT INTRODUCTION

㈜원드롭은 체외진단 헬스케어 솔루션을 제공하는 기업으로, 모바일 헬스케어 시스템 '1drop™'과 분자진단 qPCR Kit 제품 '1copy™' 제품을 보유하고 있습니다.

We are 1drop Inc. we are providing products which is a IVD healthcare solution. Our company has two kinds of products, $1drop^{TM}$ (mobile healthcare system) and $1copy^{TM}$ (molecular diagnostic qPCR kit).

COMPANY & PRODUCT INTRODUCTION

360biolabs is a contract research organisation, providing specialist laboratory services for the development of new therapeutics, vaccines and diagnostics in a quality assured environment. We support pharmacokinetic (PK) and a diverse range of pharmacodynamic (PD) endpoints providing a single laboratory for all your clinical trial requirements (Phase1-4). Our Quality Management Systems include internationally recognised accreditation (ISO/IEC17025, ISO/15189 and OECD GLP) and our assay validation process and reporting is consistent with FDA and EMEA guidelines.

Œ

Hospital-based Business Innovation Center

Korea Innovative Pharmaceutical Company



3E Co., Ltd.

㈜쓰리이

COUNTRY Republic of Korea

CEO Yunseo Jo 조윤서

URL www.3eiris.com

E-mail ceo@3eiris.com

ABLBio,Inc.

에이비엘바이오㈜

COUNTRY Republic of Korea

CEO Sang Hoon Lee 이상훈

URL www.ablbio.com

E-mail weonkyoo.you@ablbio.com

EXHIBIT CLASSIFICATION

홍채분석기반 신체내 장기별 독소를 측정 솔루션

A solution for measuring toxins by organ in the body based on iris analysis $% \left(1\right) =\left(1\right) \left(1\right$

COMPANY & PRODUCT INTRODUCTION

3E는 10여년간 홍채데이터분석을 R&D하였으며 2015년 설립이래, 홍채를 통해 신체부위별 건강상태를 꾸준히 연구개발 해온 결과 신체부위별로 80%이상 질환의 근원인 독소를 측정하는 솔루션을 개발하는데 성공하였습니다. 3E는 지난 1월 CES2020 국제전시회에 참가하였고 올해 독소측정솔루션을 통해 초개인화 맞춤형서비스를 제공하는 것이 목표입니다.

3E have been researching and developing iris data analysis for more than 10 years and based on its R&D. It was established at 2015 and has steadily researched and developed the health status of each part of the body through the iris.

We developed 3E's own 'iris analysis data-based toxin measurement solution' 3E participated in the CES2020 International Exhibition in January and aims to provide ultra-personalized customized services through the toxin measurement solution this year.

EXHIBIT CLASSIFICATION

ABL001(NOV1501): 악성 고형종암에 대한 이중 항체 치료제

COMPANY & PRODUCT INTRODUCTION

ABL Bio는 항체와 항체결합플랫폼 기술을 기반으로 면역-종양학 및 신경퇴화질환 분야에서 새로운 혁신항체치료제를 개발하는 대한민국의 생명공학기업입니다.

ABL Bio is a South Korean biotechnology company developing novel innovative antibody therapeutics in the field of immuno-oncology and neurodegenerative diseases based on bispecific antibody and antibody drug conjugation platform technology.

COVID-19 SPECIAL PAVILION



K-Healthcare start-ups



AccuGene, Inc

㈜어큐진

COUNTRY Republic of Korea

CEO Jong Yoon Kim 김종윤

URL www.accugenelab.co.kr

E-mail kmcho@accugenelab.co.kr

Agerabiotech

아제라바이오텍

COUNTRY Republic of Korea

CEO Shin SoonYoung 신순영

URL www.agerin.co.kr

E-mail help@agerabiotech.com

EXHIBIT CLASSIFICATION

바이러스 검체채취도구 및 수송배지

AccuViral Collection Kit

EXHIBIT CLASSIFICATION

항노화, 면역력 개선 기능성식품, 아토피와 같은 피부질환에 도움을 줄 수 있는 기능성화장품

Functional cosmetics that can help skin diseases such as anti-aging, immune improvement functional foods, and atopic dermatitis.

COMPANY & PRODUCT INTRODUCTION

당사는 2014년에 설립한 바이오벤처기업으로서 전 세계적으로 관심이 집중되고 있는 헬스케어 시장에 발 맞추어 NGS, ddPCR 등의 미래분자진단에 특화된 기술로 종합적인 인간 유전자검사를 통해 환자의 질병을 완화, 제거하는 궁극적인 목표를 위해 창립하였습니다.

가정의학과 전문의들로 구성된 임상의들과 분자진단 경력의 생화학 및 분자생물 석, 박사 연구원들을 중심으로 유전자검사, 최첨단 진단법 개발, 맞춤의학 등을 통해 치료에서 예방의 패러다임 변화에 앞장 서고 있습니다.

AccuGene Inc. is a bio-venture company founded in 2014 for the ultimate goal of alleviating and eliminating diseases through the comprehensive human genetic testing using technologies specialized in future molecular diagnostics including NGS and digital PCR in line with the healthcare market, which is attracting worldwide attention

The members of AccuGene Inc. composed of family physicians, master and doctoral researchers in biochemistry and molecular biology field with molecular diagnostic experiences are leading the paradigm shift from treatment to prevention by developing cutting-edge diagnostic techniques, genetic testings, and personalized medicine.

COMPANY & PRODUCT INTRODUCTION

항노화, 면역력 개선 기능성식품, 아토피와 같은 피부질환에 도움을 줄 수 있는 기능성화장품 분야를 포함하는 아토피/건선 치료제를 연구·개발하고 있습니다.

We are researching and developing atopic and psoriasis treatments that that can help skin diseases such as anti-aging, immune improvement functional foods, and atopic dermatitis. **AGILEX**

A B S COVID-19 SPECIAL PAVILION



Agilex

Ahram Biosystems, Inc.

아람바이오시스템㈜

COUNTRY Australia

Australian Trade and Investment Commission

CEO Jason Valentine

URL www.agilexbiolabs.com

E-mail kurt.sales@agilexbiolabs.com

julia.jones@agilexbiolabs.com carolyn.cheer@agilexbiolabs.com COUNTRY Republic of Korea

CEO Hyun Jin Hwang 황현진

URL www.ahrambio.com

E-mail info@ahrambio.com

COMPANY & PRODUCT INTRODUCTION

Agilex Biolabs specialises in both LC-MS/MS and immunoassay/ immunobiology services. We operate a fully quality-assured, FDA-inspected laboratory in Australia (ISO/IEC17025 and OECD GLP), offering bioanalysis for small molecules and biologics for PK, PD, immunogenicity and biomarkers as well as an immunobiology service for evaluation of immunological endpoints by flow cytometry and cell-based assays. We are working with a number of sponsors in preclinical/method development/validation activities to ensure they are ready for enrolment once current COVID-19 restrictions ease in the coming months.

EXHIBIT CLASSIFICATION

COVID-19 분자진단키트

Palm PCR™ COVID-19 Fast Real-time RT-PCR Kit (Part No. DX5010, 96 tests/kit)

COMPANY & PRODUCT INTRODUCTION

아람바이오시스템은 세계적인 선도성을 가진 혁신적 신기술들을 보유하고 바이오/의료장비 및 진단 시스템을 개발, 판매하는 대한민국을 대표하는 핵 심 바이오텍 기업입니다. 세계 최초, 최고 성능의 초고속 포터블 PCR 기술을 기반으로 차세대 바이오 의료 시장을 선도할 기업이다.

At the leading edge of the PCR innovation, Ahram Biosystems is a global biotechnology company from South Korea that researches and develops bio/medical instruments and diagnostic systems. On the basis of the world's first and best ultra-fast mobile PCR system. Ahram Biosystems will lead the next generation of Bio Medical market.

AIDOT

GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION



Al Dot

아이도트

AIRLab

에어랩

COUNTRY Republic of Korea

CEO Joeng, Jae Hoon 정재훈

URL www.aidot.ai

K-Healthcare start-ups

E-mail contact@buzzpole.com

COUNTRY Republic of Korea

URL www.airlabkorea.com

Park Junho 박준호

E-mail cjh0713@gmail.com

EXHIBIT CLASSIFICATION

자궁경부암 원격판독 AI 시스템 Cerviray

Cerviray ™ Artificial Intelligence Cervical Cancer Diagnosis Solution

EXHIBIT CLASSIFICATION

에어웨이브 W, 플러스 AIRWAVE W, Plus

COMPANY & PRODUCT INTRODUCTION

자궁경부암 원격판독 AI 시스템 Cerviray™, 뇌동맥류 파열예측 AI 시스템 Nao Detection, 뇌졸중 사전 스크리닝 AI 시스템을 개발하고 있습니다.

Al Dot is a medical/healthcare Al & ICT company established in 2014. Our Al medical healthcare solutions are ;

- 1. The Al-based cervical dysplasia and cancer diagnostic system
- 2. The intracranial aneurysm rupture risk prediction AI software
- 3. Al assisted carotid ultrasound stenosis measurement software

COMPANY & PRODUCT INTRODUCTION

에어랩은 조합자극기, 저주파치료기, EMS마사지기, 미용기기 등을 개발, 생산하는 전문 기업입니다.

AIRLab is a healthcare company taking charge of the whole process of production from designing and foundational research to developing and manufacturing (OEM, ODM) ever since its establishment and is dedicated to customer satisfaction at all times.

AIRLab has a great number of excellent research personnel in medical engineering field, and has professionally run the business in medical device industry.



Hospital-based Business Innovation Center



Ajou University Hospital

아주대학교병원

COUNTRY Republic of Korea

CEO Hae-Sim Park 박해심

URL www.ajoumc.or.kr

E-mail leehna@ajou.ac.kr

Ajou University Hospital HBIC

아주대학교병원 개방형실험실

COUNTRY Republic of Korea

CEO Hae-Sim Park 박해심

URL ajoumc.hbic.or.kr

E-mail leehna@ajou.ac.kr

COMPANY & PRODUCT INTRODUCTION

아주대학교의료원은 실험동물연구센터, 세포치료센터, 의료정보연구센터, 임상시험센터 등을 통해 기초 의료 연구를 수행하고 있는 국제적 수준으 연 구역량을 가진 연구기관으로 성장하고자 합니다.

The Ajou University Medical Center, through its Laboratory Animal Research Center, Cell Therapy Center, Medical Information Research Center, and Clinical Trial Center, is conducting basic medical research

COMPANY & PRODUCT INTRODUCTION

아주대학교병원 개방형실험실은 아주대학교병원만이 보유하고 있는 인프라 활용으로 제품의 경쟁력을 제고하고 아주대학교병원 시설 장비 활용으로 기 업의 비용절감 효과를 도모하여 아주대학교병원과 기업의 동반 성장을 지원 하고 있습니다.

Ajou University Hospital HBIC Introduction

- Enhanced product competitiveness by utilizing unique infrastructure of Ajou University Hospital
- Cost reduction by using Facilties and equipment of Ajou University Hospital
- joint growth of businesses and Ajou University Hospital"

Healthcare Technology Licensing Office



Korea Innovative Pharmaceutical Company



AJOU University Medical Center

아주대학교의료원

COUNTRY Republic of Korea

CEO Park, Hae-Sim 박해심

URL www.ajoumc.or.kr

E-mail leehna@ajou.ac.kr

Alteogen, Inc.

㈜알테오젠

COUNTRY Republic of Korea

CEO Soon Jae Park 박순재

URL www.alteogen.com

E-mail erica.hh.cho@alteogen.com

EXHIBIT CLASSIFICATION

면역질환, 빅데이터, 골관절염, 난청, 뇌질환, 노인정신질환, 재생의료/의료기기, 임상빅데이터, 간암정밀의료연구

Immune disorders, Big Data, Osteoarthritis, Bradyecoia, Brain disorders, Senile mental disorders, Regenerative medicine / medical device, Clinical big data, Precision medical research for liver cancer

EXHIBIT CLASSIFICATION

 * ADC 유방암/위암치료제
 : 유방암치료제

 * ADC 난소암치료제
 : 난소암치료제

* 허셉틴 SC 바이오시밀러 : 유방암 및 위암 항체치료 * 허셉틴 바이오시밀러 : 유방암 및 위암 항체치료 * 아일리아 바이오시밀러 : 습성황반변성(WAMD) 항체치료

* 지속형 성장호르몬 : 성장호르몬 * 성장호르몬 억제제 : 말단비대증

* 피하주사용 히알루로니다제 : 피하주사용 항체치료제 원천기술인 인간

히알루로니다제 기술

* 비알코올성 지방간염치료제 : 비알코올성 지방간염치료제

* ALT-P1_Growth hormone deficiency: Growth hormone deficiency

* ALT-P7_Oncology: Breast cancer

* ALT-B4_Subcutaneous Absorption Accelerator: Oncology

* ALT-L9_Ophthalmic diseases: Wet Age Macular Degeneration

* ALT-LS2_Oncology: Breast cancer

COMPANY & PRODUCT INTRODUCTION

아주대학교의료원은 중점연구 분야에서 국제적 수준의 연구 역량을 가진 연구기관으로 성장하고자, 지난 25년간의 진료,교육,연구 경험을 바탕으로 기초의학 발전 및 연구 성과의 실용화를 위해 지속가능한 산학연병 융합연구를 진행하고 있습니다.

AJOU University Medical Center has been undertaking convergence research projects under the cooperation with industry, academy, the government and hospitals to advance preclinical medicine and commercialize research outcome with the 25 years of experience in diagnosing patients, teaching and researching with an aim to be a global international institution with corresponding research capabilities in the key research areas.

COMPANY & PRODUCT INTRODUCTION

알테오젠은 고도의 공정/분석/제형 기술이 요구되는 바이오시밀러, 기존 바이오의약품의 효능과 체내 지속력을 강화하는 차세대 Biobetter, 주사제의투여 편의성을 개선하는 신규 히알루로니다제 그리고 바이오신약 후보물질등을 연구개발하고 있는 기술선도 바이오벤처기업입니다.

ALTEOGEN Inc., located in Daejeon, South Korea, is a biotech venture company devoted to developing biobetters, Antibody-Drug Conjugates (ADC), biosimilars and novel recombinant human hyaluronidase, and new biologics.

AMICOGEN Pharma

Hospital-based Business Innovation Center

New Excellent Technology Exhibition



Amicogenpharma Inc

㈜아미코젠파마

COUNTRY Republic of Korea

CEO Song, Yeong Ho 송영호

URL www.gallexiong.com

E-mail chobs@amicogenpharma.com

AMOREPACIFIC

㈜ 아모레퍼시픽

COUNTRY Republic of Korea

CEO Kyung Bae Suh, Saehong Ahn

서경배, 안세홍

URL www.apgroup.com

E-mail ahreum@amorepacific.com

EXHIBIT CLASSIFICATION

겔라시앙 여드름 화장품 - 여드름성 피부에 적합한 클리어 3종 세트 (토너, 에 센스, 로션)

Gallexiong acne skin cosmetics - Clear 3step for acne-prone skin (Toner, Essence, Lotion)

EXHIBIT CLASSIFICATION

난용성 미백소재(멜라솔브TM)의 피부 이용률 증진기술

Technology for enhancing skin utilization rate of poorly soluble whitening material (MelasolveTM)

COMPANY & PRODUCT INTRODUCTION

㈜아미코젠파마는 우르소다이올을 원천기술인 첨단 제제공법으로 액상화에 성공하고, 퇴행성 및 희귀 안구질환 전문의약품을 개발해 난치성 환자의 삶의 질 향상에 공헌하는 기업이다. 또한 ㈜ 아미코젠파마는 겔라시앙 여드름성 피부용 화장품를 판매하고 있다.

The amicogenpharma Inc. is a company that contributes to improving the quality of life of intractable patients by succeeding in liquefying ursodiol as an advanced preparation method of source technology and developing ethical medicines for degenerative and rare eye diseases. The Amicogenpharma Inc. sell Gallexiong acne skin cosmetics

COMPANY & PRODUCT INTRODUCTION

아모레퍼시픽은 아름다움으로 세상을 변화시키는 '원대한 기업'으로의 도약을 준비합니다. NET 획득 기술은 자외선, 노화, 염증, 환경 오염 인자에 의한 피부 색소 침착에 안전한 미백기능을 가지는 소재 개발 및 제형화 기술이다.

From the day of our founding, we have existed to inspire and celebrate Asian beauty through our unparalleled blend of traditional Asian wisdom, pristine ingredients, and technological innovation to a customer base that spans the globe.

D-phase emulsification of 3, 4, 5-trimethoxy cinnamate thymol ester (TCTE, MelasolvTM) with safe whitening function for skin darkening by ultraviolet rays, aging skin hyperpigmentation, inflammatory skin hyperpigmentation, and environmental pollution factors Liposomes were formulated through the method and formulated in a stable state.



K-Healthcare start-ups

Anyair

애니에어

COUNTRY

Bae so-yeon 배소연

URL www.anyair-mask.com

E-mail anyair2019@gmail.com

EXHIBIT CLASSIFICATION

Republic of Korea

EXHIBIT CLASSIFICATION

Aptamer Sciences, Inc.

㈜압타머사이언스

COUNTRY

URL

E-mail

안면스캔(Face scan)을 이용한 개인 맞춤형 마스크

Personalized masks made by face scanning technology

최첨단 압타머 기술 플랫폼 기반 혁신 신약 및 진단 제품 개발

Republic of Korea

Dongil Han 한동일

www.aptsci.com

euisushin@aptsci.com

The cutting-edge Aptamer Technology Platforms for the development of innovative therapeutic and diagnostic products.

COMPANY & PRODUCT INTRODUCTION

어플을 이용하여 얼굴을 스캔한 다음, 개인 맞춤 노즈 와이어 디자인 및 제작 을 하고, 본체와 결합하면 나에게 맞는 단 하나의 맞춤형 마스크

Users use face scanning mobile app that will enable designing and manufacturing personalized nose wire. Combining the wire to the fabric makes the one mask that fits the user

COMPANY & PRODUCT INTRODUCTION

2011년 4월 ㈜압타머사이언스는 "글로벌 No. 1 생명 공학 회사"의 비전을 바 탕으로 압타머 기술 분야의 전문가들로 설립되었습니다. 당사는 최첨단 압타 머 기술 플랫폼을 바탕으로 혁신 신약 및 진단 제품을 개발하고 있는 R&D 기 반 바이오 벤처 회사입니다. 또한, 압타머 기반 플랫폼에는 고품질 압타머 발 굴 및 압타머 최적화, 새로운 신약 및 진단 기술 개발이 가능합니다.

Aptamer Sciences, Inc. was founded in April 2011 by world-class experts in the field of aptamer technology with the vision of "Global No.1 Biotech Company". The company is an R&D based bio venture company focused on commercializing cutting-edge Aptamer Technology Platforms for the development of innovative therapeutic and diagnostic products. We offer high quality aptamers with superior binding affinity and specificity. Our aptamer-based platforms include the generation of high-quality aptamers, aptamer optimization, and development of new therapeutic and diagnostic techniques.

New Excellent Technology Exhibition



K-Healthcare start-ups Pharmace

ARCA FIR PHARMACEUTICAL Inc.

Aram Huvis Co., Ltd.

아람휴비스㈜

COUNTRY Republic of Korea

CEO Park Dong Soon 박동순

URL www.aramhuvis.com

E-mail hclee@aramhuvis.com

Arcaeir

아크에이르

COUNTRY Republic of Korea

CEO Byong-Cheol Shin 신병철

URL www.arcaeir.com

E-mail jiae87@arcaeir.com

EXHIBIT CLASSIFICATION

센서 착탈식 휴대용 의료영상 및 개인건강정보 취득장치

Mobile medical image & personal health information obtaining device with attachable sensor

COMPANY & PRODUCT INTRODUCTION

다수의 영상장치과 진단현장의 온습도 모니터링이 가능한 개발장치로, 모바일 장치의 소모전력 제어기술, 소형카메라 응용기술, UVC Interface 장치개발, 통신기술과 영상진단장치의 카메라 기술개발 조명, 액추에이터, 생체진단센서 등의 통합 기술을 융합한 기술

Device is featured with hybrid integration technologies, capable of measuring temperature/humidity of surrounding site, controlling electricity consumption of mobille device, application technology for small-size camera, UVC Interface device development, telecommunication technology and lighting for image diagnositic camera, actuator, and biometric diagonsis sensor.

EXHIBIT CLASSIFICATION

동물실험 대체 및 신약 약물 스크리닝 시스템

Alternatives to animal testing and drug screening : Organ On-Chip $\mbox{\sc System}$

COMPANY & PRODUCT INTRODUCTION

전자회로가 놓인 칩 위에 살아있는 특정 장기를 구성하는 세포를 배양함으로 써, 해당 장기의 기능과 특성 뿐만 아니라, 역학적, 생리적 세포반응을 모방하는 기술로, 특정 장기의 세포운동이나 물리 화학적 반응의 메커니즘을 상세하게 연구할 수 있음

We are developing the organ on-chip experimental device which can provide a service for prescribing more suitable patient-specific drug through detailed drug screening



COVID-19 SPECIAL PAVILION



Asan Medical Center

서울아산병원

Republic of Korea **COUNTRY** CEO Sang-Do Lee 이상도 URL www.amc.seoul.kr

ails.amc.seoul.kr

E-mail sbjang@amc.seoul.kr

ASKO Co., Ltd

아스코 주식회사

COUNTRY Republic of Korea

SEOKJUN NA 나석준

URL www.asmedi.net

E-mail henry@asko119.com

EXHIBIT CLASSIFICATION

연구원 주요 Core Lab(융합연구지원센터) 소개

Introducing the research capability and infrastructure of Asan Medical Center, focusing on the Core Laboratories

EXHIBIT CLASSIFICATION 이동형 음압기

Portable Negative Pressure Machine

COMPANY & PRODUCT INTRODUCTION

서울아산병원은 국내 최대·최고 수준의 진료경험과 탁월한 연구진, 풍부한 임상자원을 바탕으로, 연구중심병원으로서 기초-중개-임상연구의 탁월한 역 량과 인프라를 갖추고 있다.

ASAN Medical Center, one of the "Research-driven hospitals" designated by the Korean Ministry of Health and Welfare is the largest medical center in Korea with top-quality medical care. ASAN Institute for Life Sciences is a global bio-cluster which enables a one-stop system for basic, translational and clinical research, and it aims to bridge the academia and industry. At BioKorea 2020, we would like to introduce the Core Laboratories.

COMPANY & PRODUCT INTRODUCTION

메르스 및 코로나19 대응 질병관리본부 지정 음압기 납품업체

Designated Negative Pressure Machine supplier as management for MERS and COVID-19 by KCDC(Korean Centers for Disease Control and Prevention)

Korea Innovative Pharmaceutical Company



K-Healthcare start-ups



AstraZeneca Korea

한국아스트라제네카

COUNTRY Republic of Korea
Unno Kim 김상표

URL www.astrazeneca.co.kr

E-mail

Atommerce

아토머스

COUNTRY Republic of Korea

CEO Kyutae Kim 김규태

URL

E-mail contact@atommerce.com

COMPANY & PRODUCT INTRODUCTION

EXHIBIT CLASSIFICATION

* 이레사 : 비소세포폐암 * 타그리소 : 비소세포폐암 * 임핀지 : 비소세포폐암 * 린파자 : 난소암 * 파슬로덱스 : 유방암 * 포시가 : 제2형 당뇨병 * 브릴린타 : 급성관상동맥증후군 * 심비코트 : 천식. COPD

* IRESSA : Non-small cell lung cancer * TAGRISSO : Non-small cell lung cancer * Imfinzi : Non-small cell lung cancer

* Lynparza : Ovarian Cancer* Faslodex : Breast Cancer* Forxiga : Type 2 diabetes

* Brilinta : Acute coronary syndrome

* Symbicort : Asthma, COPD

EXHIBIT CLASSIFICATION

모바일 심리상담 플랫폼, 마인드까페

mindcafe

amall call lung cancor 페 서비스가 탄생하였습니다. 마인드카페는 약

현대인들은 심리적으로 취약해져 가는 반면, 전문 정신건강 서비스에 대한 접근성과 인식은 여전히 부족한 사회적 문제를 해결하기 위해 마인드카페 서비스가 탄생하였습니다. 마인드카페는 익명 커뮤니티를 기반으로, 전문 가로부터 심리상담을(24시간 어디서든 익명의 모바일 공간에서 저렴한 비용으로) 받을 수 있는 비대면 원격 상담 서비스입니다. 정식 론칭 2년반 동안 국내 약 70만 명의 사용자를 확보하였으며, 정신건강 분야 가장 많은 수의 회원 및 데이터를 확보 하고 있습니다(국내 1위). 이를 기반으로 '인공지능 감성 대화 챗봇' 및 자가 심리 치료가 가능한 '디지털 치료제'를 개발해 나가고 있습니다.

Atommerce Inc. offers online psychotherapy service based on an anonymous community called Mindcafe. Mindcafe(No.1 Korean therapy plattform) can be used anytime and anywhere for a low cost. Users of Mindcafe can post their feelings and concerns on an anonymous SNS platform and our professional liscenced counselors will selectively answer those posts for free. If the users want to have one-on-one counselling service with the licensed therapists, they are able to get have teleconsulting on for a low cost via text, telephone, or video.

COMPANY & PRODUCT INTRODUCTION

혁신적인 과학, 우수한 연구개발 및 상용화를 통해 삶을 변화시키는 의약품을 환자들에게 제공하는 과학 기반의 바이오제약회사입니다. 종양, 당뇨, 순환기, 호흡기 등 주요 영역에서 의약품을 연구개발, 상용화하는데 집중하고 있습니다.

AstraZeneca Korea is a science-led biopharmaceutical business delivering life changing medicines to patients through innovative science and excellence in development and commercialization. It focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory.

Australian Trade and Investment Commission



Australian Trade and Investment Commission



Ausbiotech

Australian Trade and Investment Commission 주한호주대사관 무역투자대표부

COUNTRY Australia

CEO Ms Lorraine Chiroiu
URL www.ausbiotech.org

E-mail Ichiroiu@ausbiotech.org

COUNTRY Australia

CEO Rodney Commerford

URL www.austrade.gov.au/korea

E-mail juliet.woo@austrade.gov.au

COMPANY & PRODUCT INTRODUCTION

AusBiotech is Australia's national industry organisation, working on behalf of members for more than 30 years to provide representation and services to promote the global growth of the Australian life sciences. AusBiotech is a well-connected network of over 3,000 members in the life sciences, including therapeutics, medical technology (devices and diagnostics), food technology and agricultural biotechnology sectors. AusBiotech is dedicated to the development, growth and prosperity of the Australian biotechnology industry, by providing initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for members nationally and around the world.

COMPANY & PRODUCT INTRODUCTION

호주의 무역,교육,관광 및 해외 투자 유치를 촉진하기 위해 설립된 호주정부 기관입니다. 호주기업들이 성공적으로 해외 진출을 할 수 있도록 각종 서비 스를 제공하고 있습니다.

The Australian Trade and Investment Commission - Austrade - contributes to Australia's economics prosperity by helping Australian businesses, education institutions, tourism operators, governments and citizens as they:develop international markets and promote international educationwin productive foreign direct investmentstrengthen Australia's tourism industry seek consular and passport services Austrade leverages the deep commercial knowledge and relationships of our international and domestic networks, and the badge of governments, to deliver value for our clients and investors

Hospital-based Business Innovation Center



Korea Doctor Preneur



Awesomepia Co. Ltd.

㈜오썸피아

Bang & Ok Consulting Co., Ltd.

방앤옥컨설팅

CEO Republic of Korea

Mun Ho, Min 민문호

URL www.awesomepia.kr

E-mail jmc@awesomepia.kr

CEO Republic of Korea
Bang, Yeong ju

URL www.boconsulting.io

E-mail bangyj@boconsulting.io

EXHIBIT CLASSIFICATION

터치브레인 인지평가 콘텐츠

Touch Brain: Cognitive Evaluation Application

EXHIBIT CLASSIFICATION

신약개발 기술자문

Technical Advisory on New Drug Development

COMPANY & PRODUCT INTRODUCTION

본 사는 2015년 설립된 VR/AR/ICT 융합 콘텐츠 및 S/W기술개발 회사로, 벤처기업인증, 서울시 강소기업 하이서울브랜드 인징을 받은 우수기업입니다. 2019년부터 고대구로병원의 개방형실험실 입주기업으로써 ICT 기술을 이용한 스마트헬스케어 및 원격의료 콘텐츠 개발에 힘 쓰고 있습니다.

Awesomepia is established in 2015, certified as a venture company specialized in VR, AR contents designing, production, and S/W technology development.

From 2019, Awesomepia is collaborating with Korea University Guro Hospitals to develop Smart Healthcare digital therapeutics. As a flagship project of the HBIC, Awesomepia is developing digital therapeutics for people of all ages and dementia patients.

COMPANY & PRODUCT INTRODUCTION

모든 인류의 삶의 질을 향상시키기 위해 정밀 의학 시대의 신약 개발 전략을 전문적으로 컨설팅

The company specializes in consultation of new drug development strategies to improve quality of life of all mankind in the era of precision medicine.

Korea Innovative Pharmaceutical Company



Australian Trade and Investment Commission



BC WORLD PHARM. CO., LTD.

㈜비씨월드제약

COUNTRY Republic of Korea

CEO Sung Han Hong 홍성한

URL bcwp.co.kr

E-mail lenajung@bcwh.co.kr

Bentleys R and D Services

COUNTRY Australia

CEO

URL www.bentleys.com.au/biopharma

E-mail mike@bentleysrdi.com.au

EXHIBIT CLASSIFICATION

메펨주 500mg, 1g, 실라신주, 반코마이신주 500mg, 1g, 메로겔, 튜비스정, Ethambutol HCl, 튜비스투정 150/300mg, 비씨아토르바스타틴정, 비니카핀 주 5ml, 10ml, 20ml, 뮤코피드정 100mg, 비씨펜타닐스트르산염주, 나르코설 하정, 티바레주, 비씨모르핀황산염수화물주, 멀티포텐9주

* Meropenem Inj : Merop * Meropenem Inj : Meropenem

 * Imipenem+Cilastatin Inj. : Imipenem hydrate+Cilastatin sodium

* Vancomycin Inj. : Vancomycin HCl * Metronidazole Gel. : Metronidazole

* Rifampicin+Isoniazid+Pyrazinamide+Ethambutol Tab.: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol HCl

* Tubes2 Tab. : Isoniazid. Rifampicin

* Atorvastatin Tab. : Atorvastatin calcium trihydrate

* Nicardipine HCl Inj. : Nicardipine HCl
* Rebamipide Tab. : Rebamipide
* Fentanyl Inj. : Fentanyl citrate
* Fentanyl Sublingual Tab. : Fentanyl citrate
* Remifentanyl Inj. : Remifentanil HCl
* Morphine Inj. : Morphine sulfate

* Multipotent Inj. : Zn, Cu, Se, Cr, Mn, F, Fe, I, Mo

COMPANY & PRODUCT INTRODUCTION

Bentleys RDI BioPharma delivers a best practice, full service and low-cost solution for non-Australian controlled Biotech/MedTech enterprises seeking to create a corporate presence in Australia and make use of the R&D Tax Incentive. The Australian R&D Tax Incentive is a Federal Government program that enables eligible Australian companies, including those that are foreign controlled, to undertake R&D activities (such as clinical trials) in Australia and potentially receive a refundable tax credit (cash refund) of up to 43.5% of eligible Australian expenditure.

COMPANY & PRODUCT INTRODUCTION

비씨월드제약은 DDS 기술을 선도하는 글로벌 제약기업으로서 DDS 특화 4 대 Platform technology를 확보하고 있으며 매년 매출액 대비 약 15% 이상의 R&D 투자를 통하여 경쟁력 있는 독과점 품목, 개량신약, 니치버스터 제품을 개발하고 있습니다.

BC WORLD PHARM is a technology-driven pharmaceutical company in Korea whose expertise in formulation and process development enable it to provide quality generics. We strive to establish its position as a pioneer in developing innovative products through cutting-edge formulation technology including immediate/controlled release as well as fast-dissolving DDS, GRS and depot formulation by way of proactive investments in R&D and strategic alliances.

베르티스

New Excellent Technology Exhibition



BERTIS inc.

㈜베르티스

COUNTRY Republic of Korea

CEO Seungman Han 한승만

URL www.bertis.com

E-mail youngseo.lee@bertis.com

BIO Asia-Taiwan (Taiwan Bio Industry Organization)

COUNTRY

Chinese Taipei

CEO

URL

E-mail

lori.tsang@hkbio.org.hk

EXHIBIT CLASSIFICATION

마스토체크(조기유방암진단 다중마커 혈액검사 솔루션)

Mastocheck (blood test solution for early breast cancer)

EXHIBIT CLASSIFICATION

BIO Asia-Taiwan 2020

COMPANY & PRODUCT INTRODUCTION

유방암에 특이적인 3종 혈장 단백질 수치를 알고리즘 계산 값을 통해 유방암의 발병 유무를 선별해주는 기술로, 유방암 조기 진단에 특화된 기술로 0기~2기 진단에 도움을 주는 체외 진단 기술이며, 혈장 1ul(0.001cc)의 극미량만으로도 분석이 가능해 최소량의 채혈만 필요로 하는 기술

It is an in vitro diagnosis technology that helps screening for early breast cancer(stage 0-2), through algorithm calculation of three protein markers concentration, and can be analyzed only with 0.001cc amount of plasma.

COMPANY & PRODUCT INTRODUCTION

Jointly organized by both the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO), the BIO Asia-BIO Asia-Taiwan 2020 Online + Live will bring together biotechnology and pharmaceutical executives and investors from North America, Europe and Asia to meet and explore business opportunities with Taiwan's emerging biotech sector in both online and live settings.

The five-day event will feature rich programming, online company presentations from Asia and around the world, BIO One-on-One Partnering™ meetings, online seminars and workshops, and an online exhibition.



Korea Doctor Preneur

BIO HK2020 (Hong Kong Biotechnology Organization)

Bio Ink Solution, Inc.

㈜바이오잉크솔루션

COUNTRY Hongkong

CEO

URL

E-mail maki@taiwanbio.org.tw

COUNTRY Republic of Korea

CEO Jang Soo Suh 서장수

URL www.bioinksolution.com

E-mail msbae@bioinksolution.com

EXHIBIT CLASSIFICATION

Promoting Hong Kong biotechnology industry

COMPANY & PRODUCT INTRODUCTION

Hong Kong Biotechnology Organization is founded by pioneering scientists with extensive life science backgrounds and multicultural experience in research and development, engineering and business, the vision of the Hong Kong Biotechnology Organization is to establish and facilitate a worldwide platform for the Hong Kong biotech industry, promoting awareness, encouraging and enabling international collaboration and providing informed opinion and technical advice to government bodies, healthcare institutions, and the general public.

EXHIBIT CLASSIFICATION

- 1. Gel4Cell
- 2. Gel4Cell-peptides (BMP, VEGF, TGF)
- 3. Gel4Tissue
- 4. Col4Cell

COMPANY & PRODUCT INTRODUCTION

주식회사 바이오잉크솔루션은 3D 바이오 프린팅의 소재로 쓰이는 바이오 잉크를 연구, 개발 및 제조하는 기업으로 전 세계 3D 바이오 잉크를 제조하는 10여 곳의 전문 기업 중 하나입니다. 당사의 제품들은 생분해성, 세포증식률, 인체적합성 등이 높아 바이오 잉크의 최종 목표인 '인공장기'의 소재로서 손색이 없을 것으로 판단됩니다. 또한, 글로벌 경쟁업체의 바이오 잉크에 비하여 고품질, 저가격적인 강점을 가지고 시장을 확장해가고 있습니다. 아울러고품질의 바이오 잉크를 기반으로 다양한 의료기기들을 개발하고 있으며, 곧제품화를 완료할 예정입니다. 이러한 제품들을 바탕으로 바이오 잉크의 표준화를 이루고 있는 바이오잉크솔루션은 4차 산업혁명에 발맞추어 미래 지향적인 방향을 제시하고 있는 기업입니다.

Bio Ink Solution, Inc. is a company that researches, develops and manufactures bio-inks that are used as materials for 3D bio-printing, and is one of the top 10 manufacturers of 3D bio-inks worldwide. The company's products are highly biodegradable, high in cell proliferation rate and human compatibility. They will be a good material for the final goal of Bio Ink, 'Artificial Organ.' The company is expanding its market with high-quality, low-priced strengths compared to global competitors' bio-inks. Furthermore, the company is developing a variety of medical devices based on high-quality bio-inks, and its productization will soon be completed.

Based on these products, Bio Ink Solution, Inc., which standardizes bio-inks, is a company that presents a future-oriented direction in line with the Fourth Industrial Revolution.

GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION



COVID-19 SPECIAL PAVILION

BIOCORE.CO., LTD

바이오코아㈜

COUNTRY



BioActs BM&S

㈜바이오액츠BM&S

COUNTRY Republic of Korea

CEO Park Jin Woo 박진우

URL www.bioacts.com

E-mail hskim@bioacts.com

CEO Hwang seung yong 황승용

Republic of Korea

URL www.bio-core.com

E-mail hjyun@bio-core.com

EXHIBIT CLASSIFICATION

생체분자표지용 형광진단시약, 전혈종합혈액분석시약

Fluorescent Probes

COMPANY & PRODUCT INTRODUCTION

㈜바이오액츠 비엠엔에스는 광학영상 및 진단을 위한 연구용 형광시약과 동물용 광학 조영제, 혈액분석시약 등을 연구 개발, 생산하는 연구소기업입니다.

BioActs BM&S is a research and development company which produces fluorescent reagents for research of optical imaging and diagnosis, and optical contrast agents for animals.

EXHIBIT CLASSIFICATION

BioCore 2019n-CoV Real Time PCR Kit

COMPANY & PRODUCT INTRODUCTION

Konex list company

Business Category : Clinical/ Bioanalytical CRO, Genetic analysis &

Diagnostic Kits development

Establishment : May. 30. 2001

Business Entities: GLP(good laboratory practice), GMP(good

manufacturing practice)

Employees: Total: 111

Financial statement(\$): assets 19.1M liabilities 6.6M Retained Earnings

12.6M Sales revenue 18.1M Net income 1M

key member :

ceo Seung-Yong Hwang (a doctor of genetics & Hanyang University

professor)

director Sung-Hee Han (a doctor of diagnostic examination)

director Soo-Yeon Oh (a doctor of pharmacology)

BMS

COVID-19 SPECIAL PAVILION



Bio-Medical Science Co., Ltd.

㈜비엠에스

Bioneer Corporation

㈜바이오니아

COUNTRY Republic of Korea

CEO 김선기

URL www.bms.kr
E-mail info@bms.kr

COUNTRY Republic of Korea
CEO Han-Oh park 박한오
URL www.bioneer.co.kr

E-mail export1@bioneer.co.kr

EXHIBIT CLASSIFICATION

생물분자 정량 및 상호작용 분석 장비

Octet & BLltz system

EXHIBIT CLASSIFICATION

AccuPower® SARS-CoV-2 Real-Time RT-PCR Kit AccuPower® COVID-19 Real-Time RT-PCR Kit

COMPANY & PRODUCT INTRODUCTION

Fortebio사 Octet&BLItz system은 Label-free 방식으로 빛의 간섭 원리를 이용하며, 생물분자의 상호작용을 최대 96샘플 실시간 동시분석 가능한 장비 입니다

Biomolecular interaction analysis system using Bio-layer interferometry technology

COMPANY & PRODUCT INTRODUCTION

바이오니아는 1992년에 설립된 한국 최초의 바이오 벤처기업으로서 27년의 R&D 연구 경험과 약 440개의 특허를 보유하고 있습니다. 자체 기술력으로 분자진단 시스템과 진단 키트를 개발한 한국 유일의 기업으로 분자진단 시장에 진출하기 위한 수많은 독점 기술과 개발능력을 축적 했습니다. 이를 통해 핵산추출장비 및 핵산증폭장비, COVID-19, HIV, Hepatitis, STI, TB, ZIKV, RV 등의 진단 키트와 같은 제품을 개발 하였습니다.

BIONEER Corporation is the first Korea biotech company established in 1992. We have over 27 years of experience in R&D, and approximately 440 patents applied and registered. BIONEER Corporation is the only company in Korea that have developed both MDx systems and diagnostic kits using our own technologies.

We have a number of proprietary technology and developmental capability to venture into the MDx market. We have developed various products from automated instruments, including nucleic acid extractor, Real-Time PCR, MDx workstations to various MDx kits such as COVID-19, HIV, Hepatitis, STI, TB, ZIKV, RV tests and etc.

Daejeon Technopark



K-Healthcare start-ups



BIORCHESTRA Co., Ltd.

주식회사 바이오오케스트라

Biosensorlab

바이오센서연구소

COUNTRY Republic of Korea

CEO Ryu Jinhyeob 류진협

URL www.biorchestra.com

E-mail danbi918@biorchestra.com

COUNTRY Republic of Korea

CEO Myounghoon Jang 장명훈

URL franzskincare.com

E-mail skkang@biosensorlab.com

EXHIBIT CLASSIFICATION

RNA 신약 플랫폼 기술

RNA Drug platform technologies

EXHIBIT CLASSIFICATION

프란츠 팝 미세전류 마스크

FRANZ POP Micro-current Mask

COMPANY & PRODUCT INTRODUCTION

우리는 mRNA를 다중 또는 단일로 조절할 수 있는 RNA치료제 플랫폼을 보유한 혁신적인 생명공학회사입니다. 또한 안전하고 원하는 병증부위에 효과적으로 약물을 전달하기 위하여 자체적으로 스마트약물전달시스템을 보유하고 있습니다.

그렇기에 최적의 RNA신약을 개발할 수 있습니다. 우리의 RNA 신약 플랫폼 기술은 기존 치료 패러다임을 증상치료에서 질병의 근본적인 원인치료로 바 꿀 수 있습니다. 우리는 약물상용화를 위한 글로벌 파트너를 찾고 있습니다.

We are an innovative biotechnology company with an RNA therapy platform that can regulate either single or multiple mRNA.

In addition, we have our own "Smart Drug Delivery System" to safely and effectively deliver drugs to the desired site. Therefore, we are able to develop an optimal RNA drug.

Our RNA drug platform technology can change the existing treatment paradigm from symptomatic treatment to treatment of the underlying cause of the disease. We are looking for a global partner for drug commercialization."

COMPANY & PRODUCT INTRODUCTION

경피약물전달 기술 플랫폼 Tissue X™는 비침습 이온토포레시스 트렌스더마약물 및 코스메틱(Transdermal drug & cosmeceutical)으로 피부 근본을 치유하는 피부 재생 프로젝트로 개발

The mask sheet with Tissue X^{m} is the mask-type solution that allows an iontophoresis therapy at home without any equipment or expert's help

COVID-19 SPECIAL PAVILION



New Excellent Technology Exhibition

BioSpectrum, Inc.

바이오스펙트럼㈜



BioSewoom Inc.

㈜바이오세움

URL

COUNTRY Republic of Korea

CEO Hyun Soon, Yim 임현순

Republic of Rolea

E-mail bskim@biosewoom.com

www.biosewoom.com

COUNTRY Republic of Korea

CEO Deokhoon Park 박덕훈

URL biospectrum.co.kr

E-mail biosh@biospectrum.com

EXHIBIT CLASSIFICATION

Real-Q 2019-nCoV Detection Kit

COMPANY & PRODUCT INTRODUCTION

(주)바이오세움은 분자진단분야에서 독보적인 경쟁력을 확보하고 있는 분자 진단 전문기업입니다.

(주)바이오세움은 생명 존중을 기업의 가치로 삼아 축적된 탄탄한 기술력과 경험 그리고 최고의 인적자원을 바탕으로끊임없는 연구개발을 통해 분자진단 시약 분야에서 독보적인 경쟁력을 확보하고 있는 분자진단 전문기업입니다.

(주)바이오세움은 급속히 변화하는 시대의 흐름에 맞추어 적극적인 연구개발 과 투자로 고객감동의 앞서가는 제품개발을 통하여 인류의 건강에 기여하는 기업으로 도약할 것 입니다.

BioSewoom Inc. has a unique competitive edge in medical device manufacturers that develop and produce in-vitro diagnostics for molecular diagnostics.

We are specialized in molecular genetic test for the detection of dangerous pathogens, hereditary diseases, or genetic mutation. Our strong technology and expertise have an unrivaled competitiveness in this field domestically and internationally.

In line with the rapidly changing times, we aim to provide the best products to our clients with best quality through the expertise process of Research and Development and the best human resources.

EXHIBIT CLASSIFICATION

Eosidin®/감귤미숙과에서 추출한 시네프린의 피부장벽 기능 강화기술

Eosidin®/A technology that strengthens the skin barrier function of syneprin extracted from unripe citrus fruits

COMPANY & PRODUCT INTRODUCTION

본 기술은 감귤미숙과 유래 시네프린의 피부염증 완화 및 피부장벽 기능 강화에 관한 것으로, 해당 기술로 만들어진 Eosidin®은 건강한 피부를 유지하는데 도움을 줄 수 있는 기능성 제품이다.

This technology is related to the relieve of skin inflammation and enhanced skin barrier function of synephrin extracted from unripe Citrus unshiu.. Eosidin made with this technology is a functional product that helps maintain healthy skin.

K-Healthcare start-ups





Biot Korea

바이오트코리아

COUNTRY Republic of Korea

Chang Yeongjun 장영준

URI www.biotinc.com

E-mail yeongjun.chang@biotinc.co.kr

EXHIBIT CLASSIFICATION

세계 최초의 전자기장 구동 약물/세포치료제 담지형 마이크로 로봇 시스템

New delivery system for cell therapeutics that is unforeseen in the existing therapies.

COMPANY & PRODUCT INTRODUCTION

바이오물질을 탑재 가능한 마이크로 사이즈의 구조체를 비침습적 방식으로 투여하고, 이를 외부 전자기 제어장치를 이용하여 체내 환부로 이동시켜 치 료효과를 극대화시킬 수 있는 의료기기

Stem Cell Navigator is medical device platform capable of encapsulating biologics and enabling minimally-invasive, target-specific delivery through external electromagnetic actuation.

Through prevent systematic circulation of therapeutic materials, higher treatment efficacy could be achieved

BIOTOXTECH CO., Ltd

㈜바이오톡스텍

COUNTRY Republic of Korea

Jong-Koo Kang 강종구

URL www.biotoxtehc.com

E-mail mst@biotoxtech.com

EXHIBIT CLASSIFICATION

안전성평가연구사업

- 일반독성시험

- 발암성시험

- 국소독성시험

- 생식발생독성시험 - 유전독성시험

- 면역독성시험

- 안전성약리시험 - 수생생태독성시험

- 조직병리/임상병리 - 발육기동물시험

- 체내분포시험

- 동물대체시험법

유효성(효능)평가연구사업

- 건강기능성식품

- 식품

- 기능성화장품

약물대사분석사업

- PK/TK/ADME - VALIDATION

- 생체시료분석

- Medical Food - Food field

- Cosmetics field

Safety evaluation research field - General Toxicity Studies

- Reproductive & Developmental Studies

- Histopathology/Clinical Pathology

Efficacy evaluation research field

- Carcinogenicity Studies

- Local Toxicity Studies

- Genotoxicity studies

- Safety Pharmacology

- Ecotoxicology Studies

- Juvenile animal toxicity

- Biodistribution analysis

- Alternative method

- Immunotoxicity Studies

Analysis research field - PK/TK/ADME

- VALIDATION - Bio analysis

COMPANY & PRODUCT INTRODUCTION

㈜바이오톡스텍은 창립 이래, 우수한 인재, 최신 기술 및 최첨단 시설을 바탕 으로, 비임상 GLP(Good Laboratory Practice)시험에 대한 최다 인증 항목 및 최다 수행 실적은 물론 국내외 고객들의 신물질의 미국, 일본, 유럽 등의 허가 당국에 대한 수백건의 자료 제출 경험을 가지고 있습니다.

Biotoxtech Co., Ltd. is founded on competent people, latest technology and state-of-the-art facilities, and has the experience of submitting hundreds of documents to the regulatory agencies including the US, Japan, Europe, etc. for new compounds for domestic and international customers as well as performing the most GLP certified non-clinical GLP studies in Korea.

SEOUL Biohub



Korea Doctor Preneur



Bioway

주식회사바이오웨이

COUNTRY Republic of Korea

CEO Kim, Jong Wo 김종우

URL www.bioway.co.kr

E-mail yhuh@bioway.co.kr

BioZentech Co., Ltd.

㈜바이오젠텍

COUNTRY Republic of Korea

CEO Chae Seung Lim 임채승

URL biozentech.co.kr

E-mail malarim@korea.ac.kr

EXHIBIT CLASSIFICATION

DOS 기술을 활용한 항암제 신약 재창출

Bioway Inc is a pancreatic / hepatocellular tumor drug-based research company especially on pi3k delta kinase inhibitor.

EXHIBIT CLASSIFICATION

- 1. Microscanner
- 2. Microscanner plus
- 1. Microscanner
- 2. Microscanner plus

COMPANY & PRODUCT INTRODUCTION

질병의 생물의학적 이해와 Open Innovation에 기반을 둔 혁신 신약개발 플랫폼을 구축, 항암제 및 대사성질환 신약을 연구·개발하는 바이오 회사 입니다.

Bioway, Inc. is a bio-company that focuses on R&D for developing innovative novel drugs about cancer/metabolic disease based on biomedical understanding and open innovation.

COMPANY & PRODUCT INTRODUCTION

바이오젠텍은 2015년 11월에 창립되어, 구로 에바다빌딩에 위치한 의료기기 제조 회사입니다.

바이오 칩 기반의 체외진단기기를 통해 누구나 이용하기 쉽고, 빠르며 정확한 진단을 실현하기 위해 설립 되었습니다.

BioZentech was founded in November 2015. It is a medical device manufacturing company located in the Evada Building in Guro.

The company is established to carry out diagnosis that is easy, fast and accurate for anyone to use through bio-chip-based in vitro diagnostic devices.

BLUE BEAKER

K-Healthcare start-ups

KER
Korea Innovative Pharmaceutical Company

B BORYUNG
Pharmaceutical

Blue Beaker

㈜블루비커

COUNTRY Republic of Korea
CEO Lance Kwon 권우혁
URL www.bluebeaker.co
E-mail lance@bluebeaker.co

Boryung pharmaceuticals Co., Ltd.

보령제약 주식회사

COUNTRY Republic of Korea

CEO Jae-hyun Ahn, Sam-soo Lee

안재현, 이삼수

URL www.boryung.co.kr

E-mail minjyun@boryung.co.kr

EXHIBIT CLASSIFICATION

3D 메디컬 일러스트 플랫폼

3D Medical Illustration Platform

COMPANY & PRODUCT INTRODUCTION

의학정보를 쉽게 전달하는 3D 메디컬 일러스트

3D Medical illustration Platform bests for prime content

EXHIBIT CLASSIFICATION

* 카나브 : Fimasartan

* 듀카브 : Fimasartan, Amlodipine * 투베로 : Fimasartan, Rosuvastatin * 카나브 플러스 : Fimasartan, HCTZ

* 듀카로 : Fimasartan, Amlodipine, Rosuvastatin * 겔포스엠현탁액 : Colloidal Aluminum phosphate, Magnesium

hydroxide, Simethicone

* 스토가 : Lafutidine
* 맥스핌 : Cefepime
* 젬자 : Gemcitabine
* 제넥솔 : Paclitaxel
* 젤로다 : Capecitabine"
* Kanarb : Fimasartan

* Dukarb : Fimasartan, Amlodipine * Tuvero : Fimasartan + Rosuvastatin

* Kanarb plus : Fimasartan+HTCZ

* Dukaro : Fimasartan, Amlodipine, Rosuvastatin

* Gelfos M :Colloidal, Aluminum, Phosphate, Magnesium,

hydroxide, Simethicone

* Besto : Lafutidine

COMPANY & PRODUCT INTRODUCTION

보령제약은 인류건강에 이바지하는 공존공영의 정신을 바탕으로 'Lifetime Care Company'라는 미래상을 실현하기 위해 노력하고 있습니다. 보령제약은 심혈관 질환, 항암제, 대사질환 영역을 중점으로 R&D에 투자하고 고품질 제품을 생산하기 위해 꾸준히 노력하고 있습니다.

Boryung Pharmaceutical strives to be a company which will continue to practice contributing to the health of mankind by preparing for the future and taking on challenges with innovation.

We have made every effort to free everyone from the pains of disease.

ES Care

Wonju Medical Industry Technovalley

Korea Innovative Pharmaceutical Company



BS Care Co., Ltd.

㈜비에스케어

BUKWANG PHARMCEUTICAL CO., LTD.

부광약품 주식회사

COUNTRY Republic of Korea

CEO 김민석

URL bscare.co.kr

E-mail bscare@bscare.co.kr

COUNTRY Republic of Korea

CEO Hee-Won Yoo 유희원

URL bukwang.co.kr

E-mail bizcontact@bukwang.co.kr

EXHIBIT CLASSIFICATION

내성발톱교정기

NAIL UP&IN

EXHIBIT CLASSIFICATION

* 레보비르 캡슐: B형 간염

* 덱시트 정 : 당뇨병성 다발성 신경염

* Levovir® cap : Chronic hepatitis B virus infection * Dexid® tab : Diabetic polyneuropathy

COMPANY & PRODUCT INTRODUCTION

네일업앤인은 수술적 치료를 바탕으로 3점압 원리에 의해 파고들어간 발톱을 들어올려주는 네일업(견인기), 들어 올린 발톱을 교정시켜주는 네일인(교 정장치)로 구성되어 있고, 지속적인 3점압 원리로 네일 매트릭스 교정효과를 볼 수 있습니다. 그리고 발톱을 잡아 주는 니들홀더, 큐렛이 함께 구성되어 있습니다.

NAIL UP & IN-MEDICAL is a nail-up (retractor) that lifts the claws dug by the three-point pressure principle based on surgical treatments, and a nail-in (calibrator). You can see the nail matrix correction effect - Needle holders to hold the claws and cullet

COMPANY & PRODUCT INTRODUCTION

부광약품 주식회사는 대한민국 혁신형 제약기업 일원으로 1960년 설립 이후 우수한 의약품 보급에 앞장 서 왔습니다. 지난 50년 간 괄목할만한 성장을 해 왔으며, 올해 2020년도 2,000억 원의 매출을 목표로 하고 있습니다.

Bukwang, founded in 1960, is dedicated to bringing novel and outstanding medicines to the public.

We have been actively investing in R&D, and continuing to pursue new drug development

with various partners worldwide.

Korea Doctor Preneur



New Excellent Technology Exhibition



CAIMI Co., Ltd.

㈜카이미

CaltecBio Co., Ltd.

㈜칼텍바이오

COUNTRY Republic of Korea

CEO Jun Won Jung 정준원

URL www.caimi.co.kr (오픈예정)

E-mail junwonchung@daum.net

COUNTRY Republic of Korea

EO Geumhee, Kim 김금희

URL caltecbio.co.kr

E-mail rnd@caltecbio.kr

EXHIBIT CLASSIFICATION

- 1. 복강경 수술용 탐지 센서
- 2. 지능형 위병변 탐지 알고리듬
- 1. Laparoscopic surgical detection sensor
- 2. Intelligent gastrointestinal detection algorithm

EXHIBIT CLASSIFICATION

CT-CCP50, 팜크린, Waguzabi, VK 스프레이 CT-CCP50, FarmClean, Waguzabi, VK Spray

COMPANY & PRODUCT INTRODUCTION

주식회사 카이미를 설립하게 된 동기는 복강경 수술 시 현재 사용하는 잉크 (ink) 문신법, 형광염색 표지법, 자가혈 표지법 등의 단점을 해소하고 미 충족 수요가 발생하여 이를 해결하기 위함입니다.

주식회사 카이미는 복강경 수술 시 종양 위치를 정확히 찾아내는 '종양 위치 탐지 센서'를 개발하고 있습니다. 위/대장에 종양이 있는지 인공지능으로 정 확하고 안전하게 진단 후 정확한 종양 위치를 찾기 위한 센서를 만들고 있습 니다. 프로토 타입 제작품이 개발되었으며, 제품화하기 위해 박차를 가하고 있습니다.

The motivation for the establishment of Caimi Co., Ltd. is to solve shortcomings such as ink tattooing, fluorescent dyeing labeling, and self-blood labeling that are currently used in laparoscopic surgery, and to solve the unmet demand.

Caimi Co., Ltd. is developing a Tumor Detection Sensor that accurately locates tumors amidst laparoscopic surgery. The company is making sensors to accurately and safely diagnose the existence of a tumor in the stomach/colon using Al, and to find its exact location. Prototype products have already been developed and much effort is currently being put into its commercialization."

COMPANY & PRODUCT INTRODUCTION

기술: 칼슘 생산과 관련된 설비와 공정에 관한 특허 2건 보유; 제품: CT-CCP50(산호칼슘), 팜크린(탈취제), 와구잡이(닭진드기 방재제), 브이케이(탈취,살균제), 산호칼슘파우더(1종 세척제) 등

Technique: two patents about facility and process for the production of calcium powder; Products: CT-CCP50(coral calcium powder), FarmClean (deodorant), Waguzabi (acaricide against red mite), VK Spray (deodorant/deinfectant), and Coral calcium powder (Cleaner class I), etc.

CANCERROP

COVID-19 SPECIAL PAVILION

Korea Doctor Preneur



Cancer Rop Co., Ltd.

㈜캔서롭

COUNTRY Republic of Korea

CEO Lee Wang Jun 이왕준

URL www.cancerrop.com

E-mail cancerrop@cancerrop.com

CartiPrime Co., Ltd.

주식회사 카티프라임

COUNTRY Republic of Korea

CEO Dong Hwi Park 박동휘

URL www.cartiprime.com

E-mail bdome@hanmail.net

EXHIBIT CLASSIFICATION

Q Sens 2019-n Cov Detection Kit

EXHIBIT CLASSIFICATION

- 1. Recombinant oligonucletoide medication
- 2. In vitro OA screening system
- 3. Exosome based MMP13 medication

COMPANY & PRODUCT INTRODUCTION

21세기 포스트 지놈 시대를 맞이하여 생명과학의 화두는 유전자 염기 서열 속에 포함된 정보를 어떻게 잘 활용하여 인류의 건강과 복지에 기여하느냐 입니다.

이에 (주)캔서롭은 생명의 잉태와 탄생에서부터 성장과 노화단계에 이르기까지 인간의 삶의 모든 과정에서 발생할 수 있는 유전 질환을 진단할 수 있는 최신 분자진단법을 개발하여 제품화하고 있습니다. 또한, 한국인 게놈 프로젝트를 통해서 확보한 한국인 고유의 유전자를 이용하여 국내에서 유일하게 마이크로어레이를 제작하고 있습니다. 캔서롭의 마이크로어레이 기술을 이용하여 특정 염색체의 수적 이상 및 구조적 이상을 빠르고 정확하게 확인할 수 있는 이점이 있습니다.

In the 21st century 'post-genome era', major concern of life sciences is how to correctly use information contained in gene sequences in order to contribute to human health and welfare. MGMED has developed and commercialized molecular diagnostic techniques to diagnose genetic diseases occurring at all stages of human life. MGMED has exclusively produced microarray based on the genes obtained from the Korean Genome Project. For instance, BAC chip microarray can quickly and accurately determine numerical and structural abnormalities of chromosomes.

COMPANY & PRODUCT INTRODUCTION

본 회사는 중추신경계, 근골격계의 치료제를 개발하는 바이오벤처 회사입니다.

CartiPrimeCo., Ltd. is a bio-venture company that develops treatments for the central nervous system and musculoskeletal system.

SEOUL Biohub

CAT Beam Tech

주식회사씨에이티빔텍



기톨릭관동대학교 CATHOLIC KWANDONG UNIVERSITY

Catholic Kwandong University University

- Industry Cooperation Foundation

가톨릭관동대학교 산학협력단

Healthcare Technology Licensing Office

COUNTRY Republic of Korea

CEO Chong-Gil Cho 조종길

URL

E-mail cgcho@catbeamtech.com

COUNTRY Republic of Korea

CEO Kim, Byung-Yun 김병윤

URL uicf.cku.ac.kr

E-mail dipc999@naver.com

EXHIBIT CLASSIFICATION

엑스레이 상용화기술을 활용한 차세대 방사선 기기 개발

developing X-ray source, the core component of next generation radiation equipment

COMPANY & PRODUCT INTRODUCTION

주식회사 씨에이티빔텍은 CNT(탄소나노튜브) 기술을 통해 차세대 방사선기 기의 핵심부품인 엑스레이소스를 개발하였습니다.

CAT Beam Tech Co., Ltd. has developed X-ray source, the core component of next generation radiation equipment based on CNT (carbon nanotube) technology.

EXHIBIT CLASSIFICATION

보건의료 우수 기술의 발굴 및 연구개발 성과의 기술사업화

Development of superior healthcare technology and commercialization of R&D outcome

COMPANY & PRODUCT INTRODUCTION

가톨릭관동대학교 산학협력단은 융복합 미래 선도 연구 분야 발굴 및 지원과 함께 차별화된 연구진흥 프로그램, 연구자 친화형 연구행정시스템 구축, 연 구개발 성과의 사업화 추진, 기업친화형 산학협력을 통하여 명실공히 글로벌 리더 대학으로 도약하기 위해 최선의 노력을 기울이고 있습니다.

University-Industry Cooperation Foundation, Catholic Kwandong University is endeavoring to take a leap forward to be a global leader in deed as well as in name through the differentiated R&D support program along with development effort in the future-leading convergence research area, establishment of research-friendly administration system, commercialization of R&D outcomes and business-friendly university-industry cooperation.

СЬН

SEOUL Biohub

K-Healthcare start-ups



CBH Inc.

(주)씨비에이치

COUNTRY Republic of Korea

CEO Yoon Jong Kyu 윤종규

URL www.c-bh.co.kr
E-mail cbh@c-bh.co.kr

Cellengene

㈜셀렌진

COUNTRY Republic of Korea

CEO Jae Hyung An 안재형

URL cellengene.com

E-mail hrpark@cellengene.com

EXHIBIT CLASSIFICATION

개인 맞춤형 척추 건강관리 IoT 서비스를 적용한 척추 이완 기기

Smart Chair, Carbon Table, and medical devices

EXHIBIT CLASSIFICATION

고형암을 치료할 수 있는 새로운 표지 물질을 발굴하여 이를 활용한 고형암 표적의 새로운 CAR-T를 개발

We committed to the development of gene & cell therapy, particularly a new type of anti-cancer immunotherapy using induced pluripotent stem cells (iPSC)-derived immunocytes, T- or NK.-cells.

COMPANY & PRODUCT INTRODUCTION

(주)CBH는 바이오헬스의료기기제조 전문업체로서, 주요사업으로는 의료 헬스케어, 탄소소재 및 융합기술의 SMART CHAIR, 카본테이블, 카본소재 의료 기기를 개발 및 생산하고 있습니다.

CBH was founded on February 19, 2016, and CBH's major products include Smart Chair, Carbon Table, and medical devices made of carbon fibers based on the fields of medical health care, carbon materials, and convergence technologies.

COMPANY & PRODUCT INTRODUCTION

㈜셀렌진은 열정, 혁신, 협력의 경영철학을 바탕으로 암과 같은 난치성 질환 치료를 위한 유전자 치료제를 개발하기 위해 2019년 6월 창업한 기업입니다.

Cellengene Inc. was founded in June 2019 to develop gene therapy products for the treatment of intractable diseases based on the management philosophy of passion, innovation and cooperation.

Initially, pioneering the development of CAR-T against solid cancer, CellenGene will expand pipelines that develop therapeutics against type-1 diabetes, neurodegenerative diseases to be a leading global biocompany.



Korea Innovative Pharmaceutical Company



Cellivery Therapeutics, INC.

㈜셀리버리

COUNTRY Republic of Korea

CEO Daewoong Jo 조대웅

URL www.cellivery.com

E-mail choiyj@cellivery.com

Celltrion

셀트리온

COUNTRY Republic of Korea

CEO Kee Woo Sung 기우성

URL www.celltrion.com

E-mail yonggun.sung@celltrion.com

EXHIBIT CLASSIFICATION

iCP-NI (싸이토카인폭풍 억제 중증패혈증 치료신약): 바이러스에 감염된 세 포는 염증성 전사인자들을 핵 내로 이동시켜 싸이토카인을 분비하고 염증을 일으킨다. 과도한 싸이토카인 분비를 싸이토카인폭풍이라 하며, 이는 패혈성 쇼크와 사망을 유발한다. iCP-NI는 이들 전사인자가 핵으로 이동할 때 사용하 는 Importin 단백질에 대신 결합하여 염증성 전사인자들의 핵 내 이동을 차단하고 싸이토카인의 발현을 억제한다.

iCP-NI(cytokine storm suppressive anti-sepsis agent): The Inflammatory transcription factors are translocated into the nucleus to produce cytokines in virus-infected cells. The excessive secretion of a cytokines, called cytokine storm, usually results in septic shock and death. iCP-NI inhibits translocation of these transcription factors by competitive binding with Importin and suppresses the expression of cytokine leading inflammation.

EXHIBIT CLASSIFICATION

* 램시마SC : 류마티스 관절염

* 램시마 : 류마티스 관절염, 강직성 척추염, 궤양성 대장염,

성인 크론병, 소아 크론병, 건선, 건선성 관절염

* 트룩시마 : 림프종, 류마티스관절염, 만성 림프구성 백혈병,

베게너육아종증 및 현미경적 다발혈관염

* 허쥬마 : HER2 과발현된 전이성 유방암과 조기 유방암,

전이성 위암

* 리네졸리드 : 항상제 내성균 감염 및 결핵

* Remsima SC : Rheumatoid Arthritis

* Remsima / Inflectra: Rheumatoid Arthritis, Ankylsoing Spondylitis,

Ulcerative Colitis, Crohn's Disease, Psoriasis

* Truxima : Non-Hodgkin's Lymphoma, Chronic Lymphocytic

Leukemia, Rheumatoid Arthritis, Granulomatosis with Polyangiitis, Microscopic Polyangiitis

* Herzuma : HER2-Positive Metastatic Breast Cancer, Early

Breast Cancer, Metastatic Gastric Cancer

* Linezolid : Pneumonia, Skin and Skin Structure Infections,

Vancomycin-resistant Enterococcus faecium

Infections

COMPANY & PRODUCT INTRODUCTION

약리물질 생체 내 전송기술 (TSDT)로 단백질 소재 신약 연구·개발 및 라이센싱

Cellivery Therapeutics is biotech company with a proprietary platform (TSDT) allowing the development of cell-permeable therapeutics

COMPANY & PRODUCT INTRODUCTION

셀트리온은 제약산업의 불모지에서 세계 최초로 '항체 바이오시밀러' 라는 신 산업을 개척한 대한민국 대표 글로벌 종합생명공학 기업입니다. 셀트리온 은 케미컬의약품과 신약 개발, U-헬스케어 플랫폼 사업 등 차별화된 사업 전략을 기반으로 글로벌 생명공학기업으로 지속 성장해나갈 것입니다.

A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world's first "antibody biosimilar" from a country with a relatively underdeveloped pharmaceutical sector.

Korea Doctor Preneur



New Excellent Technology Exhibition



Celvertics Co., Ltd.

㈜셀버틱스

CGBIO 시지바이오

COUNTRY Republic of Korea

CEO Hong Seok Suh 서홍석

URL www.cellvertics.com (추후 오픈 예정)

E-mail yyoon@cellvertics.com

COUNTRY Republic of Korea

CEO Yoo Hyun-seung 유현승

URL www.cgbio.co.kr

E-mail bhkim82@cgbio.co.kr

EXHIBIT CLASSIFICATION

신체 장기의 세포에너지대사 불균형을 개선함으로써 심부전, 심근증, 고혈압, 죽상동맥경화 등의 심혈관질환과 대사증후군, 면역계 질환, 퇴행성 질환 등에 대한 원인 치료 신약 개발중

Developing new drugs to treat cardiovascular diseases such as heart failure, cardiomyopathy, high blood pressure, and atherosclerosis by improving cell energy metabolic imbalance in body organs, as well as metabolic syndrome, immune system disease, and degenerative diseases

EXHIBIT CLASSIFICATION

환자맞춤형 척추 임플란트 제조를 위한 생체활성 유리세라믹의 정밀공정 기술

Precision machining of bioactive glass-ceramics for manufacturing patient-specific spinal implants

COMPANY & PRODUCT INTRODUCTION

㈜셀버틱스는 심혈관질환, 대사증후군, 종양, 면역계 질환, 퇴행성 질환 등에 대하여 신체 장기의 기능부전 개선 및 세포에너지대사 기반으로 원인 치료 신약을 개발하는 회사입니다.

Celvertics Co., Ltd. is a company that develops new medicines for treatment of causes based on cell energy metabolism and improvement of dysfunction of body organs for cardiovascular disease, metabolic syndrome, tumor, immune system disease, and degenerative disease.

COMPANY & PRODUCT INTRODUCTION

컴퓨터 설계/가공기술을 접목하여 고강도 생체활성 유리세라믹 BGS-7 환자 개개인의 인체 특성을 반영한 맞춤형 척추 임플란트와 골결손부 대체제를 제 작하는 정밀가공 기술

Precision machining technology of high-strength bioactive glass-ceramics that manufactures patient-specific spinal implants and substitutes for bone defects using by computer-aided design and machining technology

Healthcare Technology Licensing Office





DISCOVERY

CHA Bundang Medical Center

분당차병원

COUNTRY

Republic of Korea

CEO Kim, Jae Hwa 김재화

URL bundang.chamc.co.kr

E-mail dohhj@chamc.co.kr

CHAYON Laboratories, Inc.

자연과학

COUNTRY Republic of Korea

CEO 김선기, 이민아

URL www.chayon.kr

E-mail info@chayon.co.kr

EXHIBIT CLASSIFICATION

중점연구1 : 세포치료/재생의료기술(뇌신경계, 근골격계 분야 난치성 질환)

연구2: 항암, 난임/생식 등 여성의학, 항노화 등(차세대 호발질환 진단/치료기술)

Key research # 1: Cell therapy / regenerative medicine (intractable diseases in relation with brain-nervous system and musculoskeletal system)

Research #2: Anticancer treatment and Gynaecology such as fertility and reproductive medicine, anti-aging medicine (diagnostic and treatment technology for the next generation diseases)

EXHIBIT CLASSIFICATION

신약개발분석/제작서비스

Drug discovery Service

- Kinase service
- GPCR service
- ADME service
- Safety service
- Oncopanel service

COMPANY & PRODUCT INTRODUCTION

분당차병원은 오랜 난임/생식의학 연구로 다양한 세포치료 분야의 핵심 기술들을 축적하여 왔으며, 이러한 세계 수준의 연구 경쟁력과 인프라를 인정받아 보건복지부 지정 연구중심병원으로 선정되었고, 지난 2016년부터 연구중심병원 육성R&D사업을 통해 줄기세포 연구를 통한 난치성 질환 치료제 개발을 추진중에 있습니다.

CHA Bundang Medical Center has accumulated core technologies in cell therapy based on its relentless research on fertility and reproductive medicine. In recognition of its world-class research competitiveness and infrastructure, it was designated as a Research-Oriented Hospital by Ministry of Health and Welfare. Also, it has been undertaking a treatment development project for incurable diseases as a part of R&D Support Project for Research-Oriented Hospital from 2016.

COMPANY & PRODUCT INTRODUCTION

Eurofins Discovery는 40 년 넘게 Drug Discovery 연구를 지원해 왔습니다. 신약개발 스크리닝 및 효능분석 서비스를 제공합니다.

Eurofins Discovery has been supporting Drug Discovery research for over 40 years. We provide new drug development screening and efficacy analysis services. New Excellent Technology Exhibition

Healthcare Technology Licensing Office

◈ 전남대학교병원

CHEM.I.NET, Lrd

켐아이넷㈜

Chonnam National Unversity Hospital

전남대학교병원

COUNTRY Republic of Korea

CEO Hunjoo Lee 이헌주

URL www.chem-inet.kr

E-mail jhsuh@cheminet.kr

COUNTRY Republic of Korea

CEO Lee, Sam Yong 이삼용

URL www.cnuh.com

E-mail lavieenroad@naver.com

EXHIBIT CLASSIFICATION

화학물질의 통합위해성 평가를 위한 빅데이터 플랫폼

Big-data platform for chemical risk assessment in food

EXHIBIT CLASSIFICATION

암, 백신, 재생의학, 의료기기, 정밀의학

Cancer, Vaccine, Regenerative medicine, Medical equipment and precision medicine

COMPANY & PRODUCT INTRODUCTION

켐아이넷㈜는 화학물질의 위해성 평가 분야 ICT 시스템 개발 전문 기업임. 최근 빅데이터 및 AI를 활용한 식품, 소비자제품 및 환경 등 다양한 매체에 대한 CHEERS, MIMS/MAP 플랫폼을 출시함.

Since 1998, Chem.I.Net has been designing, developing and providing an innovative database and data-mining platforms for multi-media chemical and microbial exposure and risk assessment.

COMPANY & PRODUCT INTRODUCTION

- 목적: 전남대학교병원은 고등교육법에 의한 의학, 치의학, 간호학 및 약학 등에 관한 교육, 연구와 진료를 통하여 의학 발전을 도모하고 국민 보건 향 상에 이바지함을 목적으로 하고 있습니다.
- 미션 : 탁월한 진료, 교육, 연구와 헌신적인 봉사로 의학발전과 인류의 건강 증진에 기여한다.
- 비전 : 의료계의 표준이 되고 고객의 신뢰를 받는 스마트병원이된다.
- Purpose: Chonnam National University Hospital aims to promote medical advancement and contribute to the improvement of public health with medical training, research, and treatment on medicine, dentistry, nursing, and pharmacy under the Higher Education Act.
- Mission: Contributing to medical advancement and health promotion of the people with excellent medical care, Education, research and dedicated service.
- Vision: Medical standard and Smart Hospital built upon the trsut of the customers

Hospital-based Business Innovation Center



Chonnam National Unversity Hospital HBIC

전남대학교병원 개방형실험실

COUNTRY Republic of Korea

CEO Byeong-Chae Kim 김병채

URL www.cnuh.hbic.or.kr

E-mail cnuh_openlab@daum.net

COMPANY & PRODUCT INTRODUCTION

전남대학교병원 개방형실험실은 광주 AI 산업단지와 연계할 빅데이터센터, 정형외과용 생체이식 융합의료기기산업 지원센터, 고령친화산업지원센터 등 인프라를 기반으로 지능형 의료기기 및 코스메슈티컬 제품 개발을 위해 주력하고 있습니다.

Chonnam National University Hospital (CNUH)'s open laboratory is focusing on the development of intelligent medical devices and cosmeceutical products based on BigData Center connected with GwangJu Al Industrial Complex, Industry Support Center for Orthopedic Bioimplant Fusion Medical Device, Gwangju Senior Technology Center, and etc.

Healthcare Technology Licensing Office



Chungbuk National University Industry -University Cooperation Foundation Dean

충북대학교 산학협력단

COUNTRY Republic of Korea

CEO Choi, Sang Hoon 최상훈

URL sanhak2.coreicc.net

E-mail abc@cbnu.ac.kr

EXHIBIT CLASSIFICATION

의료 진단. 신약 후보 물질, 동물 장기 이식

Medical diagnosis, New drug candidates and Xenotransplantation


COMPANY & PRODUCT INTRODUCTION

충북대학교산학협력단은 산업교육을 진흥하고 산학협력을 촉진함으로써 대학의 경쟁력을 강화하고 지역사회와 국가 경쟁력 발전에 이바지하기 위하여설립하였습니다. 산학협력단은 산업발전에 필요한 학교의 새로운 기술·지식을 개발·보급·확산하여 학교와 산업사회가 서로 윈윈할 수 있는 중간역할을 담당함으로써 대학 경쟁력과 취업률 향상 그리고 지방산업체의 경쟁력 발전에 기여할 것입니다.

Chungbuk National University Industry-University Cooperation Foundation was established to promote industrial education and promote industry-academia cooperation to strengthen the competitiveness of the university and therefore, to contribute to the development of local and national competitiveness. The foundation is playing an intermediary role between the school and industrial society by supporting development, dissemination and proliferation of the technology and knowledge of the school for the mutual growth, thereby contributing to the improvement of college competitiveness, employment rate, and the competitiveness of regional industry.

CSTEM

Korea Doctor Preneur









CISTEM Co., Ltd.

㈜씨아이에스티이엠

COUNTRY Republic of Korea

Ji Hyeon Ju 주지현

URL cistem.com

E-mail juji@catholic.ac.kr

CKD Pharmaceutical Corp.

㈜종근당

COUNTRY Republic of Korea

YOUNG JOO KIM 김영주

URL www.ckdpharm.com

E-mail ellej800@ckdpharm.com

EXHIBIT CLASSIFICATION

- 1. Customized iPS cell line 제작 및 품질검증
- 2. 면역질환 모델링 및 유효성 평가 플랫폼
- 3. 유도만능줄기세포 유래 세포 치료제 "MIUChon, MIURon, MIUKin"
- 1. Customized iPS cell line Production and Quality Verification
- 2. Immunity disease modeling and validation platform
- 3. Induced pluripotent stem cell-derived cell therapeutic "MIUChon, MIURon, MIUKin"

EXHIBIT CLASSIFICATION

* 캄토벨 : belotecan * 듀비에 : Lobeglitazone * 딜라트렌 : Carvedilol * 타크로벨 : Tarcrolilmus * 리피로우 : Atrovastatin * 글리아티린 : Choline Alfoscerate

* Camtobell Inj : Belotecan * Duvie Tab : Lobeglitazone * Dilatrend Tab : Carvedilol * Tarcrobell Cap : Tarcrolilmus * Lipilou Tab : Atrovastain * CKD Gliatilin Soft Cap: Choline Alfoscerate

COMPANY & PRODUCT INTRODUCTION

CiSTEM은 임상면역학(Clinical immunology) 과 줄기세포 (stem cell) 연구를 진행하고 있으며,이를 기반으로 한 유도만능줄기세포 연구와 치료제 개발을 목적을 두는 회사입니다.

유도만능줄기세포는 자기복제능력과 전분화능을 가지고 있어 전세계적으로 이를 이용한 광범위한 연구가 진행되고 있습니다.

CiSTEM은 의뢰자 맞춤형 유도만능 줄기세포주 수립 서비스를 제공하고 있 으며, 고도화된 특성분석을 통한 품질검증을 제공하고 있습니다. 또한, 유도 만능줄기세포주 기반의 세포치료제를 개발중입니다.

CiSTEM is a company that aims to research induced pluripotent stem cells and develop treatments based on Clinical Immunology and Stem Cell research

The induced pluripotent stem cells have autocomplication and electrolysis, so extensive research has been conducted around the world.

CiSTEM provides client-specific induced pluripotent stem cell lines service, and provide quality verification through advanced factor analysis. Also, the company is developing a cell therapeutic based on induced stem cell lines.

COMPANY & PRODUCT INTRODUCTION

종근당은 1941년에 설립한 이래, 생명의 존엄성을 바탕으로 우수한 의약품 개발과 질병 없는 건강 사회 구현을 이념으로 오직 제약 한 길만을 걸어 왔습 니다. 종근당은 1968년에 Chloramphenicol, (Chloramphenicol palmitate and sterile Chloramphenicol sodium succinate)원료로 국내 제약업계 최초 로 원료에 대한 미국 FDA 승인을 획득하였습니다.

Chong Kun Dang Pharmaceutical Corp. (CKD) was established in 1941 with a goal of supplying the best quality medicines and is dedicating its efforts to develop novel therapeutics for improving human health and quality of life. In 1968, CKD received US FDA approval for Chloramphenicol, Chloramphenicol palmitate and sterile Chloramphenicol sodium succinate.

COVID-19 SPECIAL PAVILION



K-Healthcare start-ups



ClariPI Inc.

㈜클라리파이

COUNTRY Republic of Korea

CEO Kim Jonghyo, Park Hyunsook

김종효, 박현숙

URL www.claripi.com

E-mail claripi@claripi.com

Clips

클립스

COUNTRY Republic of Korea

CEO Ji, Joon Hwan 지준환

URL www.clipscro.com

E-mail jhkim@clipscro.com

EXHIBIT CLASSIFICATION

ClariCT.AI, ClariPulmo

COMPANY & PRODUCT INTRODUCTION

클라리파이는 빅데이터와 AI 기술의 융합을 통해 의료영상 분야 최고의 솔루션을 공급하기 위해 설립되었습니다.

21세기 맞춤형 헬스케어 시대를 열어가는 전문가들과 협력 연구개발을 통해 임상 현장의 Unmet Needs를 채울 수 있는 AI 기반의 솔루션을 개발·공급합니다.

고객과 함께 혁신하고 함께 성장하는 최고의 솔루션 파트너가 되는 것이 저희 회사의 목표입니다

ClariPI provides innovative solutions to complex problems in the field of medical imaging by integrating big data with artificial intelligence image processing technologies.

Our solutions provide imaging experts with clearer information and easy-to-use decision guidance for making confident diagnosis.

EXHIBIT CLASSIFICATION

안질환 줄기세포 치료제

eye disease stem cell therapy

COMPANY & PRODUCT INTRODUCTION

윤부줄기세포결핍증에서 "윤부유래상피세포판 이식 치료"는 생검한 윤부조 직을 체외이식으로 배양하여 줄기세포를 증폭시킨 세포판을 만든 후 환자 안 표면에 이식하여 줄기세포를 공급하는 원리의 치료임

"Limbus-derived epithelial cell transplantation treatment" for limbal stem cell deficiency has a principle that the biopsy limbal tissue is cultured by in vitro transplantation to make a cell plate that amplifies limbal stem cells, and then the stem cells are supplied by implanting them on the eyeball surface of the patient.

Australian Trade and Investment Commission



SEOUL Biohub



CMAX

CMLAB

㈜씨엠랩

COUNTRY Australia

CEO Jane Kelly

URL www.cmax.com.au

E-mail Jane.kelly@cmax.com.au

Zoe.harrison@cmax.com.au

COUNTRY Republic of Korea

CEO Tony Ha 하태호

URL www.savelife-cmlab.com

E-mail

COMPANY & PRODUCT INTRODUCTION

CMAX has been a leader in delivering early phase clinical trials for over 26 years, making it one of the most respected clinical trial businesses in Australia.

Our modern facility is equipped with 50 inpatient and 14 outpatient beds and has ready access to state-of-the-art facilities, equipment and world-class medical and pharmacology specialists.

Australian clinical trials are known for their quick start-up timelines, cost competitiveness and high quality. CMAX's services are eligible for the generous Australian R&D Tax Incentive scheme.

EXHIBIT CLASSIFICATION

안진단 플랫폼

Eye diagnosis platform

COMPANY & PRODUCT INTRODUCTION

CMLAB은 AI, VR, IoT 기술을 융/복합하여 지금까지 없었던 새로운 개념의 의료기술/서비스를 개발하는 회사이며 "사람 살리는 의료기술" 개발로 일류 기업을 목표로 합니다.

CMLAB aims to offer an unprecedentedly new kind of medical technology and service by integrating/combining loT, VR, and AI technologies ${\sf CMLAB}$

COAGULANT THERAPEUTICS

SEOUL Biohub

K-Healthcare start-ups



Coagulant Therapeutics Coporation

㈜코애귤런트테라퓨틱스

COUNTRY Republic of Korea

CEO Kirk Dornbush

URL www.coagulanttherapeutics.com

E-mail daseri@pensees.co.kr

Coreline

(주)코어라인소프트

COUNTRY Republic of Korea

CEO Jin Kook Kim 김진국

URL www.corelinesoft.com

E-mail heekyung.park@corelinesoft.com

EXHIBIT CLASSIFICATION

안전성과 우수한 지혈 효능을 겸비한 제7혈액응고인자 기반 급성출혈 신약 개발

Through a genetic manipulation and post-translational modifications, we have created an efficacious and safe factor 7 based molecule for treating acute bleeding

EXHIBIT CLASSIFICATION

인공지능기반 저선량 CT용 폐질환 진단 의료기기 SW

AVIEW Metric™-Lung

COMPANY & PRODUCT INTRODUCTION

당사 연구팀 및 경영진은 신약 후보물질 개발 및 연구개발, CMC, 임상 및 사업개발 분야에 총 100여년 이상의 산업 경력과 검증된 실적을 보유한 전문 가로 구성되어 있는 신약개발사임.

Our team is composed of experts with nearly 100 years of industrial experience and an excellent track record in lead discovery and optimization, pre-clinical studies, CMC, clinical studies and business development.

COMPANY & PRODUCT INTRODUCTION

폐질환 조기진단으로 폐결절 자동 검출하여 표준화된 방식으로 평가, COPD의 원인인 폐기종과 기관지염을 결정하기 위해 표준선량 CT분석및 측정 진단 보조 가능

AVIEW Metric™-Lung is software, for quantitative image biomarker of COPD using chest CT images.

It provides various quantitative analysis reports, such as LAA/ LAA size analysis, air-trapping analysis, airway measurement and lung vessel analysis, through easy-to-use automatic pre-processing steps. Easy workflow minimizes user interaction during lung/lobe segmentation, airway segmentation and, elastic inspiration/expiration registration.



Hospital-based Business Innovation Center



Corestem, Inc

코아스템㈜

COUNTRY Republic of Korea

CEO Kyung Suk Kim 김경숙

URL CORESTEM.com

E-mail hwkim@corestem.com

COSCALdebio

㈜코스칼드바이오

COUNTRY Republic of Korea

CEO Shin Jihun 신지훈

URL www.coscaldebio.com

E-mail coscalkorea@naver.com

EXHIBIT CLASSIFICATION

* 뉴로나타-알주: 3근위축성측상경화증

* NeuroNATA-R: myotrophic lateral sclerosis (ALS)

EXHIBIT CLASSIFICATION

용해성 마이크로 니들, 히알루론산 저분자를 이용한 창상피복제

soluble micro needle, sphenoloid cloning agent with hyaluronic acid low molecule $% \left(1\right) =\left(1\right) \left(1\right)$

COMPANY & PRODUCT INTRODUCTION

코아스템은 난치성 질환 치료를 위한 줄기 세포 치료제를 개발 및 생산하는 바이오의약품 전문기업입니다. 다양한 질환의 파이프라인을 보유하고 있으 며, 루게릭병 줄기세포치료제 개발 성공 사례를 기반으로 희귀 난치성 질환 에 대한 치료제 개발에 집중해 시장을 선점할 계획입니다.

CORESTEM is a bio-pharmaceutical company specializing in research and development of personalized stem cell therapies for incurable disease. Corestem's research and development is focused on advancing preferred stem cell treatments for intractable diseases, driving scientific advancement, and expanding patient care offerings.

COMPANY & PRODUCT INTRODUCTION

- * 환자 맞춤형 임플란트
- * 임플란트 시술이 필요로 하는 환자의 해부학적 정보와 수요자(임상의, 환자)와 제조처간의 소통을 바탕으로 적응증 맞춤형의 임플란트 설계, 이를 3D 프린팅 기법을 이용하여 제조 및 공급함으로써 병원 연계 맞춤형 임플란트 제조 플랫폼을 구축하고자 함
- * 개발하고자 하는 임플란트는 1. 두개골 골대체제, 2. 척추 추간체 유합 보형 재, 3. 인공 고관절 비구컵으로 환자의 상태와 수술 부위의 손상 정도에 따라 기존 시판 제품의 사용에 어려움이 있는 적응증을 대상으로 함
- * 히알루론산 저분자를 이용한 창상피복제
- * 일반 거즈가 상처에 생긴 진물로 인하여 굳게 되면 통증 유발, 흉터 및 상처 회복 기간 지연 될 수 있으므로 히알루론잔 저분자물질이 거즈에 도포되어 막을 형성하여 진물이 굳는 것을 방지 하여 회복 속도를 가속
- * patient-adapted implant An implant manufacturing platform cooperating with a hospital is constructed by manufacturing and supplying an implant design suited to adaptations on the basis of anatomical information of a patient requiring an implant operation and communication between a consumer (clinical, patient) and a manufacturer using a 3D printing technique. The implants to be developed are targeted for adaptations that have difficulty using existing commercial products depending on the patient's condition and the degree of damage to the operating site in the cranial pair structure, spinal fusion and shape-retaining material, and hip joint ratio cup.
- * Flaw covering agent using hyaluronic acid low molecule Because the induction of pain, scar and recovery period of the wound may be prolonged when the normal gauze is solidified by the mucus formed in the wound, the hyaluronzan low-molecular substance is applied to the gauze to prevent the mucus from solidifying by forming a film, and the recovery rate is accelerated.

Australian Trade and Investment Commission



New Excellent Technology Exhibition



Cosec Corporate Services

코스맥스㈜

COSMAX,INC

COUNTRY Australia

CEO Mr Blair Lucas

URL www.cosec.com.au

E-mail blair.lucas@cosec.com.au

COUNTRY Republic of Korea

CEO Byung-man Lee, Gyeong Choi

이병만, 최경

URL www.cosmax.com

E-mail jhjang@cosmax.com

COMPANY & PRODUCT INTRODUCTION

CoSec specialises in international expansion. Offering fast, comprehensive support to help foreign companies to do business in Australia, CoSec brings together a full suite of incorporation, finance and compliance services to fast track international expansion.

We make it simple for life sciences companies to enter the Australian market to conduct clinical trials, R&D, sales and distribution. We provide the corporate structure and compliance services required to run clinical trials or do product development in Australia and qualify for Australia's R&D Tax Incentive.

Our competencies include Company Incorporation, Resident Director Services, Financial & Tax Compliance Services, R&D Advisory Services, and Registered & Virtual Office Services. Our suite of integrated compliance, management and advisory services allows you to fulfill all your regulatory and reporting obligations in Australia. Moreover, our flat-rate pricing structure provides budget-predictability.

EXHIBIT CLASSIFICATION

세라프레소, 세라마이드 기반 생친화성 피부전달체 기술

CeraPresso, Ceramide-based skin competible formulation

COMPANY & PRODUCT INTRODUCTION

코스맥스(주)는 세계 1위 화장품 ODM 회사이며 연간 약 16억 3천만 개 이상 의 높은 생산성을 보유하고 있으며 세계 최고 수준의 기술력으로 세계 화장 품 시장을 선도하고 있다.

COSMAX is the world's No. 1 cosmetic ODM company and has a high productivity of more than 1.63 billion products annually and leads the world cosmetics market with world-class technology.

COVID-19 SPECIAL PAVILION

Korea Innovative Pharmaceutical Company



COVID-19 SPECIAL PAVILION

COVID 19 특별관

COUNTRY Republic of Korea

CEO

URL

E-mail yoon123@khidi.or.kr

CrystalGenomics, Inc.

크리스탈지노믹스㈜

COUNTRY Republic of Korea

CEO Joong Myung Cho 조중명
URL www.crystalgenomics.com

E-mail skim@cgxinc.com

COMPANY & PRODUCT INTRODUCTION

「COVID-19 특별관」은 해외에서 호평받고 있는 우리나라 COVID-19 대응력과 전 세계적으로 수요가 증가하고있는 국산 COVID-19 진단기기와 필수 의료장 비에 대해 만나보실 수 있습니다.

The COVID-19 Special Pavilion offers access to Korea's COVID-19 response capacity, which is well-received overseas, as well as domestic COVID-19 diagnostic devices and essential medical equipment that are in increasing demand worldwide.

EXHIBIT CLASSIFICATION

* 아셀렉스 2밀리그램 캡슐: 고관절염

* 아셀렉스 2밀리그램 정: 고관절염

* Acelex 2mg Capsule : osteoarthritis * Acelex 2mg Tablet : osteoarthritis

COMPANY & PRODUCT INTRODUCTION

크리스탈지노믹스㈜는 2000년 설립하여 구조기반 신약 발굴 기반기술을 바탕으로 염증, 감염 및 종양 등 미충족 의료수요가 높은 질환에 대한 글로벌 혁신 신약을 연구개발하고 있습니다.

CrystalGenomics is a commercial stage biopharmaceutical company dedicated to the R&D and commercialization of novel pharmaceuticals to address significant unmet medical needs in the therapeutic area of infectious disease, oncology and inflammatory diseases.

Australian Trade and Investment Commission



K-Healthcare start-ups



CSIRO

Curigin

(주)큐리진

COUNTRY Australia

CEO

URL www.csiro.au/en/Research/BF

E-mail Jon.spaits@csiro.au

COUNTRY Republic of Korea

CEO Lee wan 이완

URL www.curigin.co.kr

E-mail hsy1990@curigin.co.kr

COMPANY & PRODUCT INTRODUCTION

At CSIRO, we solve the greatest challenges using innovative science and technology. This year, we worked with 1750 private industry customers, including 400 major Australian companies, more than 1060 Australian small to medium enterprises (SMEs), and 280 overseas corporations. Working with our partners, we're assembling strong multidisciplinary research teams to tackle major national and international health and biosecurity challenges. In doing so we're protecting the health of our farming sector, environment, people, and our way of life.

EXHIBIT CLASSIFICATION

항암 바이러스 기반의 치료제

anti-cancer virus-based treatment

COMPANY & PRODUCT INTRODUCTION

큐리진의 치료제는 항암 바이러스 기반의 치료제로, 암세포 내에서 지속적으로 바이러스가 복제되며 이를 통해 암세포가 용해되는 효과가 나타납니다.

Curigin's treatment is an anti-cancer virus-based treatment. Viruses are constantly replicated within the cancer cells, which lyse the cancer cells

Daejeon Technopark



K-Healthcare start-ups



Curocell.Inc.

주식회사 큐로셀

COUNTRY Republic of Korea

Gunsoo Kim 김건수

URL www.curocellbtx.com

E-mail jjbaek@curocellbtx.com

Custom my skin

커스텀마이스킨

COUNTRY Republic of Korea

Kim Jayeon 김자연

URL

E-mail nature8006@naver.com

EXHIBIT CLASSIFICATION

회사소개자료

company introduction

EXHIBIT CLASSIFICATION

관리를 위한 진단, 케어 를 할 수 있는 뷰티 디바이스

It is a multi-smart beauty device that can diagnose and care sensitive skin

COMPANY & PRODUCT INTRODUCTION

큐로셀은 암에 대한 혁신적인 CAR-T 치료법을 발견하고 개발하는 생명공학 회사입니다.

전세계 수백만 명의 암환자들의 생명을 구할 수 있는 잠재력을 가진 치료법 을 연구하고 있습니다.

Curocell is a biotechnology company discovers and develops the innovative CAR-T therapies for cancer. We are researching on therapeutic solutions that have the potential to save the lives of the millions of cancer patients worldwide.

COMPANY & PRODUCT INTRODUCTION

복합 유수분 측정기기로 고객의 피부 상태를 진단하여, 맞춤 카운셀링을 진 행하고, 이에 따라 개인 피부에 맞는 1:1 맞춤 유기농 화장품을 제공하는 서비 스를 개발 중에 있습니다.

Custom my skin is a complex oil and moisture measuring device that diagnoses the skin condition of the customer, performs customized counseling for each skin, and is developing a service that provides 1:1 customized organic cosmetics for individual skin.

Daejeon Technopark



Healthcare Technology Licensing Office



Customedi

커스터메디

COUNTRY Republic of Korea

CEO Cheongwoon Cho 조청운

URL www.customedi.com

E-mail bluevet627@gmail.com

COUNTRY Republic of Korea

Daegu-Gyeongbuk Medical

Innovation Foundation

대구경북첨단의료산업진흥재단

CEO Lee, Young Ho 이영호

URL www.dgmif.re.kr

E-mail codori79@dgmif.re.kr

EXHIBIT CLASSIFICATION

환자 맞춤형 수술 가이드

patient-specific surgical guide

EXHIBIT CLASSIFICATION

합성신약, ICT 기반 첨단의료기기, 동물실험지원, 의약품 생산 및 분석지원 등

New synthetic drug, ICT-based advanced medical device, Support for animal testing, Medicine production and Analysis support, etc.

COMPANY & PRODUCT INTRODUCTION

저희는 반려동물을 위한 환자 맞춤형 가이드 서비스를 제공하는 기업입니다

We provide patient-specific surgical guide service for veterinary medicine

COMPANY & PRODUCT INTRODUCTION

우리 재단은 합성신약, ICT 기반 첨단의료기기 개발을 위한 공동연구부터 최종 단계인 식약처 허가를 받기까지 전 과정에 있어서 맞춤형 지원을 하고 있는 기관으로서, 세계 첨단의료 산업을 선도하는 글로벌R&BD 허브를 향해 나가고 있습니다.

Daegu-Gyeongbuk Medical Innovation Foundation makes its way to be a Global R&BD Hub to lead the global advanced medical industry, providing customized support tailored to each stage of the entire process from joint research on development of new of synthetic drugs and ICT-based, cutting-edge medical device to the final stage of approval of FDA.



Daejeon Technopark



DAEHWA Pharm

대화제약㈜

COUNTRY Republic of Korea

CEO Byung-Tae, No, Eun-Seok, Kim

노병태, 김은석

URL www.dhpharm.co.kr

E-mail crispaul@dhpharm.co.kr

Daejeon Technopark

대전테크노파크

COUNTRY Republic of Korea

CEO suman Choi 최수만

URL www.djtp.or.kr

E-mail mhy3228@djtp.or.kr

EXHIBIT CLASSIFICATION

* 세파메칠정 : Methylol cephalexin lysinate

* 후로스판정 : Phloroglucinol * 아세렌캡슐 : Diacerein * 대화와르파린정 : Warfarin sodium * 토프롤연질캡슐 : Ginseng, Vitamin

* Cephamethyl Tab. : Methylol cephalexin lysinate

* Flospan Tab.
* aceren Cap.
* Warfarin tab
* Warfarin sodium
* Toproll Soft Cap.
* Ginseng, Vitamin

COMPANY & PRODUCT INTRODUCTION

"글로벌 산업 육성의 거점기관" 기업중심의 프로그램 개발과 기술자문, R&D 지원, 특허와 디자인 개발지원, 투자유치와 마케팅까지 종합적인 맞춤형 지원으로 대전기업성장의 밑거름이 되겠습니다.

"The Hub of Global Industry Promotion" We will contribute to the business growth of Daejeon through a comprehensive customized support in the fields of the enterprise-oriented prograqm development, technology consulting, R&D support, patent and design development support, investment promotion and marketing support.

COMPANY & PRODUCT INTRODUCTION

대화제약은 1984년도 "약업을 통하여 사회에 봉사하고, 인류를 위한 더 나은 세계를 만들어 간다"는 창업정신으로 설립되어, 인간을 존중하는 마음으로 국민의 건강증진을 위해 최선을 다하고 있습니다. 대화제약은 특화된 핵심 기술을 기반으로 다양한 제품군을 보유하고 있으며, 세계적인 제약회사로서 성장하고 있습니다.

Daehwa, with spirit of "serving society to create a better place for human being through pharmaceutical business", has a goal to improve quality of life with respect for human life.

paewon

Daewon Pharm.Co., Ltd.

대원제약주식회사

COUNTRY Republic of Korea

CEO Seung Ryel Baek 백승열

URL www.daewonpharm.com

E-mail nuboti@daewonpharm.com

EXHIBIT CLASSIFICATION

펠루비서방정, 펠루비정, 네렉손서방정, 크로우정, 리피원정, 엑스콤비정, 티지페논정, 트윈콤비정, 트리인원정, 업타바캡슐, 에스원엠프정, 오티렌F정, 코대원포르테시럽, 베포스타서방정, 베포스타정, 엘스테인정, 원트란세미서 방정, 리카뉴로서방정, 프리폴MCT주1,2%, 레나메진캡슐 * Pelubi CR Tab.
* Pelubi Tab.
* Pelubi Tab.
* Pelubiprofen
* Nerexone SR Tab.
* Eperisone
* Clow Tab.
* Rosuvastatin
* Lipiwon Tab.
* Atorvastatin
* Exombi Tab.
* Varsartan/amlodipine
* TG Fenone Tab.
* Choline Fenofibrate

* Tri-in-one Tab. : Telmisartan/amlodipine/Rosuvastatin

* Uptava Cap. : Pitavastatin/Fenofibrate

* Eswonamp Tab. : Esomeprazole

* Twincombi Tab.

* Otillen F Tab. : Artemisia herb isopropanol soft extract(20→1)

: Telmisartan/amlodipine

* Codaewon Forte Syr. : Dihydrocodeine/ammonium chloride/

chlorpheniramine/dl-methylephedrine

* Beposta SR Tab. : Bepotastine * Beposta SR Tab. : Bepotastine * Elsteine Tab. : Erdosteine

* Wontran ER Tab. : Acetaminophen/Tramadol

* Lyicaneuro ER Tab. : Pregabalin * Freefol MCT Inj.1,2% : Propofol

* Renamezin Cap. : Spherical adsorptive carbon

COMPANY & PRODUCT INTRODUCTION

대원제약은 1958년 "인류건강의 실현"이라는 창업이념을 바탕으로 설립되었으며, 많은 시대적 환경변화 속에서도 순수 치료제 전문기업으로서 인류의 건강을 지키기 위해 끊임없이 노력해왔습니다. Daewon Pharmaceutical's believe that customers is the most important core value of corporate management. Since Established in 1958 based on the founding philosophy of "partner for people to promise their healthy lives", we have effort to protect the healthy life of people as a company specialized in pure competent pharmaceutical company.



COVID-19 SPECIAL PAVILION



Daewoong Pharmaceutical Company Ltd

㈜대웅제약

Daiwha Corp.,Ltd

대화기기㈜

COUNTRY Republic of Korea

CEO Jeon Seng Ho 전승호

URL www.daewoong.co.kr

E-mail Doyoung.kim@daewoong.co.kr

COUNTRY Republic of Korea

CEO DAEYOUNG YOON 윤대영

URL www.diawha.com

E-mail pm@daiwha.com

EXHIBIT CLASSIFICATION

* 우루사 : 담즙분비 부전의 간질환, 담도계 질환, 바이러스성 C형 간염

* 베아제 :소화제

* 이지에프 :당뇨병성 족부궤양 * 노보시스 :Dental sinus lift graft

* 케어트로핀 :성장호르몬 분비 결핍 및 터너증후군 * 에포시스 :만성신부전증 빈혈(ESRD)

* 나보타 : 미간주름

* 루피어 데포주 : 전립선암, 자궁내막증, 폐경전 유방암, 중추성 사춘기조발증

* 올로스타 : 고혈압 및 고지혈증

* Ursa : Cholestasis (including PBC, PSC), viral hepatitis C,

gallstone

* Bearse : Multilayer digestives * Easyef : Diabetic foot ulcer * Novosis : Dental sinus lift graft

* Caretropin : Growth hormone deficiency and Turner syndrome

* Eposis : Anemia in end stage renal disease (ESRD)

* Nabota : Glabella lines

* Luphere Depot : Prostate cancer, endometriosis, uterine fibroid,

postmenopausal breast cancer, central precocious

puberty

* olostar : Concomitant hypertension and dyslipidemia

EXHIBIT CLASSIFICATION

의약품주입펌프

Infusion Pump

COMPANY & PRODUCT INTRODUCTION

대화기기는 1979년 창립 이래 세계 각국 우수 의료장비 국내도입을 시작으로 1980년대부터 전기수술기 90년대 의약품주입펌프 2010년대 수술용 에너지 디바이스를 국내 최초 개발하여 현재 국내 뿐 아니라 세계 50여개국에 수출하고 있는 국산 의료기기 전문 기업입니다.

Starting by importing medical devices in 1979, DAIWHA then firstly developed infusion pumps, electrosurgical units and surgical energy devices in Korea and has been exporting over 50 countries worldwide. It is a complete domestic medical device manufacturer. Nowadays, DAIWHA is once again in the spotlight of domestic and international market due to the release of new products.

COMPANY & PRODUCT INTRODUCTION

대웅제약은 1945년 창립 이후 '국민의 건강을 지키고 건강한 사회에 기여하기 위한 양질의 의약품 개발'이라는 기업철학에 따라 끊임없는 도전과 혁신을 통해 한국의 선도적인 제약회사로 성장해 왔습니다.

Since 1945, we have grown into Korea's leading company in line with corporate philosophy of 'developing quality medicine to safeguard the people's health and contribute to a healthier society'.

Healthcare Technology Licensing Office





Dankook University Cheonan Campus Industry Academic Cooperation Foundation

단국대학교 천안캠퍼스 산학협력단

Datasee Co., Ltd.

데이터씨

COUNTRY Republic of Korea Kim

EO Kim, Cheol hyeon 김철현

URL iacf.dankook.ac.kr
E-mail ldy@dankook.ac.kr

COUNTRY Republic of Korea

CEO Kwon Jung-Bin, Choi Young-Jin

권정빈 최영진

URL cacheby.com

E-mail choi@cacheby.com

EXHIBIT CLASSIFICATION

광의료기기, 조직재생, 줄기세포 치료제, 천연물 신약, 신경전달물질 분석 등

Optical medical equipment, Tissue regeneration, Stem cell treatment, New natural products, Neurotransmitter analysis

EXHIBIT CLASSIFICATION

캐시바이

CacheBy

COMPANY & PRODUCT INTRODUCTION

단국대학교 병원의 미션은 "인간중심의 진료, 연구, 교육을 통하여 건강한 삶에 공헌하다."입니다. 이를 실현하기 위해 첫째, 최상의 의료를 제공하는 병원, 둘째, 선도적 교육, 연구를 실천하는 병원, 지역 및 교직원과 함께 발전하는 병원 등의 비전을 가지고 조금씩 정진하고 있습니다.

단국대학교 병원은 한단계 앞선 연구와 노력으로 체계적이고 전문화된 의료 서비스를 펼치고 있습니다. 지속적인 투자와 차별화된 시스템을 통해 최고 수준의 전문센터를 완성하고 있습니다. 끊임없이 연구하고 축적된 노하우로 아낌없이 봉사하는 대한민국 최고 수준의 병원. 지역주민의 건강과 사회의 안녕을 위해 봉사하는 단국대학교 병원은 바로 지금도 움직이오 있습니다.

Dankook University Hospital has a mission "to promote healthy life through human-centered medical treatment, research, and education." It devotes itself to realize the visions of 1. Hospital with outstanding medical care; 2. Hospital leading education and research; and 3. Hospital advancing together with local and faculty members. Offering systematic and specialized medical services thanks to advanced research and efforts, the Hospital has been operating the outstanding center with continuous investment and management of its differentiated system.

The Best Hospital in Korea with relentless research effort and accumulated know-how, Dankook University Hospital is moving forward persistently, serving to improve health of local residents and well-being of the society."

COMPANY & PRODUCT INTRODUCTION

캐시바이는 바이오 연구소 및 생산에 필요한 실험자재를 쉽게 검색하고 구매할 수 있는 B2B 바이오 유통 플랫폼 서비스입니다

CacheBy is a B2B platform service that makes it easy to search and trade products for bio labs and production.

Disappear to a to The Andrew All Sections for the Medicing

Korea Doctor Preneur

Hospital-based Business Innovation Center



DEEVO

디보㈜

COUNTRY Republic of Korea

CEO Yang Jae Kang 강양제

URL ai.deevo.co.kr

E-mail furim@hanmail.net

DNBIO Pharm, Inc.

독립바이오제약

COUNTRY Republic of Korea

CEO TAE GEE, JUNG 정태기

URL www.dnbio.kr

E-mail jungminlee@dnbio.kr

EXHIBIT CLASSIFICATION

1. 빅데이터 기반 의생명 산업 의사결정 지원시스템

- 2. 의생명정보 통합, 수집 및 DB시스템
- 3. IoT 기반 정보 수집 장치 개발시스템
- 1. Big data-based decision-making support system for biomedical industry
- 2. Integration, collection and database system of bioinformation
- 3. IoT-based development system device for data collection

EXHIBIT CLASSIFICATION

티온밴드

T.ONBAND

COMPANY & PRODUCT INTRODUCTION

디보는 의생명 빅데이터 수집 관리 활용 전문 기업으로서 병원에서 생성되는 다양한 데이터 (이미지, 유전체 등), 이미 알고 있는 의생명 지식을 통합하여 의생명 의사결정을 도울 수 있는 데이터베이스 및 예측 모델을 작성합니다.

Deevo specializes in bioinformation collection for big data and management. By integrating the various data generated by the hospital(image and Genome), and the knowledge of bio that we already know, the company creates databases and predictive models that can help decision-making about biology.

COMPANY & PRODUCT INTRODUCTION

독립바이오제약은 신약개발, 체외진단, 의료IT를 전문으로 의사 주주들이 중심이 되어 탄생시킨 제약회사입니다.

'티온밴드'는 블루투스를 이용한 IoT 기반 스마트 체온계입니다.

DNBIO is a pharmaceutical company created by medical doctors' shareholders, and our business is new drug development, in vitro diagnostics, and medical IT solutions.

The T.ONBAND is a Smart IoT thermometer that measures the realtime temperature of the sensor attached to the band and sends it to the device connected to Bluetooth and manages it with your smartphone mobile app. 등아대학교 DONG-AUNIVERSITY

Healthcare Technology Licensing Office

Healthcare Technology Licensing Office

동국대학교 의료원



DONG-A UNIVERSITY

동아대학교 산학협력단

COUNTRY Republic of Kore

CEO Lee, Jaeyeol 이재열

URL www.donga.ac.kr

E-mail kky1216@dau.ac.kr

COUNTRY Republic of Korea

CEO Cho, Sung Min 조성민

Donnguk University Medical Center

URL www.dumc.or.kr

E-mail jhlee_dumc@naver.com

EXHIBIT CLASSIFICATION

심혈관질환,뇌혈관,갑상선, 당뇨병 등에 특화

Research specialized in cardiovascular disease, cerebrovascular disease, thyroid and diabetes

COMPANY & PRODUCT INTRODUCTION

동아대학교는 2013년 기준 10개 대학원(일반대학원, 국제전문대학원, 의학전문대학원, 법학전문대학원, 경영대학원, 교육대학원, 산업정보대학원, 사회복지대학원, 법무대학원, 문화예술대학원), 12개 단과대학(인문과학대학, 자연과학대학, 생활과학대학, 법과대학, 사회과학대학, 경영대학, 생명자원과학대학, 공과대학, 건축·디자인·패션대학, 스포츠과학대학, 예술대학, 의과대학), 2개 학부(석당인재학부, 국제학부)로 구성되어 있다. 특히, 동아대학교 병원은 30여 개의 진료과 중에서 특히 신경과와 심뇌혈관 분야에 특화되어 있으며, 상급종합병원으로 운영되고 있다.

Dong-A University is a home to 10 graduate schools (General, International Studies, Medicine, Law, Business Administration, Education, Industry and Information, Social Welfare, Cultural and Arts, and Dong-A Law School), 12 colleges (Humanities, Natural Sciences, Social Sciences, General Education, Social Sciences, Business Administration, Natural Resources and Life Science, Engineering, Design and Environment, Health Science, Art and Sports, and Medicine), and 2 undergraduate schools (College of Global Business and College of Seokdang Honors) as of 2013. In particular, Dong-A University Hospital is specialized in the areas of neurology and cardiocerebrovascular, among 30 medical departments, operated as a tertiary and general hospital in Korea.

EXHIBIT CLASSIFICATION

심뇌혈관 치료제 개발, 만성 호흡기질환 치료제 개발, 당뇨병 치료제 개발, 의료기기, 건강기능식품

Development of therapeutics agents for cardio-cerebrovascular diseases, Development of therapeutics agents for chronic respiratory diseases, Development of therapeutics agents for diabetes, Medical Equipment, Functional food

COMPANY & PRODUCT INTRODUCTION

동국대학교 의료원은 일산캠퍼스 15만평 부지에 동국대학교 일산병원을 비롯하여, 약학대학, 바이오시스템학과, 식품공학과 등이 집적하는 일산바이오메디캠퍼스 (BT특성화캠퍼스)를 설립, 조성하여 (1995년 교육부 승인), 바이오산업의 저변을 확대하고, 이를 통한 기술개발을 촉진하며, 다시 BT 분야의산업경쟁력을 강화하는 선순환 구조를 구축함

- 바이오메디캠퍼스는 의료기기 및 R&D의 value-chain을 구축함으로써, 전 세계적으로 심화되고 있는 BT산업 경쟁에서 기술 선점을 통한 우위 확보를 가능하게 하는 핵심 인프라로 기능함

Dongguk University Medical Center established Bio Medi Campus specialized in BT, at Ilsan Campus (approved by Ministry of Education in 1995) where is home to Dongguk University Ilsan Hospital, College of Pharmacy, Department of Biosystem, and Department of Food Science and Technology with a total size of about 495,867.769m². It has also launched a virtuous cycle from expanding the base of bioindustry to facilitate technology development to strengthening industrial competitiveness in BT.

 Bio Medi Campus has established a value-chain for medical devices and R&D, and acted as a core infrastructure to ensure competitive edge with technological preemption at the intensifying competition of the global BT industry. Hospital-based Business Innovation Center



COVID-19 SPECIAL PAVILION



Dongguk University Medical Center HBIC

동국대일산병원 개방형실험실

COUNTRY Republic of Korea

CEO Hae-won Lee 이해워

URL www.dumc.or.kr

dumc.hbic.or.kr

E-mail mail.dumc.or.kr/webmail

Dowgene Co., Ltd.

㈜다우진유전자연구소

COUNTRY Republic of Korea

CEO Choonhong Hwang 황춘홍

URL www.dowgene.com

E-mail dowgene825@gmail.com

COMPANY & PRODUCT INTRODUCTION

동서의학이 공존하는 본원을 중심으로 의대, 한의대, 약대, 바이오시스템대학 등이 집적되어 있는 동국대학교일산병원 개방형 실험실은 의·생명과학 인프라를 기반으로 교육연구, 연구개발, 산학협력 및 현장연계, 창업기업의 입주 공간 확보 등 지속적으로 기업의 창업을 지원하기 위해 개설되었습니다.

동국대일산병원 개방형실험실은 창업기업의 제품은 물론 예비창업자들의 아이디어가 시장에서 성공할 수 있도록 꼼꼼하게 지원하고 있습니다.

The open laboratory at Dongguk University Ilsan Hospital, where school of medicine, oriental medicine, pharmacy and bio system are integrated, was established to continuously support startups in educational research, R&D, industry-university cooperation and field connection, and space for tenant companies based on biomedical science infrastructure.

Dongguk University Ilsan Hospital's open laboratory provides thorough support from the beginning to end, so the products of startups, as well as the ideas of prospective entrepreneurs can succeed in the market.

EXHIBIT CLASSIFICATION

Dow QuickFinderTM 코로나19 실시간중합효소연쇄반응 키트 Dow QuickFinderTM 2019-nCoV Real-time PCR Kit

COMPANY & PRODUCT INTRODUCTION

(주)다우진유전자연구소는 기술표준원 한국인정기구(KOLAS)로부터 2009 년~현재까지 [KOLAS 국제공인 시험기관]인증을 획득한 공신력 있는 검사기관으로, 벤처기업 인증 및 한국산업기술진흥협회로부터 기업부설연구소 인증, 기술혁신형 중소기업(INNO-BIZ)과 경영혁신형 중소기업(MAIN-BIZ)인증을 획득하였으며, 보건복지부 산하 한국유전자검사평가원으로부터 2007년부터 현재까지 14년 연속 90점이상의 높은 점수를 획득하여 [A 등급 유전자검사기관]으로 평가받은 국내 유전자감식분야의 대표적인 유전자검사 기관임. 2020년 현재 유전자감식 시약개발 기술경험을 통해 코로나 진단제품을개발하였으며, 식품의약품안전처로부터 체외진단 의료기기 수출허가 인증, CE인증, ISO13485 인증을 획득하였음.

DowGene Co., Ltd. develops and provides DNA-related services and products, and ourservices and products include DNA profile tests for paternity verification, kinship verification, individual identification, remains identification, DNA profile tests for prevention of missing children, food foreign substance detection and kind identification tests, DNA analysis services and DNA storage cards. DowGene Co., Ltd. is a KOLAS internationally certified testing laboratory and has been Korea's leading DNA testing organization certified by the Ministry of Health and Welfare- affiliated Korean Institute of Genetic Testing Evaluation as a Class A DNA testing institution since the year 2007. All tests performed by DowGene Co., Ltd. are carried out in accordance with a testing quality management system and the best research personnel composed of doctoral researchers who participate in the testing activities to provide the best test quality and accuracy.

Korea Doctor Preneur



K-Healthcare start-ups



Dr. daddy Co., Ltd.

㈜닥터대디

CEO Republic of Korea
Daewon Lee 이대원
www.drdaddv.co.kr

E-mail

DR.PROLAB

㈜닥터프로랩

COUNTRY Republic of Korea
CEO JungHun Lee 이정훈
URL www.drprolab.com

E-mail hrlee@drprolab.com

EXHIBIT CLASSIFICATION

tepid pad

tepid pad

COMPANY & PRODUCT INTRODUCTION

유아의 발열시 가정과 응급실에서 많이 시행하고 있는 미온수마사지를 가정에서 보다 쉽고 효과적으로 할 수 있는 응급처치용 미온수패드를 개발하여자녀의 발열시 효과적인 응급처치수단의 제공과 함께 불필요하게 응급실을 찾는 사회적 비용지출 절감 효과를 목적으로 개발

Aims to develop a first aid tepid pad that can be used more easily and effectively in homes and emergency rooms for baby fever. The pad is developed for the purpose of providing effective first aid measures for child's fever and reducing social expenditure of visiting emergency rooms unnecessarily.

EXHIBIT CLASSIFICATION

슈퍼박테리아가 생성하는 내성 유전자 검출을 위한 체외진단키트와 자동화 장비

Detection kit and automated equipment for detecting antibacterial resistance genes and novel antibiotic resistance inhibitors.

COMPANY & PRODUCT INTRODUCTION

저희 닥터프로랩은 인류의 생활과 건강 증진을 위한 신약개발과 연구를 진행하는 기업입니다. 닥터프로랩은 항생제 내성균 극복을 위하여 항균제 내성 진단키트와 자동화 장비 및 새로운 항균제(저해제)를 개발하고 있습니다. 진단키트는 병원에서 분리 동정 된 싱글 콜로니를 사용하여 PCR 기법으로 항생제 내성유전자를 진단할 수 있는 키트이며, 최소한의 인력을 필요로 하는 자동화 장비를 개발하고 있습니다.

DR.PROLAB is developing antibacterial resistant diagnostic kits, automated equipment and novel antibacterial agents(inhibitors) to overcome antibacterial resistance. The diagnostic kit(bla Detection Kit) is a PCR based detection kit that can detect antibacterial resistance genes using single colony identified from the hospital. The bla Finder is our equipment that automates all diagnostic processes with the kit.



주식회사 대성마리프



DS MAREF (DAESUNG MAREF CO., LTD.)

㈜대성마리프

Dxome Co., Ltd.

Korea Doctor Preneur

㈜디엑솜

COUNTRY Republic of Korea

CEO Jae Kyung Lee 이재경

URL www.dsmaref.com

E-mail info@dsmaref.com

COUNTRY Republic of Korea

CEO Jong Rak Choi 최종락

URL www.dxome.com

E-mail shseo@dxome.com

EXHIBIT CLASSIFICATION

DVT (정맥혈전) 예방장치 / 공압지혈시스템 / 냉온공압통증완화시스템 / 부종개선시스템 /핸드 재활 장비

DVT prevention system, Pneumatic Tourniquet System, Cryo Thermo Compression system, Air Compression System for Lymphatic drainage and Hand rehabilitation exercise device

COMPANY & PRODUCT INTRODUCTION

1994년 설립된 ㈜대성마리프는 지난 33년간 공압 전문 의료기기 전문기업으로서 DVT (정맥혈전) 예방장치 / 공압지혈시스템 / 냉온공압통증완화시스템 / 부종개선시스템 /핸드 재활 장비 등 다양한 시장의 니즈를 반영하는 제품라인업을 중심으로 약 80여개국에 수출하는 국내외 공압의료기기 분야 글로벌 선두를 지키고 있습니다.

Founded in 1994, DS MAREF (DAESUNG MAREF CO., LTD.) is a company specializing in pneumatic medical equipment for the 33 years, having various products lineup such as DVT prevention system, Pneumatic Tourniquet System, Cryo Thermo Compression system, Air Compression System for Lymphatic drainage and Hand rehabilitation exercise device and exporting to about 80 countries.

EXHIBIT CLASSIFICATION

- 1. DxSeq
- 2. DxLiquid
- 3. DxTube

COMPANY & PRODUCT INTRODUCTION

디엑솜은 최근에 각광받는 액체생검 (Liquid biopsy)을 통한 진단기법에 주목하여 차세대염기서열분석 (NGS) 기반의 체외진단 키트를 개발하고 있습니다. 극소량의 혈중 암 유래 DNA (ctDNA)를 검사하기 위해 자체 기술 역량을 바탕으로 개발된 시약 및 분석 프로그램을 통해 높은 정확도의 결과가 제공됩니다. 현재 ctDNA를 분석하여 암의 조기진단 및 예후진단이 가능한 정밀진단키트 및 분석방법 개발을 진행하고 있습니다.

Dxome is currently developing an in vitro diagnostic kit based on next-generation sequencing (NGS) by focusing on diagnostic techniques through recently-spotlighted liquid biopsies. When a very small amount of blood cancer-derived DNA (ctDNA) is tested, highly accurate results are provided through reagents and analysis programs that are developed based on the company's technical capabilities. Currently, the company is developing a precision diagnostic kit and analysis method that enables early diagnosis and prognostic diagnosis of cancer by analyzing ctDNA.

Daejeon Technopark



600

E&S Healthcare Co., Ltd.

㈜이앤에스헬스케어

EBO

㈜이비오

COUNTRY Republic of Korea

CEO Cheongwoon Cho 서경훈

URL www.customedi.com

E-mail bluevet627@gmail.com

COUNTRY Republic of Korea

CEO Sun Bok Jeon 전순복

URL www.ebo.kr

E-mail ebosolution@gmail.com

EXHIBIT CLASSIFICATION

유방암 체외진단 키트

Breast Cancer in vitro diagnostic Kit

EXHIBIT CLASSIFICATION

비임상 유효성(효능)평가

Nonclinical Efficacy Evaluation Experiments

COMPANY & PRODUCT INTRODUCTION

혈액을 이용하여 높은 정확도의 진단율을 보이는 세계 최초 유방암 체외진단 용 의료기기

The world's first medical device for in vitro diagnosis of breast cancer that shows a high accuracy diagnosis rate using blood

COMPANY & PRODUCT INTRODUCTION

비임상 유효성(효능)평가 시험 수행 (의약품, 건강기능식품, 화장품)

Nonclinical efficacy test (Medicines, Function Foods, Cosmetics)

Korea Doctor Preneur



K-Healthcare start-ups

📤 e de n l u x

Ecoderm Co., Ltd.

㈜에코덤

COUNTRY Republic of Korea

CEO Seong Jin Kim 김성진

URL www.ecoderm.co.kr

E-mail wisedosh@naver.com

Edenlux

주식회사 에덴룩스

COUNTRY Republic of Korea

CEO SUNG YONG PARK 박성용

URL www.edenlx.com

E-mail lyn@edenlx.com

EXHIBIT CLASSIFICATION

- 1. 의약품 화장품 소재개발
- 2. 냉감수용체 활성물질
- 3. 과민성대장증후군 치료제
- 1. Development of Materials for Pharmaceutical Cosmetics
- 2. Cold-sensitizing receptor active substance
- 3. Hypersensitive colorectal syndrome therapeutic

COMPANY & PRODUCT INTRODUCTION

2009년부터 벤처인증 창업기업으로 출발하여 연구개발분야에 꾸준히 투자하여, 의약품 화장품 소재개발 국내 등록 특허 20여건, 해외 미국 EU포함 15 개국 등록 과민성대장증후군 특허 2건 있습니다. 화장품 소재개발기술과 안전성 평가기술은 국내 최고수준으로 국내 1,2위 대기업화장품 회사들과 공동연구 중입니다. 중재적 임상의학 분야의 다양한 연구개발을 통해 국내외 제약회사에 기술이전하였고 새로운 분야를 끊임없이 도전합니다.

Starting as a venture-certified start-up company in 2009, the company has invested steadily in research and development.

There are about 20 domestic patents for drug, cosmetics material development, and two patents for hypersensitivity colorectal syndrome registered in 15 countries including the United States.

Cosmetics material development technology and safety evaluation technology are the best in Korea and are jointly researched with the nation's top two largest cosmetics companies.

Through various research and development in the field of mediated clinical medicine, technology has been transferred to domestic and foreign pharmaceutical companies and the company is constantly challenging on new fields.

EXHIBIT CLASSIFICATION

시력회복용 웨어러블 디바이스 : 오투스

Wearable device for vision recovery: otus

COMPANY & PRODUCT INTRODUCTION

각기 다른 도수의 디옵터 렌즈들이 삽입되어있는 리볼버형 구조물이 일정시 간에 따라 위치가 바뀌면서 눈의 수정체 조절근력의 수축과 이완 반응을 반 복시켜 눈의 근력을 강화함으로 시력을 건강하게 관리

The device can detect the eye information of each users' right and left eyes and based on that data, the product can be provided as customized training device.

Korea Doctor Preneur



K-Healthcare start-ups



Edisbiotech Co., Ltd.

㈜에디스바이오텍

COUNTRY Republic of Korea

CEO Seung Jae Myung 명승재

URL edisbiotech.com

E-mail sjmyung@gmail.com

ELI Frontier

㈜엘리프런티어

COUNTRY Republic of Korea

CEO Kim Jun-hwan 김준환

URL

E-mail june6259@gmail.com

EXHIBIT CLASSIFICATION

- 1. M-ChESS(다중형광 분자영상내시경)
- 2. 내시경 프로브
- 3. 대장암진단 키트
- 4. 형광조영제
- 1. M-ChESS(Multi-fluorescent molecular imaging endoscope)
- 2. Endoscopic probe
- 3. Colorectal cancer diagnostic kit
- 4. Fluorescent contrast medium

EXHIBIT CLASSIFICATION

국내 최초의 식용곤충 종합 플랫폼(유투벅스)

The first edible insect commercial platform, "You to Bugs", in Korea

COMPANY & PRODUCT INTRODUCTION

식용곤충을 기반으로 종합 플랫폼부터 신약개발까지 식용곤충과 관련된 모든 분야의 사업을 진행하는 회사입니다.

"You to Bugs" develops businesses based on edible insects. Our services range from building commercial platform to drug development

COMPANY & PRODUCT INTRODUCTION

㈜에디스바이오텍은 바이오마커를 발굴하고, 이를 활용하여 다중형광분자영 상내시경, 체외진단키트를 개발하는 기업입니다. 국내최초로 임상적용이 가 능한 스마트내시경용 형광조영제를 개발하여 고정밀 대장암 진단의 가능성 을 높였습니다. 더불어 소화기정밀진단을 위한 다중형관 기반의 채널삽입형 융복합 스마트내시경 시스템 및 임상니즈를 반영한 내시경 부속제품들을 개 발하였습니다. 발굴한 대장암 바이오마커를 활용하여 혈액검사로 대장암을 조기에 진단할 수 있는 분자진단키트를 개발하였습니다.

Edisbiotech Co., Ltd. is a company that discovers biomarkers and utilizes them to develop multi-fluorescent photomultiplieries and in vitro diagnostic kits. For the first time in Korea, the company has developed a clinically applicable fluorescent contrast medium for smart endoscopes and increased the possibility of a high-precision colorectal cancer diagnosis. In addition, the company has developed a multi-type channel-based convergence smart endoscopic system for a precise diagnosis on digestive organ, and endoscopic accessories that reflect clinical needs.

The company has also developed a molecular diagnostic kit that can diagnose colon cancer early through blood tests using the colon cancer biomarker that the company has discovered.

Daejeon Technopark



K-Healthcare start-ups



ENTEROENOMICS

㈜엔테로지노믹스

CEO Republic of Korea Chuljun, KIM 김철준

URL

E-mail parkso22@hanmail.net

EXHIBIT CLASSIFICATION

근감소증 개선 제품 - 시니어층의 근감소증을 개선 medifunctional food concept-senior sarcopenia

COMPANY & PRODUCT INTRODUCTION

당사는 환자 재활과 장내미생물과 관련된 영역에 전문화된 식품을 개발하고 있으며 올해 근감소증 예방 및 개선에 특화된 식품을 런칭예정

We specializes in developing therapeutic functional products based on rehabilitation & human microbiome. We are going to launching medifuntional food for sarcopenia in June

EROP Co, Ltd

㈜이롭

COUNTRY Republic of Korea

CEO Junseok Park 박준석

URL

E-mail jiwan.erop@gmail.com

EXHIBIT CLASSIFICATION

일회용 내시경 투관침(트로카)

The dual path on TS Trocar has been applied for patent in which the design enables discharging the exudates through a groove to secure a clear vision for surgeons

COMPANY & PRODUCT INTRODUCTION

복강경 수술 시 조직을 천자, 천공 하여 시술기구의 삽입 통로를 확보하기 위한 것으로, 캐뉼라, 투관침으로 구성되어 있는 일회용 멸균 의료기기 제품

Professor Park (surgeon at KNUH and CEO at EROP) leads the research and development of surgical device. By holding regular advisory conferences with incumbent surgeons, feedback regarding usability and development direction is continuously updated.

The dual path on TS Trocar has been applied for patent in which the design enables discharging the exudates through a groove to secure a clear vision for surgeons. Since its launch in June 2019, TS Trocars have been distributed nationwide and we strive to expand our distribution network with advanced quality.

K-Healthcare start-ups



Everex

에버엑스

COUNTRY Republic of Korea

CEO Chan Yoon 윤찬

URL www..everex.co.kr

E-mail smartxglobal@gmail.com

EXHIBIT CLASSIFICATION

무릎운동을 획기적으로 개선하는 스마트 디바이스

Revolutionary smart device for knee exercises

COMPANY & PRODUCT INTRODUCTION

KneeEx를 통해 기존의 불편함을 개선하고 무릎 주변 근육을 강화하고 싶은 전 연령층에게 보다 효과적인 운동 기기를 소개하여 예방의 효과 역시 제공 하려고 한다.

KneeEx is an effective exercise equipment for people of all ages who want to strengthen knee muscles

Korea Doctor Preneur

EvidNet Co., Ltd.

에비드넷

COUNTRY Republic of Korea

CEO Brian Jo 조인산

URL www.nanofaentech.com

E-mail jo_brian@evidnet.co.kr

EXHIBIT CLASSIFICATION

1. 바이오 빅데이터 플랫폼

1. Bio Big Data Platform

COMPANY & PRODUCT INTRODUCTION

(주)에비드넷은 이질적 헬스케어 데이터의 상호운용성, 연결성, 표준화를 위한 통합 헬스케어 데이터 네트워크 구축이라는 비전을 위해 끊임없이 노력하고 있습니다. 통합 헬스케어 데이터 네트워크는 임상 의학연구 혁신에 기여하며, 데이터 생태계에서 생성되는 real world evidence는 혁신적인 의료 서비스와 획기적인 의료 기술 발전을 촉진하여 실 의료 현장에서의 의료의 질향상에 크게 이바지할 것입니다.

EvidNet Co., Ltd. continues to strive for the vision of creating an integrated healthcare data network for interoperability, connectivity and standardization of heterogeneous healthcare data.

The integrated healthcare data networks contribute to clinical research innovation. The real world experience generated by the data ecosystem will greatly contribute to improving the quality of health care in real health care sites by promoting innovative health care services and epochal medical technology advances.

Healthcare Technology Licensing Office



Korea Doctor Preneur



Ewha University-Industry Collaboration

이화여자대학교 산학협력단

COUNTRY Republic of Korea

CEO Bahn, Hyokyung 반효경

URL research.ewha.ac.kr

E-mail sojoong@ewha.ac.kr

E-wireligner Co., Ltd.

E-wireligner(주)

COUNTRY Republic of Korea

CEO Youn-Sic Chun

URL ewireligner.creatorlink.net

E-mail yschun@ewha.ac.kr

EXHIBIT CLASSIFICATION

바이오·의료, 화학, 정보통신 및 융·복합 분야

Biomedical science, chemistry, telecommunication and convergence

EXHIBIT CLASSIFICATION

1. E-Wire

1. E-Wire

COMPANY & PRODUCT INTRODUCTION

이화여자대학교 연구처/산학협력단은 21세기 지식기반사회를 선도하는 연구중심대학 체제를 구축하고, 학제적 · 연계적 영역을 포괄하는 다양한 영역에서 연구의 수월성을 제고하며, 경쟁력 강화를 위해 교수들의 연구 활동과연구 인프라를 적극적으로 지원하고 있습니다.

기업들의 첨단지식에의 접근성과 신기술 개발을 촉진하며 세계적 수준의 여성전문인력 양성을 위한 산학협력 사업을 지원하여, 대학과 산업계의 상호성공전략을 추구하기 위한 산학협력 네트워크를 구축하고 활성화하고 있습니다. 나아가 세계적인 연구인력 유치, 국내외 유수 학술기관, 연구소, 산업체들과의 학술・연구 교류 및 산학협동 확대의 창구 역할을 하고자 합니다

Ewha University-Industry Collaboration has been enhanceing multi- and interdisciplinary research excellence, and supporting research infrastructure and research of professors to strengthen competitiveness with a research-oriented system for the university leading the 21st century knowledge-based society,

It has been vitalizing industry-academic cooperation network to pursue the win-win strategy by supporting the cooperation projects to nurture world-class female professionals, and promoting the access to the latest knowledge, and technology development. Also, it is committed to serve a role of window to attract world-class researchers and expand academic and research exchanges with leading academic institutions home and abroad.

COMPANY & PRODUCT INTRODUCTION

이와이어라이너(주) 는 이화여자대학교 의과대학 전윤식 교수의 20년 임상 경험 및 학술적 성과를 기반으로 설립된 이화여자대학교 기술지주회사의 첫 번째 자회사입니다.

치아 교정과 관련된 연구개발 성과를 기반으로, 기존 교정장치 한계점을 극복 가능한 새로운 형태의 치아교정장치 및 교정 방법과 관련된 아이템 개발및 사업화를 계획하고 있습니다.

- E-Wireligner was founded on the basis of 20-year clinical experience and academic achievements of Youn-Sic Chun, a professor at Ewha Womans University's School of Medicine. The company is the first subsidiary of Ewha Womans University's technology holding company
- Based on research and development results related to orthodontic surgery, the company is planning to develop and commercialize items related to new types of orthodontic devices and calibration methods that can overcome limitations of the existing calibration devices.

Korea Doctor Preneur

SEOUL Biohub



Ex Lumina Therapeutics & Technology

Ex Lumina Therapeutics & Technology

COUNTRY Republic of Korea

CEO Tae Gwan Park 박태관

URL

E-mail minsook7629@daum.net

EXoPERT

주식회사 엑소퍼트

COUNTRY Republic of Korea

CEO Yeonho Choi 최연호

URL www.exopert.com

E-mail jewon@exopert.com

EXHIBIT CLASSIFICATION

- 1. 줄기세포기반 신약개발 플랫폼
- 2. 안과용 의료기기
- 1. Stem Cell-Based New Drug Development Platform
- 2. Ophthalmic medical device

EXHIBIT CLASSIFICATION

엑소좀 분리 및 엑소좀 기반 암 진단기기 개발

EXOPERT is a company that uses exosomes containing biometric information to contribute to the medical industry such as for diagnosis and treatment.

COMPANY & PRODUCT INTRODUCTION

(주)엑소퍼트는 생체정보를 가진 엑소좀을 활용하여 진단 기술 및 치료제 개 발 로 의료산업 전반에 기여하고자 합니다.

EXOPERT is a company that uses exosomes containing biometric information to contribute to the medical industry such as for diagnosis and treatment.



Korea Doctor Preneur

Korea Doctor Preneur



Eye Bio Korea Co., Ltd.

㈜아이바이오코리아

COUNTRY Republic of Korea

CEO Jae Wook Yang 양재욱 URL www.eyebiokorea.com

oculoplasty@gmail.com E-mail

EXHIBIT CLASSIFICATION

1. EB-111

2. EB-171

3. EB-201

4. EB-301

COMPANY & PRODUCT INTRODUCTION

아이바이오코리아는 인체 및 동물용 의약품을 개발하는 신약연구개발전문기 업으로 안과질환 치료제를 비롯해 다수의 신약후보물질을 개발하고 있습니 다. 안과에 특화된 전문 기술 및 풍부한 연구 경험을 보유한 임상/비임상연구 진과 의료·바이오산업 기획·마케팅 전문가들과 함께 안과분야 신약개발을 통 한 국민의 삶의 증진을 위해 노력하는 기업입니다.

Eye Bio Korea is developing a number of new drug candidates as a company specializing in research and development of new drugs for human and animal use.

The company strives to improve the lives of the people through the development of new drugs in the field of ophthalmology. The vision is shared with clinical and nonclinical researchers with specialized ophthalmology skills and abundant research experience, along with medical and bio industry planning and marketing experts.

Finemedix Co., Ltd

㈜파인매딕스

COUNTRY Republic of Korea

Seongwoo Jeon 전성우 **URL** www.finemedix.com

E-mail swjeon@finemedix.com

EXHIBIT CLASSIFICATION

ClearCut Knife[H type]

2. ClearEndoclip

3. Clear-Tip EUS-FNA

COMPANY & PRODUCT INTRODUCTION

2009년 설립된 ㈜파인메딕스는 ESD Knife를 시작으로, ERR, Polypectomy 등 내시경 시술에 사용되는 진단 및 치료관련 악세서리를 개발 및 판매하고 있으며, 자체 R&D 센터와 함께 국산화 제품을 선도하는 업체로 자리 잡아가 고 있습니다.

ERCP 및 EUS와 같은 췌담도 시술에 사용되는 악세서리도 출시하면서 취급 하는 제품의 영역이 한층 넓어 졌으며, CE 인증 및 최근 FDA 허가를 득하면 서 해외로 수출을 진행하며 글로벌 전문의료기기 업체로 발돋움하고 있습니

Established in 2009, Finemedix Co., Ltd. is steadily becoming a leading company for using localized products with its own R&D Center. Starting with ESD Knife, the company is developing and selling diagnostic and treatment-related accessories used for endoscopic procedures such as ERR and Polypectomy.

Accessories used in pancreatic treatment such as ERCP and EUS have also been released and the range of products handled has become wider. With CE certification and FDA approval, the company has been exporting to foreign countries and becoming a global medical device company.

FOREST-RUNNIG

K-Healthcare start-ups

Healthcare Technology Licensing Office

University of Ulsan

울산대학교 산학협력단



Forest running

착한런닝 숲닝머신

COUNTRY Republic of Korea

CEO Park, Min-Young 박민영

URL

E-mail pmy0426@snu.ac.kr

COUNTRY Republic of Korea

CEO Cho, Hong Rae 조홍래

Foundation for Industry Cooperation.

URL fic.ulsan.ac.kr

E-mail kihaky1126@ulsan.ac.kr

EXHIBIT CLASSIFICATION

스마트 런닝 머신

Smart running machine

EXHIBIT CLASSIFICATION

의료, 바이오, 조선, 자동차, 기계

Medical, Bio, Shipbuilding, Automobile, Machinery

COMPANY & PRODUCT INTRODUCTION

가정에서 숲길을 뛰는 것을 체험할 수 있게 해주는 스마트 런닝 머신

Treadmill that will bring your favorite trail into your home

COMPANY & PRODUCT INTRODUCTION

- 산업도시에 위치한 여건을 바탕으로 산학협동사업을 지속적으로 추진 (자동차, 조선)
- 인재육성 및 공동연구 강화를 위한 산업체 장기인턴십, 산학협력교수제, 지역특화연구팀(센터)운영, 가족회사제확대, 기술이전 및 창업보육사업 등을 진행하고 있으며, 산학협력교수제도(2005년시행) 및 산업체장기인턴십제도(2008년시행), 글로벌기술마케터양성센터(비이공계 산학협력프로그램)등을 통한 저국 최고의 산학협력 선도대학으로 발전
- 의과대학과 협력,교육 병원을 통한 효율적인 현장밀착형 바이오,의료 분야 산학협력 추진 및 수익창출모델 개발
- Continues to promote industry-academic cooperation projects, taking advantage of its location in an industrial city (automobiles and shipbuilding)
- Accelerates its efforts to be an outstanding university in leading industry-academic cooperation though University-industry Collaboration Faculty (2005), Long-term internship (2008), and Training Center for Global Technology Marketers (Bio industry-academia cooperation program), and to nurture talents and strengthen joint research through Industry-academic Cooperation Professor System, Regional Research Team (Center), Expansion of Family Company and projects on technology transfer and support for start-up.
- Develops a revenue model and promotes efficient and practical industry-academic cooperation in bio and medical areas by collaborating with the medical school and training hospital

Freevis

GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION



Freevis inc

프리비스

COUNTRY Republic of Korea

CEO Lee Jae Yoon 이재윤

URL

E-mail ankun@13f.kr

EXHIBIT CLASSIFICATION

휴대용 소독기

COMPANY & PRODUCT INTRODUCTION

휴대용 소독기로 언제어디서나 안전한 생활환경을 만드는 회사

Gachon University Gil Medical Center

가천대 길병원

COUNTRY Republic of Korea Kim

CEO Yang Woo 김양우

URL https://www.gilhospital.com/

E-mail sichun36@gilhospital.com

jiyun93@gilhospital.com byundh82@naver.com ssj@iheuron.com oculight@naver.com

EXHIBIT CLASSIFICATION

가천대 길병원 홍보자료: 가천대 길병원의 중점연구분야(대사성질환, 노인성 뇌질환), 차세대 연구분야(재생의료, 의료기기, 유전체, 인공지능, 빅데이터) 연구 내용 소개 자료

가천대길병원 기술사업화와 자원개방/교원 창업기업 홍보자료 : 가천대 길병원의 기술사업화 및 자원 개방 현황 소개 / 임상연구진의 교원 창업 기업 소개자료

Gachon University Gil Medical Center Promitional materials Faculty Co. Promitional materials

Healthcare Technology Licensing Office



Korea Innovative Pharmaceutical Company



Gachon University Gil Medical Center

가천대 길병원

COUNTRY Republic of Korea

CEO Lee, Tae-Hoon 이태훈

URL www.gilhospital.com

E-mail lee073@naver.com

EXHIBIT CLASSIFICATION

- 대사성 질환에 특화된 혁신 신약개발 플랫폼 강화 및 활용
- 대사성 질환 신약개발 플랫폼 서비스의 total solution 제공: 오픈 플랫폼 서비스
- 자체 혁신형 대사성질환 신약개발
- Strengthening and utilizing innovative new drug development platform specialized for metabolic diseases
- Providing total solution of new drug development platform for metabolic diseases: Open platform service
- Development of new innovative drugs for metabolic diseases

COMPANY & PRODUCT INTRODUCTION

가천대 길병원은 가천의생명융합연구원을 설립하여 세계적 수준의 기초과학 연구기관인 뇌과학연구소, 이길여 암당뇨 연구원, 가천바이오나노연구원 등 연구 인프라를 기반으로 연구중심병원 운영하고 있습니다. 이에 연구개발 사업화를 추진 하고자 기술사업단을 구성하여 전문인력을 중심으로 보건의료핵심기술발굴, 특허 출원 및 등록 관리, 기술이전 협상, 계약, 기술마케팅, 대외 협력 네트워크, 교원 창업기업 지원하고 있습니다. 가천대 길병원만의 핵심분야 최고수준의 인프라를 기반으로 핵심기술, 우수연구자 발굴하여 의료기술 사업화를 활발히 추진 하도록 하겠습니다.

With the establishment of Gachon Advanced Institute for Health Sciences & Technology (GAIHST), Gachon University Gil Medical Center has been a research-oriented hospital based on the research infrastructure including Gachon Advanced Institute for Health Sciences & Technology (GAIHST), Neuroscience Research Institute Gachon University, Lee Gil Ya Cancer and Diabetes Institute, and Gachon Bionano Research Institute Furthermore, it formed a technology foundation to commercialize the R&D outcome, which is responsible for support for discovery of core healthcare technology, application, registration and management of patent, negotiation regarding technology transfer, contracts, technology marketing, operation of external cooperation networks, and promotion of startups of faculty members, centering around its professional personnel.

Based on the outstanding infrastructure of the center in the core areas, it is committed to support development of core technology and researchers to actively facilitate the commercialization of medical technology .

GC Pharma

GC녹십자

COUNTRY Republic of Korea

CEO Eun-Chul Huh 허은철

URL www,greencross.com

E-mail perious@greencross.com

EXHIBIT CLASSIFICATION

- * 아이비-글로불린에스엔주5%
- 저 및 무감마글로불린혈증 중증감영증에 항생물질 병용
- 특발혈소판감소자색반병 길랑바레증후군(급성특발다발신경염)
- 가와사키병(관상동맥합병증예방목적)
- * 녹십자-알부민주20%
 - 알부민의 상실(화상, 신증후군 등) 및 알부민 합성저하(간경변증 등)에 의한 저알부민혈증, 출혈성 쇽
- * 그린에이트주
- 혈액응고제VIII인자 결핍환자에 대해 혈장중의 혈액응고제VIII인자를 보충 하여 출혈을 억제
- * I.V.-Globulin SN inj.

A-/HypogammaglobulinemiaCombinedtherapywithantibioticsforse verebacterialorviralinfections Idiopathicthrombocytopenicpurpura Guillain-Barresyndrome Kawasakisyndrome

* Albumin inj.-GCC

For hypoalbuminemia and shock in acute hemorrhage from loss of albumin (burns, nephrotic syndrome, etc.) and low synthesis of albumin (hepatic cirrhosis, etc.)

* Green-VIII inj.

For the treatment of hemophilia A with supplies of blood coagulation factor $\mbox{\sc VIII}$

* GreenGene F inj.

For the prevention and control of bleeding episodes and preoperative management in hemophilia ${\sf A}$

COMPANY & PRODUCT INTRODUCTION

GC녹십자는 지난 1967년 창립 이래 혈액제제와 백신, 재조합 단백질 등 생물학적 제제 분야를 선도하고 있는 회사입니다.

GC Pharma has been a leading biotech company for developing innovative biotherapies including vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies.

COVID-19 SPECIAL PAVILION



COVID-19 SPECIAL PAVILION



Genematrix

㈜진매트릭스

COUNTRY Republic of Korea

CEO Soo-Ok Kim 김수옥

URL www.genematrix.net

E-mail kmlee@genematrix.net

EXHIBIT CLASSIFICATION

네오플렉스 코비드-19 진단제

NeoPlexTM COVID-19 Detection Kit

COMPANY & PRODUCT INTRODUCTION

진매트릭스는 2009년 기술성장기업으로 코스닥에 기술성 특례상장한 이래 세계 시장에서 지속성장과 파급력 있는 기술융합 분야에 연구개발을 집중하여 사업화에 각고의 노력을 기울여 왔습니다. 진매트릭스는 기존기술과 차별화되는 분자진단원천기술을 개발하여, 의료·바이오 산업의 미래상인 맞춤의약을 실현하고 있으며, 질병치료를 위한 신약 개발에도 노력을 기울이고 있습니다.진매트릭스는 글로벌 시장에서 파트너링을 통해 성장모멘텀을 지속적으로 창출하고자, 영국 옥스퍼드대 Spin-Off 회사 Vaccitech에 투자를 수행하였습니다. 진매트릭스는 일자리 창출과 국민보건경제에 기여하기 위해임직원 모두 힘쓰고 있는 기업입니다.

GeneMatrix Inc.is a biotechnology company developing innovative molecular diagnostics and companion diagnostics with a broad R&BD portfolio incorporating three different genotyping platform technologies, including multiplex real-time PCR and liquid bead microarray based genotyping. In molecular diagnostics, GeneMatrix develops an extensive knowledge and product system based on genomic and proprietary data, which allows company, differentiate the market with the advantages over exiting players

- Single- tube reaction High multiplicity in a single channel
- High Flexibility of multiplex feature on targets

Genesystem Co., Ltd.

㈜진시스템

COUNTRY Republic of Korea

CEO Yujin Seo 서유진

URL www.genesystem.co.kr

E-mail ajung@genesystem.co.kr

EXHIBIT CLASSIFICATION

 $\label{eq:smarrchek} SMARTCHEK^{\scriptsize @}\ Novel\ Coronavirus\ (SARS-CoV-2)\ Detection\ Kit$ $\ GENECHECKER^{\scriptsize @}\ UF-300\ Real-time\ PCR\ System$

COMPANY & PRODUCT INTRODUCTION

주식회사 진시스템은 유전자진단 및 세포분석을 통해 인체 및 동물의 질병진 단, 농·축산물의 원산지 확인 등과 같은 건강한 사회와 인간 삶의 질 향상을 위해 노력하는 Mpoct Multiplex 분자진단 시스템 개발 및 제조 전문회사입니다.

Genesystem developes and manufactures mPOCT Multiplex MDx system pursuing improvement of the quality of human life offering such life revamping solutions as diagnosis of human and animal diseases, and confirmation of origins of agricultural and livestock products through genetic testing and cell analysis.

GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION



Korea Innovative Pharmaceutical Company

Genexine, Inc.

㈜제넥신

COUNTRY

Genexine

Geneunitech

지뉴인텍

COUNTRY Republic of Korea

CEO Han Eun Young 한은영

URL www.geneuintech.com

E-mail jjh8656@geneuintech.com

CEO Young Chul Sung 성영철

URL www.genexine.com

E-mail taesook.yoon@genexine.com

Republic of Korea

EXHIBIT CLASSIFICATION

CAR-T 세포 치료제, 백신 플랫폼, 생산세포주

CAR-T cell therapy, Vaccine platform, Production Cell line

COMPANY & PRODUCT INTRODUCTION

(주)지뉴인텍은 재조합 바이러스를 활용하여 바이오 의약품을 연구 개발하는 기업으로 다양한 기술적인 노하우를 확보하고 있고 경쟁력을 인정받고 있으며 유전자 및 세포치료제 분야에서 글로벌 기업이 되고자 설립되었습니다. 재조합 바이러스 기술을 근간으로 표적 항암 면역 치료제인 CAR-T 치료제와 백신 플랫폼, 생산 세포주 등 많은 기술을 보유하고 있습니다. 향후 기술이전 계약을 통해 글로벌 제약사 또는 국내 대기업에 기술을 판매할 계획에 있습니다.

㈜지뉴인텍은 "생명을 주는 진실한 기업"이라는 비전을 가지고 인간 원형으로 회복하는 통로가 되기를 소망합니다.

Geneuin-Tech Co., Ltd is a company that use recombinant virus to develop and research Biomedicine. We have various technologies which are competitive.

Our company was established for becoming a global company in the field of gene and cell therapy.

Based on recombinant virus technology, we have abundant technologies such as CAR-T therapies as targeted anti-cancer immunotherapy, vaccine platforms, and cell lines for production.

In the future, we are planning to sell our technologies to global pharmaceutical companies or big domestic companies though technology transfer contracts.

We have a vision of "a true company giving life" and hope to be a connection to recover original form of human.

COMPANY & PRODUCT INTRODUCTION

(주)제넥신은 글로벌 생명공학기업으로서 혁신적인 면역 치료 약물 및 차세대 항체융합단백질을 연구 개발하고 있으며 이를 상용화하기 위한 노력을 다하고 있습니다. 아울러, 제넥신은 혁신적인 치료제를 발하여 많은 환자들의 생명을 구하고 삶의 질을 향상시키는 것을 사명으로 하고 있습니다.

Genexine is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next generation novel long-acting biologics. Our goal is to bring to patients medicines that will transform their lives.

Korea Doctor Preneur



K-Healthcare start-ups



Geninus Co., Ltd.

지니너스㈜

Genome & Company

지놈앤컴퍼니

COUNTRY Republic of Korea

CEO Woong Yang Park 박웅양

URL www.kr-geninus.com

E-mail woongyang@gmail.com

COUNTRY Republic of Korea
CEO Jisoo Pae 배지수

URL

E-mail jenny.shin@genomecom.co.kr

EXHIBIT CLASSIFICATION

- 1. HealthSCAN
- 2. CancerSCAN
- 3. LiquidSCAN
- 4. Single cell
- 5. InsideMe
- 6. WithMe

EXHIBIT CLASSIFICATION

마이크로 바이 옴 기반 기술 플랫폼(제약, 화장품, 식이보충제 개발예정)

microbiome-based technology platform

COMPANY & PRODUCT INTRODUCTION

지니너스는 삼성서울병원 삼성유전체연구소의 연구성과를 상용화하기 위해 설립된 유전체분석 전문기업입니다.

유전체분석 기술을 활용하여 유전적으로 취약한 질병을 예측하고 정밀의학 구현을 위한 암유전체분석 솔루션을 제공하는 기술 중심의 바이오벤쳐기업 입니다.

Geninus is a company that specializes in genetic analysis, aimed to commercialize the research results of Samsung Genome Research Institute at Samsung Medical Center. The company is a technology-focused bio-venture company using genetic analysis to predict genetically vulnerable diseases and provides a complete cancer genetic analysis solution for the implementation of precision medicine.

COMPANY & PRODUCT INTRODUCTION

마이크로 바이 옴 기반 사용화가 가능한 제약, 화장품, 식이보충제 개발

Microbiome pipeline with a portfolio of synergistic approach with significant near commercialization and mid / long-term upside potential

Korea Doctor Preneur



Australian Trade and Investment Commission



Genome Opinion Co., Ltd.

㈜지놈오피니어

COUNTRY Republic of Korea

URL www.genomeopinion.com

Youngil Koh 고영일

E-mail snuhgo01@gmail.com

George Clinical

COUNTRY Australia

CEO James Cheong

URL www.georgeclinical.com

E-mail jcheong@georgeclinical.com

EXHIBIT CLASSIFICATION

1. LifeEx® CVD Clone Test

2. LifeEx®FH Test

3. LifeEx t-MN Test

COMPANY & PRODUCT INTRODUCTION

(주)지놈오피니언은 각종 유전체 데이터와 건강기록을 접목시켜 HEALTH BIG DATA 를 생산하고 이를 활용하여 인류의 건강을 증진 시키기 위해 것을 비전으로 설립되었습니다. 지놈오피니언은 2017년 전산학, 의학, 종양학, 유전체학에서 10년 이상 경력을 갖는 전문가들이 공동창업 하였으며, 당사는 현재 국내 유수의 기관들과의 제휴를 통해 유전자 데이터를 기반으로한 치료가이드와 조기진단 기술을 개발하고 있습니다.

Genome Opinion Co., Ltd. was established with the vision of combining genetic data with health records to produce HEALTH BIG DATA and utilize it to improve human health.

Genome Opinion was co-founded in 2017 by experts with more than 10 years of experience in computer science, medicine, oncology and genomics.

The company is currently developing treatment guides and early diagnosis technologies based on genetic data through partnerships with leading domestic organizations.

COMPANY & PRODUCT INTRODUCTION

George Clinical is a leading independent Asia-Pacific based contract research organisation (CRO), headquartered in Australia and with a global reach. We bring a unique value proposition of combining scientific expertise with operational excellence. Through our panel of scientific leaders, many of whom leading thought leaders in their respective fields, we have access to extensive investigator networks in a number of therapeutic areas including renal medicine, cardiovascular diseases and oncology. With staff operating in 16 countries and covering 38 locations in USA, China, India, Australia and the broader Asia-Pacific region, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration and post-marketing trials.

Daejeon Technopark



GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION



GGulb co.

주식회사 꿀비

GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION(GIBF)

김해산업진흥의생명융합재단

COUNTRY Republic of Korea

CEO Perata Choi 최원재

URL ggulb.net

E-mail eoakd9091@naver.com

COUNTRY Republic of Korea

CEO Jung won Yoon 윤정원

URL gibf.or.kr

E-mail pshyun16@naver.com

EXHIBIT CLASSIFICATION

SaaS 기반의 유전자 분석 소프트웨어

Quntum

EXHIBIT CLASSIFICATION

김해산업진흥의생명융합재단 김해의생명센터의 주요사업 및 시설장비 소개 Major projects and Facility equipment of GIMHAE Bio-Medical Center

COMPANY & PRODUCT INTRODUCTION

빅데이터, 머신러닝을 기반해 소프트웨어 개발을 하며, Quntum은 SaaS 기반 RNA-seq 유전자 분석 도구로 지능형 논문 데이터베이스 구축 자동화 시스템과 면역항체 스크리닝 시스템 구축을 목표로 하고있다

We develop software based on big data and machine learning .

Quntum is a SaaS-based RNA-seq gene analysis toolIntelligent thesis database construction automation system and It aims to build an immune antibody screening system.

COMPANY & PRODUCT INTRODUCTION

김해산업진흥의생명융합재단 김해의생명센터는 의생명산업의 연구개발 역 량 확충, 기업 및 창업지원, 지역혁신 역량강화 등 미래 전략산업 육성의 허브 로서 동남권 의료산업 발전을 선도합니다.

The GIMHAE Bio-Medical Center is leading the development of the healthcare industry in the shoutheastern region as a hub of future strategic industry promotion while expanding the R&D capacity of the biomedical industry, supporting companies and startups, and strengthening regional innovation capacity.

GILON

Hospital-based Business Innovation Center

GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION



Gilon

길온

COUNTRY Republic of Korea

CEO Stephan Kim 김남선

URL www.myisol.com

E-mail shjeon@gilon.co.kr

Glaceum Incorporation

글라세움

COUNTRY Republic of Korea

CEO 유상구

URL www.glaceum.com

E-mail kwlim@glaceum.com

EXHIBIT CLASSIFICATION

스마트 인솔, I-SOL

For your healthy Life Create correct walking habits, I-SOL

COMPANY & PRODUCT INTRODUCTION

㈜길온은 Wearable 빅데이터 수집 및 공급, 이를 기반으로 한 솔루션/서비스 서비스 제공 사업을 목표로 하며, 각종 IoT device 에 사용되는 센서의 독자 신호처리 기술력을 기반으로 wearable healthcare device및 솔루션 개발 진 행중임

- 스마트 인솔 기반 보행 및 러닝 분석 솔루션 공급
- 브랜드 업체 상용 솔루션 및 완제품 공급
- 압력센서/IMU(관성측정장치) 센서를 내장한 블루투스 기반의 스마트 인솔

Gil-on Inc. is a company that has developed and launched commercial smart insoles and a variety of walking/running analysis solutions, thinking that correct walking is a very important measure in improving quality of life.

We will work actively with experts such as hospital staff to develop solutions to improve the quality of life at an aging age by developing pre- and post-treatment comparison and rehabilitation support and senile disease prediction solutions.

- Smart Insole Product and walking/running Analysis Solution
- Completed commercialization of product through shoes brand $% \left(1\right) =\left(1\right) \left(1\right)$

EXHIBIT CLASSIFICATION

저분자 화합물

1. HSG4112

2. HGR4113

Small oral molecule

1. HSG4112 - Obesity & NASH

2. HGR4113 - T2DM & others

COMPANY & PRODUCT INTRODUCTION

글라세움은 항염증 작용에 기초하여 비만 및 NASH등을 포함한 대사질환을 안전하게 치료하는 'first-in-class' 약물을 개발합니다.

Glaceum is a clinical-stage biotech company dedicated to discovering and developing novel synthetic small molecules for the treatment of metabolic diseases. Our approach is to restore cells' mitochondrial function through mitochondrial biogenesis and mitophagy, thereby increasing energy expenditure while ameliorating chronic inflammation. HSG4112 normalizes bodyweight and liver histopathology in dietinduced mouse models of obesity and NASH; currently, it is in Phase 1 MAD study for obesity in South Korea, and in IND for Phase 1b/2a study for NASH in USA

Korea Doctor Preneur



Hospital-based Business Innovation Center



Goodplayground Co., Ltd.

㈜좋은운동장

COUNTRY Republic of Korea

Mingu Lee 이민구

URL www.goodplaygroundkorea.com

E-mail goodplayground@naver.com

GOS

지오에스

COUNTRY Republic of Korea

ChangGeol KIM 김창걸

URL www.goscare.com

E-mail hayoung.yoon@goscare.com

EXHIBIT CLASSIFICATION

- 1. JOYnT
- 2. 운동동영상
- 3. 운동소품
- 1. JOYnT
- 2. Exercising video
- 3. Exercising equipment

EXHIBIT CLASSIFICATION

고스케어 세라

GOSCARE SERA

COMPANY & PRODUCT INTRODUCTION

장애인을 위한 장애유형별 맞춤 운동프로그램과 홈트레이닝 장비를 개발하 여 보급하는 회사입니다.

Goodplaygound is a company that develops and distributes customized exercise programs and home training equipment for the disabled.

COMPANY & PRODUCT INTRODUCTION

GOS는 재활 의료기기/보조기기 전문기업으로서 하나님의 사랑으로 힘들고 지친 자들을 CARE하기 위해 설립되었습니다.

'고스케어 세라'는 뇌졸중으로 인한 편마비 환자들이 병원에서 사용하던 보행 전기자극 치료를 퇴원 후에도 가정에서 손쉽게 사용할 수 있도록 하는 제품 입니다.

GOS is a company specializing in medical devices and assistive devices for rehabilitation, established to care for people who are troubled and exhausted with God's Love.

"Goscare Sera" is a product developed for paraplegic patients with stroke to easily use walking electrostimulation treatment used in hospitals even after they are discharged from the hospital.

Wonju Medical Industry Technovalley



New Excellent Technology Exhibition

HANBIT

HAHO MEDI

하호메디

COUNTRY Republic of Korea
CEO Kim ha young 김하영
URL www.hahomedi.com
E-mail rotc054@nate.com

HANBITMD

주식회사 한빛엠디

COUNTRY Republic of Korea

CEO Lee doo yong 이두용

URL www.hanbitmd.com

E-mail ivic@hanvitmd.com

EXHIBIT CLASSIFICATION

고주파기기

Care me

COMPANY & PRODUCT INTRODUCTION

케어미는 하이드로 겔 패치를 이용한 고주파기기로 사용자의 편의성과 안정성을 높인 제품입니다. 고주파가 진피의 4mm까지 침투하여 심부열을 발생시켜 콜라겐 생성 및 혈액순환 촉진에 도움을 줍니다.

Care me is a high frequency device that uses hydrogel patch to enhance user convenience and safety. High frequency penetrates 4mm into dermal layer to cause deep heat, helping generation of collagen and accelerating blood circulation. Five minutes a day, care with Care me.

EXHIBIT CLASSIFICATION

IVIC PRO: IVIC PRO는 수액속도를 쉽고 정확하게 설정하고 측정 할 수 있는 의료 기기입니다. 수액세트를 연결해야할 필요가 없는 이 휴대용 장치는 여러 환자에게 적용 할 수 있으며 정확한 수액 치료 시간을 알려주기 때문에 수액치료의 안전성 및 치료효과가 향상됩니다.

IVIC PRO is a medical device allowing easy and precise control and measurement of IV flow rate. Portable device without requirements for connecting to IV set can be administered to multiple patients, and calculation of precise IV injection time enhances job efficiency.

COMPANY & PRODUCT INTRODUCTION

- · IV 점적 간격을 간편하게 계산
- · 점적 간격을 소리로 확인하며 정확하게 설정.
- · 현재 수액주입속도를 확인할 수 있으며, 수액 치료 중 수액속도의 보정이 가능
- · Do smart calculation of IV drip intervals
- \cdot Set the drip intervals precisely
- \cdot Check ongoing flow rates and allow for corrections during IV treatment

Korea Innovative Pharmaceutical Company



COVID-19 SPECIAL PAVILION



HANDOK.Inc.

㈜한독

HANDOKMEDICAL

한독메디칼

COUNTRY Republic of Korea

CEO Young Jin Kim 김영진

URL www.handok.co.kr

E-mail sohyun.kwon@handok.com

COUNTRY Republic of Korea

CEO Lee Pyunghwan 이평환

URL www.handokmedi.com

E-mail mayend0531@naver.com

EXHIBIT CLASSIFICATION

* 아마릴엠, 아마릴멕스 : Glimepiride Metformin * 테넬리아엠 : Teneligliptin, Metformin

* 다오닐 : Glibenclamide

* 에스파손 : Desoxymethasone Semi-solid

* 푸리지움 : Clobazam * 라식스 : Furosemide * 케토톱, 케토톱 핫 : Ketoprofen

* Amaryl M. Amaryl MEX : Glimepiride Metformin * Tenelia M : Teneligliptin, Metformin

* Daonil tab : Glibenclamide

* Esperson oint.0.25% : Desoxymethasone Semi-solid

* Frisium tab.10mg : Clobazam * Lasix tab. : Furosemide * KETOTOP Plaster : Ketoprofen

EXHIBIT CLASSIFICATION

호흡기용 마스트

Filter Mask

COMPANY & PRODUCT INTRODUCTION

HANDOKMEDICAL

Since HANDOKMEDICAL.CO. has been established in 1997, with unremitting efforts and innovation has earned national and international leading technology and experience. Our products are ergonomically designed and manufactured for both patients and medical personnel to suit the characteristics and purposes. These products are especially those that maximize safety, convenience, and efficiency.

COMPANY & PRODUCT INTRODUCTION

한독은 1954년 창립 이후 국내 제약산업의 국제화, 선진화를 이끌며 발전의 선두에서 성장을 거듭해 왔습니다. 한독은 전문의약품, 일반의약품, 진단기기 및 시약, 건강기능식품, 메디컬뉴트리션(특수의료용도식품), 유전체 분석 서비스 등 질병의 예측, 예방, 진단, 치료 및 건강증진을 위한 다양한 제품과 서비스를 제공하는 토탈헬스케어 기업입니다.

Handok has a core business focus in diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies.

Hospital-based Business Innovation Center



COVID-19 SPECIAL PAVILION

한림의료기

COUNTRY

URL

E-mail



Hankyul healthcare

㈜한결헬스케어

COUNTRY Republic of Korea

CEO Jung hyun LEE 이정현

URL

E-mail dhrwjd03@naver.com

의료용 침대, 카트, 내시경장, 스크럽

EXHIBIT CLASSIFICATION

음장검사시스템 / 보청기 / LED중이염치료기

Soundfield System / a hearing aid / Otitis media treatment

COMPANY & PRODUCT INTRODUCTION

음장검사 시스템

- 1. 음향장 시스템의 시험자를 위한 스피커 높이 조절 가능
- 2. 스피커와 테스트 대상자 사이의 거리 유지
- 3. 머리 받침대로 검사자 위치를 유지한다

LED 중이염치료기

- 1. 근적외선 LED를 이용하여 중이염증 치료
- 2. IR-LED를 이용하여 온열감을 느끼며 귀 가려움증을 치료
- 3. TIMER적용으로 효과적인 치료를 함

Soundfield Checkup system for pocket size booth

- 1. Adjustable height of Speaker for testee of sound field system $\,$
- 2. Maintain distance between speaker and testee
- 3. Maintain testee position by headrest.

LED Inflammation of the middle ear Therapy Machine

- 1. Therapy(Cure) Inflammation of the middle ear by near-infrared ray LED
- 2. The rapy(Cure) Urtication of the ear by IR-LED
- 3. Apply timer for effective therapy(Cure)

EXHIBIT CLASSIFICATION

Hospital Bed, Cart, Scrub Station, Endoscopic Cabinet etc.

Hanlim Medical Equipment Co., Ltd

Republic of Korea

YEON HO OH 오연호


www.han-lim.co.kr

medical@han-lim.co.kr

COMPANY & PRODUCT INTRODUCTION

병원용 의료가구 제조사

Hanlim medical co. is specialized in medical funitures and supplies for the use of hospital Korea Innovative Pharmaceutical Company



Korea Innovative Pharmaceutical Company



한미약품

HANLIM PHARM. CO., LTD.

한림제약㈜

COUNTRY Republic of Korea

CEO Jae Yoon Kim, Jung Jin Kim

김재윤, 김정진

URL www.hanlim.com

E-mail omijin@hanlim.com

Hanmi Pharmaceutical Co., Ltd.

한미약품

COUNTRY Republic of Korea

CEO Jong-Soo Woo, Se Chang Kwon

우종수, 권세창

URL www.hanmi.co.kr

E-mail james.chung@hanmi.co.kr

EXHIBIT CLASSIFICATION

FRABONE 은 인체 치밀골의 Haversian canals구조를 모방한 형태로 기공을 포함한 연결된 구조와 과립 사이에 형성된 공간을 통해 뼈성장에 필수적인 영양분 공급을 위한 혈관생성 및 신생 골형성에 시초가 되는 조골세포 형성을 크게 향상시킵다.

QBONPLUG는 소켓 보존에 사용되도록 설계된 플러그 형 합성 뼈 대체재로, 우수한 세포 부착 및 분화를위한 가장 이상적인 프레임 구조를 형성하여 뼈 를 빠르게 재생 및 복원합니다.

* T-Sporin Eye Drops : Cyclosporin 0.5mg

* Nasaflex/ Nasal Spray : Mometasone furoate 0.5mg, Azelastine HCl 1.4 mg)

* Risenex Plus Tab. : Sodium Risedronate 35mg, Cholecalciferol 5,600lU

* Dages Cap. : Pepsin 25mg, Paparatin 50mg, Diastase 15mg,

Cellulase 15mg, Pancreatin 50mg, Pancrelipase

13mg, UDCA 25mg

EXHIBIT CLASSIFICATION

[순환기 품목]

- 아모잘탄(고혈압 복합제): Amlodipine
- 아모잘탄 플러스(고혈압 복합제): Amloidpine + Losartan + Chlorthalidone
- 아모잘탄 큐(고혈압 복합제): Amloidpine + Losartan + Rosuvastatin
- 로수젯(이상지질혈증 복합제): Ezetimibe + Rosuvastatin
- 아모디핀(고혈압 치료제): Amlodipine camsylate
- 로벨리토(고혈압, 고지혈증 복합제): Irbesartan + Atorvastatin
- 카니틸(뇌기능 개선제): Acetyl-L-carnitine hydrochloride
- 피도글(항혈전제): Clopidogrel napadisilate

[소화기 품목]

- 에소메졸(위식도역류질환 치료제): Esomeprazole strontium

[Cardiovascular disease]

- Amosartan(Hypertension): Amlodipine
- Amosartan Plus(Hypertension): Amloidpine + Losartan + Chlorthalidone
- Amosartan Q(Hypertension, dyslipidemia): Amloidpine + Losartan + Rosuvastatin
- Rosuzet(Dyslipidemia): Ezetimibe + Rosuvastatin
- Amodipin(Hypertension): Amlodipine camsylate
- Rovelito(Hypertension, dyslipidemia): Irbesartan + Atorvastatin
- Carnitil(Alzheimer's disease, dementia): Acetyl-L-carnitine hydrochloride
- $\hbox{- Pidogul(Antiplatelet): Clopidogrel napadisilate}\\$

[Gastrointestinal disease]

- Esomezol (GERD, Gastric ulcer): Esome
prazole strontium $\,$

Framezal/CERD Castri

COMPANY & PRODUCT INTRODUCTION

1973년 창립한 한미약품은 업계 최고 수준의 R&D 투자를 통해 글로벌 신약 창출에 매진하는 한국의 대표적인 R&D 중심 제약기업입니다.

Hanmi Pharm is a global pharmaceutical company focused on the development and commercialization of new pharmaceutical products, with presence in Korea and China.

COMPANY & PRODUCT INTRODUCTION

고귀한 인간의 생명을 질병으로부터 지키는 것"이 한림의 사명이라는 기업이 념으로 한결같이 국민보건향상에 일익을 담당하고자 치료의약품 연구개발에 최선의 노력을 경주해 왔으며, 저희 한림제약은 국내에서 제약산업을 선도 하는 기업으로 성장하였습니다.

With the corporate mission of protecting the precious human life from various forms of

diseases, HANLIM has consistently endeavored to improve the health standards of people,

and we have grown to become one of the leading companies in Korea.

COVID-19 SPECIAL PAVILION



Hospital-based Business Innovation Center



Hanwool TPC Co., LTD

㈜한울티피씨

COUNTRY Republic of Korea

CEO Jeon Sung Hwan 전성환 URL www.hanwooltpc.com

E-mail ij.whang@hanwoolbio.com

HAPPY FARM

해피팜협동조합

COUNTRY Republic of Korea
CEO Jinseol Kim 김진설

URL ohhappyfarm.kr

E-mail happyfarm7@naver.com

EXHIBIT CLASSIFICATION

NC-15 PLUS 자동핵산추출장비

NC-15 PLUS

COMPANY & PRODUCT INTRODUCTION

한울티피씨는 분자진단의학 검사용 DNA추출장비 개발을 시작으로 관련장비와 소모품을 자체 연구개발과 동시에 타회사와의 활발한 제휴와 개발협력을 통해 국내 및 해외시장에 선보이고 있습니다.

Starting with the development of DNA extraction equipment for molecular diagnostic medical testing, HanwoolTPC has developed related equipment and consumables in-house, and is presenting them to overseas markets through active cooperation and development cooperation with other companies.

EXHIBIT CLASSIFICATION

- 1. 케이움 진 허니 바디 오일 솝
- 2. 케이움 스프라우트 진 바디로션
- 3. 케이움 진가인 모이스춰 크림
- 4. 케이움 진가인 베리어 크림
- 5. 케이움 진가인 풋 크림
- 1. K-WOOM GIN HONEY BODY OIL SOAP
- 2. K-WOOM SPROUT GIN BODY LOTION
- 3. K-WOOM JINGAIN MOISTURE CREAM
- 4. K-WOOM JINGAIN BARRIER CREAM
- 5. K-WOOM JINGAIN FOOT CREAM

COMPANY & PRODUCT INTRODUCTION

해피팜은 스마트농업 선도기업으로 청정 새싹삼을 재배생산하고, 이를 소재로 화장품을 연구 개발하여 'K-WOOM'이라는 브랜드를 런칭 하였으며, 스마트농업과 바이오산업의 창의융합 플랫폼 기업으로 나눔과 공유를 실천하고 취약계층에게 일자리를 제공하는 등 사회적 가치 창출을 통해 함께 성장하는 사회적경제 기업입니다.

The Happy Farm Cooperative focuses on the development of skin whitening and wrinkle-improving functional cosmetics using sprout-ginseng extracts, we launched a barand called by 'K-WOOM' and especially on the development of cosmetics that help skin health and protect senior skin, and implements partial reduction of social food revenue through job creation and job creation and social services to the vulnerable groups.

Wonju Medical Industry Technovalley



COVID-19 SPECIAL PAVILION

Healcerion Co., Ltd

㈜힐세리온



HBOTmedical Co., Ltd.

㈜에이치비오티메디칼

COUNTRY Republic of Korea

CEO Cheon Jeong Min 천정민 URL www.hbotmedical.com E-mail sales@hbotmedical.com COUNTRY Republic of Korea

CEO Ryu Jeong won 류정원 URL www.healcerion.com

E-mail William@healcerion.com

EXHIBIT CLASSIFICATION

고압산소챔버 O2 Fresh-M50

EXHIBIT CLASSIFICATION

소논 300L, 소논 300C Sonon 300C & 300L

COMPANY & PRODUCT INTRODUCTION

(주)에이치비오티메디칼은 고압산소챔버 전문 제조회사로써 관련 분야 15년 이상 전문가로 이루어진 회사입니다. 우리는 고압산소제조의 오랜 노하우 를 바탕으로 의료기관 및 가정에서 보다 쉽게 접할 수 있는 고압산소챔버를 개발 생산 하고 있습니다.

HBOTmedical Co., Lte. Is the specialized manufacturer of HBOT chambers

O2 Fresh-M50 is a Monoplace Hyperbaric Chamber designned and manufactured by HBOTmedical Co., Ltd.

COMPANY & PRODUCT INTRODUCTION

2012년에 설립된 힐세리온은 의료진과 환자에게 최상의 POC(Point of care) 서비스를 제공 할 수 있는 mobile health care system을 개발하고있습니다.

힐세리온은 첨단 IT기술을 기반으로 모바일 기술과 의료기기를 접목시켜 언제 어디서나 진료 및 진단을 수행할 수 있는 Mobile medical device를 개발하고, 이를 활용하여 다가오는 원격진료 및 현장 진료 시대에 선두주자가 되고자 합니다.

Sonon 300C & 300L Portable Ultrasound Healcerion's SONON is a truly mobile ultrasound device compatible with iOS and Android technology. Small enough to fit in your pocket, SONON is highly portable and flexible for healthcare providers. SONON also offers strong wireless connectivity, requiring only an existing smartphone or tablet to conduct scans. The SONON mobile application supports the device so providers can scan patients and transmit images and recordings securely to any hospital via Wi-Fi, 3G, or LTE networks.

HealingSound

Wonju Medical Industry Technovalley

Healthcare Technology Licensing Office



HEALING SOUND

㈜힐링사운드

Healthcare Technology Licensing Office

COUNTRY Republic of Korea
CEO Kang Jungu 강준구

URL www.healingsound.kr

E-mail jooncap@naver.com

COUNTRY Republic of Korea

Kwon, Deok Cheol

URL www.khidi.or.kr

보건의료기술이전전담기관(H+TLO)

E-mail savvy0@khidi.or.kr

EXHIBIT CLASSIFICATION

스마트히어링디바이스

Noise Cancelling Haedphone

COMPANY & PRODUCT INTRODUCTION

<의사소통 증진을 통한 의료용 스마트 어시스턴트 플랫폼>

의료 환경에서 의료진과 환자간의 명확한 의사소통을 제공. 의료 질의 향상 및 청각보호, 공포감 감소로 인한 만족도 증가 및 의료현장의 신뢰도 증가를 기대함.

Healing sound make hearing Protection device for dental use. Hearing loss occurs when 80dB of noise is exposed for more than 8 hours. Dental workers hear dental noise for about 8~10 hours daily. hearing loss among dental workers of 40% or more (> 5 times than normal workers). Existing products can decrease ambient noise. But patients do not hear well whenever the doctor talks, so they should peel off the product to communicate each other. Wearing Healing sound's product, doctor and patient communicate freely. Healing sound's products have following benefits; noise isolation, communicating dentist voice, use of multimedia equipment.

EXHIBIT CLASSIFICATION

보건의료 TLO는 R&D 연구성과의 사업화 촉진을 위해 보건의료 R&D 사업단, 국공립연구소, 연구중심병원으로 구성된 협의체로 지난 2013년 28개 기관으로 처음 출범한 이래 현재 의료기관, 병원 등 60개 기관이 참여하고 있으며 매년 기술이전 및 사업화 성과가 지속적으로 성장하고 있다. 이번 H+TLO 가상 전시 홍보관을 통해 가톨릭대학교 산학협력단, 경희대학교 산학협력단, 국립암센터, 삼성서울병원, 서울아산병원, (재)범부처신약개발사업단 등의 산학협력을 통한 보건의료 기술 사업화 트렌드를 홍보하고자 한다.

H+TLO (Health Technology Licensing Office) consists of biohealth R&D centers, national research institutes, and research-centered hospitals established with the aim of promoting commercialization of R&D research outcomes. Since its foundation in 2013 with 28 constituting organizations, it currently features about 60 organizations including medical institutes and hospitals, demonstrating a steady growth in technology transfer and commercialization every year. In its participation in Virtual Exhibition, H+TLO Pavilion will promote commercialization trends of biohealth technologies through industrial/academic collaborations with Research and Business Development Foundation of The Catholic University of Korea, Kyung Hee University, National Cancer Center, Samsung Medical Center, Asan Medical Center, Korea Drug Development Fund, and others.

Korea Doctor Preneur

Korea Innovative Pharmaceutical Company



Hedgehog Co., Ltd.

㈜헤지호그

COUNTRY Republic of Korea

CEO Sang-Chul Oh 오상철

URL www.hedgehogtec.com

E-mail sachoh@korea.ac.kr

Helixmith Co., Ltd

(주)헬릭스미스

COUNTRY Republic of Korea

CEO Sunyoung Kim 김선영

URL www.helixmith.com

E-mail contact@helixmith.com

EXHIBIT CLASSIFICATION

고형암 치료제 (HH101, HH102, HH103, HH201)

Drugs for Solid tumor (HH101, HH102, HH103, HH201)

COMPANY & PRODUCT INTRODUCTION

㈜헤지호그는 기존 항암치료제의 부작용을 최소화하고 헤지호그 신호전달을 효과적으로 억제하여 항암효능을 극대화하는 것을 목표로 내성 극복 문제해결과 안전성 확보를 위한 새로운 항체 및 저분자화합물 신약을 개발하여 독보적인 원천기술력을 확보하고 시장을 선점할 수 있는 항암치료제를 개발하고 있습니다.

Hedgehog Co., Ltd. aims to minimize the side effects of existing anticancer drugs and effectively suppress hedgehog signalling to maximize anticancer efficacy. The company is developing anti-cancer drugs that can secure original technology and preempt the market by developing new antibodies and new drugs for low molecular compounds to solve resistance problems and secure safety.

EXHIBIT CLASSIFICATION

* VM202 : 당뇨병성 신경병증, 당뇨병성 족부궤양, 허혈성 심장질환

* Orphan Drug : 근위축성 측삭 경화증

* VM206 : 유방암

* VM202 : Diabetic peripheral neuropathy, Diabetic foot ulcer,

Ischemic heart disease

*Orphan Drug $\,:\,$ Amyotrophic lateral sclerosis

*VM206 : Breast cancer

COMPANY & PRODUCT INTRODUCTION

헬릭스미스는 1996년에 설립되었으며 20여년간 유전자 치료제 연구개발에 전념해 왔습니다. 이를 통해 얻은 독자적인 기술과 노하우를 바탕으로기존에 치료제가 없는 질병에 대해 새로운 접근법을 연구하고 있으며 허혈성질환 또는 신경 근육 질환을 타겟으로 한 다양한 파이프라인을 가지고 있습니다.

Founded in 1996, Helixmith has been dedicated to research in gene therapy for over 20 years. Led by Sunyoung Kim and his lab in Seoul National University, the Helixmith team has developed an extremely powerful gene expression system and has tested it in various therapeutic areas.

Wonju Medical Industry Technovalley



Korea Innovative Pharmaceutical Company

에이치케이이노엔 주식회사

HK inno.N Corporation



Hi Medical

에이치아이메디칼

COUNTRY Republic of Korea

CEO Cheolhui Won 원철희

URL www.medicoson.com

E-mail sales@medicoson.com

COUNTRY Republic of Korea

CEO Seok Hee Kang. Sang Hyun Yoon

강석희, 윤상현

URL www.hkinno-n.com

E-mail sun.park@kolmar.co.kr

EXHIBIT CLASSIFICATION

집속형초음파자극기

DUOLIF

COMPANY & PRODUCT INTRODUCTION

에이치아이메디칼의 DUOLIF 는 개인용 미용기기로 HIFU(고강도 집중형 초음파)와 RF(고주파)의 두 기술을 간단히 카트리지를 바꿔 한 개의 메인 바디로 사용할 수 있습니다. 또한 무선 충전 기술을 적용하여 사용 중 간편히 충전 크래들에 올려 놓아 충전을 할 수 있어 사용이 간편하며, 컴팩트한 크기로 사용 중 그립이 용이합니다. DUOLIF는 아름다운 디자인으로 2018년 굿디자인 상을 수상하였습니다. 원리는 HIFU 에너지가 피부 3mm 깊이에 열응고점을 만들어 피부를 수축하고 콜라겐의 형성을 촉진합니다. 또한 RF 에너지로이 과정을 촉진하여 피부 탄력을 항상시켜 주름을 제거합니다.

DUOLIF is a face lifting and tightening device for personal use which that is combined two technologies, HIFU and Multi-polar RF in one Body. It has wireless charging cradle with ergonomic design for easy grip. HIFU energy iift and tighten deep skin layers and Multi-polar RF simulates from epi-dermis to deep dermis, so it can deliver the thermal energy all skin layers through two different cartridges.

- HIFU plus Multi-polar RF lifting
- Bluetooth communication for treatment guide
- Wireless charging cradle
- Simply changed HIFU or RF cartridge
- Beautiful and Ergonomic design

EXHIBIT CLASSIFICATION

- * 케이캡정(Tegoprazan): 위식도역류질환 치료
- * 에포카인(rh-EPO): 만성신부전 환자에게 나타나는 빈혈(국내 최초, 세계 3번째 개발)
- * 반코마이신(Vancomycin): 표재성 2차감염증, 페니실린계 및 세팔로스포린 계 항생물질로 치료가 되지 않는 중증 감염증
- * 타포신(Teicoplanin): 페니실린이나 세팔로스포린 등의 항생물질로 치료될 수 없는 감염증을 비롯한 잠재적으로 중증의 그람양성 감염증
- * 모벨록신(Moxifloxacin): 4세대 플루오로퀴놀론계 항생제
- * K-CAB Tab. (Tegoprazan): Gastroesophageal reflux disease (GERD)
- * Epokine Inj.(rh-EPO): Anemia of hemodialysis patients with end-stage renal disease
- * Vancorin Inj. (Vancomycin): Serious, life-threatening infections by gram-positive bacteria
- * Tapocin Inj. (Teicoplanin): Serious infections by gram-positive bacteria
- * Moveloxin I.V. solution bag (Moxifloxacin): Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia and so on

COMPANY & PRODUCT INTRODUCTION

HK 이노엔(전 씨제이헬스케어)은 전문의약품과 Health&Beauty사업을 펼치고 있습니다. 주로 간, 암, 면역질환을 중심으로 신약 및 바이오의약품을 개발하고 있습니다. 'Heal the World For Better Life' 미션을 갖고 혁신적인 글로 벌 신약을 개발하여 고객이 신뢰할 수 있는 자랑스러운 글로벌 제약 기업이되겠습니다.

As a well-established local pharma in prescription drugs and Health & Beauty, HK inno.N(Fomer CJHC) is at its preparation for the future by allocating resources to R&D for new drugs, biologics mainly in liver, cancer, and immune disease areas.

Hospital-based Business Innovation Center



COVID-19 SPECIAL PAVILION

HuBDIC

Hospital-based Business Innovation Center

개방형실험실사업단

HuBDIC

(주)휴비딕

COUNTRY

Republic of Korea

CEO

URL

E-mail

COUNTRY Republic of Korea

CEO SHIN JAE HO 신재호

URL www.hubdic.co.kr

E-mail plan@hubdic.com

COMPANY & PRODUCT INTRODUCTION

병원의 우수한 역량 및 인프라 활용을 통한 창업, 기술실용화 활성화 및 병원 중심의 개방형 혁신 플랫폼

EXHIBIT CLASSIFICATION

비접촉 체온계

Thermometer

COMPANY & PRODUCT INTRODUCTION

세계 최고의 체온, 혈압, 당 측정 센싱기술을 비롯하여 고주파, 중주파, 저주파 자극 및 치료 기술, 원격진료 및 진단 솔루션, VOCs, 공기 중 유해물질의 측정 기술 제품을 통하여 다양한 전문의료기기를 비롯하여 다양한 건강관리 기술 제품을 세계 30여 개국에 제품을 수출하고 있으며, 차세대 융합의료기술을 통한 다양한 진단센서 및 치료기, 원격진단시스템등의 연구개발을 통해 진단 바이오 분야의 최고 기업이 되고자 합니다.

HuBDIC established its own research and development organization and has since invested heavily in the development and design of new and innovative technologies for healthcare products. HuBDIC is actively involved in improving its existing products, and in the development of new and innovative items. The product development activities focus on "Human Healthcare" issues and on innovative solutions

HUINNO

COVID-19 SPECIAL PAVILION

Korea Doctor Preneur



HUINNO

(주)휴이노

COUNTRY Republic of Korea

CEO Yeongjoon Gil 길영준

URL www.huinno.com

E-mail kyzoon@huinno.com

Huniverse Global Co., Ltd.

주식회사 휴니버스글로벌

COUNTRY Republic of Korea

CEO Sang Heon Lee 이상헌

URL

E-mail spinelee@gmail.com

EXHIBIT CLASSIFICATION

메모와치, 메모패치, 메모 인공지능

MEMO Watch / MEMO Patch / MEMO A.I.

EXHIBIT CLASSIFICATION

- 1. 정밀의료 병원정보시스템(P-HIS)
- 2. P-HIS 부가서비스
- 1. Precision Medicine Hospital Information System (P-HIS)
- 2. P-HIS Supplementary Service

COMPANY & PRODUCT INTRODUCTION

휴이노는 클라우드를 통한 AI 진찰 서비스와 Cardiac Monitor 기술이 탑재된 스마트 워치 및 패치 등의 웨어러블 솔루션들을 통하여 지금까지 진단이 어 려웠던 부정맥, 심방세동, 고혈압 등 심장질환 환자들의 진찰과 진료를 더욱 편리하고 효율적이게 만듦과 동시에 더욱 저렴하고 빠르게 진행 할 수 있어 병원, 의료진, 환자 등 모두에 게 유용한 서비스를 만들고 있습니다.

HUINNO is a healthcare wearables startup building a digital healthcare solution with clinically-tested and KFDA-approved wearables with patient monitoring echnologies, along with the state-of-the-art Al-based cloud analytics software. Huinno aims to help healthcare providers to avoid critical knowledge gaps by allowing for more convenient and continous ECG and cardiac vitals data.

COMPANY & PRODUCT INTRODUCTION

㈜휴니버스 글로벌은 4차 산업혁명 디지털 헬스케어 변화의 중심에서 미래 의료 혁신을 선도하는 클라우드 기반의 정밀의료 병원정보시스템 개발 전문 기업입니다.

국내 2,3차 종합병원에 클라우드 기반 병원정보 시스템(P-HIS)을 보급·확산하고, 임상 용어/코드 체계화를 통한 의료 빅데이터를 구축하고 이를 활용한 인공지능(AI) 기반 예측, 진단, 치료를 지원하는 디지털 병원의 중심인 병원정보시스템 플랫폼을 서비스 합니다.

Huniverse Global Co., Ltd. is is at the center of digital healthcare changes in the fourth industrial revolution. The company focuses on developing a cloud-based precision medical hospital information system that leads future healthcare innovation.

The company supplies and distributes cloud-based hospital information system (P-HIS) to the nations's 2nd and 3rd general hospitals. It also builds healthcare big data through clinical terminology/code systemization, and uses this to provide hospital information system platform, which is the center of a digital hospital that supports artificial intelligence (AI) based prediction, diagnosis, and treatment.

Korea Innovative Pharmaceutical Company



Korea Doctor Preneur



Huons co., Ltd

㈜휴온스

CEO Republic of Korea

Key-An, UM 엄기안

WRL www.huons.com

E-mail hyosup.kim@huons.com

Hutom Co., Ltd.

㈜휴톰

COUNTRY Republic of Korea

CEO Woojin Hyung 형우진

URL www.hutom.io

EXHIBIT CLASSIFICATION

1. Surgical Rehearsal

2. Surgical Navigation

E-mail WJHYUNG@yuhs.ac

EXHIBIT CLASSIFICATION

* 휴온스리도카인 에피네프린주 : Lidocaine HCl, Epinephrine Bitartrate

* 리도카인주 1% : Lidocaine HCl
* 클레이셔점안액 : Cyclosporine
* 휴톡스주 100Units : Botulinum Toxin
* 하이히알플러스주 : Hyaluronic Acid
* 생리식염주사 : Sodium Chloride

* Medicaine Inj. : Lidocaine HCl, Epinephrine Bitartrate

* Lidocaine Inj. 1% : Lidocaine HCl

* Clacier Eye Drop : Cyclosporine

* Hutox Inj. 100 Units : Botulinum Toxin

* Humia Inj. : Hyaluronic Acid

* Sodium chloride Inj. : Sodium chloride

3. Surgical Analytics

COMPANY & PRODUCT INTRODUCTION

수술이 필요한 환자에게 보다 나은 수술 기회를 제공하며 기술이 환자에게 향하는 Human Touch In Medicine 을 추구합니다. 휴톰의 기술은 환자의 진단에서부터 수술 예후까지 수술 전 과정에 걸쳐 인공지능을 부여해 단기적으로 수술시간 단축과 합병증 감소와 같은 Surgical outcome을 개선하고, 장기적으로 수술을 받은 환자의 Quality of Life를 향상하는 최적화된 수술 기회를 제공합니다. 또한 수술 후에는 수술을 받은 환자에게 발생 가능성이 있는 단기적 또는 중·장기적 합병증에 대해 예측함으로써 그 환자에게 특화된 사후 관리와 더불어 최적화된 Nutritional support, Medication, Follow up schedule까지 공급합니다. 이는 Total Medical Cost를 감소시키며 수술이 필요한 환자에게 폭넓은 수술 기회를 제공하게 될 것입니다. 휴톰은 거기서 더나아가 영상 및 의료 빅 데이터 기반 수술 플랫폼을 개발해 환자 치료 수준을 향상 시킬 것 입니다.

The company provides better surgical opportunities for patients in need of surgery, and pursues 'Human Touch In Medicine' where technology is focused on treating the patients.

Hutom's technology improves surgical outcomes such as shorter operating hours and reduced complications in the short term, by applying artifical intelligence throughout the entire surgical process, from diagnosis of patients to the prognosis of surgery. The company provides optimized surgical opportunities to improve quality of life for long-term patients.

In addition, it provides optimized nutritional support, medication, and follow up schedule as well as specialized follow-up care for patients by predicting short, medium, or long-term complications that may occur in post-surgery patients."

COMPANY & PRODUCT INTRODUCTION

휴온스는 1965년 광명약품공업사로 출발하여 50여년간 끊임없는 도전과 혁 신으로 독창적이고 우수한 필수의약품을 생산하는 글로벌 회사로 도약하였 습니다

Huons is one of the fastest growing company manufacturing quality finished pharmaceutical product since 1965 and possess cGMP standard of manufacturing site.

GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION



Wonju Medical Industry Technovalley



HUWANT Inc.

㈜휴원트

CEO Republic of Korea
Wookjin Lee 이욱진
URL www.huwant.co.kr

E-mail huwant@naver.com

HYOIL Corporation

㈜효일

COUNTRY Republic of Korea

CEO 송주희

URL

E-mail robotv@hanmail.net

EXHIBIT CLASSIFICATION

'브리드-온', '브리드-체커'

Breathe-On, Breathe-Checker

EXHIBIT CLASSIFICATION

근전도센서

COMPANY & PRODUCT INTRODUCTION

IoT 기반의 디지털헬스케어 제품. 디바이스와 전용 앱으로 구성. 스마트폰, 태블릿, PC 등에 앱 설치 후 사용. 호흡훈련 및 호흡기능 측정. 데이터 저장 및 화요

Breathing training & respiratory function measurement products. (devices & apps)

COMPANY & PRODUCT INTRODUCTION


주식회사 효일은 IOT ICT 기반 인공지능 운동관리 시스템을 통하여 스마트 헬스케어 서비스 전문기업입니다. 근전도 센서, 심박센서를 통한 생체신호 측정과 3D 모션센서를 통한 동작 정확도 평가로 과학적인 데이터 기반 개인 맞춤형 운동처방 솔루션을 제공합니다.

- 신체부위별 근육 사용량 및 근육 피로도를 생체 신호 데이타를 분석하기 위해 측정하는 센서임
- 신체 각 부위별 근육 부위에 피부 접촉식으로 부착하여 사용함
- 신체 능력을 판단하여 개인에게 적합한 운동처방 및 운동 추천을 하기 위한 디바이스로 신체의 좌 우측 근육발달 밸런스 및 근육 사용량을 통한 파워를 측정 분석함."

Hyoil Corporation is an IOT & ICT based, smart health care specialized company, utilizing artificial intelligence exercise programming system.

Scientific data based and individualized exercise prescription solution will be provided through bio-signal measurement, using electromyography sensor and movement accuracy evaluation, using 3-dimension motion sensor.

- Muscle engagement and muscle fatigue measurement sensor in order to analyze biological signal of the body according to each body parts.
- Used by attaching to the body parts, where the muscle group is being used.
- A device utilized for exercise prescription and recommendation according to the individual's physical ability examination, which can also be used for muscle balance measurement and power measurement from the data of muscle engagement rate.



Korea Innovative Pharmaceutical Company



HysensBio Co., Ltd.

하이센스바이오

COUNTRY Republic of Korea

CEO Joo-Chul Park 박주철

URL www.hysensbio.com

E-mail shyi@hysensbio.com

HYUNDAI Pharm. Co., Ltd

현대약품㈜

COUNTRY Republic of Korea

CEO Sang-Joon, Lee 이상준

URL www.hyundaipharm.co.kr

E-mail bgrhee@hdpharm.co.kr

EXHIBIT CLASSIFICATION

상아질 재생 기술 기반의 치아지각과민증 (시린이) 및 치아우식증 (충치) 치료제

Treatment of dental hypersensitivity and dental caries through dentin regeneration technology

COMPANY & PRODUCT INTRODUCTION

(주)하이센스바이오는 치아 발생 및 재생 분야의 우수한 기술력을 보유하고 있으며, 세계 최초로 상아질 재생 원천기술을 확보하여 치아우식증 및 시린이 치료제를 개발하고 있습니다

HysensBio Co., Ltd. was established in 2016 based on the result of basic and clinical research of dentistry for last 20 years. In our regenerative dental medicine R&D center, dentists and dental science researchers are cooperating with many expert groups from Seoul National University(SNU) and SNU Dental Hospital.

EXHIBIT CLASSIFICATION

- * 마이녹실 3%, 5% 액/ 3% 겔 : 탈모증 치료
- * 복합마이녹실액 5% : 탈모증 치료
- * 테놀민정: 고혈압, 협심증
- * 유레민정: 야뇨증
- * 멀타핀정: 주요 우울증
- * 미라프정/서방정: 특발성 파킨슨증, 특발성 하지불안증후군
- * 하이페질정: 알츠하이머형 치매
- * 디만틴정: 중등도~중증의 알프하이머형 치매
- * 타미린서방정: 경등도~중등도의 알프하이머형 치매
- * 페미로살정/건조시럽: 기관지 천식, 다년성 알레르기성 비염
- * 설포라제캡슐/CR서방정: 급만성 호흡기질환
- * 레보투스정/시럽: 급만성 기관지염
- * Minoxyl- 3%, 5% Solution / Minoxyl -3%, 5% Gel: Androgenetic alopecia
- * Minoxyl complex Solution 5%: Androgenetic alopecia
- * Tenormin Tab. : Hypertension. Angina Pectoris
- * Uremin Tab. : Nocturnal enuresis
- * Mirtapin Tab. : Major depressive disorder
- * Mirap Tab. / ER Tab. : Parkinson's disease
- * Hipezil Tab. : Alzheimer's disease
- * Dimantin Tab. : Alzheimer's disease * Tamirin SR Tab. : Alzheimer's disease
- * Pemirosal Tab. / Dry Syrup : Bronchial Asthma, Allergic Rhinitis
- * Pemirosai Tab. / Dry Syrup : Bronchiai Asthma, Allergic Rhin
- * Surfolase Cap. / CR Tab. : Acute & chronic Bronchitis
- * Levotuss Tab. / Syrup : Acute & chronic Bronchitis
- * Clinium Vaginal Tab. : Bacterial & Candida Vaginitis

COMPANY & PRODUCT INTRODUCTION

현대약품(취는 인간존중의 사상과 투명한 기업 정신을 지향하는 최고 경영자의 철학을 담아 「인류의 보건 향상에 기여한다」라는 기업이념으로 1965년 의약품 전문기업으로 창립되었습니다. 신약개발 혁신성 및 우수성을 인정받아혁신형 제약기업 및 ATC(우수기술연구센터)에 선정되었으며 지속적인 인적, 물적 인프라 투자로 업계 상위 R&D 투자비율을 유지하고 있습니다.

HYUNDAI Pharm. was founded in 1965 as a pharmaceutical company with the corporate philosophy of "Contributing to the improvement of the health of mankind" based on the philosophy of the CEO who aims at the esteem of human respect and transparent corporate spirit. As a global R&D company, we aim to fulfill our responsibilities for improving public health by focusing on developing new drugs and incrementally modified drugs through continuous investment.

K-Healthcare start-ups

Korea Doctor Preneur



IJ

아이지

COUNTRY

Republic of Korea

CEO Moon Iji 문이지

URL www.iji-design.com

E-mail ciean4@naver.com

I-Key Co., Ltd.

㈜아이키

COUNTRY Republic of Korea

CEO Yong Wook Kwon 권용욱

URL www.ikeymed.com

E-mail kyw2848@hanmail.net

EXHIBIT CLASSIFICATION

생리컵(월경컵) 소독기 제품

Menstrual cup sterilizer

COMPANY & PRODUCT INTRODUCTION

현재 개발 중인 소독기로는 듀얼 자외선 소독기인 '이지' 소독기와 전해수 소독기인 '아이' 소독기

Dual ultraviolet sterilizer "Easy" and electrolytic water sterilizer "I" currently under development

EXHIBIT CLASSIFICATION

- 1. 신개념 비절골 하지교정 임플란트
- 2. Cannulated screw 7.0, 4.0
- 3. 골수내고정막대
- 1. A new concept of non-isolated lower limb correction implant
- 2. Cannulated screw 7.0, 4.0
- 3. Intramedullary Ikey Nail

COMPANY & PRODUCT INTRODUCTION

주식회사 아이키 기업은 2016년 교원창업으로 시작하여 의료인 맞춤형 정형외과 임플란트 및 시술기기 개발을 통해 국내 의료서비스 질 향상과 Fast Follower 보다는 First mover 전략을 통해 Global healthcare company 구축을 목표로 하고 있습니다.

i-Key Co., Ltd. was founded in 2016 by faculty start-up. It aims to improve the quality of domestic medical services through the development of orthopedic implants and treatment devices tailored to medical personnel. The company also aims to build a global health care company through First Mover strategy rather than Fast Follower.

Korea Doctor Preneur

Korea Innovative Pharmaceutical Company



IKooB

㈜아이쿱

ILDONG PHARMACEUTICAL CO., LTD.

일동제약㈜

COUNTRY Republic of Korea

CEO Jae Hyung Cho 조재형 URL company.ikoob.com/

E-mail drhopper@ikoob.com

COUNTRY Republic of Korea

CEO Paul Woong - sup Yun 윤웅섭

URL www.ildong.com

E-mail youngkyoung.pak@ildong.com

EXHIBIT CLASSIFICATION

1. 아이쿱클리닉(iKooB Clinic)

2. 올튼(ALL-TEUN)

1. iKooB Clinic

2. ALL-TEUN

COMPANY & PRODUCT INTRODUCTION

㈜아이쿱은 2011년 설립된 ICT 기업으로 다양한 스마트 기기를 통한 지식과 경험을 공유하고 소통할 수 있는 플랫폼 개발을 지향하고 있습니다. 특히 헬 스케어 산업부문에서 ㈜아이쿱은 더욱 주목을 받고 있습니다.

헬스케어 정보의 매를 의사와 환자간의 지식공유,교육이라는 새로운 정의를 통해 정보/교육 커뮤니케이션이라는 특화된 비즈닛 모델로 자사의 서비스 모 델을 구측하고 있습니다.

의사용 디지털 환자교육 플랫폼 '아이쿱클리닉(iKooB Clinic)'을 선두로 양방 향 피드백의 정보, 교육 커뮤니케이션 플랫폼 서비스를 만들어 나가고 있습니다.

iKooB Co., Ltd. was established in 2011, aiming to develop a platform that can share knowledge and experience, and communicate through various smart devices

iKooB is spotlighted especially in the healthcare industry.

the company is exploring its own service model with the specialized Biznet model of information/education communication through the new definition of knowledge sharing and education between doctors and patients, with healthcare data as a medium.

With the lead of the digital patient education platform 'iKooB Clinic', the company is creating information and educational communication platform services with interactive feedback."

EXHIBIT CLASSIFICATION

* 베시보 : 만성 B형간염 * 피레스파 : 특발성폐섬유증 * 후루마린 : 항생제 * 사미온 : 뇌순환개선 * 텔로스톱 : 고혈압과 고지혈증 * 토타스플러스 : 고형아

* 투탑스플러스 : 고혈압 고지혈증 * 텔로스톱플러스 : 고혈압 고지혈증 * 라비에트 : 위산분비억제제 * 아로나민 시리즈 : 종합 비타민영양제

* 엑세라민 : 고함량 비타민영양제 * 푸레파인 : 치질

* 푸레파인 : 치질
* 메디터치 시리즈 : 습윤드레싱재
* 마이니 시리즈 : 건강기능식품 브랜드
* 지큐랩 시리즈 : 프로바이오틱스
* 아로골드D : 비타민D 드링크
* 퍼스트랩 : 코스메슈티컬 브랜드

* Besivo : chronic hepatitis B treatment * Pirespa : Idiopathic pulmonary fibrosis drug

* Flumarin : antibiotic

* Sermion : Cerebral blood flow enhancer

* Telostop : hypertension and hyperlipidemia treatment

* Twotops Plus : hypertension treatment

* Telostop Plus : hypertension and hyperlipidemia treatment

* Rabiet : Gastric acid inhibitor * Aronamin : Multivitamin

* Exeramine : High-content vitamin supplement

* Prepain : Hemorrhoids treatment

* Meditouch : Moist wound healing dressing

* MyNi : health functional food brand

* gQlab : probiotics * Arogold D : Vitamin D)

* First Lab : A cosmeceutical brand

COMPANY & PRODUCT INTRODUCTION

일동제약그룹은 '의약품의 근본은 사람이다'라는 창업이념을 바탕으로 1941 년 설립되어, 사람과 생명을 귀하게 여기는 마음으로 건강한 삶을 위해 힘써 왔습니다. 일동 임직원들은 인류의 건강과 행복을 위해 존재한다는 신념으로, 긴 시간동안 사람들의 건강과 행복을 위해 많은 가치들을 만들어왔고, 또 만 들어 갈 것입니다.

Since Ildong Pharmaceutical Group was founded in 1941 under the philosophy of 'pharmaceuticals are rooted in humans', we have strived for the healthier lives of people placing our highest value on humanity and lives, we have created and shared significant value for health and prosperity throughout many years and will continue this endeavor.

New Excellent Technology Exhibition



Korea Innovative Pharmaceutical Company



IMEDICOM Co., Ltd.

아이메디컴㈜

COUNTRY Republic of Korea

CEO Ju Don Soo 주돈수

URL www.imedicom.co.kr

E-mail sunghui@imedicom.co.kr

ImmuneMed Inc.

㈜이뮨메드

COUNTRY Republic of Korea

CEO Yoon-Won Kim, Byoung-Ok Ahn

김윤원, 안병옥

URL www.immunemed.co.kr

E-mail sppark@immunemed.co.kr

EXHIBIT CLASSIFICATION

EZX/재수술의 부정적인 영향을 최소화한 인공고관절 비구컵 제거 기술

The EZX System is minimizing the side effects of fracture and bone loss and reducing the time for extracting.

EXHIBIT CLASSIFICATION

VSF : 바이러스 감염세포의 표면에 나오는 vimentin과 결합하여 바이러스 복제 및 염증을 억제함

VSF: VSF targets to cell surface vimentin from virus-infected cells and inhibits viral replication and inflammation.

COMPANY & PRODUCT INTRODUCTION

자사는 정형외과수술용 의료기기, 신경외과의 최소침습 의료기기들을 제조하며, EZX는 효율적이며, 부정적인 영향을 최소화할 수 있는 인공고관절 비구컵을 제거기 입니다.

IMEDICOM Co., Ltd. manufactures medical devices. And the EZX System is minimizing the side effects of fracture and bone loss and reducing the time for extracting.

COMPANY & PRODUCT INTRODUCTION

신약(바이러스질환,염증질환치료제)부문과 급성감염성질환 신속진단사업 부문을 운영 중

ImmuneMed Inc. operates new drugs (viral diseases, treatments for inflammatory diseases) and rapid diagnosis of acute infectious diseases.

Korea Doctor Preneur



K-Healthcare start-ups



Immunoforge Co., Ltd.

이뮤노포지㈜

COUNTRY Republic of Korea

CEO Sung-Min Ahn, Kiho Chang

안성민, 장기호

URL www.immunoforge.com

E-mail smahn@gachon.ac.kr

immunomax

(주)이뮤노맥스

COUNTRY Republic of Korea
CEO Se-Ho Park 박세호

URL www.immunomax.co.kr

E-mail jjyoon.imx@gmail.com

EXHIBIT CLASSIFICATION

- 1. 바이오신약
- 2. 합성신약
- 1. Bio-new drug
- 2. Synthetic new drug

EXHIBIT CLASSIFICATION

면역기반 바이오의약품

Biopharmaceutical Company via Optimal Immunity

COMPANY & PRODUCT INTRODUCTION

이뮤노포지는 단백질 치료제 중심의 신약개발기업입니다. 근위축중 관련 질 환 2가지의 미국 임상2상을 준비하고 있으며, 초기 단계의 First-in-class 단 백질 신약 2종류를 개발하고 있습니다. 우수한 국내외 R&D 네트워크를 활용 해 글로벌 경쟁력이 있는 회사로 성장하기 위해 노력하고 있습니다.

Immunoforge is a new drug development company focused on protein drugs. The company is preparing for Phase II clinical trials of two types of myotrophic-related diseases, and developing two early-stage first-in-class protein drugs. The company strives to grow into a globally competitive company by utilizing excellent domestic and international R&D network.

COMPANY & PRODUCT INTRODUCTION

기억 T세포 증진 기술을 활용한 항암면역 T-세포 치료제 및 바이러스 백신과 단백질 의약품의 생산성을 증가시키는 플랫폼 기술 개발

ImmunoMax is developing anti-tumor T cell therapy with memory T cell boosting technology and the Platform Technology on enhancing the production for the virus vaccine

InBody

COVID-19 SPECIAL PAVILION

New Excellent Technology Exhibition



InBody Co. Ltd.

(주)인바디

INCELL BIO

㈜인셀바이오

COUNTRY Republic of Korea
CEO Ki Chul Cha 차기철

URL www.inbody.com

E-mail jina@inbody.com

COUNTRY Republic of Korea
CEO Kwon hee jae 권희재
URL www.incellbio.co.kr

E-mail geonwoohan@incellbio.co.kr

EXHIBIT CLASSIFICATION

혈압계

Blood Pressure Monitor

EXHIBIT CLASSIFICATION

wiseprep kit & Equipment/액상세포검사

wiseprep kit & Equipment/Liquid based Cytology

COMPANY & PRODUCT INTRODUCTION

(주)인바디는 한국 의료기기 제조업체입니다. 주요 사업은 체성분 분석기, 자동 혈압계, 자동 신장 체중계 등 의료장비 제조와 판매이며, 미국, 중국 ,일본, 등 6개의 국가에 해외법인이 있습니다. ㈜인바디 혈압계는 유럽고혈압학회 (ESH) 임상 시험을 통과함으로써 혈압 측정의 정확성까지 검증받아 혈압계측정 대표 브랜드로 거듭나고 있습니다.

InBody Co., Ltd. is a Korean company that manufactures medical equipment. We manufacture and sell body composition analyzer, blood pressure monitor, and automatic stadiometer, etc. and we have 6 branch offices in overseas including USA, China, and Japan. InBody's blood pressure monitor is becoming a representative brand of blood pressure monitor by passing the European Society of Hypertension (ESH) clinical tests and thus being proven for convenience and accuracy.

COMPANY & PRODUCT INTRODUCTION

wiseprep Duet&TLA /자동화장비

Nwiseprep Duet&TLA /Fully automation unit

Healthcare Technology Licensing Office



Industrial-Academic Cooperation Foundation of Daegu Catholic University

대구가톨릭대학교산학협력단

COUNTRY Republic of Korea

CEO Joe, Keuk Rae 조극래

URL iacf.cu.ac.kr

E-mail seyom@cu.ac.kr

EXHIBIT CLASSIFICATION

의학, 약학, 바이오(제약, 식품 등)

Medicine, Pharmacology, Biotechnology (ie. Pharmacy, food)

COMPANY & PRODUCT INTRODUCTION

산학협력단에서는 대학과 기업 그리고 지역사회가 공동으로 연구하고 새로 운 기술을 개발하는 R&BD 사업, 대학이 가진 기술을 산업체에 이전하여 기 술사업화하는 사업 등을 운영하고 있으며, 학생들이 실제 산업현장에서 교육 훈련하는 현장실습제 등 다양한 산·학·연 협력시스템 구축을 통해 실질적인 지역사회와의 협력에 노력하고 있습니다.

Industrial-Academic Cooperation Foundation of Daegu Catholic University undertakes R&BD projects on new technology searched and developed jointly by universities, businesses and local communities, and technology transfer projects to commercialize technologies originally possessed by universities, accelerating practical effort to cooperate with local communities through establishment of a variety of industry-academy-business cooperation systems such as on-the-job training for students to practice their knowledge at industrial sites.

Healthcare Technology Licensing Office



Industry-Academic Cooperation Foundation

가톨릭대학교 산학협력단

COUNTRY Republic of Korea

CEO Jeon, Shin Soo 전신수

URL cukrnd-iacf.ac.kr

E-mail jeno1222@catholic.ac.kr

EXHIBIT CLASSIFICATION

제약, 바이오 및 의료기기 등

Pharmaceuticals, Bio and Medical devices, etc

COMPANY & PRODUCT INTRODUCTION

가톨릭대학교 산학협력단은 고부가가치의 지식창출 역량을 지닌 인적자원 육성에 매진하고 있으며, 가톨릭 정신에 부합하는 생명윤리에 근거한 첨단 연구를 위하여 교수 연구활동의 지원 및 각종 인프라 구축에 노력하고 있습 니다.

대학은 연구개발을 통해 창출된 각종 성과들이 산업활동에 활발히 이용될 수 있도록 산(産),학(學),연(研) 인프라를 구축하고, 이에 대한 지식재산권을 체계적으로 관리함으로써 기술개발 전략 및 기술이전 사업이 성공적으로 이루어지도록 노력할 것입니다.

성공적인 운영과 발전을 위해 앞으로도 지속적인 관심과 성원 부탁드립니다. 감사합니다.

The Foundation is committed to nurturing human resources with capabilities to develop high-value-added knowledge and to support establishment of infrastructures and professors for the cutting-edge research based on bioethics in compliance with the Catholic Spirit.

Furthermore, the University is sparing no effort for successful technology transfer and development strategy by establishing industry-academy-research infrastructures and systematically managing intellectual property rights thereof.

The continued interest and support are sincerely asked for successful operation and development.

Thank you

Healthcare Technology Licensing Office



Industry-Academic Cooperation Foundation Kyung Hee University

경희대학교 산학협력단

게벙내악교 산약엽



Industry-Academic Cooperation Foundation, Keimyung University

계명대학교 산학협력단

Healthcare Technology Licensing Office

COUNTRY Republic of Korea
CEO Lee, Jae Yeol 이재열

URL research.khu.ac.kr

E-mail topdeputy@khu.ac.kr

COUNTRY Republic of Korea

CEO Nam, Jae Yeal 남재열

URL sanhak.kmu.ac.kr

E-mail pjm5639@kmu.ac.kr

EXHIBIT CLASSIFICATION

한의과대학,약학대학,의과대학,치과대학을 중심으로 양·한방의 다양한 바이오의료분야 기술 등

Numerous biomedical technologies of western and oriental medicine centering around College of Oriental Medicine, College of Pharmacy, College of Medicine and College of Dentistry

EXHIBIT CLASSIFICATION

의약품, 건강기능성 제품, 기능성소재, 메디컬디바이스, 인프라/융복합 기술 등

Pharmaceuticals, Functional products (Health), Functional materials, Medical devices, Infrastructure / convergence technology, etc

COMPANY & PRODUCT INTRODUCTION

경희대학교 산학협력단은 2004년 3월에 설립되어 본교 교원의 지속적인 학문의 발전과 적극적인 연구활동을 지원하고 있는 기관으로,

대외연구계약 및 연구결과물의 지식재산권 관리 등의 업무를 담당하고 있으며, 또한 산학협력 분야별 전문조직을 통해 산업체 수요 기반의 산학협력 활동을 수행하고 있음

Industry-Academic Cooperation Foundation Kyung Hee University is an institution established in March 2004 to support the continuous academic development and active research of the university. Also, it is responsible for conclusion of research contracts with third parties and management of intellectual property regarding the research outcome with specialized organizations for each area of industry-academic cooperation to pursue activities based on the demand of industries.

COMPANY & PRODUCT INTRODUCTION

계명대학교 산학협력단은 「산업교육진흥및산학협력촉진에관한법률」의 규정에 따라 안으로는 우수연구를 진흥하고 밖으로는 산학협력을 강화함으로서학교의 발전과 지역산업에 이바지하고 나아가 국가경제에 기여함을 목적으로 2004년 4월에 설립하였습니다.

Industry-Academic Cooperation Foundation, Keimyung University was established in April, 2004 with the founding purposes to advance the university by promoting excellent research and strengthening academy-industry cooperation in accordance of "PROMOTION OF INDUSTRIAL EDUCATION AND INDUSTRY-ACADEMIC COOPERATION ACT", and therefore, to contribute to the local community as well as the national economy.

InfoMeditech

Hospital-based Business Innovation Center

InfoMeditech

인포메디텍

COUNTRY Republic of Korea

CEO YeongHyuk Kwon 권영혁 **URL** www.infomeditech.com E-mail jerry@infomeditech.com

EXHIBIT CLASSIFICATION

Neuro I / 뇌영상 정량분석 기술

Neuro I / Brain Image Quantitative Analysis System

COMPANY & PRODUCT INTRODUCTION

(회사) 주식회사 인포메디텍은 알츠하이머치매를 포함한 치매발병 예측, 조 기진단, 예방 및 케어 서비스 등 치매 토탈솔루션을 제공하는 사업을 진행하 고 있습니다.

(제품/기술) Neuro I(뉴로아이)는 자기공명영상 (MRI)를 이용하여 뇌의 부피 와 두께의 변화를 정량화하고 동일 성별, 연령대별 정상인 집단 데이터와 비 교하여 뇌질환 진단을 지원하는 시스템

(Company) InfoMeditech have been developing a business that provides total solutions for dementia, such as 1) predicting the onset of dementia, including Alzheimer's disease, 2) early diagnosis and 3) prevention & care services

(Product/Technical) "Neuro I" quantify changes in volume and thickness of brain regions associated with Alzheimer's disease by using MRI, and to determine the prevalence and progression of Alzheimer's disease by comparing data with normal populations of the same gender and age group.

Healthcare Technology Licensing Office



Inha University Research and **Business Foundation**

인하대학교 산학협력단

COUNTRY Republic of Korea

Seo, Tae-Beom 서태범

URL rnd.inha.ac.kr E-mail wjy@inha.ac.kr

EXHIBIT CLASSIFICATION

바이오메디컬 응용기기, 헬스케어 및 바이오 뷰티 소재

Biomedical applications and Healthcare and bio-beauty materials

COMPANY & PRODUCT INTRODUCTION

인하대학교는 2004년 산학협력단 설립 이래 지역 산업 발전과 기업의 성과 창출을 주도하며 인천지역 산학협력을 선도하고 있습니다.

- 최고의 특허 교육 대학(2017): 캠퍼스 특허전략 유니버시아드 6년 연속 최다 수상 대학 선정
- 중앙일보 대학평가 종합 8위(2017): 학생성과 TOP3, 신입사원으로 뽑고 싶은 대학 TOP6, 입학 추천대학 TOP6
- 인천지역 지식재산권 최다 보유대학(2018) : 인천지역내 인하대 특허보유 비율이 71.6%를 차지함

Leading industry-academic collaboration in Incheon Metropolitan City, Inha University has been promoting regional industry development and high corporate performance since its establishment of Research and Business Foundation in 2004.

- Top Leading Patent Institution (2017): the biggest winner for Campus Patent Strategy Universiade Competition for 6 consecutive years
- Ranked 8th in the university evaluation by JoongAng Ilbo (2017): TOP 3 universities for student achievement, TOP 6 universities for graduate employability, TOP 6 recommended universities for admission
- No.1 Institution granted intellectual property rights in Incheon (2018): Inha University accounts for 71.6% of the patents in the region

Hospital-based Business Innovation Center



New Excellent Technology Exhibition



Inje university Busan Paik hospital

인제대학교 부산백병원

COUNTRY Republic of Korea

CEO Lee Soonhyung 이순형 URL www.paik.ac.kr/busan

E-mail kang0924@busanpaik.ac.kr

Innoway Co., Ltd.

(주)이노웨이

COUNTRY Republic of Korea

CEO Lee ho yung 이호영

URL www.innoway.co.kr

E-mail jinjun3028@naver.com

EXHIBIT CLASSIFICATION

개방형 실험실

Inje university Busan Paik hospital H.BIC

EXHIBIT CLASSIFICATION

닥터아미노20/초고압효소가수분해물 아미카도프로/초고압효소가수분해물 혼합음료

- 1. Dr.amino20 (powder)/ high-pressure enzymatic hydrolysis
- 2. amicado pro (liquid) / high-pressure enzymatic hydrolysis

COMPANY & PRODUCT INTRODUCTION

- 1. 보건의료분야 창업기업 발굴 및 육성 지원
- 2. 맞춤형 컨설팅 및 기술 고도화를 통한 사업화
- 3.기업의 자립화를 위한 병원-기업 협력 시스템 구축
- Finding and nurturingstartup companies in the health and medical servicesector
- 2. Commercializing the new technologies of companies through tailored consultations and technological advancements
- 3. Establishing a cooperation system between Inje University Busan Paik Hospital and the companies to help them become self-reliant.

COMPANY & PRODUCT INTRODUCTION

천연육류 단백질 닥터아미노20은 필수아미노산과 비필수아미노산 20가지가 모두 함유된 제품이다.

이노웨이는 20년 노하우로 초고압효소가수분해를 통한 추출기술을 가지고 고기능성 물질을 추출한다.

The natural meat protein supplement Dr.amino 20° contains all 20 essential and non-essential amino acids that humans require.

Innoway Co., Ltd. has worked for more than 20 years to develop a patented high-pressure enzymatic hydrolysis and extraction technology. Innoway is a specialized company that manufactures highly functional customized products and provides functional biomaterials.

New Excellent Technology Exhibition



Korea Innovative Pharmaceutical Company



INOBONE CO., LTD.

㈜이노본

COUNTRY Republic of Korea

CEO Dong Woo Jang 장동우

URL www.inobone.com

E-mail steve.park@inobone.co.kr

Institut Pasteur Korea

한국파스퇴르연구소

COUNTRY Republic of Korea

CEO Wangshick Ryu 류왕식

URL www.ip-korea.org

E-mail sukyon.yang@ip-korea.org

EXHIBIT CLASSIFICATION

FRABONE 은 인체 치밀골의 Haversian canals구조를 모방한 형태로 기공을 포함한 연결된 구조와 과립 사이에 형성된 공간을 통해 뼈성장에 필수적인 영양분 공급을 위한 혈관생성 및 신생 골형성에 시초가 되는 조골세포 형성을 크게 향상시킵다.

QBONPLUG는 소켓 보존에 사용되도록 설계된 플러그 형 합성 뼈 대체재로, 우수한 세포 부착 및 분화를위한 가장 이상적인 프레임 구조를 형성하여 뼈 를 빠르게 재생 및 복원합니다.

FRABONE has a unique design including micropores that mimic the harversian canal structure of the human cortical bone which provides angiogenesis and nutrients through spaces between the granules and canals of FRABONE, which is essential for new bone growth.

QBONPLUG is a plug-type synthetic bone substitute designed to be used for socket preservation, which forms the most ideal frame structure for excellent cell attachment and differentiation, leading to rapid bone regeneration and restoration.

COMPANY & PRODUCT INTRODUCTION

(주)이노본은 세계적 수준의 미세 세라믹 제어 원천기술을 기반으로 다양한 골 대체재를 개발, 생산하는 합성골이식재 전문기업입니다. 당사에서 개발한 합성골이식재(FRABONE) 및 복합재료이식용뼈(QBON)은 기술우수성을 인정받아 보건복지부로부터 보건신기술인증(NET)을 받았습니다.

INOBONE Co., Ltd. is specialized in developing, producing and supplying various synthetic bone substitutes based on world-class fine ceramic control source technology. The synthetic bone graffs, FRABONE and composite synthetic bone grafts, QBON developed by our company have been recognized for its technological excellence and received the New Excellent Technology Certificate (NET) from the Ministry of Health and Welfare.

EXHIBIT CLASSIFICATION

* 시클레소니드(천식약)

스테로이드계 물질로서 원래 천식약으로 개발 승인된 약물임. 최근 연구결과들에 의하면 코로나19에 대한 항바이러스 효과가 있음이 밝혀졌고 또한바이러스의 NSP15 단백질에서 내성변이 관찰된 바, 해당 단백질의 기능을직접적으로 방해하는 역할이 있을 것으로 판단됨. 따라서 시클레소니드는바이러스에 직접 작용하여 바이러스 감염을 방해할 뿐만 아니라 스테로이드 약물로서 항염증 작용도 동시에 할 것으로 예측됨

* 니클로사마이드(구충제)

구충제로서 알려져 있는 약물임. 그러나 여러 문헌을 통해 다양한 바이러스에 항바이러스 활성이 있음이 보고된 바 있음. 가장 최근 메르스 코로나바이러스 연구에서 니클로사미드는 숙주세포의 자가포식기능을 활성화하여 바이러스의 복제를 감소시킨다는 기전이 밝혀졌음.

* Ciclesonide

Ciclesonide is registered as asthma treatment and found antiviral activities against COVID-19. Also, a recent study observedresistant to NSP15 protein, it will work disturbance of COVID-19 Spike protein. Ciclesonide will be effective on disturbance of COVID-19 Virus and anti-inflammation as Steroid drug.

* Niclosamide

Niclosamide is well known as anthelmintic, but many references reported the antiviral activities. Lately, this material have shown reduction of virus copy by using self-autoreproduction in the study.

COMPANY & PRODUCT INTRODUCTION

국제 공중 보건 이슈에 초점을 맞춘 국제적인 연구 기관으로, 질병의 메커니 즘을 이해하고새로운 치료제 개발을 위해 최첨단 방법을 융합해 연구하고 있음. 또한 여러 분야에 걸친 연구 프로젝트를 장려함으로 신약 개발에 앞장서고 있으며, 연구·교육·기술 혁신을 통해 대한민국의 미래 과학 자원 개발에 기여하고 있음.

Institut Pasteur Korea is an infectious disease-focused research institute located in Gyeonggi Province, Rep. of Korea. Its mission is to identify novel molecular targets and discover small molecules by utilizing its proprietary platforms to diagnose, treat and address serious unmet global public health needs

(주)**인토본**

GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION

COVID-19 SPECIAL PAVILION

㈜인트론바이오테크놀로지

INtRON Biotechnology



Intoborn

(주)인토본

COUNTRY Republic of Korea

CEO Chun Young Ryu 류춘영

URL

E-mail kk990410@hanmail.net

COUNTRY Republic of Korea

CEO Kyung Won, Yoon 윤경원

URL www.intronbio.com

E-mail wongil@intron.co.kr

EXHIBIT CLASSIFICATION

엘리시움 아이 900 (의료용 전자기장발생기)

ELYSIUM EYE 900

EXHIBIT CLASSIFICATION

LiliF™ COVID-19 Real-time RT-PCR Kit

COMPANY & PRODUCT INTRODUCTION

주식회사 인토본은 의료용 전자기장을 제작하는 벤처기업입니다. 인체 전신을 혈액순환 시키는 엘리시움-100 에 이어, 안구와 망막에 혈류와 신경세포를 활성화 시키는 엘리시움 아이 900을 이번 바이코리아 2020에 소개합니다.

ELYSIUM EYE 900

COMPANY & PRODUCT INTRODUCTION

㈜인트론바이오는 박테리오파지 및 엔도리신 분야에 대해 집중 투자를 해오고 있으며, 특히, 코스닥상장 이후에는 다양한 여타의 신약 파이프라인 구축에 박차를 가하고 있습니다.

회사는 "글로벌 R&BD 그룹"을 지향하면서, 'First-in-Class' 바이오신약 파이 프라인을 다수 개발하는 것은 물론, 다양한 신약 파이프라인들에 대해 단계 적으로 국내외 임상 진입을 시켜 나감으로써, 바이오신약 기업으로서의 가치를 점차 증대시켜 나가는 것입니다.

iNtRON Biotechnology has been making intensive investments in the fields of bacteriophage and endorisin, In particular, after listing on the KOSDAQ, we are accelerating the construction of various new drug pipelines. The company pursues "Global R & BD Group",In addition to developing a number of 'First-in-Class' biopharmaceutical pipelines, By gradually entering the clinical trials at home and abroad for various new drug pipelines, It is gradually increasing its value as a bio-new drug company.

COVID-19 SPECIAL PAVILION



Korea Innovative Pharmaceutical Company



IONEBIO Inc.

㈜아이워바이오

ISU ABXIS CO., LTD.

이수앱지스

CEO Republic of Korea
CEO Minbae Kim 김민배
URL www.ionebio.com

E-mail lucy.lee@ionebio.com

COUNTRY Republic of Korea
CEO Seok Joo Lee 이석주
URL www.abxis.com

E-mail danielyang@isu.co.kr

EXHIBIT CLASSIFICATION

진단키트(LAMP PCR)

Detection Kit

EXHIBIT CLASSIFICATION

* 애브서틴®: Imiglucerase

* 파바갈®: Agalsidase beta

* 클로티냅®: Abciximab

* Abcertin[®] : Imiglucerase * Fabagal[®] : Agalsidase beta * Clotinab[®] : Abciximab

COMPANY & PRODUCT INTRODUCTION

㈜아이원바이오는 4차 산업혁명 시대를 이끌어갈 미래 신성장 산업으로 주목받는 바이오 산업의 선두 기업으로 광학의료기기장비, 바이오 진단 장비및 유전자분석 개발을 통해 빠른 성장을 이루어 가고 있습니다. ㈜아이원바이오는 향후 급변하는 산업계 요구에 발빠르게 대처하고 응용할 수 있는 무한한 잠재력을 가지고 있는 광학및 바이오 기술을 보유하고 있습니다.

iONEBIO is making headway in the future New Growth Industry that is to lead the 4th Industrial Revolution Era, via development of optics medical equipment, bio-diagnostic products, and genetic analysis. Our optics technology and bioindustry technology possess potentially infinite possibilities to nimbly accommodate the quick-trended industry's needs.

COMPANY & PRODUCT INTRODUCTION

이수앱지스는 앱지스 (ABXIS = AntiBody + aXIS) 회사명에 담긴 의미처럼 항체치료제 개발의 기준이 되는 회사가 되기 위해 2001년 창립한 바이오 기 업입니다. 이수앱지스는 항암 신약, 희귀질환치료제 바이오시밀러 등의 다양 한 개발 파이프라인을 구축하며 바이오의약품 개발에 특화된 기업으로 국내 바이오산업을 이끌어 나가고 있습니다.

ISU ABXIS is a biopharmaceutical company founded in 2001 with a desire of being an axis of therapeutic antibody as its names stands for ABXIS = AntiBody + aXIS. We will be dedicated to improving the lives of patients with cancers and incurable diseases.

New Excellent Technology Exhibition

It°S HANBUL

K-Healthcare start-ups



IT'S HANBUL

㈜잇츠한불

COUNTRY Republic of Korea

CEO Hong Dong Serk 홍동석

URL itshanbul.com

E-mail kjhi@itshanbul.com

Itsnuh

인더스마트

COUNTRY Republic of Korea

CEO Lee Chong Hee 이충희

URL

E-mail jykim@itsnuh.com

EXHIBIT CLASSIFICATION

세포외기질 실록산 중합체를 이용한 피부 보호 기술

The technology of skin protect using the extracellular matrix siloxane polymer

EXHIBIT CLASSIFICATION

4K 수술용 형광 내시경 시스템

4K Fluorescence Endoscopy System

COMPANY & PRODUCT INTRODUCTION

Global Leading Cosmetic Company

잇츠한불은 유기적인 네트워크 시스템, 엄격한 품질 보증, 환경을 생각하는 녹색 경으로 소비자들이 안심하고 사용할 수 있는 안전하고 건강한 제품을 만듭니다.

Global Leading Cosmetic Company

IT'S HANBUL creates safe and healthy products that consumers can use with confidence through its organic network system, strict quality assurance, and environmentally conscious green management.

COMPANY & PRODUCT INTRODUCTION

초고화질 내시경 시스템의 기능에 '실시간 형광이미징' 기술을 적용, 이 기술을 통해 ICG조영제 투입 후 혈관 흐름, 조직 및 림프절 관찰 가능, 이를 통해 수술 중 조직 확인 및 출혈을 최소화하여 수술시간 및 환자의 회복시간을 줄일 수 있음

ITS Model-L6K is UHD endoscope system with fluorescence image. It consists of three parts: a camera, a camera control unit (CCU), and a light source unit (LSU). The LSU illuminates the target area by irradiating visible light and near infrared rays in the dark body cavity through the inserted scope to the patient. Images captured by the camera are post-processed in real time through the CCU to provide the best image suitable for medical staff.

TECHNOLOGY

Daejeon Technopark

Korea Innovative Pharmaceutical Company



IVIM Technology, Inc.

아이빔테크놀로지 (주)

CEO Republic of Korea
CEO Pilhan Kim 김필한
URL www.ivimtech.com

E-mail suiin.park@ivimtech.com

Janssen Korea

한국얀센

COUNTRY Republic of Korea

CEO Jenny Zheng, Lee Jung-Hee

정레이, 이정희

URL www.janssen.com/korea

E-mail jlee61@its.jnj.com

EXHIBIT CLASSIFICATION

올인원 생체현미경

All-in-One IntraVital Microscopy Platform

COMPANY & PRODUCT INTRODUCTION

아이빔테크놀로지(주)가 세계 최초로 개발한 일체형 생체현미경 (IVM) 플랫폼은 생체 내부의 수많은 세포들 간 상호작용을 탐구하고, 여러가지 인간 질환의 복잡한 발생 과정을 밝히기 위한 기초의생명 연구의 차세대 첨단 영상 장비가 될 것입니다.

The world's first All-in-One microscopy (IVM) platform developed by IVIM Technology explores the interactions among numerous cells inside the living organisms and will be the next generation high-tech imaging equipment to elucidate the complex processes of human diseases.

EXHIBIT CLASSIFICATION

* 인베가 서스티나 : 조현병 * 인베가 트린자 : 조현병

* 벨케이드 : 다발골수종, 외투세포림프종

* 다잘렉스 : 다발골수종

* 임브루비카 : 외투세포림프종, 만성림프구성백혈병

*자이티가 : 전이성거세저항성전립선암,

* 서튜러 : 다제내성결핵 * 옵서미트 : 폐동맥고혈압 * 울트라셋 : 중등도 중증의 통증 * 뉴신타 : 중증 만성통증

* 심퍼니 : 류마티스 관절염, 강직척추염, 건선관절염

*레미케이드 : 류마티스 관절염, 강직척추염, 크론병, 궤양성대장염

* 스텔라라 : 건선, 건선성관절염, 크론병, 궤양성대장염

* 트렘피어 : 건선

* Invega Sustenna : Schizophrenia * Invega Trinza : Schizophrenia

* Velcade : Multiple Myeloma, , Mantle Cell Lymphoma

* Darzalex : Multiple Myeloma

* Imbruvica : Mantle Cell Lymphoma, Chronic Lymphocytic

Leukemia

* Zytiga : Meta Castration-Resistant Prostate Cancer

* Sirturo : Multi-Drug Resistant Tuberculosis * Opsumit : Pulmonary Hypertension * Ultracet : Moderate to severe Pain

* Nucynta : Severe Pain

* Simponi : Rheumatoid Arthritis, Ankylosing Spondylitis,

Psoriatic Arthritis

* Remicade : Rheumatoid Arthritis, Ankylosing Spondylitis,

Crohn's Disease, Ulcerative Colitis

* Stelara : Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative

Colitis

* Tremfya : Psoriasis

COMPANY & PRODUCT INTRODUCTION

한국안센은 Johnson & Johnson의 제약부문 한국 법인으로, 1983년 유한양 행과 합작 회사로 설립되었습니다. 지난 30여년 간, 다양한 질환의 치료에 유 용한 의약품을 제공하기 위해 노력해왔습니다.

Janssen Korea, the Korean branch of the pharmaceutical division of Johnson & Johnson, started as a joint company with Yuhan Corporation in 1983. For the last 30 years, it has been committed to provide useful medicines for the treatment of diverse diseases.

JEIOS Medical

K-Healthcare start-ups

JEIOS,.Inc

제이어스㈜

COUNTRY Republic of Korea

CEO Jeon jeanhong 전진홍

URL www.jeios.com

E-mail jeiosmedi@naver.com

EXHIBIT CLASSIFICATION

보행분석 장비 : 모션코어

gait analysis device: Motion Core

COMPANY & PRODUCT INTRODUCTION

모션코어는 3차원 휴먼 동특성을 IMU센서를 이용하여 신경계, 근골격계, 전정계 및 심혈관계 이상 유무를 검사하는 기기로 간단한 보행검사를 통해 동작균형 상태를 수치화 할 수 있는 검사장비

Motion Core is a device that examines the presence or absence of abnormalities in the nervous system, musculoskeletal system, vestibular system, and cardiovascular system using IMU sensors for 3D human dynamic characteristics.

Healthcare Technology Licensing Office



Jeju National University Industry - Academic Cooperation Foundation

제주대학교 산학협력단

COUNTRY Republic of Korea

CEO Doh, Yang Hwe 도양회

URL https://iucf.jejunu.ac.kr:446

E-mail nhm2637@jejunu.ac.kr

EXHIBIT CLASSIFICATION

- 해양바이오
- 아열대생물과 말 산업
- IT융합과 청정에너지
- 융합관광 MICE
- · Marine Biology
- Subtropical plant and Horse industry
- IT convergence and Clean energy
- · Convergence Tourism MICE

COMPANY & PRODUCT INTRODUCTION

[To the Basic, For the Future]

제주대학교는 국가 보건산업분야에 기여하고자 보건,의료, 생명과학분야의 연구는 물론, 제 3차 진료기관을 갖춘 국립거점대학입니다. 의학전문대학원, 수의과대학, 간호대학, 약학대학 등 의료분야의 전문인력 양성 및 과학기술개 발 체계를 갖추고 있으며, 생명자원과학대학, 해양자원과학대학, 자연과학대 학 등 생명자원의 소재발굴에서 사업화까지 보건의료분야의 전 주기적 연구 지원시스템을 갖추고 있습니다.

[To the Basic, For the Future]

Jeju National University is one of the flagship Korean National Universities with a tertiary medical institution as well as research facility in health, medical treatment, and life science. It established comprehensive systems to nurture medical personnel and develop science and technology with School of Medicine, College of Veterinary Medicine, College of Nursing, and College of Medicine as well as to support whole cycle of research on healthcare from discovery of materials to commercialization with College of Applied Life Sciences, College of Ocean Science, and College of Natural Sciences.



Healthcare Technology Licensing Office



inwoo bio

JEONBUK National University Industrial Cooperation Foundation

전북대학교 산학협력단

COUNTRY Republic of Korea

Cho, Jae Young 조재영

if.ibnu.ac.kr **URL**

E-mail heesang@jbnu.ac.kr

JINWOO BIO

SEOUL Biohub

㈜진우바이오

COUNTRY Republic of Korea

Dong-Keon Kweon 권동건

URL www.jinwoobio.com

E-mail jyhong40@naver.com

EXHIBIT CLASSIFICATION

남성 불임증 치료 예방 및 치료용 조성물, 재생용 멤브레인 제조장치 및 제조 방법, 피부질환 예방 또는 치료용 조성물

A composition for treating and preventing Male Infertility, FABRICATION APPARATUS FOR REGENERATION AND METHOD THEREOF, Composition for prevention or treatment of skin disease

EXHIBIT CLASSIFICATION

미생물 발효 히알루론산나트륨 원료를 활용한 의약/의료기기 개발 medical devices using Solid HA Technology Platform (SHTP).

COMPANY & PRODUCT INTRODUCTION

전북대학교 산학협력단은 지역사회 및 지역기업을 위한 선진형 산학협력 체 계 구축을 목표로 지역혁신협력 체계 구축, 교육/연구 활성화, 다양한 제도개 선을 실시하고 있습니다.

Chonbuk National University Industry-Academy Cooperation Group established a regional innovation cooperation system, and is supporting education, research and institional improvement with the goal of launchingg an advanced industrial-educational cooperation system for local communities and local companies.

COMPANY & PRODUCT INTRODUCTION

(주)진우바이오는 고체형 히알루론산 기술 플랫폼(Solid HA Technology Platform, SHTP)를 기반으로 고부가가치 신규 형태의 바이오 의약품과 의료기기 제형화 기술 개발 전문업체입니다.

JINWOO BIO is a company that specializes in developing novel value-added biopharmaceuticals and medical devices using Solid HA Technology Platform (SHTP).

K-Healthcare start-ups



Wonju Medical Industry Technovalley



JLK, Inc

제이엘케이인스펙션

JNBIO

㈜제이앤바이오

COUNTRY Republic of Korea

CEO Won Tae Kim, Dong Min Kim

김원태, 김동민

URL jlk-inspection.com

E-mail jmhong@jlk-inspection.com

COUNTRY Republic of Korea

CEO Lee Jaeseok 이재석

URL www.ejnbio.com

E-mail lee@ejnbio.com

EXHIBIT CLASSIFICATION

의료 인공지능 솔루션

Al medical solutions

EXHIBIT CLASSIFICATION

진단폐활량계

SPIROLENIS

COMPANY & PRODUCT INTRODUCTION

MRI, CT, X-Ray, Mammography, 병리 영상 등 8가지의 의료영상을 활용하여 37개의 의료 인공지능 솔루션을 개발하고, 이러한 솔루션들이 탑재된 올인원 플랫폼 "AIHuB"를 통하여 빠르게 사업화에 성공한 인공지능 의료 솔루션 전문 업체

JLK developed 37 medical AI solutions using 8 types of medical images such as MRI, CT, X-Ray, Mammography, and pathology images. Specialized in intelligent medical solutions, and We lead Medical AI field through dynamic Technology Development and Commercialization

COMPANY & PRODUCT INTRODUCTION

(주)제이앤바이오는 호흡기 질환을 쉽게 측정하고 치료할 수 있는 것을 목표로 합니다. 우리는 전세계의 환자, 의사, 연구원들이 쉽게 진료할 수 있는 기술을 제공합니다.

 $\ensuremath{\mathsf{JNBIO}}$ aims to make respiratory diseases measurable and more treatable.

We provide cutting edge technology to enable the right decisions for patients, physicians and researchers around the world.

SPIRO LENIS Spirometer make it a useful, cost-effective device for detecting and managing pulmonary disease.

It is packed with a host of features including full color touch screen, icon driven menu and highly accurate and robust flow sensor technology."

JSKBIOMED

SEOUL Biohub

Korea Doctor Preneur



JSK BIOMED

제이에스케이바이오메드㈜

JSR Medical Co., Ltd.

COUNTRY Republic of Korea
CEO Jinwoo Jeon 전진우
URL www.jskbiomed.co.kr
E-mail jjw@jskbiomed.co.kr

COUNTRY Republic of Korea
CEO Jae Hwang Kim 김재황
URL www.jsrmed.co.kr
E-mail kosjsr@gmail.com

EXHIBIT CLASSIFICATION

바늘 없는 약물주입시스템 개발

medical device for needle-free injection, Transdermal Drug Delivery System.

EXHIBIT CLASSIFICATION

1. Colo-BTS

1. Colo-BTS

COMPANY & PRODUCT INTRODUCTION

당사는 모든 인류의 건강하고 아름다운 삶을 위해 공헌하는 안티에이징 글로 벌 리더를 꿈꾸는 메디컬바이오기업입니다.

We are a medical biotechnology company that dreams of becoming an anti-aging global leader that contributes to the healthy and beautiful life of all mankind.

COMPANY & PRODUCT INTRODUCTION

주식회사 제이에스알메디컬은 대장항문용 외과 시술기구의 연구개발을 바탕으로, 대장용 의료제품 및 시술방법을 개발하는 의료기기 연구개발 기업입니다.

모든 구성품이 개발 완료되었고, 제품 최적화를 위한 수정과 인허가 준비단계에 있습니다.

JSR Medical Co., Ltd. is a research and development company for medical devices that develop medical products and treatment methods for colon. This is based on R&D of surgical instruments for colon anus.

All the components for the products have been developed, and we are in the preparation stage for modification and licensing for product optimization."

K-Healthcare start-ups

Korea Innovative Pharmaceutical Company



Juvic

주빅

COUNTRY Republic of Korea

CEO Kim Joon Bae 김준배

URL juvicbio.com

E-mail hsyang@juvicbio.com

JW Pharmaceutical

JW중외제약

COUNTRY Republic of Korea

CEO SHIN YOUNG SUB, LEE SEUNG RYLL

신영섭, 이성열

URL www.jw-pharma.co.kr

E-mail jiseon_lim@jw-pharma.co.kr

EXHIBIT CLASSIFICATION

생분해성 마이크로니들

Dissolving microneedle

COMPANY & PRODUCT INTRODUCTION

약물을 탑재할 수 있는 탑재기술, 약물을 보존할 수 있는 원심성형기술, 마이 크로니들 전달률을 극대화하는 전달기술을 모두 보유하여 마이크로니들의 약물 정량 전달을 구현, 의약품을 실현할 수 있음. 이러한 기술을 융합하여 다 양한 약물전달제품을 개발

We have all the drug loading technology, the centrifugal manufacturing process to preserve drugs, and the delivery technology to maximize the microneedle delivery efficacy. Therefore, it is possible to realize drug delivery by realizing the drug delivery of the microneedle. Various drug delivery products can be developed by fusion of these technologies.

EXHIBIT CLASSIFICATION

- * 카바페넴계열 항생제
- * 아미노산 수액제
- * 일반 수액제 및 무균제
- * 항균제 및 항진균제
- * 소화기 제품
- * 피부 외용제
- * 멀티 비타민제
- * 항생제류
- * 카바페넴계열 항생제: 이미페넴/실라스타틴, 메로페넴
- * 항진균제: 케토코나졸, 이트라코나졸, 플루코나졸
- * Chiral & 특수아미노산 제제
- * Carbapenem Antibiotics
- * Amino Acid Solutions
- * General I.V Solutions & Other Sterile Solutions
- * Antimicrobial & Antifungal Agents
- * Gastrointestinal Agents
- * Topical
- * Multivitamins
- * Agents for Antibiotics
- * Carbapenem Antibiotics: Imipenem/Cilastatin
- * Anti-fungals: Ketoconazole, Itraconazole, Fluconazole
- * Chiral Products for Custom Synthesis & Specialty Amino Acid

COMPANY & PRODUCT INTRODUCTION

JW그룹은 환자들의 생명 유지를 위해 필수적인 항암제, 항생제와 같은 전문 의약품을 공급하는 일류 제약회사이자 글로벌 수액 제조회사로 발전해왔습 니다. JW중외제약은 혁신적 기술력과 양질의 서비스로, 1945년 설립 이래 75 년이 넘는 기간 동안 전문의약품, 일반의약품, 헬스케어, 진단, 의료기기 등 인 류의 건강문화 항상에 기여해 왔습니다.

JW group Provides pharmaceuticals vital for maintaining the lives od patients such as anticancer drugs and antibiotics, and has developed into a leading pharmaceutical company and global manufacturer of I.V. Solutions. For 75 Years ever since its foundation in 1945, JW Pharmaceutical focuses on healthcare, ETC, OTC, diagnostics and medical equipment.

GMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION



K-Healthcare start-ups



J-WELL Co., Ltd.

㈜제이웰

케이허브

K- Herb

COUNTRY Republic of Korea

CEO Jin Muck Park 박진묵

URL www.jwell.kr

E-mail jwell1050@naver.com

COUNTRY Republic of Korea
Lee, Jiwon 이지원

URL Myherb.app

E-mail admin@myherb.app

EXHIBIT CLASSIFICATION

특허받은 척추견인기

Patented spine stretching machine

EXHIBIT CLASSIFICATION

마이허브 영양제 정보 플랫폼 서비스

Supplement information service platform 'My Herb'

COMPANY & PRODUCT INTRODUCTION

재활 의료기기 제조회사로서 주요 생산 제품은 가정에서 척추(경추, 흉추, 요추)질환 치료 및 예방에 도움이 되는 가정용 척추견인기 입니다.

As a manufacturer of rehabilitation medical devices, the main production product is a spinal traction device used at home to help treat and prevent spinal diseases.

COMPANY & PRODUCT INTRODUCTION

서울대 출신 약사, 임상영양사가 직접 참여한 영양 상담을 통해 개인화된 섭취량 정보 및 영양학 정보를 제공하여 영양제 시장의 정보 불균형을 해결하는 것을 목표로 하고 있습니다.

It aims to provide personalized intake information through nutrition counseling questions directly made by pharmacists and clinical nutritionists from Seoul National University





Healthcare Technology Licensing Office

KANGBUK SAMSUNG HOSPITAL

강북삼성병원

COUNTRY Republic of Korea

CEO Yook, Hyun Pyo 육현표

URL www.kbsmc.co.kr

E-mail dn.kang@samsung.com

COMPANY & PRODUCT INTRODUCTION

환자중심의 헬스케어를 선도하는 100년 병원을 꿈꾸는 강북삼성병원은 1968년 11월 2일 유서깊은 경교장 터에 대한민국 최고의 병원을 모토로 개원 했습니다. 강북삼성병원은 오랜 전통과 함께 우수한 의료진, 첨단 시설로 건강한 대만민국을 위한 미래의학의 선도병원으로 최선을 다하고 있습니다.

On November 2, 1968, KANGBUK SAMSUNG HOSPITAL was established in a historic site of gyeonggyojang with a founding motto of the Korea's Best Hospital and dream of leading patient-oriented healthcare for next 100 years. With long tradition, it has been endeavoring to be a leading hospital in the future medicine with outstanding medical personnel and advanced facilities.

Healthcare Technology Licensing Office



Kangwon National University-Industry Cooperation Foundation

강원대학교 산학협력단

COUNTRY Republic of Korea

CEO Yoon, Kyeong Ku 윤경구

URL uicf.kangwon.ac.kr

E-mail kimsanghyuck@kangwon.ac.kr

EXHIBIT CLASSIFICATION

고지혈증 치료제 (키랄 베타 아미노산 유도체), 천연유래 유효약물의 효과기술, 동반진단 기반 암 치료 약물의 최적 처치 기술 개발

Hyperlipidemia treatment (Chiral β -Amino acid derivative), Natural product-derived drug technology, Development of optimal treatment with cancer drugs based on a companion diagnostic

COMPANY & PRODUCT INTRODUCTION

강원대학교의 창조자산 창출을 기업가 정신으로 지원하고 대학의 미래가치로 전화시킴으로써 국가와 지역사회에 공헌한다

We contribute to the nation and the community by supporting the invention of Kangwon National University's creative assets with entrepreneurship and transforming them into the future value of the university.

COVID-19 SPECIAL PAVILION



K-Healthcare start-ups

KH Medical

㈜케이에이치메디칼

K-Healthcare start-ups

보건의료창업기업

COUNTRY Republic of Korea

CEO Adam Hong 홍만형 URL www.khmedical.co.kr

E-mail cecile@khmedical.co.kr

COUNTRY Republic of Korea

CEO Kwon, Deok Cheol 권덕철

URL www.khidi.or.kr

E-mail chihiun89@khidi.or.kr

EXHIBIT CLASSIFICATION

RADI COVID-19 Detection Kit

EXHIBIT CLASSIFICATION

디지털헬스케어, 진단기기, 수술기기, 제약, 화장품 등

Digital healthcare, diagnostic devices, surgical instruments, pharmaceuticals, cosmetics, and etc.

COMPANY & PRODUCT INTRODUCTION

KH Medical은 Korea Healthcare Medical의 약자로 국산 기술을 이용한 의료기기 및 진단 제품을 해외로 수출하고자 설립한 회사입니다. KH Medical의 Mission은 지구상의 모든 사람이 양질의 헬스케어-진단에 평등하게 접근할수 있도록 하는 것, 개발 도상국, 특히 아프리카 대륙에 우리의 진단 Solution을 통해 그들의 진단 시스템을 개선하고자 하는 것입니다.

KH Medical which means Korea Healthcare Medical is a company established to export medical devices and diagnostic products using domestic technology overseas. KH Medical's mission is to provide equal access to quality healthcare-diagnostics for all people on the planet, and to improve their diagnostic systems through our diagnostic solutions in developing countries, especially the African continent.

COMPANY & PRODUCT INTRODUCTION

보건산업 분야의 창의적인 아이디어가 기술사업화로 이어질 수 있도록 맞춤형 1:1 상담, 전문 컨설팅, 시제품 제작 등 사업화 지원, 투자유치를 위한 IR 행사 개최, 판로개척 지원 등 원스탑 서비스를 제공하고 있습니다.

To help creative ideas in the health industry lead to technology commercialization, we provide one-stop services such as customized 1:1 counseling, professional consulting, and support for commercialization of prototypes, IR events to attract investment, and support for market development.

Korea Doctor Preneur



COVID-19 SPECIAL PAVILION



Kim-Cell-Engine Co., Ltd.

㈜킴셀앤진

COUNTRY

Republic of Korea

CEO Hyo Soo Kim

URL 제작예정

E-mail 777jaehee@gmail.com

KogeneBiotech Co., Ltd.

㈜코젠바이오텍

COUNTRY Republic of Korea

CEO Nam Young Suk 남용석

URL www.kogene.co.kr

E-mail bnlee@kogene.co.kr

EXHIBIT CLASSIFICATION

자회사 (주)네오진팜에서 간섬유화 치료제 개발을 위한 연구중

Parent Company of Neo-Gene-Pharm Co., Ltd. is researching on the development of liver fibrosis drugs.

COMPANY & PRODUCT INTRODUCTION

나노 테크닉 기반의 안전하고 효율적인 간섬유화 억제 유전자치료제를 개발 하고자 함.

Aims to develop safe and efficient liver fibrosis inhibiting gene therapeutic based on nanotechnics.

EXHIBIT CLASSIFICATION

PowerChek™ 2019-nCoV Real-time PCR Kit

COMPANY & PRODUCT INTRODUCTION

㈜코젠바이오텍은 2000년에 설립되어 분자진단업계의 히든챔피언으로 명성을 얻었습니다.

특히 코로나19 진단시약은 국내 최초로 긴급사용승인을 받았으며, 800종이 넘는 식품, 체외진단, 가축질병분야의 PCR 키트를 개발, 제조, 판매하고 있습니다.

2009년 신종플루, 2015년 메르스, 2020년 코로나19 등 이처럼 아직 범용화되지 않은 신종유입 감염병과 같은 분야에서 국민보건과 공공의료에 기여하기 위하여 최선을 다하고 있습니다.

Since KogeneBiotech was founded in 2000 our company has earned a reputation for innovation in Molecular Diagnostics. We develop, manufacture and market about 800 PCR and Real-time PCR Kits and the great part of these products are developed by Government's grant and collaboration with national research institute. Our main business units are the production of Real-time PCR / conventional PCR Kit based on the active R&D works and Testing Service for Food, Human and Animal. We continue to assist you to ensure that our products lead to improve the public health and safety

Hospital-based Business Innovation Center



Korea Innovative Pharmaceutical Company



KOIBIG

코이빅

COUNTRY Republic of Korea

CEO Seung-ku Yu 유승구

URL www.koibig.com

E-mail koibig@koibig.com

EXHIBIT CLASSIFICATION

경피성 통증완화 전기 자극기, 플라즈마 피부 미용기기, 피부미용 5종 미용기기

Pain Block, Plajet, Sonicool

COMPANY & PRODUCT INTRODUCTION

코이빅은 경피성 통증 진단 및 통증 완화 전기 자극기를 개발하는 기업입니다.

"Pain Bloc"은 통증완화를 위한 경피성 전기자극장치로, 신경제어기술을 활용하여 환자의 통증신호를 무통증 신호로 인식하는 시스템입니다.

"Plajet"은 피부 미용 기기로, 살균, 피부 재생, 약물 전달 향상 및 발모에 효과 적입니다.

"Sonicool"은 바늘과 고통없이 약물 침투가 가능한 미용기기로, 어떠한 성분 도 쉽고 빠르게 피부속에 전달 할 수 있는 효과가 있습니다.

Koibig is a company that develops percutaneous pain diagnosis and pain relief electric stimulators.

"Pain Block" is a transcutaneous Electrical Stimulation Device for the relief of pain. It is a system that recognizes pain signals through nerve control technology.

"Plajet" is a skin beauty equipment, effective in cleaning, skin vibration, irritation delivery, and hair growth.

"Sonicool" is a beauty device capable of penetrating drugs without needles and pain. It has the effect of quickly and easily delivering any ingredients into the skin.

KOLMAR KOREA

한국콜마 주식회사

COUNTRY Republic of Korea

CEO Lee Ho Kyeong 이호경

URL www.kolmar.co.kr

E-mail yjjoo@kolmar.co.kr

EXHIBIT CLASSIFICATION

* 하이포지정 : Valsartan, Amlodipine * 텔로핀정 : Telmisartan, Amlodipine

* 리파르정 : Atorvastatin

*케이토스메트정: Pioglitazone, Metformin

* 페북트정: Febuxostat* 넥스페졸정: Esomeprazole* 라푸톤정: Lafutidine

* 페인리스정, 페인리스서방정 : Acetaminophen, Tramadol HCI

* 한국콜마세레콕시브캡슐 : Celecoxib

* 펠리움시럽, 정 : Pelagonium Sidoides

* 엘도브론정, 캡슐 : Erdosteine * 시클로원스네일라카 : Ciclopirox

* 프로솔로션, 연고, 액: Clobetasol Propionate* 파라케이주(프리믹스): Acetaminophen* 펜타아민주, 써프라민주: Amino acid* 콜린케이리드캡슐: Choline alfoscerate

* Hiforge Tab : Valsartan, Amlodipine

* Telopin Tab : Telmisartan, Amlodipine

* Lipar Tab : Atorvastatin

* Febuxt Tab : Febuxostat
* Nexpesol Tab : Esomeprazole

* Painless Tab : Acetaminophen, Tramadol HCl

* Celecoxib Cap : Celecoxib

* Pelium Syrup, Tab : Pelagonium Sidoides

* Ciclopirox Nail lacqer : Ciclopirox

* Prosol Ointment, Lition : Clobetasol Propionate

* Para-K : Acetaminophen

* Suppramin : Amino acid

* Colin-K Lidcap : Choline alfoscerate

COMPANY & PRODUCT INTRODUCTION

한국콜마는 2002년 제약사업을 시작하여 국내 최초로 개발, 생산 전문시스템을 갖추고 토털 CMO 서비스를 시행하고 있습니다. 고객사의 경쟁력 확보를목적으로 우수 의약품제조 및 품질관리기준(KGMP)에 부합한 설비 및 우수한 생산성을 통해 고객 만족을 실현하고 있습니다.

Since its establishment in 2002, Kolmar Korea offers one-stop CMO service. Our facility is KGMP certified (PIC/S GMP) with excellent capacity and quality management.

Healthcare Technology Licensing Office



Korea Doctor Preneur



KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP.

건국대학교 산학협력단

COUNTRY Republic of Korea

CEO Song, Chang Seon 송창선

URL research.konkuk.ac.kr

E-mail dplee@konkuk.ac.kr

Korea Doctor Preneur

의사창업자

COUNTRY Republic of Korea

CEO Kwon, Deok Cheol

URL www.khidi.or.kr

E-mail savvv0@khidi.or.kr

EXHIBIT CLASSIFICATION

디스플레이, 사물인터넷, 차세대반도체, 미래차, 기능성 식품, 바이오헬스, 동물바이오, 대기환경 등

Display, IoT, Next-generation semiconductor, Future car, Functional food, Bio-health, Animal biotechnology and Atmospheric environment

COMPANY & PRODUCT INTRODUCTION

건국대학교 산학협력단은 2004년 정식으로 설립된 이후 연구자가 최고의 성과를 도출할 수 있는 연구 환경을 조성하고, 연구 지원·기획 및 관리에서부 터 지식재산 관리, 대외 기관과의 협력은 물론, 최근에는 교내 우수 연구자 및 기술을 기반으로 건국대학교 기술지주회사의 자회사를 통한 기술사업화를 더욱 활성화하고 있습니다.

Since its establishment in 2014, KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP. has built a research environment where the efforts of researchers come to full fruition. It supports R&D planning and management, intellectual property management, external cooperation as well as commercialization of the technology based on the outcome of the research through the Konkuk Technology Holdings.

COMPANY & PRODUCT INTRODUCTION

의료현장에서 얻는 아이디어를 기술 사업화하여 창업한 의사커뮤니티인 닥터프러너는 국내 우수한 기술을 가진 의사창업기업간의 상호 정보교류와 의사 스타트업 생태계와 함께하는 네트워크 플랫폼이다. 이번 닥터프러너 홍보관은 창업의사간 상호 교류, 산·학·연·병 상생협력과 병원중심 기술사업화 촉진의 과정에서 시작 된 창업기업들과 그 기업의 기술을 소개하는 네트워크의장으로 구성된다.

Doctorpreneur is a community of medical professionals founded upon commercialization of ideas attained from practical medical fields. It is a network platform where leading doctor-corporates share mutual exchange of information alongside the ecosystem of startups established by former doctors. Doctorpreneur Pavilion will offer networking opportunities while promoting the co-prosperity of constituting organizations, advocate mutual business exchange, and introduce technologies of startup companies originated from within the process of endorsing hospital-centered commercialization.

Healthcare Technology Licensing Office



Korea Innovative Pharmaceutical Company

혁신형제약기업홍보관



Korea Drug Development Fund

(재)범부처신약개발사업단

COUNTRY Republic of Korea

CEO Muk, Hyun sang 묵현상

URL www.kddf.org

E-mail sblee@alteogen.com

Korea Innovative Pharmaceutical Company

COUNTRY Republic of Korea

CEO

URL

E-mail limitkim0821@khidi.or.kr

EXHIBIT CLASSIFICATION

글로벌 혁신신약(합성, 바이오, 천연물) 개발 지원

Support for development of global innovative new drugs (synthetic, bio, natural)

COMPANY & PRODUCT INTRODUCTION

사업단은 대한민국이 글로벌 신약개발 국가로 도약하는 데에 기여하고, 글로 벌 블록버스터 신약개발 촉진을 목적으로 설립된 기관으로 과학기술정보통 신부, 산업통상자원부, 보건복지부 3개 부처가 공동으로 추진하는 범부처전 주기신약개발사업을 수행하고 있습니다. 신약개발 전주기를 대상으로 단절 없는 연구비 지원 및 신약개발 특성을 반영한 마일스톤 관리방식 도입 등 다 양한 측면에서 기존 신약개발 관련 국가연구개발사업과 차별화되는 특성을 보유하고 있습니다.

Established with founding goals to promote development of new global blockbuster drug and help Korea leap forward to be a leader in the global new drug development, Korea Drug Development Fund has been undertaking governmentwide projects on life cycle of new drug development jointly carried by 3 ministries, Ministry of Science and ICT, The Ministry of Trade, Industry and Energy and Ministry of Health and Welfare. These are distinguishable compared to other national R&D projects on new drug development in various aspects including smooth financial support for the entire life cycle of new drug development and adoption of management strategy of Milestones that reflects unique characteristics of new drug development.

COMPANY & PRODUCT INTRODUCTION

국내 제약기업의 구조 선진화 글로벌 경쟁력을 확보하고 미래 신성장 동력사 업으로 육성을 선도하기 위해 연구개발 비중이 높은 제약기업을 혁신형 제약 기업으로 인증 및 지원

Certification and support pharmaceutical companies with a high proportion of R&D as innovative pharmaceutical companies in order to advance the structure of domestic pharmaceutical companies and secure global competitiveness and lead the development as new growth engine businesses in the future.

아국한의학연구원

New Excellent Technology Exhibition

Korea Innovative Pharmaceutical Company



Korea Institute of Oriental Medicine

한국한의학연구원

COUNTRY Republic of Korea

CEO Jong Yeol Kim 김종열

URL www.kiom.re.kr

E-mail rkim70@kiom.re.kr

Korea Otsuka

한국오츠카제약주식회사

COUNTRY Republic of Korea

CEO Moon, Sung-ho 문성호

URL www.otsuka.co.kr

E-mail hufs91@otsuka.co.kr

EXHIBIT CLASSIFICATION

혀의 상태를 촬영하여 만성질병을 진단하는 체외진단 의료기기

The diagnostic medical device to diagnose chronic disease by photographing the status of a tongue

COMPANY & PRODUCT INTRODUCTION

혀의 색상 분석 뿐만이 아니라 신뢰성이 확보된 혀 영상으로 기하 정보 및 입체특성 추출 및 분석을 바탕으로 인체 내부의 생리/병리적 변화를 진단하는 기술

NTechnology for diagnosing physiological / pathological changes inside the human body based on the extraction and analysis of geometric information and cubic features with reliable tongue images as well as color analysis of the tongue

EXHIBIT CLASSIFICATION

* 아빌리파이정 : Aripiprazole * 아빌리파이 OD 정 : Aripiprazole * 아빌리파이 메인테나 주 : Aripiprazole * 프레탈 정 : Cilostazol * 프레탈 서방캡슐 : Cilostazol : Tolvaptan * 삼스카 정 * 무코스타 정 : Rebamipide * 부설펙스 주 : Busufan * 아이클루시그 정 : ponatinib * 델티바 정 : Delamanid

* Abilify Tab : Aripiprazole * Abilify OD Tab : Aripiprazole * Abilify Maintena Inj : Aripiprazole : Cilostazol * Pletaal Tab * Pletaal SR Cap : Cilostazol * Samsca Tab : Tolvaptan * Mucosta Tab : Rebamipide * Busulfex vial : Busufan * Iclusing Tab : ponatinib * Deltyba Tab : Delamanid

COMPANY & PRODUCT INTRODUCTION

1982년 설립된 한국오츠카제약은 한국인의 건강한 삶에 공헌하는 회사'라는 미션을 바탕으로 질병의 치료뿐 아니라 일상 건강의 유지 및 증진에 기여할 수 있는 우수하고 혁신적인 의약품과 헬스케어 제품을 공급하고 있는 일본계합자 법인입니다.

Founded in 1982, Korea Otsuka Pharmaceutical is a Japanese-affliated joint corporation supplying excellent and innovative pharmaceutical and healthcare products to not only treat diseases but also help maintain and improve health in everyday life with the mission to become 'A company contributing to the healthy life of Koreans'

Korea Innovative Pharmaceutical Company



Hospital-based Business Innovation Center



KOREA UNITED PHARM

한국유나이티드제약㈜

COUNTRY Republic of Korea

CEO DUK YOUNG KANG 강덕영

URL www.kup.co.kr

E-mail withkt@kup.co.kr

Korea University Guro Hospital

고려대학교 구로병원

COUNTRY Republic of Korea

EO Han Seunggyu 한승규

URL guro.kumc.or.kr

E-mail dahi.kumc@gmail.com

EXHIBIT CLASSIFICATION

* 클란자CR정 : 소염진통 * 클라빅신듀오캡슐 : 항혈전 * 실로스탄CR정 : 항혈전 * 가스티인CR정 : 기능성소화불량 * 레보틱스CR정 : 기관지염

* 유니그릴CR정 : 항혈전 * 페노릭스EH정 : 고지혈 * 칼로민S정 : 기관지염 * 글리세틸시럽 : 뇌기능개선 * 오메틸큐티렛연질캡슐 : 고지혈증

* Clanza CR Tab : anti-inflammatory
* Clavixin Duo Cap. : antithrombatic
* Cilostan CR Tab. : antithrombatic
* Gastiin CR Tab. : functional dyspepsia
* Levotics CR Tab. : bronchitis
* Unigril CR Tab. : antithrombatic

* Unigril CR Tab. : antithrombatic

* Fenorics EH Tab. : hyperlipidemia

* Kalomin S Tab. : bronchitis

* Glicetil Syrup : brain functioning

* Omethyl QTlet Soft Cap. : hyperlipidemia

EXHIBIT CLASSIFICATION

1. 비전: 첨단 의료기술과 융합 네트워크로 의료가치를 창조하는 차세대 리더

2. 중점 연구분야

· 중점연구 분야 및 사업화 플랫폼: 기술사업화 기반 조성을 위하여 4대 중점 분야를 백신, 진단기기, 치료제 플랫폼으로 구축 운영

· 진단기기/치료제: 지역 클러스터 기반 산학연병 네트워크 확대

· 백신: 임상시험센터 기반 사업화 모델 구축

3. 전략목표

· 글로벌 리더를 지향하는 차별화된 연구 역량보유

· 지속적인 수익 창출이 가능한 최적의 산업화 기능 구현

· 융합연구 허브 구축을 위한 연구 지원체계 고도화

1. Vision: Korea University Guro Hospital strives to be an innovative leader who creates new values in medicine by utilizing cutting-edge medical technology and converged network.

2. Major Research Areas

· We'll operate the platforms that focused on Vaccine, Diagnostic device and Therapeutic agent for technology industrialization-based construction.

· Diagnostic Device/Therapeutic Agents: Expanding the Network Involving industry, University and Lab based on Regional Clusters.

 \cdot Vaccine: Commercialization Model with a Clinical Trial Center at its Hub.

3. Strategic Goals:

With our enormous research capacity, we aim to be the global leader in medical researchWe implement optimal business practices to ensure sustained revenue growth We advance support systems to establish a fusion research network hub.

COMPANY & PRODUCT INTRODUCTION

1987년 설립된 한국유나이티드제약은 매년 업계 최고 수준의 R&D 투자와 풍부한 노하우의 연구진들로 다양한 제품을 지속적으로 개발해 왔으며, 다양한 개량신약을 개발해 개량신약의 강자로 자리매김했습니다. 미국 경제전문지 포브스로부터 성장 가능성을 크게 인정받아 아시아 200대 유망 기업에 연이어 선정되기도 했습니다.


Established in 1987, Korea United Pharm. Inc. has continued to develop various products through prestigious R&D investment. It was named one of Asia's 200 most promising companies by the US economy magazine Forbes in recognition of its growth potential.

COMPANY & PRODUCT INTRODUCTION

고려대학교 구로병원은 환자 최우선의 가치를 실현을 위해 최첨단 로봇수술 장비, 감마나이프 등을 도입하고 안전한 병원을 위해 환자맞춤형 시스템을 구축 하는 등 의료시스템을 혁신하며 최상의 의료서비스를 제공합니다. 새로 운 국가성장동력을 위한 연구중심병원의 주축으로 미래 의학을 선도합니다.

Korea University Guro Hospital innovates the medical system and provides the best medical services by introducing state-of-the-art robotic surgery equipment, gamma-knife, etc. to realize the value of patients first, and establishing a patient-specific system for safe hospitals. Leading future medicine as the main pillar of research-oriented hospitals for the new national growth engines.

Hospital-based Business Innovation Center



Korea University HBIC

고려대학교 구로병원 개방형실험실

COUNTRY Republic of Korea

CEO Song HaeRyong 송해룡

URL kumc.hbic.or.kr

E-mail samuel.kumc@gmail.com

EXHIBIT CLASSIFICATION

1. 비전: 미래 선도형 보건산업 우수기업 발굴 및 육성

- 2. 사업목표: 병원-기업 협력을 위한 병원 기반 개방형 혁신 플랫폼 구축
- 3. 전략목표:
- 임상의사와 기업간 공동연구 및 개발 전주기 지원 개방형 플랫폼 구축
- 원격의료및 원격모니터링을 위한 웨어러블 스마트 헬스케어 기기및 개인별 맞춤형 디지털 치료제 공동 연구개발 플랫폼구축
- 미래 의료 선도를 위한 창업기업 발굴과 육성(SPARK, Acceleration)
- i Hospital 4.0 구현을 위한 의료기기 개발 협력네트워크 구축과 성과 확산

- Vision: Discover Health Care Companies with Future-leading Technology
- Goals: To establish Open Innovation Platform for Hospital-Company Collaboration
- 3. Strategic Goals:
 - To build up Open platform to support the total phase on collaborative R&D between clinicians and corporate.
 - To build up Joint R&D platform to develop wearable smart healthcare device and the personalized digital therapeutics for telemedicine and remote monitoring
 - To Find and foster the prospective start-ups to lead the future medical service(SPARK, Accleration partners)
 - To build up cooperative networks for the medical device development for i Hospital 4.0 and spread the results

COMPANY & PRODUCT INTRODUCTION

고려대학교 구로병원 개방형 실험실은 원격의료와 원격모니터링을 지원하는 빅데이타,AI 기반의 웨어러블 스마트 헬스 케어 및 디지털 치료제를 개발하여 미래 스마트 융복합 서비스 병원및 개인별 맞춤형 치료제를 구현할 수 있도 록 개발 전주기 지원 인프라를 제공합니다.

AI 빅데이타, 재활/의료기기, 스마트 약물 전달 3개 분야의 공동연구회를 조성하여 만성질환, 심뇌혈관, 인지장애, 재활,근골격계 분야에서 환자상태의 스마트 모니터링및 예측, 예방,예후 관리를 할 수 있는 스마트헬스케어 기기 개발을 위해 임상의사-기업 간 협력네트워킹을 통한 병원 기반의 기업 혁신 성장을 지원하고 있습니다.

또한 비대면 의료 서비스를 위해 VR,AR 기술 기반 디지털 컨텐츠 플랫폼을 구축하고자 노력하고 있습니다

Hospital-based Business Innovation Center(HBIC) of Korea University Guro Hospital, provides the infrastructure to support the total phase of bio-health product development to enable the personalized medicine and future smart convergence sevice hospital by development of Al based wearable smart healthcare device and digital therapeutics supporting telemedicine and remote monitoring. HBIC also organized 3 Joint Research forums at the area of Big data & Al , Rehabilitaiton & Medical device, Smart Drug Deivery System and has supported the hospital based innovative corporate growth through the collaboration between clinicians and corporates to develop the smart healthcare medical device to monitor, predict, prevent the indications on chronical, cardio cerebrovascular, cognition disorder, rehabilitation, musculoskeletal diseases and enabling its prognosis management at home For UNTACT healthcare service, we are also on way to build up VR,AR technology based digital contents platform.



Healthcare Technology Licensing Office



Korea University Medicine

고려대학교 의료원

Korea University Medicine Research and Business Foundation

고려대학교 의료원산학협력단

COUNTRY Republic of Korea

CEO Young-Hoon Kim 김영훈

URL www.kumc.or.kr

E-mail wooju2014@korea.ac.kr

COUNTRY Republic of Korea

CEO Kim, Byung-Jo 김병조

URL research.kumc.or.kr

E-mail limreo@korea.ac.kr

EXHIBIT CLASSIFICATION

- * 고려대학교 의료원
- * 고려대학교 의과대학
- * 고려대학교 안암병원, 구로병원, 안산병원
- * 고려대학교 의료기술지주 자회사
- * Korea University Medicine
- * Korea University College of Medicine
- * Korea University Anam Hospital, Guro Hospital, Ansan Hospital
- * Korea University Medical Technology Holdings Subsidiarie

EXHIBIT CLASSIFICATION

유전체, 신약, IT 융합기술, 줄기세포, 암치료제, 스마트헬스케어, 의료기기

Genome, New drug, IT convergence technology, Stem cell, Therapeutic agents in cancer, Smart healthcare and Medical device

COMPANY & PRODUCT INTRODUCTION

- * 고려대학교 의료원 연구전략본부
- * 연구중심병원(안암병원, 구로병원)
- * 고려대학교 의료기술지주 15개 자회사(회사소개 및 제품소개)
- * Korea University Office of Research Strategy
- * Research-Driven Hospitals(Korea University Anam Hospital, Guro Hospital)
- * Korea University Medical Technology Holdings Fifteen Subsidiaries(About Company, Product Information)

COMPANY & PRODUCT INTRODUCTION

고려대학교 의료원산학협력단은 고려대학교의료원 산하기관인 의과대학과 안암병원, 구로병원, 안산병원 소속의 연구자들의 연구역량 강화와 연구 결과의 사업화 증진을 위한 산·학·연·병 협력 시스템을 통해 연구지원 업무를 수행하며 고려대학교 의료기술지주(취)을 통해 연구자 창업을 지원하고 있습 니다.

Korea University Medicine Research and Business Foundation has been operating industry-academia-research-hospital cooperation system to reinforce capabilities of researchers from College of Medicine of Korea University Medical Center, Anam Hospital, Guro Hospital and Ansan Hospital, and commercialization of their research outcome. Moreover, it supports researchers to launch startup companies with KU Holdings.

New Excellent Technology Exhibition



Korea Innovative Pharmaceutical Company



KPIND Co., Ltd.

㈜케이피아이엔디

COUNTRY Republic of Korea
CEO Inyoung Choi 최인영
URL www.kpind.co.kr
E-mail kpi13@kpind.co.kr

Kuhnil Pharmaceutical Co., Ltd.

건일제약㈜

COUNTRY Republic of Korea

CEO Kim Young Joong 김영중

URL www.kuhnil.com

E-mail hklee@kuhnil.com

EXHIBIT CLASSIFICATION

앤아이스

N-Ice

COMPANY & PRODUCT INTRODUCTION

자외선 살균 제빙기

UV Sterilizing Ice Maker

EXHIBIT CLASSIFICATION

* 오마코 캡슐 : Omega-3-acid ethyl esters

* 로수메가 캡슐 : Omega-3-acid ethyl esters, Rosuvastatin

* 엑스페리드산 파우더: Deferasirox* 써카딘 서방정: Melatonin

* 풀미칸 분무용현탁액 : Budesonide micronized
* 포메롤 건조시럽 : Fomoterol fumarate
* 로딘 정, XL정, 서방정 : Etodolac Micronized
* 웰콘정 : Calcium polycarbophil
* 비오플 250 산제 : Saccharomyces boulardii

* 라스비정, 라스비디정:

Potassium bismuth citrate, Panitidine hydrochloride, Sucralfate hydrate

* 아모크라 정, 듀오정, 시럽, 듀오시럽, 네오시럽, 주 Potassium clavulanate diluted, Amoxicillin hydrate

* Omacor Cap : Omega-3-acid ethyl esters

* Rosumega Cap : Omega-3-acid ethyl esters, Rosuvastatin

* Experid Pow : Deferasirox * Circadin Tab : Melatonin

* Pulmican Respule
 * Formerol Dry syr.
 * Lodine kuhnil Cap/Tab/SR Tab: Etodolac Micronized
 * Wellcon Tab.
 * Bioflor 250 Pow
 * Saccharomyces boulardii

* RasB Tab, RasBD Tab

Potassium bismuth citrate, Panitidine hydrochloride, Sucralfate hydrate

* Amocla Duo Tab/Syr/inj : Amoxicillin, Potassium clavulanate

COMPANY & PRODUCT INTRODUCTION

건일제약은 삶의 질 개선에 공헌하는 Global 기업'이라는 비전 아래 신물질 신약, 글로벌 바이오의약품, 제형 및 DDS 개량형 신약, 복합제 개발을 통해 차별화된 연구개발 중심의 글로벌기업으로 성장하기 위해 끊임없이 노력하고 있습니다.

Under a vision of being a Global pharmaceutical company contributing to improving quality of life, Kuhnil continues to become an unique research focused global company, through development of new drugs, innovative global biopharmaceuticals, DDS and combinations drug products in an effort to improve quality of life in patients.

Healthcare Technology Licensing Office





COVID-19 SPECIAL PAVILION

㈜랩지노믹스

URL

LabGenomics Co., Ltd



Kyungpook National University Industry -Academic Cooperation Foundation

경북대학교 산학협력단

Republic of Korea **COUNTRY**

CEO Lim, Ki Byung 임기병

URL knu.ac.kr

ac knu ac kr

E-mail goodiszerg@knu.ac.kr **COUNTRY** Republic of Korea

CEO Sung Hyun Chin 진승현

www.labgenomics.co.kr

E-mail kyh@labgenomics.com

EXHIBIT CLASSIFICATION

바이오의약(뇌과학, 바이오약물전달, 항암제, 진단마커), 의료기기, 바이오의 학(천연물 소재 등)

Biopharmaceuticals (brain science, biopharmaceutical delivery, anticancer drugs and diagnostic markers), medical devices, and biomedicine (natural materials)

EXHIBIT CLASSIFICATION

랩건 코비드 19 PCR 키트

LabGun™ COVID-19 Assay PCR Kit

COMPANY & PRODUCT INTRODUCTION

경북대학교는 대한민국 교육의 기본이념에 입각하여 전문 학술의 심오한 이 론과 응용방법을 교수, 연구하는 동시에 교양을 넓히고 인격을 도야하여 국 가 사회에 공헌할 수 있는 유능한 지도적 인재를 양성하는 데 목적을 두고 설 립되었습니다. 지역민 모두가 한 마음 한 뜻으로 우리 지역에 국립 종합대학 교 설립을 희망하였고, 이 뜨거운 열망은 해방과 전쟁이라는 시대적 혼돈 속 에서도 결실을 맺었습니다.

Kyungpook National University was established with a founding goal to cultivate competent leaders to contribute to the Korean society by helping build their characters and sophistication as well as by teaching and researching profound academic theories and application based on the basic philosophy of the Korean education. The aspiration of the locals to establish a national university in the region with their heart and soul came to fruition even in the difficult times of war and a path to independence.

COMPANY & PRODUCT INTRODUCTION

랩지노믹스는 2002년부터 PCR(Polymerase Chain Reaction) 기법으로 한 제품에 판매를 하였고 이 분야에서 세계적인 리더입니다. 그리고 한국에 산 전기형아 검사를 첫 도입한 업체입니다.

LabGenomics is a world leader of PCR Kit since 2002 and founder of NIPT(non-invaisive Prenatal Test) in S.Korea.

LAB ∩ PEOPLE ਗੁਆਸੁ (주)

SEOUL Biohub

COVID-19 SPECIAL PAVILION



LABnPEOPLE

랩앤피플주식회사

LAMEDITECH

라메디텍

COUNTRY Republic of Korea

CEO Sung-Youn Cho 조성윤

URL www.labnpeople.com

E-mail tuptim@labnp.com

COUNTRY Republic of Korea

CEO Choi Jong Soek 최종석

URL www.lameditech.com

E-mail sales@lameditech.com

EXHIBIT CLASSIFICATION

마이크로 니들 및 약물 전달 기기를 활용한 약물 전달 응용 제품 개발

developing drug delivery devices using biodegradable metals and minimally invasive medical devices.

EXHIBIT CLASSIFICATION

핸디레이, 핸디레이-프로 : 바늘없이 의료용 레이저인 (Er: YAG laser)를 이용하여 말초혈액을 채혈하는 제품

Brand new device for the comfortable and safe blood collection. HandyRay makes the capillary blood collection comfortable and safe with low pain, no risk of cross infection and fast regeneration of skin.

COMPANY & PRODUCT INTRODUCTION

랩앤피플(주)는 세계 최초로 생분해성 금속을 이용한 약물전달 기기와 미세 침습 의료기기를 개발하는 바이오 벤처 기업입니다.

LABnPEOPLE is a R&D based company for bioabsorbable metal and minimal invasive medical devices.

COMPANY & PRODUCT INTRODUCTION

(주)라메디텍은 특화된 레이저 소형화 기술을 보유한 회사로 라메디텍의 레이저 소형화 기술이 적용된 레이저 제품들은 사용 편의성 및 가격 측면에 서 기존 제품들보다 높은 경쟁력을 가지고 있습니다.

Lameditech has grown to become a global company that develops and sells laser medical devices based on the technology recognized in domestic. Our goal is to be a global leader in this market.

Korea Innovative Pharmaceutical Company



New Excellent Technology Exhibition



LG Chem, Ltd

㈜LG화학

COUNTRY Republic of Korea

CEO Hak Cheol Shin 신학철

URL www.lgchem.com

E-mail jayden@lgchem.com

Lifecore Instrument Inc.

라이프코어인스트루먼트㈜

COUNTRY Republic of Korea

CEO James Lim 임동원

URL www.lifecoreworld.com

E-mail kim@lifecore.co.kr

EXHIBIT CLASSIFICATION

* 팩티브 : 퀴놀론 항생제 * 제미글로 : 당뇨병

* 제미로우 : 당뇨병/이상지질혈증

* 유트로핀 : 인성장호르몬

* 에스포젠 : 만성신부전 조혈치료제

* 폴리트롭 : 과배란유도제 * 히루안플러스 : 고분자 골관절염

* 유펜타주 : 디프테리아·파상풍·백일해,·B형간염·뇌수막염 예방

* Factive® : quinolone antibiotic

* Zemiglo[®] : A novel dipeptidyl peptidase IV (DPP IV) inhibitor

for T2DM

* Zemiro® : gemigliptin and rosuvastatin for patients with

T2DM and dyslipidemia.

* Eutropin® : managing short stature recombinant human

growth hormo

* Espogen[®] : anemia of chronic renal failure

* Follitrope $^{\mathbb{B}}$: female infertility in controlled ovarian hyperstimulation

to induce the development of multiple follicles

* Hyruan Plus® : osteoarthritis

* Eupenta $^{\circledR}$: Combined Diphtheria, Tetanus, whole cell Pertussis,

Hepatitis B and Haemophilus influenza typeB.

EXHIBIT CLASSIFICATION

STERION-H: 손세정용 전해이온살균수기 / 감염관리용 살균수 생성 3조

1포트식 전기분해 기술

STERION-H: Hand Washer Ionized Electrolysis (water sterillant

generator) / 3 cell 1 port electrolysis technolgy for

infection control

COMPANY & PRODUCT INTRODUCTION

1. 화학소독제 없이 박테리아, 바이러스 사멸

2. 친환경적인 전해이온수로 손 세정

3. MERS, SARS, COVID, 신종플루 등 살균

4. 병원, 학교, 유치원, 식당, 가정에 사용

5. 인체위해성 제로! 금속부식 없는 신기술

1. Killing bacteria, Virus without Chemilal.

2. Clean and wash your hands with eco-friendly water electrolysis.

3. MERS, SARS, COVID, Swine flu viruses, including sterilization.

4. Hospital, School, kindergarten, restarurant and home use.

Human hazards Zero! Apply new technology without corrosion to metals.

COMPANY & PRODUCT INTRODUCTION

LG화학은 1980년대부터 이어온 생명공학 R&D 역량을 바탕으로 국내 최초 당뇨 신약, 인성장호르몬 등을 개발한 성공 경험을 가지고 있습니다. 국내를 넘어 해외 시장을 적극 공략하고 있으며 지속적인 투자와 R&D 강화로 신약개발을 위한 파 이프라인을 확대해 글로벌 제약사로 성장하기 위해 노력하고 있습니다.

Based on our superior biotechnology and R&D capabilities accumulated since1980s, we have been successful in developing a variety of original products. We are actively moving beyond the domestic market into overseas markets, and with continued investment and R&D reinforcement, we are expanding the pipeline for new drug development and pushing to become a global pharmaceutical corporation.

COVID-19 SPECIAL PAVILION

K-Healthcare start-ups

Looxid Labs Inc.

룩시드랩스

COUNTRY



LISTEM CORPORATION

(주)리스템

COUNTRY Republic of Korea

CEO Moon Chang Ho 문창호

URL www.listem.co.kr
E-mail ex1@listem.co.kr

CEO Chae Yongwook 채용욱

URL looxidlabs.com

E-mail brian.chae@looxidlabs.com

Republic of Korea

EXHIBIT CLASSIFICATION

엑스선촬영장치

X-ray System

EXHIBIT CLASSIFICATION

VR 기반 인지기능 평가 및 훈련 솔루션

VR Cognitive Performance Assessment and Training Solution

COMPANY & PRODUCT INTRODUCTION

㈜리스템은 1960년 창립되어 반세기가 넘는 기간 동안 X-선 분야의 기술 성장과 발전에 주도적 역할로 의료기기 산업을 선도해 왔습니다. 인간 중심, 생명 존중의 기업이념을 바탕으로 첨단기술의 개발과 국내 의료 환경의 개선 및 보건의료산업의 향상에 선두 역할을 위해 끊임없는 노력을 기울여 왔으며, 국내 유일의 X-ray 일괄생산 Full System을 갖추고 있습니다. 1979년 파키스탄 수출을 시작으로 미국, 유럽, 아시아, 아프리카, 중동 등 세계 76여 개국에 수출을 해오고 있으며, 국내는 물론 글로벌 시장에서도 독보적인 기업으로 자리매김할 수 있도록 더욱 더 정진해 나아가겠습니다.

LISTEM Corporation was founded in 1960, and is the first company in Korea having CE mark for X-ray systems. It reflects our technical advance and endeavor for customer's satisfaction in its quality & service. With strong foundation in the local market, LISTEM has exported our products to over 76 countries in America, Europe, Asia, Africa and Middle East since their first export to Pakistan in 1979. Recently, all of the staffs in LISTEM are trying their best to be the best of X-ray system in the world.

COMPANY & PRODUCT INTRODUCTION

VIVE 및 Oculus 등의 VR에서 사용 가능한 시선추적 및 뇌파 센서 제품인 Looxid Link 와 Looxid Pro 센서를 미국, 유럽, 한국에서 출시하고 판매 중

"Looxid Link & Looxid Pro"

World's first eye tracking and brain wave sensor for VR and analytics platform $% \left(1\right) =\left(1\right) \left(1\right) \left($

Sales started at 2020. Jan. 10 in US, EU, Japan, Korea

Hospital-based Business Innovation Center



Australian Trade and Investment Commission



LTOP

㈜엘탑

Luina Bio

COUNTRY Republic of Korea

CEO Gwang Cheol Song 송광철

URL

E-mail skc0328@nate.com

COUNTRY Australia

CEO

URL www.luinabio.com.au

E-mail max.rossetto@luinabio.com.au

EXHIBIT CLASSIFICATION

낙상,욕창,심박,호흡 등 실시간 감지시스템이 적용된 와상환자용 스마트매트

Smart mat for patients with real-time detection system such as falls, bedsores, heartbeat, and breathing

COMPANY & PRODUCT INTRODUCTION

건강관리 서비스 수요 증가와 의료 전문인력 부족에 따른 환자 안전사고 발생증가압력신호 기반 스마트 매트 개발을 통한 생체신호 측정, 욕창예방, 낙상감지스마트 매트 기반 환자안전관리 서비스 구축 및 제공

Increased patient safety accidents due to increased demand for health care services and a shortage of medical professionals Biosignal measurement, prevention of pressure sores, and falls through the development of a pressure signal-based smart mat Establish and provide smart mat-based patient safety management service

COMPANY & PRODUCT INTRODUCTION

Luina Bio is a Brisbane, Australia based, drug development and contract manufacturing organization (CMO) serving the pharmaceutical, biotechnology and veterinary industries. Luina Bio is a manufacturer of Biopharmaceutical products, offering contract development, scale-up, manufacturing and regulatory support services to organisations requiring Active Pharmaceutical Ingredients (API) for clinical trials or commercial applications. Luina Bio is the most experienced provider of bacterial/yeast expressed biopharmaceutical contract services in Australia.

Drawing on more than 20 years of contract manufacturing experience, Luina Bio scientists have the expertise, training and experience to ensure a successful outcome to any project. Utilising our TGA/APVMA licensed facilities operating to international cGMP standards, we can provide comprehensive manufacturing solutions for both biological and small molecule drugs. In the past, we have manufactured recombinant proteins, live therapeutics, whole cell vaccines, viral vaccines, purified plant extracts, pro-biotics for pre-clinical, phase 1 to 3 human clinical trials and commercial product for veterinary product for clients both within Australia and internationally in the United States, New Zealand and Asia. At Luina Bio, we realise that three of the most important issues in developing a successful commercial relationship are communication, flexibility and trust. We pride ourselves on being client focused, involving the client as much as possible throughout the development and manufacturing processes and in providing a flexible solution to their needs

COVID-19 SPECIAL PAVILION



Korea Doctor Preneur



Lunit Inc.

(주)루닛

COUNTRY

Republic of Korea

CEO Brandon Beomsoek Suh 서범석

URL www.lunit.io

E-mail chanick.park@lunit.io

M&B Meditech Co., Ltd.

엠엔비메디텍㈜

COUNTRY Republic of Korea

CEO Keum-Joon Cho 조금준

URL

E-mail md_cho@hanmail.net

EXHIBIT CLASSIFICATION

루닛 인사이트 CXR

Lunit INSIGHT CXR

EXHIBIT CLASSIFICATION

1. 태아 3D 프린팅

2. 임산부 질병 예측 솔루션

1. 3D-Printed Fetus

2. Maternal Disease Prediction Solution

COMPANY & PRODUCT INTRODUCTION

'인공지능을 활용한 암 정복'을 미션으로 설립된 루닛은 국내 최초의 딥러닝 의료 인공지능 기업입니다. 딥러닝 기술을 기반으로 한 인공지능을 통해, 암 의 진단 및 치료에 기여하는 솔루션을 개발 및 제공합니다.

Lunit is a medical AI software company devoted to conquering cancer and advancing medical intelligence to the next level. Lunit develops and provides novel AI-powered solutions for cancer diagnostics and therapeutics that can save time and save lives.

COMPANY & PRODUCT INTRODUCTION

엠엔비메디텍은 임산부 및 태아의 건강 증진을 위한 의료기기부터 솔루션까지 제공하는 전문 기업입니다. 임산부 및 태아의 질명 예측 모델을 개발하고, 자체 초음파 영상 3D 변환기술로 조형물을 제작하고 있습니다.

'태아 3D조형물 제작'은 초음파 이외의 영상을 자체 변환할 수 있는 기술을 자체 보유하고 있어 실제 초음파 영상을 바탕으로 변환하기 때문에 태아와 똑같은 모형을 맞춤 제작이 가능합니다.

M&B Meditech is a company specializing in medical devices and solutions to improve the health of pregnant women and fetuses.

The company is developing a model for predicting the quality of pregnant women and fetuses, and producing sculptures with its own ultrasound image 3D conversion technology. The 3D-sculpted fetus can be customized as the company possesses its own technology to convert the actual ultrasound images.

Hospital-based Business Innovation Center



COVID-19 SPECIAL PAVILION

MEDIANA CO., LTD

㈜메디아나



MD Healthcare

MD헬스케어

COUNTRY Republic of Korea

CEO Yoon-Keun Kim 김윤근

URL www.mdhc.kr
E-mail hrlee@mdhc.kr

COUNTRY Republic of Korea

CEO Khil MoonJong 길문종

URL www.mediana.co.kr

E-mail gavin@mediana.co.kr

EXHIBIT CLASSIFICATION

나노소포

Extracellular NanoVesicles, Evs

EXHIBIT CLASSIFICATION

환자감시장치(고출력 제세동기 기능)

Patient monitors,/Manual Defibrillator

COMPANY & PRODUCT INTRODUCTION

세포 밖으로 분비되는 나노소포는 유전자, 단백질, 저분자 화합물을 함유하고 있는 나노 크기(20-100nm)의 지질 이중막으로 된 물질입니다. 세포의 증식 및 사멸과정에서 다른 세포와의 정보교환을 위해 분비되며, 미생물에서 분비 된 나노소포는 인체 세포와 지속적으로 정보교환을 하면서 체내 대사와 면역 체계의 항상성 유지에 핵심적인 역할을 합니다.

Nanovesicles, or EVs (Extracellular Vesicles) are 20 to 100 nm in size and are excreted out of a cell with its DNA, protein, and low molecular compounds within its lipid bilayer membrane. EVs are excreted during cellular growth and death for intercellular communication purposes. Immune system and metabolism homeostasis is maintained through continuous communication between human cells and Microbial EV

COMPANY & PRODUCT INTRODUCTION

㈜메디아나는 1993년 이후부터 신규 해외시장을 개척하기 위해 노력을 기울여 왔습니다. 특히 메디컬 시장에서 메디아나는 다년간 세계적으로 유명한회사와 ODM 비즈니스를 구축하였습니다. 제세동기, 환자감시 모니터 및 유아용 장비를 기본적으로 보유하고 있으며, 추가적으로 PICC 및 체성분 분석기 제품을 준비하고 있습니다.

MEDIANA CO., Ltd has been expanding into new Overseas markets and continuing in its efforts since 1993. Especially, We make ODM business with the famous company in the world and Mediana brand business for years in Medical equipment industry. We have AED/Defibrillator, Patient monitors, Fetal products as basic products. In addition, we are developing PICC, Body composition.

Korea Doctor Preneur



COVID-19 SPECIAL PAVILION



Medical IP Co., Ltd.

메디컬아이피 주식회사

COUNTRY Republic of Korea

CEO Sang Joon Park 박상준

URL www.medicalip.com

E-mail aramoh@medicalip.com

MEDICAL STANDARD Co., Ltd.

(주)메디칼 스탠다드

COUNTRY Republic of Korea

CEO Seung Mook Lee 이승묵

URL www.medicalstandard.com

E-mail hjko@medicalstandard.com

EXHIBIT CLASSIFICATION

- 1. MEDIP PRO
- 2. ANATDEL
- 3. MEDIP COVID19

EXHIBIT CLASSIFICATION

PACSPLUS

PACSPLUS

COMPANY & PRODUCT INTRODUCTION

가트너(Gartner), 아이디테크이엑스(IDTechEX) 등 글로버러 시장조사 기관에 등재된 유일한 아시아 3차원(3D) 프린팅 기업입니다.

의료용 3D영상처리 소프트웨어 메딥(MEDIP)과 환자맞춤형 3D프린팅 인공 장기 모델 제작 솔루션 아낫델(ANATDEL)을 제공하고 있습니다.

Medical IP Co., Ltd. is the only Asian three-dimensional (3D) printing company listed in global market research institutes such as Gartner and IDTechEX.

The company provides medical 3D imaging software MEDIP and patient-specific 3D printing artificial organ model production solution ANATDEL."

COMPANY & PRODUCT INTRODUCTION

저희 메디칼스탠다드는 PACS와 Teleradiology 솔루션 전문업체(브랜드 PACSPLUS)입니다. 지난 2000년에 설립한 이래 많은 임상 경험과 의 공학 기술, 다수의 프로젝트 경험을 보유하고 있습니다.

Medical Standard is one of leading companies for PACS in Korea and has good sales and service reference in overseas countries.

We have 1,700 customers locally and have a special software development team as well to comply with Telemedicine and Teleradiology requirement such as DICOM, HL.7, and IHE.

Medical Standard has achieved the FDA, ISO 9001, ISO 13485 and CE Certificate approval.

We also hold many patents related to the improvement of image quality, diagnosis, mammography and more.

For the above reasons, now many doctors trust the solutions of Medical Standard all over the world, such as Northern America, Europe, Japan, China, Middle East, and many other areas. As a company which makes a good business with trust, Medical Standard never stops working for you.

Medicos Biotech

Daejeon Technopark Biote



Medicosbiotech

메디코스바이오텍

COUNTRY

CEO WonMin Yoo 유원민

URL drgraft.co.kr

E-mail pearlzheng@medicosbiotech.com

Republic of Korea

COUNTRY Republic of Korea

COVID-19 SPECIAL PAVILION

(주)메디멕스코리아

CEO Mr. YoungKeun Choi 최영근

MEDIMAXKOREA ENGINEERING Co., Ltd

URL www.medimax.co.kr

E-mail korea@medimax.co.kr

EXHIBIT CLASSIFICATION

탈모샴푸, 탈모토닉

Scalp Shampoo,Tonic

COMPANY & PRODUCT INTRODUCTION

피부 재생 및 탈모 증상에 효과적인 각종 성장인자들을 연구하여 홈 케어만 으로도 두피와 탈모 관리를 할 수 있도록 제품을 개발하였습니다.

To regenerate damaged scalp cells, Medicosbiotech's Research Center developed a combination of various growth factors that are effective for skin regeneration and hair loss symtoms

EXHIBIT CLASSIFICATION

의료가스중앙공급장치

Crown Console Unit, Wall suction unit, O2 Flowmeter with humidifier

COMPANY & PRODUCT INTRODUCTION

메디멕스코리아는 1999년에 설립되어 국내외 종합병원, 대학병원과 개인 병원에 의료가스공급장치를 제조.설치 및 수출를 하고 있으며, 또 CE와 ISO 13485 인증서, GMP를 획득하여, 증동, 아프리카, 아시아와 남아메리카 35여 개국에 수출중에 있습니다.

Medimaxkorea established in 1999 is the Korea's leading manufacturer of medical gas equipments in providing the most technologically advanced products in the marketplace with CE mark obtained and ISO 13485:2003 approved.

Korea Innovative Pharmaceutical Company



COVID-19 SPECIAL PAVILION



Medytox Inc.

㈜메디톡스

COUNTRY Republic of Korea

CEO Jung Hyun Ho 정현호

URL medytox.com

E-mail junghwan.kim@medy-tox.co.kr

MEINNTECH

메인텍㈜

COUNTRY Republic of Korea

CEO Sang-bin Lee 이상빈

URL www.meinntech.com

E-mail marketing@meinntech.com

EXHIBIT CLASSIFICATION

* 메디톡신주 : 클로스트리디움 보툴리눔 독소A형 (Hall 균주) * 이노톡스주 : 클로스트리디움 보툴리눔 독소A형 (Hall 균주)

* 코어톡스주 : 클로스트리디움 보툴리눔 독소A형 (150kDa) (Hall 균주)

* Neuronox® : Clostridium botulinum toxin type A(Hall strain)
* Innotox® : Clostridium botulinum toxin type A(Hall strain)
* Coretox® : Clostridium botulinum toxin type A (150kDa) (Hall strain)

EXHIBIT CLASSIFICATION

실린더식 의약품 주입펌프 (애니퓨전)

Cylinder Pump (Anyfusion)

COMPANY & PRODUCT INTRODUCTION

국내 최초로 보툴리눔 톡신 제제를 개발한 메디톡스는 업계를 선도한다는 자부심과 책임감을 느끼고 있습니다. 이에 보다 객관적이고 과학적인 가이드라인을 이행함으로써 대한민국 바이오 업계의 투명성과 경쟁력을 이끌어내는데 앞장서고 있습니다.

As the first botulinum toxin product developer in Korea, we feel pride and responsibility for this industry. Which is why we pursue to improve the transparency and the competitiveness of Korea's biopharmaceutical businesses by implementating of more scientific guidelines for industry practice.

COMPANY & PRODUCT INTRODUCTION

혁식 원천기술로 의료산업분야의 글로벌리더를 목표로 도약하는 의료기기 저무기어

Medical device company that aims to become a global leader with core source innovation technology

Korea Doctor Preneur



Korea Doctor Preneur



Microt Co., Ltd.

㈜마이크로트

COUNTRY Republic of Korea

CEO Jong cheol Han 한종철

URL www.microt.kr

E-mail jc79.han@samsung.com

Minds Al Co., Ltd.

㈜마인즈아이

COUNTRY Republic of Korea

CEO Jeong Ho Seok 석정호

URL blog.naver.com/mycheeu

www.cheeu.co.kr (예정)

E-mail johnstein.mindsai@gmail.com

EXHIBIT CLASSIFICATION

1. M1 (microtube + Injector)

2. F1 (finetube + injector)

EXHIBIT CLASSIFICATION

1. MINDS.NAVI

2. CHEEU.Forest

3. CHEEU.Coun

4. CHEEU.Tip

COMPANY & PRODUCT INTRODUCTION

㈜마이크로트는 새로운 의료 기술로 쉽고 안전한 도구를 합리적인 가격으로 제공하는 것을 목표로 하는 기업입니다. 현재는 그동안의 연구성과로 얻은 녹내장 수술의 합병증을 최소로 하기 위한 임플란트 튜브의 적정 내,외경 정보와 필요한 재료의 성질 및 구조적 특성에 대한 노하우로 쉽게 사용하면서 효과적으로 합병증을 최소화할 수 있는 녹내장 임플란트를 개발중에 있습니다.

Microt Co., Ltd. aims to provide easy, secure tools at a reasonable price with new healthcare technologies. Currently, the company is developing glaucoma implants that can be used easily and effectively to minimize complications while minimizing internal and external information of implant tubes by knowing more about the properties and structural characteristics of necessary materials.

COMPANY & PRODUCT INTRODUCTION

Vision: 한 사람의 몸과 마음, 영혼이 온전히 건강하도록 돕는 기업

Mission:

1. 인공지능을 활용한 중증우울증의 선별진단을 위한 바이오마커발굴


2. 한국형 고위험우울증 통합치료프로그램 개발 및 보급 센터 설립

Vision: An enterprise that helps a person's body, mind and soul to be fully healthy.

Mission:

- 1. Biomarker Discovery for Screening Diagnosis of Severe Depression Using Artificial Intelligence
- Establishment of a Korean style program of the Development and Distribution of Integrated Treatment Program for high-risk Depression"

Korea Doctor Preneur



SEOUL Biohub



Mirabelsoft

㈜미라벨소프트

COUNTRY Republic of Korea

URL www.mirabellsoft.com

E-mail insun.shin@innobrew.com

Kiho Park 박기호

MONORAMA

모노라마

COUNTRY Republic of Korea

CEO Kim Chang Ho 김창호

URL www.mono-rama.com

E-mail kimch@mono-rama.com

EXHIBIT CLASSIFICATION

- 1. 전자처방전 '의연'
- 2. MD팍스
- 3. MD검진
- 1. E-prescription 'Euyeon' App.
- 2. MCPACS
- 3. MD Examination

EXHIBIT CLASSIFICATION

병원 처방전 기반, SNS를 통한 인공지능 복약지도·알림 모니터링 서비스

platform for medication guidance, notification, and medication compliance analysis to monitor the medication of the elderly and chronic patients.

COMPANY & PRODUCT INTRODUCTION

미라벨소프트는 다양한 진료과목의 전문의들이 직접 주주로 참여하여 설립한 병원경영지원 전문 기업인 ㈜엠디파크의 IT 분야 자회사입니다.

전자처방전, 신기능 PACS, 건강검진SW 등 병의원에 특화된 IT 솔루션을 개발하고 있습니다.

Mirabelsoft is an IT subsidiary of MDPAC Co., Ltd., a company specializing in hospital management support. It was founded by experts from various medical departments who joined as shareholders.

The company develops IT solutions specialized for hospitals such as electronic prescription, new PACS technology, medical examination SW.

COMPANY & PRODUCT INTRODUCTION

인공지능 인지 기술, 자연어 처리 기술 및 IoMT를 바탕으로 개인 사용자의 증상, 약물치료서비스를 SNS 기반으로 제공하며 수집된 개인의 건강, 의료데 이터를 분석하여 개인맞춤형 셀프케어 솔루션을 서비스하고 있습니다.

Based on artificial intelligence cognitive technology, natural language processing technology, and IoMT, the company develops and operates MediscanTM, a medical data collection digital healthcare platform that provides SNS-based symptom and drug treatment services for individual users.

MTEG MTEG.CO.KF

K-Healthcare start-ups

Australian Trade and Investment Commission



MTEG

엠티이지

COUNTRY

CEO Laurent Kim 김덕선

URL www.mteg.co.kr

E-mail Laurent@mteg.co.kr

MTPConnect

COUNTRY Australia

CEO Dr Dan Grant

URL www.mtpconnect.org.au

E-mail dan.grant@mtpconnect.org.au

EXHIBIT CLASSIFICATION

클라우드 기반의 동영상 저장 및 인공지능 수술 동영상 분석 플랫폼

Republic of Korea

A cloud-based video storage and Al-based analysis platform for internal surgical videos via endoscopy

COMPANY & PRODUCT INTRODUCTION

국내 최초로 수술 동영상에서 출혈 및 도구 움직임에 따른 의미 프레임을 분석해내는 인덱싱(Indexing) 엔진을 개발하여 이를 모든 소프트웨어에 적용시킨 AI기반 창업기업

MTEG Co., Ltd. developed intelligent surgical video management solution includes Al-powered engine that automatically identifies bleeding or surgery tools' movement and extracts meaningful scenes from surgical videos.

COMPANY & PRODUCT INTRODUCTION

MTPConnect is a not-for-profit organisation aiming to accelerate the rate of growth of the medical technologies, biotechnologies and pharmaceuticals sector to increase commercialisation, collaboration and establish Australia as an Asia-Pacific hub for MTP companies. Formed in December 2015 as part of the Federal Government's Industry Growth Centres Initiative, MTPConnect is an independent and trusted voice, calling for change to support the sector.

MTPConnect raises awareness, fosters collaboration and competition, aggregates existing knowledge and shares it with the broader sector. It also jointly funds projects that address the Sector Growth Priorities and the constraints and gaps identified in the sector.

MTPConnect's mandate as an Industry Growth Centre is focused on four key areas:

- Increasing collaboration and commercialisation across the sector $% \left(1\right) =\left(1\right) \left(1\right)$
- Improving management and workforce skills
- $\bullet\,$ Improving access to global supply chains and international markets
- Optimising the regulatory environment

Korea Doctor Preneur

COVID-19 SPECIAL PAVILION

NFR.

Myo-Tec-Sci Co., Ltd.

마이오텍사이언스㈜

NanoFocusRay (주)나노포커스레이

COUNTRY Republic of Korea

CEO Hyeon Soo Kim 김현수

URL

E-mail anatomykim@korea.ac.kr

COUNTRY Republic of Korea

CEO Kwon-Ha Yoon 윤권하

URL www.nanofocusray.com

E-mail paul@nfr.kr

EXHIBIT CLASSIFICATION

- 1. 근감소억제 천연물 함초
- 2. 근감소억제 인공아미노산 제제
- 3. 근감소억제 근육분비 물질
- 1. Intramuscular inhibitor made with natural herb substances
- 2. Intramuscular inhibitor drug made with artificial amino acid
- 3. Intramuscular inhibitor made with muscle secretion material

COMPANY & PRODUCT INTRODUCTION

근감소증 치료제 개발 전문회사입니다

The company specializes in the development of medicine for myotropia.

EXHIBIT CLASSIFICATION

모바일 CT

mobile CT

COMPANY & PRODUCT INTRODUCTION

엑스선영상기기(마이크로/의료용 CT) 제조 등 방사선 장치 제조업체

manufacturer of radiation devices, such as X-ray imaging devices (micro/medical CTs).

국립암센터



National Cancer Center

Healthcare Technology Licensing Office

국립암센터

COUNTRY

Republic of Korea

Lee, Eun Sook 이은숙

URL www.ncc.re.kr

E-mail woocj@ncc.re.kr

Neo-Gene-Pharm Co., Ltd.

㈜네오진팜

Korea Doctor Preneur

COUNTRY Republic of Korea

Hyo Soo Kim 김효수

제작예정 **URL**

E-mail 777jaehee@gmail.com

EXHIBIT CLASSIFICATION

글로벌 항암신약 개발의 중심축으로서 항암제 표적발굴을 위한 암 발생의 기 전 연구, 첨단 암 진료기술 및 의료기기 개발 연구 및 이행성 연구

As a central axis of the global anti-cancer drug development, the Center focuses on the implementable research on the mechanism of cancer development to discover targeted anti-cancer drugs, and advanced diagnostic technology and medical device for cancer

EXHIBIT CLASSIFICATION

간섬유화 치료제 개발을 위한 연구중

Research on the development of liver fibrosis drugs.

COMPANY & PRODUCT INTRODUCTION

국립암센터는 암에 대한 전문적인 연구와 진료를 통하여 우리나라 국민의 암 발생률과 사망률을 낮추고 암 환자의 삶의 질을 높이는 등 국민보건향상에 이바지하고자 설립된 정부출연기관입니다.

National Cancer Center is a government-funded institution established to contribute to the improvement of national health by improving the quality of life of cancer patients and reducing the incidence and mortality rates through specialized research and treatment in the nation.

COMPANY & PRODUCT INTRODUCTION

나노 테크닉 기반의 안전하고 효율적인 간섬유화 억제 유전자치료제를 개발 하고자 함.

Aims to develop safe and efficient liver fibrosis inhibiting gene therapeutic based on nanotechnics.

Korea Doctor Preneur



K-Healthcare start-ups



NeogenTC Co, Ltd.

네오젠TC

COUNTRY Republic of Korea
CEO Hee Jin Lee 이희진

URL

E-mail backlila@gmail.com

Neuro Venti

뉴로벤티

COUNTRY Republic of Korea

CEO Chan Young Shin 신찬영

URL www.neuroventi.com

E-mail jnrjchkyk@hanmail.net

EXHIBIT CLASSIFICATION

- 1. TIL 항암면역세포치료제
- 2. 신생항원 발굴 플랫폼
- 3. TCR-T 항암면역세포치료제
- 1. TIL Anti-cancer immunosuppressive cell therapy
- 2. New Antigen discovering platform
- 3. TCR-T Anti-cancer immunosuppressive cell therapy

EXHIBIT CLASSIFICATION

자폐 범주성 장애 치료제 및 천연물 HTS기반 건강기능식품, 의약품 후보 발굴 개발 플랫폼

Therapeutic Agents against ASD and HTS based drug discovery service for natural products

COMPANY & PRODUCT INTRODUCTION

㈜네오젠티씨는 효과적인 치료제가 없는 난치성 암의 치료제 개발을 목표로 하는 연구중심의 면역세포치료제 개발 기업입니다. 현재 종양침윤림프구 (tumor infiltrating lymphocyte, TIL) 면역세포치료제는 2021년 임상 1상 시험을 목표로 개발하고 있으며, 신생항원(Neoantigen) 발굴 및 획기적인 유전자 전달 시스템(Gene delivery system)을 통해 TCR-T (T cell receptor engineered T cell) 면역세포치료제를 개발하여 혁신적인 글로벌 면역세포치료제 개발 기업으로 성장해 나갈 것입니다.

Neogentc Co., Ltd. is a research-oriented immunocyte development company that aims to develop treatments for incurable cancers that have no effective treatments. Currently, tumor infiltrating lymphocyte(TIL) immune cell therapy is focused on phase 1 of clinical trials in 2021. The company is sparing no effort to grow into a company that develops innovative global immune cell therapies through discovering Neoantigen and groundbreaking Gene delivery system.

COMPANY & PRODUCT INTRODUCTION

질병 기반 및 Big data, AI 기반 질환 극복 타겟 발굴 및 자폐 범주성 장애 치료제

Development of Therapeutic Agents against ASD (Autistic Spectrum Disorder)



New Excellent Technology Exhibition

COVID-19 SPECIAL PAVILION



NF CO., LTD.

New Excellent Technology Exhibition

보건신기술NET인증 홍보관

COUNTRY Republic of Korea

CEO Kwon, Deok Cheol 권덕철

URL www.khidi.or.kr

E-mail khilee17@khidi.or.kr

NF Co., Ltd

(주)엔에프

COUNTRY Republic of Korea

CEO LEE SANG KON 이상곤

URL www.nfeco.co.kr

E-mail jdpark@nfeco.co.kr

EXHIBIT CLASSIFICATION

보건신기술(NET) 인증사업과 신기술을 인증받은 29개 기업(31개 기술)을 소개하는 전시관

Introduction of New Excellent technology certification business and Exhibition of technologies of certified companies

EXHIBIT CLASSIFICATION

의료용 산소공급시스템

Medical Oxygen Supply System

COMPANY & PRODUCT INTRODUCTION

보건신기술(NET) 인증사업은 의약품, 생명공학, 화장품, 식품, 의료기기 등 보건산업 분야에서 국내 최초로 개발된 기술에 인증마크를 부여하는 것입니다. 국내 기업 및 연구기관, 대학 등에서 개발한 신기술을 초기에 발굴하여 우수성을 인증하고, 개발된 신기술의 상용화와 더불어 기술거래를 촉진하며, 인증받은 보건신기술 제품의 신뢰성을 높여 구매력을 창출하고 이를 통한 초기시장 진출 기반을 지원합니다.

NET mark is given to the new technologies of medical, pharmaceutical, cosmetic, food, bio-technology, medical device etc. It provides several benefits such as acquisition of quality certification and technological to enterprises of the certificated technology. It promotes both transaction of technologies and commercialization of new technologies in early stage of new technology developed by companies, research institutes, universities etc. Consumers will have a higher reliability when they purchase NET certified product so that NET certification business support the successful advances of market.

COMPANY & PRODUCT INTRODUCTION

㈜엔에프가 하는 모든 일의 원칙은 저희가 추구하는 가치, 즉 "Saving Lives" 구현에 도전하기 위함입니다. 우리는 '보이지않는 혁신의 가치'를 믿습니다. 우리가 현실에 도전하는 방식은 모든 제품을 친환경 공간 구현, 유려한 디자인, 편리한 사용법, 사용자 친화적으로 만드는 것입니다.

NF is a company that strives to fulfill its vision of "Saving Lives" and to foster a natural environment and eco-friendly world.

NGeneBio

K-Healthcare start-ups

NOVOTECH[™]
The Asia Pacific CRO

ngenebio

엔젠바이오

Novotech

COUNTRY Republic of Korea

CEO Choi Daechul 최대출 URL www.ngenebio.com

E-mail ja.park@ngenebio.com

COUNTRY Australia

Australian Trade and Investment Commission

CEO

URL www.novotech-cro.com

E-mail Michelle.Park@novotech-cro.com

EXHIBIT CLASSIFICATION

NGS 기반 유전성 유방암 BRCA1/2 유전자 검사키트 및 혈액암 유전자 검사키트

NGS-based breast/ovarian cancer testing kit and Hematological malignancies kit

COMPANY & PRODUCT INTRODUCTION

주식회사 엔젠바이오 (NGeneBio Co., Ltd.)는 차세대염기서열분석 (Next Generation Sequencing; NGS) 플랫폼과 생물정보학 (Bioinformatics)이라는 정밀의료의 가장 핵심기술 분야에서 다년간의 사업 경험과 기술 역량을 보유

NGeneBio develops in vitro diagnostics (IVD)/companion diagnostics (CDx) products and bioinformatics Software with cutting-of-edge technologies including next generation sequencing (NGS) for precision diagnostics.

COMPANY & PRODUCT INTRODUCTION

Novotech is internationally recognized as the leading regional full-service contract research organization (CRO) in Asia-Pacific. Novotech has been instrumental in the success of over a thousand Phase I - IV clinical trials for biotechnology companies.

Novotech was established in 1996, with offices in 11 locations across the region, and site partnerships with major health institutions.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech obtained the ISO 27001 certification which is the best-known standard in the ISO family providing requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies.

For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert

Australian Trade and Investment Commission



Australian Trade and Investment Commission



NSW State Government

COUNTRY Australia

CEO

URL www.invest.nsw.gov.au

TEL +61 428 054 858

E-mail diane.crosdale@treasury.nsw.gov.au

COMPANY & PRODUCT INTRODUCTION

NSW is innovative and entrepreneurial. The state is a world leader in medical research and is Australia's largest, globally connected state economy.

NSW's mature digital health environment is supported by 14 health precincts, three of Australia's top five highest ranked research universities and the largest number of STEM graduates in Australia

NSW is renowned globally for its medical technology research, and the industry in NSW is Australia's largest. The state is also a global leader in biotechnology and clinical trials, with 30 per cent of all Australian trials conducted in NSW centres. It is renowned for its Statewide Biobank with over 3million human samples and digital analysis.

The NSW Government continues to invest heavily in health and education precincts across the state, including building one of the largest in Australia, the 'Westmead Health and Innovation Precinct'. In partnership with industry and the community, it is also developing the 'Sydney Innovation and Technology Precinct' which will cement Sydney as the innovation capital of Australia and as a world player in technology and ideas incubator.

NSW is a leader in supporting international collaboration between industry, research and government. The NSW Government's Trade & Investment Team can help business to establish, innovate and grow in Sydney and NSW, with its dedicated experts across all levels of government to provide customised support for business.

Nucleus Network

COUNTRY Australia

CEO

URL www.nucleusnetwork.com

TEL +61 3 9089 8227

E-mail J.Wong@nucleusnetwork.com.au

COMPANY & PRODUCT INTRODUCTION

Nucleus Network is the largest Phase 1 clinical trials specialist in Australia and the only Phase 1 specialist with clinics in both the US and Australia.

With over 200 beds, our Australian phase 1 clinics are in Melbourne and Brisbane, and our US phase I clinic is located in Minnesota. All three clinics are strategically co-located within leading medical, research and biotech precincts with unique access to services including bioanalytical laboratories, MRI, lumbar punctures, X-rays, ophthalmology assessments and other medical specializations.

New Excellent Technology Exhibition



Korea Innovative Pharmaceutical Company



Oculight Co., Ltd.

㈜오큐라이트

COUNTRY Republic of Korea

CEO NAM DONG HEUN 남동흔

URL www.oculight.co.kr

E-mail stony@oculight.co.kr

Olix Pharamceuticals, INC.

올릭스㈜

COUNTRY Republic of Korea

CEO Dong-ki Lee 이동기

URL www.olixpharma.com

E-mail hjlee@olixpharma.com

EXHIBIT CLASSIFICATION

안내조명 이용의 새로운 백내장 수술기구, 아이챠퍼(iChopper) 국내 최초로 국산화에 성공한 망막 수술용 조명기구, 아이프로브(iProbe) 한국광기술원과 협력하여 개발된 국내 최초 안과수술용 광원장치, 아이비젼(iVision)

백내장 수술기구 - iChopper 망막 수술조명기구 - iProbe 안과용 광원장치 - iVision

COMPANY & PRODUCT INTRODUCTION

오큐라이트는 안과전문의인 남동흔 대표(길병원 안과과장)가 수술환경에서 발생되는 문제점에 착안하여 발명한, 안내조명법을 이용한 "새로운 안과용 수술조명기구(아이챠퍼, 아이프로브)" 와 국내 최초로 국산화에 성공한 "보급 형 안과용 광원장치(아이비젼)"를 국내외에 보급하고자 합니다.

Oculight was founded by Dr. Dong Heun Nam, Chief Ophthalmologist at Gil Medical Center. Its goal is to supply the "ophthalmic surgical illuminator using the intraocular lighting method," which was designed to reduce problems that arise in surgical environments(iChopper, iProbe), and to develop and supply "standardized ophthalmic light source", the first light source in Korea to be fully developed domestically.

EXHIBIT CLASSIFICATION

* cp-asiRNA

비대칭 RNA구조에 간단한 화학적 변형을 도입하여 세포 투과율을 높인 올 릭스만의 독자적인 유전자 조절 구조체로, 별도의 전달체 없이 세포를 통과 하여 높은 효율로 원하는 유전자를 억제할 수 있는 기술이며 기존의 siRNA 가 가지고 있던 각종 면역반응과 비특이적 유전자 조절 부작용 등의 문제점 을 개선하였음. 폐 전달에 적합한 흡입 제형 개발하여 전신 노출에 따른 부 작용을 피하거나 최소화함.

* cp-asiRNA

Cell-penetrating asymmetric siRNA (cp-asiRNA) is a proprietary RNAi platform technology, which can efficiently internalize and induce target silencing without the aid of any delivery vehicle, such as liposome or polymer. In addition, cp-asiRNA significantly reduces siRNA-mediated adverse effects, such as off-target gene silencing and immune stimulation. Local pulmonary administration of our cp-asiRNA drugs through nebulization may be able to improve treatment efficacy and reduce systemic side effects.

COMPANY & PRODUCT INTRODUCTION

비대칭형 RNA간섭 기술로 다양한 질병에 대한 신약을 개발하는 기업

OliX is a clinical stage biotechnology company, based on our own proprietary RNA interference (RNAi) technology regulating the expression of disease-causing genes

Poptyr

K-Healthcare start-ups

New Excellent Technology Exhibition

OraPharm:

Optyr

옵티어

Orapharm

오라팜

COUNTRY Republic of Korea

EO 이동건

URL

E-mail bumbler@naver.com

COUNTRY Republic of Korea

CEO Yoon Eunsup 윤은섭

URL www.orapharm.com

E-mail ora2014@orapharm.com

EXHIBIT CLASSIFICATION

장애 맞춤형 컴퓨터 보조공학기기

Personalized handicapped assistive computer devices

EXHIBIT CLASSIFICATION

구취, 충치, 치주질환 예방 및 개선 구강유산균

Oral care probiotics for the prevention and improvement of halitosis, dental caries and periodontal diseases.

COMPANY & PRODUCT INTRODUCTION

3D프린터와 3D스캐너를 사용하여 해당 장애인의 증상과 발현에 맞게 모델링, 제조하여 맞춤형 컴퓨터 보조공학기기를 제공함

We provide assistive devices that are personalized to each person's symtoms and needs by using 3D printers and scanners

COMPANY & PRODUCT INTRODUCTION

㈜오라팜은 '박멸 시스템'이 아닌, 구강유산균을 이용한 '공생과 균형 시스템' 으로 구강문제를 해결합니다.

Orapharm Inc. solves oral problems with a 'Symbiosis & Balance System' using oral care probiotics, not 'Extermination System'.

Hospital-based Business Innovation Center



Orbitree

㈜올빛트리

COUNTRY

Republic of Korea

CEO URL Lim Hanung 임한웅 www.orbitree.co.kr

E-mail

humanbeing7@hanmail.net

EXHIBIT CLASSIFICATION

사시각 측정 장치

eyeball measuring device

COMPANY & PRODUCT INTRODUCTION

- * 디지털 영상을 이용한 눈 운동 측정 의료기기
- * 각각의 눈에 대응하는 2대의 원거리 비디오 카메라와 눈 운동 각도 도출 소프 트웨어를 구동할 수 있는 컴퓨터 등 간단한 조합으로 이루어진 측정 시스템
- * 영상과 눈 운동 예측 결과 간 상호정보수치 비교를 통한 눈 운동 측정 기술
- * 눈의 정면 기준 위치를 얻기 위한 교대 가림 및 주시 유발 기술
- * 각막 윤부 tracking 기술을 이용한 눈 운동 각도의 정량적 측정
- 각막 윤부 추적 기능을 사용하여 정확한 눈 운동 각도 계산
- 기존 기기의 홍채 추적 분석법이 아닌 각막 윤부를 이용한 분석법을 이용하 므로 안구 표면의 접선이동거리를 더욱 정확하게 측정할 수 있어 실제 안구 운동에 가까운 측정치 산출 가능
- * 회전운동과 전이운동을 구별한 눈 운동의 정확한 측정
- 현재까지 눈 운동의 분석은 '눈 운동은 회전운동'이라는 전제 하에 눈 운동 각도를 계산한 것이지만 눈 운동은 회전운동만 일어나는 것이 아니라 전이 운동이 함께 일어하는 복잡한 양상을 띈다는 것을 3차원 MRI를 통한 눈 운 동 분석을 통하여 눈 운동이 회전운동과 전이운동이 함께 이루어진다는 것 을 증명하였음.
- 이를 눈 운동 측정 알고리즘에 적용하여 회전운동과 전이운동을 구별한 눈 운동의 정확한 측정 가능

- * Eyemovementmeasuringmedicalapparatususingdigitalimage
- * Derive two long-distance video cameras and eye motion angles corresponding to each eye a simple combination of measuring systems, such as computers capable of running software.
- * eye movement measuring technique by comparison of interinformation numerical value between image and eye movement prediction result
- * bridge block shielding and gaze induction technique for obtaining front reference position of eye
- * quantitative measurement of eye motion angle using cornea ring part tracking technique
- Accurate eye movement angle calculation using the cornea ring tracking function and analysis using cornea ring parts instead of iris tracking analysis of existing equipment, so the tangential distance of the surface of the eyeball can be measured more accurately and the measurement value close to actual eye movement can be calculated.
- * accurate measurement of eye movements that distinguish rotational and metastatic movements
- The analysis of eye movement up to now has been based on the assumption that eye movement is rotational, but it has proved that eye movement is performed at the same time through the analysis of eye movement by three-dimensional MRI that eye movement is performed at the same time as that of rotation. Apply this to the eye motion measurement algorithm to accurately measure eye motion that distinguishes rotational motion from metastatic motion.

SEOUL Biohub



K-Healthcare start-ups



ORGAMEDI

㈜오가메디

COUNTRY Republic of Korea

CEO Kwon Dong Yeop 권동엽

URL www.orgamedi.com

E-mail derekwon@naver.com

ORGANOID SCIENCES

오가노이드사이언스㈜

COUNTRY Republic of Korea

CEO Jongman Yoo 유종만

URL www.organoidrx.com

E-mail kjlee@organoidrx.com

EXHIBIT CLASSIFICATION

첨단 생체적합 소재 개발

developing advanced vascular biomaterials

EXHIBIT CLASSIFICATION

오가노이드 기반 재생 치료제

Organoid based regenerative medicine

COMPANY & PRODUCT INTRODUCTION

KIST(한국과학기술연구원)와 서울대 의대등과 혈관 생체적합 소재 개발 컨소 시엄을 구축하여 첨단 생체적합 소재 개발을 하고 있다.

We are developing advanced vascular biomaterials by establishing a consortium of vascular biomaterials with KIST and Seoul National University.

COMPANY & PRODUCT INTRODUCTION

오가노이드사이언스 주식회사는 3차원 미니장기인 오가노이드를 활용하여 다년간 축적된 기술력과 노하우를 기반으로 오가노이드 플랫폼을 구축하였고 이를 상업화하기 위해 2018년 10월 설립된 국내 최초의 오가노이드 전문 바이오텍입니다.

또한, 질병 극복 기술 개발에 오가노이드 플랫폼의 활용을 대중화를 위하여 오가노이드 제작, 분석부터 교육 등 연구자가 최적의 결과를 얻을 수 있는 맞춤형 서비스를 제공합니다. 더 나아가 신약 개발에 오가노이드를 적극적으 로 활용할 수 있도록 다양한 질병 모델을 기반으로 약물 평가 플랫폼을 제시 합니다.

ORGANOIDSICENCES is the first biotech in Korea specialized in organoids in October 2018 to commercialize the organoid based technology that are developed over many years. Ogranoids is a miniaturized version of an organ produced in vitro in three dimensions and it is the most advanced platform for reproducing human organs

In addition, in order to generalize the use of organoid platforms in the development of disease overcoming technology, we provide customized services for researchers to achieve optimal results, such as organoid production, analysis, and education. Furthermore, we new drug development. it presents a drug assessment platform based on a variety of disease models to actively utilize organoids in the development of new drugs.

Korea Doctor Preneur





Ortho-heal Co., Ltd.

㈜오스힐

COUNTRY Republic of Korea

CEO Hae-Ryong Song, Young Sang Yang

송해용, 양영상

URL www.orthoheal.co.kr

E-mail jysong2603@hanmail.net

Osong Medical Innovation Foundation

오송첨단의료산업진흥재단

COUNTRY Republic of Korea

CEO Gusun Park 박구선

URL www.kbiohealth.kr

E-mail 2jaekyung@kbiohealth.kr

EXHIBIT CLASSIFICATION

- 1. BH2000
- 2. PIONAH(미용기기)
- 3. 스킨부스터(의료기기)
- 4. Porous Microsphere
- 1. BH2000
- 2. PIONAH(Beauty device)
- 3. Skinbooster(Medical device)
- 4. Porous Microsphere

EXHIBIT CLASSIFICATION

오송첨단의료산업진흥재단 사업 및 기업지원 공간 소개 (바이오신약개발, BT기반 의료기기 개발, 바이오의약생산 및 전임상시험 관련)

Introduction of KBIO Health's service area (New Drug Development, Medical Device Development, Bio Pharmaceutical Manufacturing, Preclinical trial) and the facility.

COMPANY & PRODUCT INTRODUCTION

오송첨단의료산업진흥재단은 바이오신약개발, BT기반 의료기기개발, 바이오의약생산 및 전임상시험 관련하여 도움이 필요한 기업과 기관들에 원스탑서비스 지원을 목적으로 설립되었습니다.

KBIO Health provides a comprehensive class research infrastructure to support anyone with an idea for research in developing high-tech medical technology in the area of New Drug Development, Medical Device Development, Bio Pharmaceutical Manufacturing and Preclinical trial

COMPANY & PRODUCT INTRODUCTION

보건복지부의 골결손/질환융합치료센터 사업선정 및 산학연병 연부조직 재생사업 등 연구과제 연구성과를 사업하기 위하여 설립된 회사입니다. 서방형 약물전달 시스템을 이용하여 피부, 연부조직, 골/연골조직을 재생, 치료할 수 있는 제품(기기,약물)을 연구, 개발합니다.

Ortho-heal is established to commercialize research results and projects such as the Ministry of Health and Welfare's Bone defect/disease Convergent Treatment Center and Industry-Academic Cooperation's Soft Tissue Regeneration Project.

The company researches and develops products (instruments, drugs) that can regenerate and treat skin, soft tissue, and bone/cartilage tissue using Western drug devliery system.

GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION



Korea Doctor Preneur



OTI Korea Co., Ltd.

㈜오티아이코리아

COUNTRY Republic of Korea

CEO Park, Su Jin, Kim, Dong Uk

박수진, 김동욱

URL www.otikorea.co.kr
E-mail otiko39@naver.com

Otologics

㈜오토로직스

COUNTRY Republic of Korea

CEO Jae Joon Song 송재준

URL

E-mail jjsong23@gmail.com

EXHIBIT CLASSIFICATION

이산화염소가스멸균기, 화학소독기

Chlorine Dioxide Gas Sterilizer

EXHIBIT CLASSIFICATION

1. 이명치료기

2. 뇌기능 개선 장치

- 1. Tinnitus therapeutic device
- 2. Brain function improvement device

COMPANY & PRODUCT INTRODUCTION

주식회사 오티아이코리아는 이산화염소가스 소독 및 멸균, 오염제거 장비 제조업체로 의료기기, 장비, 시설의 $\overline{\omega}/2$ 염 등을 제거할 수 있는 서비스로 쾌적한 생활을 제공합니다.

OTI Korea Co., Ltd. is a manufacturer of chlorine dioxide gas sterilization and decontamination equipment.

It provides a comfortable life with services that can eliminate germs and contamination of medical devices, equipment, and facilities.

COMPANY & PRODUCT INTRODUCTION

오토로직스는 미주신경 자극을 바탕으로 대뇌 가소성을 향상시켜 다양한 퇴행성 뇌질환을 치료하는 의료기기를 개발하고 있습니다. 현재 소리/전기 자극을 이용한 이명 치료기를 개발하고 있으며 기전의 제품과는 달리 비침습적인 방법을 이용하여 미주신경을 자극함으로서 환자의 편리성을 획기적으로 향상시켜 치료효과를 향상시킬 수 있습니다.

Otologics is developing medical devices that treat various degenerative brain diseases by improving cerebrum plasticity based on spinal nerve stimulation. The company is currently developing a tinnitus therapeutic device using sound/electrical stimuli. Unlike previous products, non-invasive methods can be used to stimulate the vagus nerve to dramatically improve patient convenience and improve treatment.

COVID-19 SPECIAL PAVILION



K-Healthcare start-ups



OTOS CO., LTD.

(주)오토스

COUNTRY Republic of Korea

CEO Moon Young Huh 허문영

URL www.otos.co.kr
TEL 010-4540-1227
E-mail kimsh@otos.co.kr

PAEAN Biotechnology Inc.

(주)파이안바이오테크놀로지

COUNTRY Republic of Korea

CEO Kyuboem Han 한규범

URL www.paeanbio.com

E-mail hendratanoto@paeanbio.com

EXHIBIT CLASSIFICATION

PAPR, 안전고글, 페이스쉴드 PAPR, Goggle, Face Shield

EXHIBIT CLASSIFICATION

미토콘드리아 기반 치료제 Mitochondrial Therapeutic

COMPANY & PRODUCT INTRODUCTION

(주)오토스는 38년 이상의 경험으로 얻은 기술과 노하우로 눈 보호 구 분야에서 국내외 최고의 자리를 지키고 있으며, 각종 산업용 안 전장비를 자동차 업계를 비롯하여 의료, 중공업, 철강, 조선, 화학 등 국내를 대표하는 주요 기간산업에 제품을 공급하고 있습니다. 꾸준한 기술 개발과 땀의 결실로 전세계에서 그 품질을 인증 받아 해외 시장에서 주목을 받고 있으며, 자동차광용접면은 세계 최고의 기술력을 가지고 있습니다.

OTOS CO., LTD. maintains the best position in the field of eye protection with technology and know-how gained from more than 38 years of experience, and supplies products to major domestic industries such as medical, heavy industry, steel, shipbuilding, and chemicals. As a result of steady technological development, it has been recognized worldwide for its quality, attracting attention from overseas markets, and its auto-darkening welding helmet has the best technology in the world.

COMPANY & PRODUCT INTRODUCTION

인간 세포에서 분리 된 미토콘드리아를 기반으로 항 염증 및 항암치료제를 개발

Paean Biotechnology (PAEAN) has been developing anti-inflammatory and anti-cancer injectable products based on mitochondria isolated from human cell.

Korea Doctor Preneur



GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION



Paprika Lab

주식회사 파프리카랩

COUNTRY Republic of Korea

CEO Jung In Kim, Jong Min Park, Hong Kyun Woo

김정인, 박종민, 우홍균

URL

E-mail madangin@gmail.com

PAUSE Co., Ltd.

㈜파우제

COUNTRY Republic of Korea

EO Seo Kye Sun 서계선

URL

E-mail kdsg3323@daum.net

EXHIBIT CLASSIFICATION

1. BinkieRT

2. CLOD

3. LUMOS

1. BinkieRT

2. CLOD

3. LUMOS

EXHIBIT CLASSIFICATION

고주파자극기

High Frequency Therapy Equipment

COMPANY & PRODUCT INTRODUCTION

2019년 방사선종양학 전문의와 의학물리학자들이 창업한 회사입니다. 방사 선치료에 필요한 보조기구, 재료, 선량측정계 등을 개발하여 판매하는 것을 목적으로 하고 있습니다. 임상에서 필요성을 느끼고 있었던 것들을 주로 다 루고 있습니다. 향후 치료장비의 개발도 고려하고 있습니다.

The company was founded by radiology specialists and medical physicists in 2019. The purpose of the company is to develop and sell assistive devices, materials, and dosimeter necessary for radiation therapy. The company mainly deals with things that are clinically necessary. Development of medical equipment is also in consideration in the future.

COMPANY & PRODUCT INTRODUCTION

주식회사 파우제는 피부미용과 의료미용 산업에 요구되는 기기 개발 및 소모 품 도소매를 주요 활동 목표로 하고 있음

고주파 자극기 PE-2020은 1MHz 고주파를 이용하여 피부탄력 개선, 지방 분해 등에 사용 가능

High frequency stimulator PE-2020 can be used for skin elasticity improvement and fat reduction by using 1MHz high frequency.

PayGenBi

K-Healthcare start-ups

New Excellent Technology Exhibition



PaxGenBio Co., Ltd

(주)팍스젠바이오

COUNTRY Republic of Korea

CEO PARK YOUNG SUK 박영석

URL www.paxgenbio.com

E-mail kkej0553@paxgenbio.com

PCL Inc.

피씨엘

COUNTRY Republic of Korea
CEO Soyoun Kim 김소연
URL www.pclchip.com

E-mail ygy@pclchip.com

EXHIBIT CLASSIFICATION

질병의 감염여부 및 유전자형 분석 기능의 분자진단키트

Molecular diagnosis kit for disease infection and genotyping

COMPANY & PRODUCT INTRODUCTION

결핵균/비결핵 항산균(TB/NTM)진단키트, 인유두종바이러스(HPV) 진단 키트, 성매개 감염질환(STI) 진단키트 개발

Tuberculosis / non-tuberculosis antibacteria (TB / NTM) diagnostic kit, Human Papilloma Virus (HPV) Diagnostic Ki, Sexually transmitted disease (STI) diagnostic kit

EXHIBIT CLASSIFICATION

- 1. HiSU System (혈액스크리닝): B형 간염, C형 간염, 에이즈, 매독, T세포 백혈병 진단용 대량검사 자동화 기기
 - 혈액스크리닝용 다중진단키트, Hi Series
- 2. PCLOK (POCT 신속 진단) : 신속진단용 자동화 기기 Ci-5, 암 5종(간암/췌장암/대장암/전립선암/자궁암) 동시검사 키트 RAI, 호흡기 A/B형 신속 진단키트

Multi-diagnosis platforms and products applied with 3D SG CapTM technology for multiple detection of high sensitivity of infectious diseases

- HiSU System (blood screening): Mass-inspection automation device for diagnosis of hepatitis B, hepatitis C, AIDS, syphilis and T cell leukemia
 - Multiple diagnostic kits for blood screening, Hi Series
- 2. PCLOK (POCT Quick Diagnosis)

Automated devices for rapid diagnosis Simultaneous examination kit for 5 types of cancer (Ci-5, liver/ pancreatic / colorectal/ prostate/Jagung cancer) RAi, Respiratory A/ B Type Quick Diagnostic Kit

COMPANY & PRODUCT INTRODUCTION

2008년 설립 이후 3차원 고정화 다중진단 기술인 SG CapTM 기반 기술을 확보하고, 고위험군 바이러스의 진단을 위한 다중체외진단시약과 이를 분석하기 위한 자동화 분석기기 및 분석 프로그램을 개발하고 있는 코스닥 상장기업입니다

Since its establishment in 2008, it has secured SG CapTM-based technology, which is a three-dimensional fixed multi-diagnosis technology, and has been developing multi-vitro diagnostic reagents to diagnose high-risk viruses and automated analysis devices and analysis programs to analyze them.

PDXen Biosystems Co.

K-Healthcare start-ups

SEOUL Biohub

Pensées

PDXen Biosystems Co.

피디젠

Pensees주식회사 팡세

COUNTRY Republic of Korea

CEO Kwang-sung Ahn 안광성

URL www.pdxen.com

E-mail dohyekwon30@gmail.com

COUNTRY Republic of Korea

EO Sung Jun Lee 이성준

URL www.pensees.co.kr

E-mail dbae@coagulanttherapeutics.com

EXHIBIT CLASSIFICATION

PCASI 실시간 세포추적 시스템

PCASI

EXHIBIT CLASSIFICATION Pensees Inc. is a South Korean bio

Pensees Inc. is a South Korean bio venture compnay that produces 3D cell culture experiment models by applying advanced precision bioprinting technology.

COMPANY & PRODUCT INTRODUCTION

PCASI는 실시간으로 세포의 성장 및 분화 정보를 확보함으로 세포의 특성을 시간과 공간에서 분석이 가능한 장비로 분석이 어려운 혈중 암세포의 특성, 줄기세포의 분화 등 다양한 세포 연구에 이용되는 장비

PCASI is an equipment that can analyze the characteristics of cells in time and space by securing the growth and differentiation information of cells in real time

COMPANY & PRODUCT INTRODUCTION

주식회사 팡세는 첨단 정밀 바이오 프린팅 기술을 응용해 3차원 배양 세포 실험 모델을 생산하고 있는 바이오 벤처 기업입니다.

Pensées Inc. is a South Korean bio venture company that produces 3D cell culture experiment models by applying advanced precision bioprinting technology.

**(-)

Korea Doctor Preneur

Korea Innovative Pharmaceutical Company



Phantomics Inc.

㈜팬토믹스

COUNTRY Republic of Korea

CEO Byung Wook Choi 최병욱

URL www.phantomics.io

E-mail bchoi@yuhs.ac

Pharam Research Products

㈜파마리서치프로덕트

COUNTRY Republic of Korea

CEO Sang-Soo Jung, Won-Joon, Ahn

정상수, 안원준

URL www.pr-products.co.kr

E-mail

EXHIBIT CLASSIFICATION

1. Myomics

1. Myomics

EXHIBIT CLASSIFICATION

* 리안 점안액 : 각막 및 결막 재생
* 리쥬비넥스 주 : 피부 및 건인대 손상 재생
* 리쥬란 : 피부 재생 및 볼륨
* 콘쥬란 : 골관절염

* Re-an eye drop : Cornea and conjunctiva regenerative eye drop * Rejuvenex Injcetion : Wound healing and tissue regenerative

injection

* Rejuran : New Regenerative Filler (Healer) for Satisfying

both skin regeneration and filler effect: Intra-articular injection for Cartilage

* Conjuran : Intra-articular injection for Cartilage regenerative osteoarthritis treatment

COMPANY & PRODUCT INTRODUCTION

파마리서치프로덕트는 라이선스 인, 공동 개발 및 전략적 투자를 통해 재생 의학 제품 파이프라인을 다각화하고 있으며, 우수한 기술 경쟁력 기반의 연구개발을 통해 국내외 시장 확대에 집중하고 있습니다. 또한 아시아 시장 과 북미 시장을 통한 글로벌 시장진출 계획을 수립하여 해외사업을 진행하고 있습니다.

PharmaResearchProducts diversified the product pipelines for regenerative medicine from on license-in, co-developments to strategic investments. PharmaResearch Products is promoting market expansion in both domestic and global.

COMPANY & PRODUCT INTRODUCTION

주식회사 팬토믹스는 특수의료영상(MRI와 CT)에서 촬영되는 영상 바이오마 커를 통해 조직검사급 자동 질병 질환 진단 플랫폼을 개발하고 있습니다. 의료영상데이터에는 심장질환을 포함한 다양한 질병을 조기예측 할 수 있는 바이오마커(몸 안의 변화를알아낼 수 있는 지표)가 있음에도 불구하고, 측정 데이터의 오차로 임상에 적용하기는 어렵습니다. 팬토믹스는 특수의료영상에서 측정되는 바이오마커를 표준화해 기존의 침습적 조직검사(생검;Biopsy)를 대체할 수 있는 임상의사결정지원시스템(CDSS)을 개발합니다. 인증 받은기준 물질로 만들어진 의료영상 표준화 '팬텀'을 통해 영상 바이오마커의 측정 오차를 표준화해, Virtual Biopsy로서 안전하고 정확한 임상의사결정지원을 가능하게합니다.

Phantomics Co., Ltd. is developing an automated disease diagnosis platform based on biomarkers taken from special medical imaging(MRI and CT). Although medical imaging data have biomarkers (index that can detect changes in the body) that can predict various diseases, including heart disease, it is difficult to apply to clinical trials due to errors in measurement data. Phantomics develops a clinical decision support system (CDSS) that can replace existing invasive biopsy by standardizing biomarkers measured in special medical images.

By standardizing measurement error of image biomarkers through medical image standardization 'Phantom', which is made of certified reference materials, Virtual Biopsy enables safe and accurate clinical decision support. New Excellent Technology Exhibition



Korea Innovative Pharmaceutical Company



PHARMBIO KOREA INC.

㈜한국팜비오

COUNTRY Republic of Korea

CEO Junsang Nam, Bongkil Nam

남준상, 남봉길

URL www.pharmbio.co.kr
E-mail yjkil@pharmbio.co.kr

Pharmicell Co., Ltd.

파미셀 주식회사

COUNTRY Republic of Korea

CEO Kim, Hyun Soo 김현수

URL www.pharmicell.com

E-mail dhiang@Pharmicell.com

EXHIBIT CLASSIFICATION

오라팡정은 보건신기술(NET) 인증을 받은 알약으로 된 대장내시경하제 입니다.

ORAFANG TABLET Is used as laxative for colonscopy having New Excellent Technology of Korean Certification.

COMPANY & PRODUCT INTRODUCTION

한국팜비오는 '지경을 넓힌다'라는 이념과 질병 없는 건강한 사회 구축을 목 표로 1999년에 설립하였으며, 외국 우수 제약사들과 함께 의약품의 개발, 제 조 및 수출입을 전문으로 하는 회사입니다.

오라팡정은 알약으로 된 대장내시경하제 입니다.

구역, 구토 없이 복용 가능하며, 삼투효과를 유발하여 우수한 장정결이 가능합니다. 기포제거제가 포함되어 대장내시경 시 점막의 관찰을 용이하게 하였습니다.

Pharmbio Korea Inc. was founded in 1999 to contribute to development in public health under the ideology of "Expanding Territory". We specializes in developing, manufacturing, importing, and exporting innovative products with foreign pharmaceutical companies over the world

ORAFANG TABLET Is used as laxative for colonscopy.

ORAFANG TABLET induces osmotic effect and result in excellent intestinal cleanliness without occurrence of nausea/vomiting. It contains simethicone to remove bubbles for easy observation of mucous membranes during colonoscopy.

EXHIBIT CLASSIFICATION

* 하티셀그램-에이엠아이 : 심근경색증 * 셀그램-엘씨 : 알콜성간경변증 * 셀그램-이디 : 발기부전 * 셀그램-디씨-피씨 : 전립선암 * 셀그램-디씨-오씨 : 난소암

* Hearticellgram-AMI : Acute Myocardial Infarction

* Cellgram-LC : Alcoholic Liver cirrhosis

* Cellgram-ED : Erectile Dysfunction

* Cellgram-DC-OC : Prostate Cancer

* Cellgram-DC-OC : Ovarian Cancer

COMPANY & PRODUCT INTRODUCTION

파미셀(주)은 2011년 세계 최초의 줄기세포치료제(Hearticellgram-AMI)를 개 발한 바이오 제약 전문기업으로 회사의 사업부문은 바이오와 바이오 케미컬 로 구분되어 있습니다.

Pharmicell Co., Ltd. is a biopharmaceutical company that developed the world's first stem cell therapy (Hearticellgram-AMI) in 2011. The company's business area divided into two sectors(bio and biochemical) as below in detail



Korea Doctor Preneur

Korea Doctor Preneur

PLC ØSKIN

Plarit Co., Ltd

㈜플라리트

COUNTRY Republic of Korea

CEO Chul Ho Kim 김철호

URL www.plarit.co.kr

E-mail ostium@ajou.ac.kr

Plcoskin Co., Ltd.

㈜플코스킨

COUNTRY Republic of Korea

CEO Woo Yeol Beak 백우열

URL www.plcoskin.com

E-mail parande@yuhs.ac

EXHIBIT CLASSIFICATION

- 1. 아토 큐어
- 2. 에코 케어
- 3. 상처, 염증 치료용 액상 플라즈마 스프레이
- 1. Ato Cure
- 2. Eco Care
- 3. Liquid plasma spray for wound and inflammation treatment

EXHIBIT CLASSIFICATION

- 1. 유방재건용 지지체
- 2. 복벽 보강용 메쉬
- 1. Mammary reconstruction support
- 2. Abdominal wall strengthening mesh

COMPANY & PRODUCT INTRODUCTION

주식회사 플라리트는 바이오플라즈마 라는 새로운 의료영역을 개척하기 위해 설립된 회사로써 현재 플라즈마를 이용한 의료기기 개발뿐만 아니라 플라즈마 관련 다양한 연구개발중에 있습니다.

Plarit Co., Ltd. is a company founded to cultivate a new medical field named Bioplasma.

The company is currently working on various research and development related to plasma as well as developing medical devices using plasma.

COMPANY & PRODUCT INTRODUCTION

㈜플코스킨은 재생의학 기술을 통한 조직재생 및 대체재료를 개발하는 회사입니다. 연부조직 재생을 위한 소재를 연구하고 있으며, 자가지방 이식이 가능한 유방재건술용 지지체와 탈장에 의한 복벽 보강용 메쉬를 개발중에 있습니다.

비용, 안전, 시간 등 다방면에서 편리하고 우월한 수술형태를 선사 할 것입니다.

Plcoskin Co., Ltd. is a company that develops tissue regeneration and alternative materials through regenerative medicine technology.

Plcoskin is doing research on a material for regenerating soft tissue. The company is also striving to develop mammary reconstruction support with autogastric transplantation and a mesh for strengthening abdominal wall hernias.

Plcoskin will provide a convenient and superior surgical form in many ways such as cost, safety, and time.



K-Healthcare start-ups

Premier Research

PrimeMediLab

주식회사 프라임메디랩

COUNTRY United States of America

Anthony Charles Nicholson

www.premier-research.com

E-mail julian.song@premier-research.com **COUNTRY** Republic of Korea

김승수

URL

E-mail bskyr@naver.com

EXHIBIT CLASSIFICATION

임상시험 서비스 제공

URL

Premier Research Provide Clinical Research Service.

EXHIBIT CLASSIFICATION

스마트 헬스케어 관련 소프트웨어 및 하드웨어

Developing software and hardware related to smart healthcare

COMPANY & PRODUCT INTRODUCTION

프리미어리서치는 30년 역사를 가지고 있는 Global CRO로써, 미국에위치한 본사를 포함하여 전세계 24개의 지사를 가지고 있으며, 1,600명의 직원들이 근무하고 있습니다.

Premier Research is a global CRO with 24 different offices in the globe. Currently 1,600employees are working at Premier Research.

Our Key Therapeutic areas are Oncology, Analgesia, CNS, Dermatology, Rare/Pediatrics and Medical Device.

Also as a biotech focused CRO. 85% of our clients are biotech or small specialty pharmas, and we provide nimble consulting and strategy development services for their global trials.

We have extensive past experience in US FDA, European EMA, and also Australia TGA.

COMPANY & PRODUCT INTRODUCTION

스마트 헬스케어 관련 소프트웨어 및 하드웨어(생체 데이터 측정 센서 개발, 헬스케어 운동 기기) 기술 개발

Developing software and hardware related to smart healthcare (Physical data meaurement sensors, healhcare exercise devices)

Healthcare Technology Licensing Office



Australian Trade and Investment Commission



Pusan National University Hospital

부산대학교병원

COUNTRY Republic of Korea

CEO Lee, Jeong Joo 이정주

URL www.pnuh.or.kr

E-mail dna3397@naver.com

Q-Gen Cell Therapeutics

COUNTRY Australia

CEO

URL www.q-gencell.com

E-mail Leon.Scott@qimrberghofer.edu.au

EXHIBIT CLASSIFICATION

- * 개인 맞춤형 스마트 헬스케어
- 스마트 헬스케어 솔루션 개발 및 헬스케어 빅데이터 센터 운영
- 커뮤니티 케어 서비스 개발 및 활용
- * 스마트 헬스케어 클러스터 조성을 통한 협업
- 모바일, IoT 기반 웨어러블 스마트기기 개발 및 실증
- 인공지능 및 블록체인 활용 정밀의료 연구기반 구축 및 운영
- 산,학,연,병 협력 네트워크 구축 및 운영
- * Personalized smart healthcare
 - Development of Smart healthcare solution and operation of Healthcare Big Data Center
 - Development and use of community care service
- * Collaboration to establish Smart Healthcare Cluster
 - Development and demonstration of Mobile and IoT-based wearable smart device
 - Establishment and operation of the research base for precision medicine utilizing artificial intelligence and blockchain
 - Establishment and operation of industry-academia-research-hospital cooperation network

COMPANY & PRODUCT INTRODUCTION

1956년에 개원하여 올해 64주년을 맞이하는 부산대학교병원은 지난 60여년 동안 최신 의학연구와 첨단진료 시스템 도입, 공공의료서비스 수행 등 의료전 분야에 걸쳐 동남권 지역 의료계를 선도해 온 지역거점 공공의료 기관으로 성장하였고 인정받아 왔습니다.

Celebrating its 64th anniversary this year, Pusan National University Hospital has been leading the medical industry in the Southeast region as a regional public medical institution with the latest medical research, introduction of advanced medical systems and public health services since its establishment in 1956.

COMPANY & PRODUCT INTRODUCTION

Q-Gen Cell Therapeutics is an Australian based CDMO focussed on the manufacture of cell therapies for clinical trials. We have been manufacturing cell therapies for more than 20 years, and have the experience, expertise and capacity to accelerate your clinical program. We currently manufacture autologous and allogeneic cell therapies for clinical trial sites in Asia, Australia and the USA. We can assist companies access Australia as a manufacturing and clinical trial hub supporting their global development and commercialization strategy..

New Excellent Technology Exhibition



K-Healthcare start-ups



Quantamatrix, Inc.

㈜퀀타매트릭스

COUNTRY Republic of Korea

CEO Sunghoon Kwon 권성훈 URL www.quantamatrix.com

E-mail yoonnar@quantamatrix.com

Rapha Korea

라파코리아㈜

COUNTRY Republic of Korea

CEO Choi Young Kwang 최영광

URL www.raphakorea.com

E-mail raphakorea@raphakorea.com

EXHIBIT CLASSIFICATION

현미경 관찰을 이용한 자동화된 신속 항균제 감수성 검사

Microscopic Imaging-based Automated Rapid Antimicrobial Susceptibility Test

COMPANY & PRODUCT INTRODUCTION

퀀타매트릭스는 체외진단의료기기로 분자 생물학, 병원 미생물학 등의 다양한 과학 분야를 융합하여 진단솔루션을 제공해 드리는 기술력있는 회사 입니다.

QuantaMatrix is a technology company that provides Clinical diagnostic solutions by incorporating various scientific fields such as molecular and microbiology as an in-vitro diagnostic medical device.

EXHIBIT CLASSIFICATION

복강경 수술에서 필수적으로 사용되는 Access Ports

rapha KOREA, Inc is the manufacturer of surgical and medical device. We have developed Surgical Access Port Product Range commercially and distributed in domestic market successfully.

COMPANY & PRODUCT INTRODUCTION

폐사는 복강경 수술용 일회용 의료기기를 주로 개발 및 제조 생산하는 한국 바이오 벤처기업입니다. 복강경 수술에서 필수적으로 사용되는 Access Ports 제품군들을 성공적으로 개발하여 상용화하고 있습니다.

Australian Trade and Investment Commission





Regeneus

Retrogenix Limited

COUNTRY Australia
Leo Lee

URL www.regeneus.com.au

E-mail Leo.lee@regeneus.com.au

COUNTRY Germany

CEO Mark Aspinall-O'Dea

URL www.retrogenix.com

E-mail mark.aspinallodea@retrogenix.com

COMPANY & PRODUCT INTRODUCTION

Regeneus Ltd is an Australian clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus

EXHIBIT CLASSIFICATION

Retrogenix identifies specific protein interactions in human cells, advancing medical research and drug discovery for its global pharmaceutical clients.

COMPANY & PRODUCT INTRODUCTION

Retrogenix provides a fast, accurate and effective solution for primary receptor identification and specificity screening of antibodies, protein ligands, CAR T cells and other biotherapeutics. Biologically-relevant targets are identified by screening for interactions against the most comprehensive set of plasma membrane and tethered secreted proteins expressed in human cells. This informs lead selection, assists with safety assessment and has generated data used in patent and regulatory submissions in multiple regions, including the US, EU, Japan & China.

RevoSketch

COVID-19 SPECIAL PAVILION

Royal Medical Co., Ltd



RevoSketch Inc.

Daejeon Technopark

레보스케치

COUNTRY Republic of Korea

CEO Sung Woon Lee 이성운

URL revosketch.com

E-mail khseo@revosketch.com

URL www.royalmedical.com

COUNTRY

㈜로얄메디칼

E-mail royalmedical@naver.com

Republic of Korea

Yool Lee 이율

EXHIBIT CLASSIFICATION

고성능 유전자 분석기기

All-IN-ONE digital PCR

EXHIBIT CLASSIFICATION

마취기

Anesthesia Machine with Ventilato

COMPANY & PRODUCT INTRODUCTION

기존 경쟁사의 Digital PCR 장치는 20,000개 수준의 분획 수를 가지며 분획을 위한 별도의 장치 사용 새로운 발명은 4,000,000개의 분획 수를 지원하며 원심력을 이용하여 1개의 장치에서 자동 분획 / 분획 성능이 획기적으로 증가하면서 Wide dynamic range digital PCR기기의 구현이 가능해짐

One-Step digital PCR/ All-in-one digital PCR and Large number of partitions(10K-4M)

COMPANY & PRODUCT INTRODUCTION

주)로얄메디칼은 1973년 설립 이래 마취기 와 마취기용 인공호흡기를 생산하고 있습니다. 당사의 모든 제품들은 국제 표준에 맞추어 생산되고 있습니다. 현재 (주)로얄메디칼은 국내 병원들뿐 아니라 전세계 20여개 국가들에 호평을 받으며 수출하고 있습니다.

Since Royal Medical Co., Ltd. have been founded in 1973, we have been dealing with and manufacturing the anesthesia machines with ventilators. All anesthesia machines and components of Royal medical are designed and manufactured in accordance with the international standards.

Royal Medical Co., Ltd. is exporting to more than 20 countries, like all Asia including middle east, south-west and east Asia, east Europe Including Africa, middle and south America.

S&E bio

Korea Doctor Preneur

Korea Innovative Pharmaceutical Company



S&E Bio Co., Ltd.

㈜에스엔이바이오

COUNTRY Republic of Korea

CEO 방오영

URL www.snebio.com

E-mail ohyoung.bang@samsung.com

Samjin Pharmaceutical Co., Ltd.

삼진제약㈜

COUNTRY Republic of Korea

CEO Hong Soon Jang 장홍순

URL www.samjinpharm.co.kr

E-mail janghlee@samjinpharm.co.kr

EXHIBIT CLASSIFICATION

- 1. 급성뇌졸중치료제
- 2. 모야모야병 치료제
- 3. 만성뇌졸중 치료제
- 1. Acute cerebral apoplexy drug
- 2. Moyamoya disease drug
- 3. Chronic cerebral apoplexy drug

EXHIBIT CLASSIFICATION

- * 플래리스정: 혈소판 응집 억제제
- * 게보린정: 해열진통제
- * 뉴스타틴 R 정 : 동맥경화용제
- * 하노마이신주 : 항생제
- * 뉴로카바 PG 캡슐 : 신경성 통증 완화제
- * 네메올 정 : PPI
- * Clopidogrel Bisulfate (Form I & Form II): 혈전치료제
- * Rosuvastatin calcium : 동맹경화용제
- * Apixaban : 항응고제
- * PlatelessTablet (Clopidogrelbisulfate): Antithrombotic
- * Geworin Tablet (Acetaminophen,etc) : NSAIDs
- * Neustatin-R Tablet (Rosuvastatin calcium): Antihyperlipidemia
- * Hanomycin Injection (Vancomycin hydrochloride): Antibiotics
- * Neurocava PG Capsule (Pregabalin) : Anticonvulsants
- * Nemeol Tablet (Esomeprazole): Proton Pump Inhibitors
- * Clopidogrel Bisulfate (Form I & Form II) : Antithrombotic
- * Rosuvastatin calcium : Antihyperlipidemia
- * Apixaban : Anticoagulants

COMPANY & PRODUCT INTRODUCTION

㈜에스엔이바이오는 세계최초로 뇌졸중환자 성체줄기세포치료제 개발 및 임상연구를 이끌어온 경험과 미세소포치료제 개발 및 플랫폼 구축의 성과 외술력을 바탕으로 줄기세포-미세소포(Stem cell-derived Extracellular Vesicles)를 이용하여 뇌졸중 등 다양한 난치성 질환에 대한 안전(Safe)하고 효율적인(effective) 치료제를 개발하는 기업입니다. 줄기세포의 고유한 효능을 극대화하면서, 안전하고 즉각적인 투여가 가능한 치료제를 개발하여 난치성 질환으로 고통받는 환자들에게 희망을 주고, 글로벌 바이오 신약의 리더가 되고자 혼신의 노력을 다하고 있습니다.

S&E Bio Co., Ltd. is the world's first company to develop safe and efficient therapeutics for various incurable diseases such as brain stroke using stem cell-derived extracular vesicles. This is based on the experience of developing adult stem cell therapeutics and clinical research for stroke patients, along with achievements and technical skills of developing micro-saturation therapeutics and platform establishment.

While maximizing the unique efficacy of stem cells, the company is making every effort to develop safe and immediate medications to give hope to patients suffering from intractable diseases and to become a global leader of new drugs in bio industry.

COMPANY & PRODUCT INTRODUCTION

삼진제약은 연구개발에 대한 끊임없는 노력과 열정으로 혁신 신약을 개발 하는 제약회사입니다. 여러 학계 기관 및 상업 기업들과 전략적 제휴를 맺으며 새로운 신약 개발을 가속화하고 있으며 다양한 비즈니스 모델을 통한 혁신적이고, 협력적인 글로벌 파트너십을 추구하고 있습니다.

Samjin is one of the Korean leading pharmaceutical companies striving to produce novel therapeutics with relentless effort. Samjin has established strategic partnerships with 20 profit/non-profit organizations to accelerate innovative drug development and is actively seeking for global partnerships via open innovation.

COVID-19 SPECIAL PAVILION

SAMSUNG

Healthcare Technology Licensing Office

삼성서울병원

COUNTRY



Samsung Electronics Co., Ltd

삼성전자(주)

COUNTRY Republic of Korea

CEO Kim, Ki Nam 김기남

URL www.samsunghealthcare.com

E-mail dada17.lee@samsung.com

Samsung Medical Center

EO Kwon, O Jung 권오정

URL www.samsunghospital.com

Republic of Korea

E-mail taemin.yoon@samsung.com

EXHIBIT CLASSIFICATION

AccE GM85

COMPANY & PRODUCT INTRODUCTION

1969년 수원에서 창립한 이래, 오늘날 삼성전자는 글로벌 IT 업계의 리더로 발전했습니다. 삼성전자 제품에는 스마트폰과 태블릿 같은 모바일 통신 제품은 물론, TV, 모니터, 냉장고, 세탁기와 같은 가전제품, 그리고 D램과 비메모리 반도체 같은 핵심 전자 부품들이 있습니다. 또한 의료기기 사업부를 통해 정확하고 빠른 진단을 도와주는 새롭고 혁신적인 의료기기를 개발하고 있습니다. 삼성은 전 세계 고객들이 편리하고 더욱 스마트한 라이프 스타일을 즐길 수 있도록 수준 높은 제품과 서비스를 만들고 공급할 것을 약속합니다. 삼성은 과감한 혁신과 가치 창조를 추구하면서 헬스케어 사업을 강화해 나가고 있습니다.

Samsung Healthcare

Samsung is committed to create a new future for medical professionals and patients with a mission to bring health and wellbeing to people's lives. Integrating its leading expertise in display, IT, mobile and electronics, our vision is to bring confident diagnosis, cost-effective solutions and improved workflow to customers.

Specializing in diagnostic imaging devices, we aim to lead Samsung's innovation in healthcare by combining advanced technologies to improve the quality of people's lives.

EXHIBIT CLASSIFICATION

정밀의학, 재생의학, 융합의학

Precision medicine, regenerative medicine and convergence medicine

COMPANY & PRODUCT INTRODUCTION

우리 병원은 개방형 융합연구 및 혁신 연구 체계를 통해 진료 선진화를 추구하는 병원으로 정밀의학, 재생의학, 융합의학을 중점분야로 설정하여 혁신의료기술 창출, 데이터 중심연구, open innovation 확대, 우수 인재 확보, 연구실용화, 연구재원다각화 전략을 추진중입니다.

Pursuing advancement of treatment with an Open-convergence research and innovative research system, Samsung Medical Center has been accelerating its effort to develop innovative medical technologies, expand data-driven research, promote Open Innovation, recruit talents, commercialize research outcome, and diversify research resources, bearing precision medicine, regenerative medicine, and convergence medicine as key areas in mind.

COVID-19 SPECIAL PAVILION

SAMSUNG

Korea Innovative Pharmaceutical Company



SAMSUNG MEDISON Co., Ltd

(주)삼성메디슨

Samyang Biopharmaceuticals Corporation

㈜삼양바이오팜

COUNTRY Republic of Korea

CEO YONGKWAN KIM 김용관

URL www.samsunghealthcare.com

E-mail mkt.sm@samsungmedison.com

COUNTRY Republic of Korea
CEO Taeung Eom 엄태웅

URL www.samyangbiopharm.com

E-mail hojin.chung@samyang.com

EXHIBIT CLASSIFICATION

HM70A with Plus

COMPANY & PRODUCT INTRODUCTION

삼성메디슨㈜은 1985년 창립한 초음파 진단기기 전문기업으로서 삼성전자의 자회사입니다. 2001년 Live 3D 초음파 진단기를 상용화했으며 2011년 삼성전자에 인수된 이후, 영상의학과, 산부인과와 현장진단 등 다양한 분야에서 삼성전자의 IT, 이미지처리, 반도체, 통신 기술을 의료기기에 접목해 빠르고 정확한 진단을 돕는 초음파 제품을 선보이고 있습니다. 높은 사용성과 영상품질을 기반으로 삼성메디슨은 전 세계 의료인들의 신뢰를 얻으며 발전을 거듭하고 있습니다.

Samsung Medison, an affiliate of Samsung Electronics, is a global medical equipment company founded in 1985. With a mission to bring health and well-being to people's lives, the company manufactures diagnostic ultrasound systems around the world across various medical fields. Samsung Medison has commercialized the Live 3D technology in 2001 and since being part of Samsung Electronics in 2011, it is integrating IT, image processing, semiconductor and communication technologies into ultrasound systems for efficient and confident diagnosis.

EXHIBIT CLASSIFICATION

* 제넥솔® 주사제 : 난소암, 유방암, 폐암

* 제넥솔[®] PM 주사제 : 난소암, 유방암, 폐암

* 나녹셀® M 주사제 : 유방암, 비소세포 폐암, 전립샘암, 난소암 , 두·경부암

* 페메드[®] 에스 주사제 : 비소세포폐암

* 프로테조밉[®] 주사제 : 다발골수종, 외투세포림프종

* 졸레닉[®] 주사제 : 악성 종양으로 인한 과칼슘혈증, 다발성 골수종 및 고형암 의 골전이 넥사틴[®] 주사제 : 전이성 결장, 직장암, 전이성 위암

* Genexol® PM Inj. : Breast cancer, NSCLC, Ovarian cancer

* Nanoxel[®] M Inj.: Breast cancer, NSCLC, Esophageal cancer, Ovarian cancer, H&N cancer, Gastric cancer, Prostate cancer

* Genexol® Ini.: Breast cancer, NSCLC, Ovarian cancer

* Docetaxel Inj. : Breast cancer, NSCLC, Esophageal cancer, Ovarian cancer, H&N cancer, Gastric cancer, Prostate cancer

* Zolenic® Inj. : Bone complications of cancer

COMPANY & PRODUCT INTRODUCTION

삼양바이오팜은 저분자 및 바이오 항암신약, 항암바이러스백신, 개량신약, 퍼스트제네릭, 약물전달기술(DDS) 분야 의약품 개발에 매진하고 있습니다.

Pharmicell Co., Ltd. is a biopharmaceutical company that developed the world's first stem cell therapy (Hearticellgram-AMI) in 2011. The company's business area divided into two sectors(bio and biochemical) as below in detail.

Korea Innovative Pharmaceutical Company



Korea Doctor Preneur



sanofi-avenetis Korea

사노피-아벤티스 코리아

COUNTRY Republic of Korea

CEO Kyung-eun (Kay) Bae 배경은

URL www.sanofi.co.kr

E-mail sanggyun.kim@sanofi.com

Sapien Med Co., Ltd.(설립예정)

사피앤메드(설립예정)

COUNTRY Republic of Korea

CEO Seung Joon Oh 오승준

URL www.sapienmed.com

E-mail sjo@snuh.org

EXHIBIT CLASSIFICATION

* 투제오 : 인슐린글라진

* 란투스

* 플라빅스 : 클로피도그렐황산염

* 아프로벨 : 이르베사르탄

* 프랄런트 : 알리로쿠맙

* 로벨리토 : 이르베사르탄, 아토르바스타틴

: 인슐린글라진

* 렌벨라 : 세벨라머탄산염

* Toujeo : Insulin Glargine

* Lantus : Insulin Glargine

* Plavix : Clopidogrel Bisulfate

* Aprovel : Irbesartan

* Praluent : Alirocumab

* Rovelito : Irbesartan, Atorvastatin* Renvela : Sevelamer Carbonate

EXHIBIT CLASSIFICATION

1. Al 요역동학검사 (Urodynamic Study) 장비

1. Al Urodynamic Study Device

COMPANY & PRODUCT INTRODUCTION

사피엔메드㈜는 복잡한 질병의 진단 정확도를 최고 수준으로 높이는 동시에 진단과정 중 의료진의 노력과 시간을 절약하기 위하여 인공지능을 적용하는 의료기기를 개발하는 기업입니다.

그 첫번째 제품으로, 지난 20년간 서울대병원에서 선행적으로 축적한 체계화된 고급의 대량 임상 빅데이터를 바탕으로 인공지능 기반 요역동학검사 장비 (urodynamic system)를 개발해 나가고 있습니다.

Sapien Med Co., Ltd. is a company that develops medical devices that apply artificial intelligence to save medical staff's efforts and time during the diagnosis process while increasing the accuracy of diagnosis of complex diseases to the highest level.

As the first product, the company is developing artificial intelligence-based epidemiological testing equipment(urodynamic system) based on high-level, systematic and advanced clinical big data that they have accumulated in advance at Seoul National University Hospital over the past 20 years.

COMPANY & PRODUCT INTRODUCTION

사노피-아벤티스 코리아는 프랑스에 본사를 둔 글로벌 헬스케어 기업 사노피 그룹의 한국 법인으로써, 희귀질환, 면역질환, 암질환 및 당뇨 고혈압과 같은 만성질환 등의 다양한 치료제 및 일반의약품과 건강식품을 공급하는 다양한 환자들의 치료요구에 부응하고자 노력하는 제약기업입니다.

Sanofi-Aventis Korea is a Korean legal entity of Sanofi group which is a global biopharmaceutical company based in France. Sanofi-Aventis Korea tries to provide innovative healthcare solution fullfilling patiensts' needs in immunology, oncology, rare disease and chrinic disease e.g. diabetes and hypertension and also consumer healthcare.

Australian Trade and Investment Commission



New Excellent Technology Exhibition



Scientia Clinical Research (SCR)

SCM Lifescience

SCM생명과학(주)

COUNTRY Australia

CEO

URL www.scientiaclinicalresearch.com.au

E-mail lisa.nelson@scientiaclinicalresearch.com.au

COUNTRY Republic of Korea

CEO BG Rhee 이병건

URL www.scmlifescience.com

E-mail kimdaham@scmlifescience.com

COMPANY & PRODUCT INTRODUCTION

Scientia Clinical Research (SCR) is a not for profit early phase clinical trial company. SCR operates a 30-bed phase I unit co-located within the Prince of Wales Hospital..

SCR conducts ~30-35 clinical trials per year, including 20-25 First Time In Human (FTIH) single and multiple dose studies, food effect, drug interaction, ethnopharmacology, biosimilar, vaccine, formulations and specialty studies incorporating a range of pharmacodynamic markers such as Flow Cytometry and Cytokine analysis. These studies are being performed in healthy volunteers as well as specialist patient populations.

The majority of our sponsors are multinational pharmaceutical and biotechnology companies from the US, China, Europe and South East Asia.

EXHIBIT CLASSIFICATION

고순도 줄기세포 분리를 위한 층분리배양법

Subfractionation Culturing Method for Isolation of More Homogeneous Stem Cells0|L \parallel

COMPANY & PRODUCT INTRODUCTION

SCM생명과학의 고순도 줄기세포 분리를 위한 층분리배양법을 사용하면 각 각의 고순도 줄기세포군들을 분리 및 배양할 수 있습니다. 층분리배양법을 통해 얻은 줄기세포주 각각의 특성에 따라 질환특이적 세포치료제 개발이 가 능하니다

With SCM Lifescience's Subfractionation Culturing Method, High-purity Homogeneous Stem Cells are Isolated and cultured. Disease-specific clonal MSC products can be developed by using Subfractionation Culturing Method.

Wonju Medical Industry Technovalley



Korea Doctor Preneur



SDS

에스디에스

SELJIN Co., Ltd.

(주)셀진

COUNTRY Republic of Korea

CEO RyangHee Sohn 손량희

URL www.emmahc.com

E-mail sales@emmahc.com

COUNTRY Republic of Korea

EO Seil Son 손세일

URL sohnlab.net

E-mail sisohn@cha.ac.kr

EXHIBIT CLASSIFICATION

의료용레이저조사기

PlaLucy

COMPANY & PRODUCT INTRODUCTION

플라루시; 소프트 콜드플라즈마, 갈바닉, 진동 기능을 융합한 신개념 피부 관리기기. 오존필터링 기능, 뛰어난 살균효과, 화장품 사용 시 흡수력 증대 기능성, KC, CE 인증

PlaLucy: Multifunctional homecare plasma device that combined with Galvanic and Vibration

- Soft cold plasma: Plasma has great effects for sterilization and hydrophilicity of the skin surface. Plasma induces skin condition as a hydrophilicity that is able to induce better absorption of cosmetics.
- Ozone filtering system: We installed a patented system called 'Ozone reduction module'. We are able to reduce the total amount of ozone.
- 3. Galvanic: After the Plasma treatment, PlaLucy offers 'Galvanic' that induces good absorption of cosmetics.
- 4. Vibration: The vibration function which offers massage during the operation. It induces better absorption into the target area.
 - 5. Certification: KC, CE"

EXHIBIT CLASSIFICATION

- 1. 금 입자 임플란트
- 2. UDCA (T)UDCA
- 3. CHA 하이드로겔
- 1. Gold Particle implant
- 2. UDCA (T)UDCA
- 3. CHA Hydrogel

COMPANY & PRODUCT INTRODUCTION

근골격계, 신경계 질환의 임상질환에서 Unmet need 를 해결하고자 Bench to Bedside 제품을 만들고자 합니다.

The company is striving to make Bench to Bedside products to solve unmet needs in clinical diseases of musculoskeletal and nervous system diseases. SEOUL Biohub



Healthcare Technology Licensing Office

SNUH[®] 분당서울대학교병원

SEOUL Biohub

서울바이오허브

COUNTRY Republic of Korea

CEO Kang Dae Wook 강대욱

URL www.seoulbiohub.kr

E-mail kjs716@khidi.or.kr

SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL

분당서울대학교병원

COUNTRY Republic of Korea

CEO Baek, Rong-Min 백롱민

URL www.snubh.org

E-mail hj.joo@snubh.org

EXHIBIT CLASSIFICATION

바이오의료 스타트업을 위한 창업 플랫폼

Innovation Platform for Biomed Startups

EXHIBIT CLASSIFICATION

ICT 기반 미래형 의료정보, 바이오융합, Big Data, 의료기기, 맞춤의료, Clinical study & trial

Future medical information based on ICT, Bio Convergence, Big Data, Medical Equipment, Personalized Medicine, Clinical study & trial

COMPANY & PRODUCT INTRODUCTION

서울바이오허브는 바이오·의료 스타트업을 위한 최적의 공간에 보건산업 전 문가의 노하우를 체계적으로 담고있는 바이오 창업 혁신 플랫폼입니다.

Seoul Bio Hub is an innovation platform for biomed startups.

The hub offers the best environment for bio and medical startups as well as the knowledge of biomedical industry experts.

COMPANY & PRODUCT INTRODUCTION

분당서울대학교병원은 '세계 최고의 교육·연구·진료를 통하여 인류가 건강하고 행복한 삶을 누릴 수 있도록 한다'는 설립이념 아래 눈부신 성장을 거듭하며 대한 민국을 대표하는 국가중앙병원으로 국민 여러분께 인정받고 있습니다.

SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL, established with a founding principle of "Pursuing world-class education, research and treatment to help people seize healthy and pleasant lives", has become a central hospital representing the nation and well recognized by the people after going through a remarkable growth.



Healthcare Technology Licensing Office



Seoul National University Hospital

서울대학교병원

Seoul National University Hospital Biomedical Research Institute

서울대학교병원 의생명연구원

COUNTRY Republic of Korea

CEO 김연수

URL

E-mail 02720@snuh.org

COUNTRY Republic of Korea

EO Park, Gyeong su 박경수

URL bri.snuh.org

E-mail mgsong0310@snu.ac.kr

EXHIBIT CLASSIFICATION

서울대학교병원 의생명연구원 시설 및 현황 소개

Introduction of Seoul National University Hospital Biomedical Research Institute

EXHIBIT CLASSIFICATION

암, 염증대사, 바이오치료, 뇌신경과학, 융합의료기기

Cancer, Metabolic inflammation, Bio-treatment, Neuroscience (brain) and Convergence medical device

COMPANY & PRODUCT INTRODUCTION

서울대학교병원 의생명연구원은 국제적이고 체계적이며 조직적인 연구활동을 통하여 의생명 관련분야의 수준을 높이고 국가의학발전에 기여하는데 목적이 있습니다.

SNUH BRI's major functions include biomedical researches required in national policy setting, clinical research to enhance public healthcare, research on the integration of basic sciences with clinical research, the development of candidate materials of new drugs, the development of medical devices and new medical materials, the fostering of professional researchers, and the conducting of clinical trials of newly developed medicines and medical devices.

COMPANY & PRODUCT INTRODUCTION

서울대학교병원 의생명연구원은 서울대학교병원이 가진 연구의 수월성을 토대로, 개방과 혁신, 융합과 협력을 통해 세계적 수준의 의생명연구를 선도 하는 연구기관이 되고자 노력하고 있습니다.

서울대학교병원 의생명연구원은 서울대학교병원의 연구를 총괄하는 조직으로 산하에 중개의학연구소와 임상시험센터, 의료기기혁신센터 및 첨단세포유전자치료센터 등의 연구조직과 이를 지원하는 의학연구협력센터, 임상연구윤리센터 및 연구지원본부 등을 두고 있습니다.

Based on the superior research of Seoul National University Hospital, it is endeavoring to be a leader in global biomedical research through openness & innovation, and convergence & cooperation.

The Biomedical Research Institute assumes full charge of research of the university, consisting of two parts: a Research group of Translational Research Institution, Medical Device Innovation Center and Center for Cell &Gene Therapy, and Support group of Headquarters of Research Administration and Coordination, Medical Research Collaborating Center, and Center for Human Research Protection.

New Excellent Technology Exhibition



COVID-19 SPECIAL PAVILION

SGhealthcare

에스지헬스케어



SEWON CELLONTECH CO., LTD

세원셀론텍㈜

COUNTRY Republic of Korea

CEO JANG, Cheong-Ho 장정호

URL www.sewoncellontech.com

E-mail cyuri@swcell.com

COUNTRY Republic of Korea

CEO JUNG SOO KIM 김정수

URL www.sghealthcare.com

E-mail sales@sghealthcare.com

EXHIBIT CLASSIFICATION

관절 연골 보호/보강을 위한 아텔로콜라겐 정제기술 (제 148호)

Purification technology of atelocollagen for protection and reinforcement of articular cartilage

COMPANY & PRODUCT INTRODUCTION

세원셀론텍㈜은 재생의학에 관한 오랜 연구개발 경험과 전문 기술 노하우를 바탕으로 전 인류 평생건강의 꿈을 실현하기 위한 구심점 역할을 하고 있는 기업이다.

SEWON CELLONTECH CO., LTD. is a company that plays a center of affairs to achieve better quality of life for all human beings, based on long years of R & D experience on regenerative medicine and expertise know-how.

EXHIBIT CLASSIFICATION

X-ray, Mobile X-ray, Ultrasound, CT

COMPANY & PRODUCT INTRODUCTION

SG HealthCare is the global leader in the medical diagnostic equipment industry with world class technology advancements.

Today, we continue to spread the importance of "Seeing more" and "Knowing Better" as opposed to mediocre diagnosis.

The information from our systems allows acute analysis, thus increasing the chance of saving lives.

X-ray, MRI & Ultrasound systems made by SG HealthCare are widely used all over the world from tiniest mobile clinics to national hospitals.

SG HealthCare has proven itself to be revolutionizing the field of medical diagnostic systems and continues to help people all around the world see better with us.

Korea Innovative Pharmaceutical Company



Wonju Medical Industry Technovalley



SHIN POONG PHARM.CO., LTD.

신풍제약㈜

CEO Republic of Korea
CEO Jei Man Ryu 유제만

URL shinpoong.co.kr

E-mail yjkim@shinpoong.co.kr

Shinoo medison

㈜신우메디슨

COUNTRY Republic of Korea

CEO 김정근

URL www.snmedison.com

E-mail snmedison@gmail.com

EXHIBIT CLASSIFICATION

- * 피라맥스정: 말라리아
- * 피라맥스과립 :말라리아(소아용)
- * 칸데암로정: 고혈압
- * 에제로수정: 고지혈증
- * 하이알포르테주: 퇴행성 관절염
- * Pyramax[®] Tablet : Malaria
- * Pyramax® Granule : Malaria (Pediatric formulation)
- * CandeAmlo[®] Tablet : Hypertension * EzeRosu[®] Tablet : Hyperlipidemia * Hyal Forte[®] Injection: Osteoarthritis

COMPANY & PRODUCT INTRODUCTION

신풍제약은 "민족의 슬기와 긍지로 인류의 건강을 위하여"라는 경영 이념 하에, 최첨단 제조설비와 품질보증시스템으로 유효성분에서부터 완제의약품을 생산하는 치료제 전문회사입니다.

Under the management philosophy of 'For the Health of the People', we are committed to realizing it with top-notch competitiveness through rigorous efforts in R&D and steady reliability from customers.

EXHIBIT CLASSIFICATION

의약품주입기

Q-Jet

COMPANY & PRODUCT INTRODUCTION

신우메디슨은 의료기기 시장에서 차별화를 보이고 독자적인 기술로 경쟁력을 갖출 수 있도록 기술과 제품 연구/개발에 주력할 예정이다. 단기계획은 피부관리와 통증 분야에 맞는 기존 기술과 제품을 지속적으로 업그레이드 할 계획이다.장기계획으로는 고령화에 적합한 노인성 질환과 문제점을 분석·이 해하고 친환경 신바이오소재 연구·개발 등을 통해 시대변화와 환경친화적 흐름에 적응할 수 있는 제품 및 소재를 상용화할 계획이다.다양한 해외 전시회와 컨퍼런스에 참여하고 수출 경쟁력을 갖춰 세계화에 부응할 수 있는 전문수출기업이 될 수 있도록 신우메디슨이 될 수 있도록 노력하겠다

Shinoo Medison Co., Ltd. will focus on technology and product research/development so that it can show differentiation in the medical device market and be competitive with its unique technology. The short-term plan will continue to upgrade existing technology and products to suit the areas of skin care and pain. For the long-term plan, we plans to commercialize product and material that can adapt to the changing times and environment-friendly flow by analyzing & understanding the geriatric diseases and problems that are appropriate for the age of aging and researching and developing eco-friendly new biomaterial. We will try our efforts to become Shinoo Medison Co., Ltd. which can contribute to the economy of Korea by participating in various overseas exhibitions and conferences and having export competitiveness so that we can be a specialized export company that can meet the globalization.

Hospital-based Business Innovation Center



Korea Innovative Pharmaceutical Company



SI SOLUTION

㈜에스아이솔루션

COUNTRY Republic of Korea
CEO In Sun Park 박인선

URL

E-mail seven-bj@hanmail.net

SK Chemicals Co., Ltd.

SK케미칼㈜

COUNTRY Republic of Korea

CEO Kwanghyun Jeon 전광현 URL www.skchemicals.com

E-mail mih@sk.com

EXHIBIT CLASSIFICATION

후각 훈련 장치

Olfactory training device

COMPANY & PRODUCT INTRODUCTION

㈜에스아이솔루션은 고객에게 최상의 솔루션 및 제품을 제공함으로써, 고객들의 기업가치와 만족도를 높일 수 있도록 끊임없이 노력하는 연구개발 기반의 전략변환장치, 에어가전, 의료기기 제조 전문 기업

SI solution is a power conversion device, air appliance, and medical device manufacturing company based on R & D that satisfies customers by providing the best solutions and products.

EXHIBIT CLASSIFICATION

* 조인스정: 관절염 치료제

* 엠빅스: 발기부전 치료제

* 기넥신 에프정: 혈액순환 개선제

* 트라스트패취: 소염진통 패취제

* Joins : Arthritis

* MVIX : Erectile Dysfunction * Ginexin : Blood circulation

* Trast Patch : Anti imflammatory analgesic

COMPANY & PRODUCT INTRODUCTION

SK케미칼은 1999년 국산 신약 1호 '선플라' 개발로 대한민국 신약 개발의 새 장을 열었습니다. 이어 천연물의약품 1호 조인스 개발과 발기부전 치료신약 엠빅스 개발에 성공하며 국산 신약 개발의 선구자 역할을 자임해왔습니다.

Beginning with "Sunpla", the nation's first self-developed drug that opened a new chapter in Korea's synthetic drug business, SK Chemical has since continued to launch new drugs such as "Mvix" (for erectile dysfunction) and "Joins" (the nation's first natural medicine), establishing a sizable product portfolio.

Korea Doctor Preneur

SKIMS-BIO

Wonju Medical Industry Technovalley



SKIMSBIO Co., Ltd.

㈜스킴스바이오

COUNTRY Republic of Korea

CEO Chang Keun Kim 김창근

URL www.hbic.or.kr/company/company_view.ht

ml?cc=gRaYhJa8gReyhBg0GJ0PGRc2gZq=

E-mail kimck@paik.ac.kr

Small Machines Co. Ltd.

주식회사 스몰머신즈

COUNTRY Republic of Korea

CEO jun-kyu Choi 최준규

URL www.smallmachines.co.kr

E-mail mch0513@smallmachines.co.kr

EXHIBIT CLASSIFICATION

1. K®-EDN ELISA KIT

2. K®-EDN Rapid KIT

3. WeezeKit[®] (상표등록)

1. K®-EDN ELISA KIT

2. K®-EDN Rapid KIT

3. WeezeKit® (Registered Trademark)

EXHIBIT CLASSIFICATION

혈구계산기

Cellop-CC

COMPANY & PRODUCT INTRODUCTION

(주)스킴스바이오는 천식 & 알러지 BIO-MARKER를 연구·개발하고 이를 시장에 맞게 생산하는 체외진단의료기기 시장을 선도하고 맞춤의학 실현을 위한 생명공학선도기업입니다.

SKIMSBIO Co., Ltd. is a biotech company that leads the in-vitro diagnostic medical device market that researches and develops asthma & allergies BIO-MARKER and produces them according to the market.

COMPANY & PRODUCT INTRODUCTION

스몰머신즈는 NT, BT, IT의 첨단기술을 융합하여 진보된 현장진단기기 사업을 영위하고 있습니다. 저희 제품은 혈구분석장비 Cellop-cc와 일회용 혈구계산판 Cellop-chip이 있습니다.

Small Machines is engaged in advanced field diagnosis equipment business by integrating cutting-edge technologies from NT, BT, and IT. Our products include cell analysis equipment Cellop-cc and disposable blood cell count Cellop-chip.

K-Healthcare start-ups



New Excellent Technology Exhibition



Smartooth korea

㈜스마투스코리아

COUNTRY Republic of Korea

CEO Hojung Vivian Son 손호정

URL smartooth.co

E-mail s.yoon@smartooth.co

SN BIOLOGICS

에스엔바이오로직스

COUNTRY Republic of Korea

CEO Heo Seong Ung 허성웅

URL www.snbiologics.com

E-mail snmedi08@daum.net

EXHIBIT CLASSIFICATION

고객이 치아 및 치주 상태를 스스로 확인하고 진단하는 개인용 구강진단 장비

After analyzing the acidity in the oral cavity, the pH decreases to the degree of 1-4 as the result of consumption of acidic fruits such as lemons or apples. You are advised to avoid immediate toothbrushing after consuming acidic foods because brushing your teeth while your oral cavity contains acid may result in the acid eroding the teeth. Dental diagnosis devices can serve as a guide to notify you of the appropriate time for toothbrushing.

COMPANY & PRODUCT INTRODUCTION

Smartooth는 구강진단 장비를 제작하고 디스플레이에 환자의 구강 내 상태를 가시적으로 표현하여, 고객이 치아 및 치주 상태를 스스로 확인하고 치과의 내원 여부 또는 내원시기를 결정할 수 있도록 하는 개인용 진단 장비를 제작하고자 한다.

The personal dental diagnostic devices Smartooth team provides allows The consumer to have an early diagnosis of inflammation or infection in The oral cavity by checking his or her own dental status more conveniently and also be aware of The appropriate check in periods to a clinic through The easily detectable display on The device showing The dental status.

EXHIBIT CLASSIFICATION

합성재료이식용뼈

synthetic bone.

COMPANY & PRODUCT INTRODUCTION

"SN바이오로직스는 인체에 안전이 확보된 인간의 자연상태와 유사한 가장 적합한 제품을 제조한다는 목표를 가진 바이오 벤처 합성골 제조회사다.

- 1. 입자코팅기술을 적용하여 쉽게 깨지는 성질인 취성을 제어할 수 있다.
- 2. 환자 맞춤형으로 1~2mm 단위로 즉시 성형이 가능하다.
- 3. 해면골과 유사한 구조를 가지고 있다.
- 4. 입자형과 블록형이 동일한 물성을 지니고 있다.
- 5. 중량대비 부피비가 크기 때문에 경제적이다."

SN BIOLOGICS is bio venture synthetic bone manufacture company with the goal of manufacturing the most appropriate product similar to natural state of human secured by safety on human body.

We fulfill the goal through continuous research and development and devote ourselves under the target to strengthen our control in global bone graft material market based on the outcome.

- 1. With particle coating control technique, control fragility, the easily broken property of ceramic
- Based on its patient-customization, able to immediately mold (1-2mm unit precise cutting)
- 3. Actualize spongy bone similar three-dimensional complex structure
- 4. Actualize uniformed particle/block type property
- 5. Economic feasibility due to high volume ratio compared to weight

COVID-19 SPECIAL PAVILION



Australian Trade and Investment Commission



SolGent

솔젠트㈜

COUNTRY Republic of Korea

CEO Jae Hyung You, Do Su Seok

유재형, 석도수

URL www.solgent.com

E-mail junho.park@solgent.com

South Australia

COUNTRY

CEO

URL www.dti.sa.gov.au/hmi

Australia

E-mail dirk.beelen@sa.gov.au

EXHIBIT CLASSIFICATION

DiaPlexQ[™] Novel Coronavirus (2019-nCoV) Detection Kit DiaPlexQ[™] Novel Coronavirus (2019-nCoV) Detection Kit

COMPANY & PRODUCT INTRODUCTION

동 업계 20년 업력으로, PCR 분자 진단 키트의개발 및 생산, 분자 진단 연구용 시약의 개발 및 생산, 농축수산물 검정용 PCR 검정키트의 개발 및 생산, 유전체 분석 서비스를 진행하고 있음

SolGent Co., Ltd. have several implementation and support service designed to develop and produce PCR molecular diagnosis detection kit, research reagents for molecular diagnostic, PCR detection kit for concentrated aquatic product assay and genome analysis with over twenty years of experience in the field.

COMPANY & PRODUCT INTRODUCTION

South Australia has internationally recognised capabilities and leadership within the health and medical industries sector.

Boasting one of the largest health precincts in the southern hemisphere, global health companies are choosing South Australia as their destination for research and development, particularly in the areas of biotech and medtech expertise, which include cancer research, clinical trials, medical device development, machine learning, genomics, wound healing, reproductive health, eye and vision research.

The state's outstanding innovation and commercialisation hubs include:

- A\$3.8 billion Adelaide BioMed City one of the largest biomedical clusters in the southern hemisphere, combining research (e.g. South Australian Health and Medical Research Institute (SAHMRI), CMAX Clinical Research), education and clinical care with business development
- Thebarton Precinct home to over 80 technology companies with 40 from the life sciences sector (e.g. Bionomics, Pfizer and Avance Clinical)
- Tonsley Innovation District a hi-tech manufacturing hub delivering a collaborative environment for start-ups, SMEs (e.g. Micro-X) and global companies (e.g. Zeiss)
- Waite Campus a partnership of 15 organisations conducting worldclass R&D in plant, agricultural, food, wine and natural resources, including plant based traditional medicine research and product development.

South Australia's export products include mobile x-ray units, surgical implants, lasers, small and large molecule drugs, cell therapies, nutraceuticals, reagents and more.

Australian Trade and Investment Commission



Australian Trade and Investment Commission



Southern Oncology Clinical Research Unit (SOCRU)

Southern Star Research

COUNTRY

Australia

CEO

URL www.socru.org.au

E-mail Meggan.oriley@socru.org.au

COUNTRY Australia

CEO

URL www.southernstarresearch.com.au

E-mail cstellatos@southernstarresearch.com

COMPANY & PRODUCT INTRODUCTION

Southern Oncology Clinical Research Unit (SOCRU) is located in Flinders Private Hospital in Adelaide, South Australia. Run by a team of five experienced oncologists, SOCRU provides patients the opportunity to contribute to ongoing cancer research whilst receiving the highest quality, evidence based clinical care from our skilled health professionals. We are experienced in regulatory submission and start up activities and have conducted trials using various interventions including cytotoxic, targeted therapies, immunotherapy and oncolytic viral therapies.

COMPANY & PRODUCT INTRODUCTION

Southern Start Research is a leading, privately owned Australian CRO that specialises in helping pharmaceutical, biotech and medical device companies accelerate their early stages of clinical development. We provide a bespoke solution for our clients and can offer full service capabilities inhouse including Clinical Operations, Biometrics, Medical Writing, Project Management as well as Medical and Safety services.

Korea Innovative Pharmaceutical Company



ST PHARM

에스티팜 주식회사

COUNTRY

Republic of Korea

CEO

Kyungjin Kim 김경진

URL

www.stpharm.co.kr

E-mail

seohyun.ahn@stpharm.co.kr

EXHIBIT CLASSIFICATION

- * C형 간염 치료제: C형 간염
- * 당뇨병 치료제: 당뇨병
- * 항생제: 항생제
- * 위암 치료제: 위암
- * MDDs 치료제: MDDs
- * 비대칭 고리화합물: 항바이러스제
- * 글루코스유도체: 항바어러스제
- * 뉴클레오사이드 모노머: RNA치료제
- * 아토르바스타틴: 고혈압
- * 클로피도그렐: 항혈전제
- * d-사이클로세린: 결핵
- * 테리지돈: 결핵
- * 가도부트롤: MRI조영제

- * HCV drug: HCV
- * Diabetes drug: Diabetes
- * Antibiotics drug: Antibiotics
- * Gastric Cancer: Gastric Cancer
- * Mitochondrial DNA Depletion Syndrome : MDDs
- * Chiral epoxide: HIV
- * Chloro-(L)-sugar: HBV
- * Nucleoside monomers: Various RNA therapeutics
- * Atorvastatin: Hyperlipidemia
- * Clopidogrel: Anticoagulant
- * d-Cycloserine: Tuberculosis
- * Terizidone: Tuberculosis
- * Gadobutrol: MRI contract

COMPANY & PRODUCT INTRODUCTION

에스티팜은 동아쏘시오홀딩스의 가족회사로서, 급변하는 시장에 대응하기 위하여 선제적으로 생산시설을 투자하여, 고객사에게 Total Service를 제공 하고자 최선의 노력을 경주할 것입니다. As a member of Dong-A Socio Holdings, ST Pharm is proactively investing our manufacturing equipments to provide cutting edge services which are comprehensive and matching to the fast phased global market.

GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION



Australian Trade and Investment Commission



ST1

㈜에스티원

COUNTRY Republic of Korea

CEO Yongjun Yoon 윤용준

URL www.samin21.com

E-mail hjnam@artipore.com

St Vincent's Hospital Melbourne

COUNTRY Australia

CEO

URL www.svhm.org.au/research

www.researchvalet.com.au

E-mail Megan.Robertson@svha.org.au

EXHIBIT CLASSIFICATION

- 1. 바이라미네이트
- 2. 나노섬유 인서트
- 3. 퍼미블 서포트 (시제품)
- 4. 그리드 메쉬 (시제품)
- 1. Bilaminate
- 2. Nanofibers Insert
- 3. Permeable Support (Trial)
- 4. Grid Mesh (Trial)

COMPANY & PRODUCT INTRODUCTION

㈜에스티원은 인간의 건강과 행복을 위한 첨단소재를 개발합니다.

독자적 특허기술을 통해 세포의 성장 및 상호 작용을 위한 체외 세포 모델과 유사한 세포배양 플랫폼을 제공합니다.

ST1 Co., Ltd. develops advanced materials for human health and happiness.

The company provides 3D Cell Culture Platform similar to Extra Cellular Matrix for Cell's growth and interaction of itself through the original patented technology.

COMPANY & PRODUCT INTRODUCTION

St Vincent's Hospital Melbourne (SVHM) is one of five tertiary teaching hospitals in Victoria with respected clinical education and clinical research programs.

- * Our clinical care is supported by an inspiring and very active translational research program:
- * Oncology / haematology breast and lung cancer
- * Gastroenterology NASH, hepatitis B/C, IBD
- * Neurosciences epilepsy, Parkinson's disease, neurosurgery
- * Cardiology interventional, devices, clinical management
- * Endocrinology diabetes, devices, complications
- * Renal medicine
- * Regenerative medicine
- * Immunology/inflammation/infection/sepsis
- * Orthopaedics sarcoma, limb reconstruction
- * Respiratory a1 anti-trypsin deficiency
- * Bioengineering: stem cells, 3-D Printing

K-Healthcare start-ups



Korea Doctor Preneur



Sullab

㈜설랩

CEO Republic of Korea Chewy Lee 이주훈

URL www.sullab.co.kr

E-mail chewy.lee@sullab.co.kr

SWEXO biotechnology

SWEXO biotechnology

COUNTRY Republic of Korea

CEO Kihwan Kwon

URL

E-mail kankadin@ewha.ac.kr

EXHIBIT CLASSIFICATION

국내 최초의 기능성 세안수인 "페이셜워터" 제조 / 판매

동/서 의학적으로 다수의 학회지 및 논문에서 피부질환 개선 효능이 증명된 유황온천수를 3중 멤브레인 정제 및 UV 자외선 살균 적용하여, 트러블 피부 전용 세안수로 개발

100% Sulphur Thermal Spring Water

COMPANY & PRODUCT INTRODUCTION

페이셜 워터 자체 제조/생산 라인 구축 및 100% 천연으로 제조 당사 제품은 세안을 위한 수돗물 대체용 화장품으로 방부제와 화학물이 전혀 없는 제품임

당사 원료 안전성 및 효능 검증

- 인체피부 누적첩보 임상실험 완료 (N수 33명 대상) (검사기관: 한국화학융 합시험연구소)
- 미생물검사 및 중금속검사 완료 (전량 불검출 확인) (검사기관: 한국화학융 합시험연구소)
- 유황성분(H2S) 국내 최대수준 3.99ppm 함량 검증 (검사기관: 한국지질 자원연구소)

We are first mover of developing new concept of cosmetic product which is providing substitutions of tap water for facial wash which is product name called "Facial Water".

Our "Facial water" is made with 100% Sulphur Thermal Spring Water and it go through Tri-Membrane Purification and UV Sterilization before finalized the product.

Verifying the safety and effectiveness of our developed ingredients.

- Completed human skin cumulative clinical trials (By Korea Testing & Research Institute)
- Completed of microbial inspection and heavy metal inspection (confirmation of all non-detection) (By Korea Testing & Research Institute)
- Verification of sulfur content with variety of water minerals (By Korea Institute of Geoscience and Mineral Resources)

EXHIBIT CLASSIFICATION

- 1. 난치성 염증 질환에 대한 First in Class 먹는 유전자 치료제
- 2. 도포용 엑소좀 기반 난치성 피부질환 치료제
- 3. 엑소좀 기반 항암제
- 1. Edible First in Class gene therapeutics for intractable inflammatory diseases
- 2. Exosome- based intractable skin disease ointment
- 3. Exosomal-based anticancer drug

COMPANY & PRODUCT INTRODUCTION

㈜엑솔런스 바이오테크놀로지는 생체적합성이 높은 약물전달체인 엑소좀을 이용한 엑소좀 기반 치료제 개발 기업입니다. 다년간의 엑소좀 관련 전문 연구를 바탕으로 개발된 체외충격파를 이용한 신개념 엑소좀 약물전달체 제작 플랫폼 기술을 이용하여 합리적인 가격에 보다 안전한 다양한 제형의 엑소좀 기반 유전자 치료제를 개발하여 엑소좀 기반 바이오 산업 영역의 세계적 선두기업을 지향하고 있습니다.

SWEXO biotechnology is a company that develops medicine based on exosome, a highly bio-compatible drug carrier.

The company has developed a new concept of Exosomal Drug Delivery Platform Technology using in vitro shock wave based on years of professional research on exosomal.

With this concept, the company is aiming to become a world leader in the field of exosome-based bio-industry by developing various types of exosomal-based gene therapy with increased safety at a reasonable cost. Korea Innovative Pharmaceutical Company



K-Healthcare start-ups



Taejoon Pharmaceutical Co., Ltd.

주식회사 태준제약

COUNTRY Republic of Korea

CEO Tae Young Lee 이태영

URL www.taejoon.co.kr

E-mail jhlee2@taejoon.co.kr

Technical Trend company

테크니컬트렌드컴패니

COUNTRY Republic of Korea

CEO IM JINHWAN 임진환

URL

E-mail kmk2900@naver.com

EXHIBIT CLASSIFICATION

- * C형 간염 치료제: C형 간염
- * 당뇨병 치료제: 당뇨병
- * 항생제: 항생제
- * 위암 치료제: 위암
- * MDDs 치료제: MDDs
- * 비대칭 고리화합물: 항바이러스제
- * 글루코스유도체: 항바어러스제
- * 뉴클레오사이드 모노머: RNA치료제
- * 아토르바스타틴: 고혈압
- * 클로피도그렐: 항혈전제

d-사이클로세린: 결핵

- * * 테리지돈: 결핵
- * 가도부트롤: MRI조영제
- * Cyporin N Eye drop 0.05% : Cyclosporin
- * Xalost-S Ophthalmic Solution: Latanoprost
- $\ensuremath{^*}$ Xalostplus Ophthalmic Solution : Latanoprost, Timolol maleate
- * Xalost Ophthalmic Solution: Latanoprost
- st Gadobirx Pre-filled Syringe Injection : Gadobutrol
- * Iobrix INJ 350 : Iohexol
- * CleanViewAL Powder: Polyethylene glycol3350

EXHIBIT CLASSIFICATION

비접촉 음압식 스마트 마스크

Contactless sound pressure type smart mask

COMPANY & PRODUCT INTRODUCTION

비접촉 방식으로 사용자의 장시간 착용 피로감 감소 및 간단한 필터 교환 방식으로 위생적이고 실용적인 특성을 가진 혁신적 마스크

Has hygienic and practical characteristics by reducing wear fatigue and simple filter exchange by non-contact users

COMPANY & PRODUCT INTRODUCTION

에스티팜은 동아쏘시오홀딩스의 가족회사로서, 급변하는 시장에 대응하기 위하여 선제적으로 생산시설을 투자하여, 고객사에게 Total Service를 제공 하고자 최선의 노력을 경주할 것입니다.

Established in 1978, Taejoon Pharmaceutical Co., Ltd. ("Taejoon") is one of the leading specialty pharmaceutical companies in ophthalmology, radiology, and GI and with a global presence in the US, Europe, Asia and Africa. With a vision to become the best pharmaceutical company specialized in ophthalmology, radiology, and GI, Taejoon has been building up company's future growth based on the business strategy by focusing its corporate resources; specialization, global marketing, and R&D innovation.

Hospital-based Business Innovation Center



Korea Innovative Pharmaceutical Company



TECHVILLAGE

테크빌리지

COUNTRY Republic of Korea

CEO David Choi 최동훈

URL www.techvillage.co.kr

E-mail ceo@techvillage.co.kr

TEGO SCIENCE

테고사이언스

COUNTRY Republic of Korea

CEO Saewha Jeon 전세화

URL www.tegoscience.com

E-mail swbaek@tegoscience.com

EXHIBIT CLASSIFICATION

뇌질환 환자용 VR재활치료 솔루션

Rehab Ware

COMPANY & PRODUCT INTRODUCTION

테크빌리지는 뇌질환 환자용 VR재활치료 솔루션을 가진 기업으로, "Rehab Ware"는 뇌졸중 환자 치료를위한 세계 최초의 VR 재활 솔루션을 갖춘 제품 입니다.

Techvillage is a company with VR rehabilitation treatment solution for patients with brain diseases. "Rehab Ware" is a product that has world 1st VR rehabilitation solutions for stroke patient treatment.

EXHIBIT CLASSIFICATION

* 홀로덤® : 자기유래피부각질세포 * 칼로덤® : 동종유래피부각질세포 * 로스미르® : 자가피부유래섬유아세포

* 네오덤[®] : 3D 인공피부

* Holoderm® : Autologous Keratinocytes * Kaloderm® : Allogenic Keratinocytes * Rosmir® : Autologous Fibroblasts * Neoderm® : 3D Human Skin

COMPANY & PRODUCT INTRODUCTION

테고사이언스㈜는 최첨단 세포배양기술을 바탕으로 상처치유용 피부세포 치료제를 비롯한 재생의료제품을 제조·판매하는 바이오 기업입니다.

Tego Science is a Seoul-based biopharmaceutical company specializing in regenerative skin cell therapy for wound healing.

Korea Doctor Preneur

Thermo Fisher SCIENTIFIC

Theracan Co., Ltd.

(주)테라캔

COUNTRY Republic of Korea

CEO Jae Hong Seo 서재홍

URL www.newflight.co.kr

E-mail cancer@korea.ac.kr

Thermo Fisher Scientific, Pharma Services (Patheon)

COUNTRY United States of America

CEO Marc N. Casper

URL www.thermofisher.com/kr/ko/home

wakako.kawada@thermofisher.com

EXHIBIT CLASSIFICATION

- 1. HSP90 저해제 혁신 신약(연구개발 진행중)
- 2. 표적 항암 테라노스틱스(연구개발 진행중)
- 3. 압타머 기반 표적 치료제(연구개발 진행중)
- 1. An innovative drug, HSP90 inhibitor (Research and development in progress)
- 2. A target for anti-cancer, Theranostics (Research and development in progress)
- 3. Aptamer-based targeted drug (Research and development in progress)

COMPANY & PRODUCT INTRODUCTION

(주)테라캔은 국내기술로 저비용, 고효율의 암 표적 치료제를 개발 및 상용화하여 전세계 표적 항암제 시장에 진출하는 것을 목표로 하며, 고가의 항암 치료 비용과 적절한 치료제의 부재로 고통받는 난치성 암환자들을 위한 표적치료제를 개발하여 보급하고자 합니다.

Theracan Co., Ltd. aims to advance into the global targeted anticancer drugs market by developing and commercializing low-cost, high-efficiency cancer target therapeutics with domestic technology. The company strives to develop and distribute targeted treatments for incurable cancer patients who suffer from the high cost of anticancer treatment and the absence of appropriate treatments.

EXHIBIT CLASSIFICATION

E-mail

Thermo Fisher Scientific provides industry-leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers of all sizes through our Patheon brand. With more than 40 locations around the world, the company can provide integrated, end-to-end capabilities across all phases of development, including API, biologics, viral vector services, formulation, clinical trials solutions, logistics services and commercial manufacturing. We give all sizes of pharma and biotech companies, including the very smallest, instant access to a fully integrated global network of facilities across North America, Europe, Asia and Australia.

Our global leadership is built on a reputation for scientific and technical excellence. This includes specialized capabilities for highly potent and controlled substances, aseptic filling and lyophilization, complex formulations, solubility enhancement and difficult-to-manufacture APIs. We also offer integrated services for drug development that aligns development of drug substance and drug product in a coordinated drive toward proof of concept that can reduce development timelines. We have more than 17,000 scientific and professional staff and over 40 years of experience. As a leading global CDMO, we deliver unrivaled quality, reliability and compliance. Together with our clients, we're rapidly turning pharmaceutical possibilities into realities.

COMPANY & PRODUCT INTRODUCTION

Thermo Fisher Scientific provides industry-leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers of all sizes through our Patheon brand. With more than 40 locations around the world, the company can provide integrated, end-to-end capabilities across all phases of development, including API, biologics, viral vector services, formulation, clinical trials solutions, logistics services and commercial manufacturing.

We give all sizes of pharma and biotech companies, including the very smallest, instant access to a fully integrated global network of facilities across North America, Europe, Asia and Australia. Our global leadership is built on a reputation for scientific and technical excellence. This includes specialized capabilities for highly potent and controlled substances, aseptic filling and lyophilization, complex formulations, solubility enhancement and difficult-to-manufacture APIs.

We also offer integrated services for drug development that aligns development of drug substance and drug product in a coordinated drive toward proof of concept that can reduce development timelines. We have more than 17,000 scientific and professional staff and over 40 years of experience. As a leading global CDMO, we deliver unrivaled quality, reliability and compliance. Together with our clients, we're rapidly turning pharmaceutical possibilities into realities.

GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION



Australian Trade and Investment Commission



THK Co., Ltd.

㈜THKC

Translational Research Initiative for Cellular Engineering and Printing (TRICEP)

COUNTRY Republic of Korea

CEO Shin Jong Ho 신종호

URL www.thkc.co.kr

E-mail thkc1300@hanmail.net

COUNTRY Australia

CEO

URL www.tricep.com.au

E-mail tbohme@uow.edu.au

EXHIBIT CLASSIFICATION

위생&요실금팬티, 자세교정밴드(벨트), 자세교정티셔츠

Functional sanitary & Urinary incontinence panties, Posture Support Band(Belt), Posture Support T-Shirt

COMPANY & PRODUCT INTRODUCTION

㈜티에이치케이컴퍼니는 고령친화 및 헬스케어 전문 기업입니다.

위생팬티, 요실금 팬티와 바른자세밴드(벨트), 바른자세티셔츠로 건강한 삶을 도와줍니다

THKC, Inc. is a senior friendly health care expert to improve senior

life and provide healthier lives of the users. Functional sanitary & Urinary incontinence panties, Posture Support Band(Belt), Posture Support T-Shirt

COMPANY & PRODUCT INTRODUCTION

TRICEP works with research institutions and industry to develop innovative technologies using 3D bioprinting. TRICEP is commercialising opportunities in bioprinting including printer manufacturing, biomaterials, bioinks, and material-cellular combinations to address industry challenges that require an exclusive, tailored solution.

TRICEP's world leading research infrastructure can assist companies to bring to life novel technology from concept stage through to prototyping and manufacture of hardware and the formulation of customised bioinks, to accelerate product development and rapidly decrease time to market.

7 TriBell Lab

COVID-19 SPECIAL PAVILION

Korea Doctor Preneur

Tribell lab

(주)트라이벨랩

Trichogen Co., Ltd.

㈜트리코진

COUNTRY Republic of Korea

CEO Lee Sang Hak 이상학

URL www.tribell-lab.com

E-mail goodscout@naver.com

COUNTRY Republic of Korea

CEO Jungchul Kim 김정철 URL trichogene.kr

E-mail jayckim@knu.ac.kr

EXHIBIT CLASSIFICATION

VDR-1000 & VMA-1000

스마트활력징후측정기 / 환자중앙감시장치

VDR-1000 & VMA-1000

(Vital sign Data Recorder & Vitalsign Management Analysis)

EXHIBIT CLASSIFICATION

1. Dr. HairTT Shampoo

2. Dr. HairTT Rinse

1. Dr. HairTT Shampoo

2. Dr. HairTT Rinse

COMPANY & PRODUCT INTRODUCTION

저희 트라이벨랩은 Vital Sign 의료기기전문 연구·제조 회사로서 IOT기술을 기반으로 하여 기존의 의료기기와는 차별화되는 의료용 웨어러블 심전계를 비롯한 다양한 의료기기들을 연구·개발하고 있습니다.

Tribell Lab is researching and developing a variety of medical devices based on IOT technology as a research and manufacturing company. Tribell Lab is constantly researching and developing to develop a healthy and comfortable life by developing and distributing devices that help prevent adult disease and early detection and treatment.

COMPANY & PRODUCT INTRODUCTION

남성형탈모 극복을 위한 치료법 및 치료제 개발을 기본 취지로 하여, 2000년 3월 경북대학교 의과대학내 벤처기업으로 창업하였습니다.

모발이식/모발교육/모발연구를 통한 수익모델을 창출하여

- 모낭분리사 양성 및 모근분리용역
- 샴푸/린스를 포함한 모발관리용품을 제조, 판매
- '탈모치료제, 모낭복제술, 모발이식 자동화기기' 연구개발

The company was established in March 2000 as a ventrue company in Kyungpook National University Medical School, with the purpose of developing medicine and treatments for overcoming male pattern hair loss.

The company is striving to create a profit model through hair transplantation/hair education/hari research and establish the following:

- Hair Transplant Nurse Training and Hair root separation service
- Manufacturing and sales of hair care products including shampoo/ rinse
- Research and development of 'hair loss therapeutic, hair follicle cloning, and hair transplantation automatic device"

Korea Doctor Preneur

Australian Trade and Investment Commission



UFU Health

유에프유헬스㈜

COUNTRY Republic of Korea

CEO Kyung Jin Jung 정경진

URL

E-mail kjchung@gilhospital.com

VIC State Government

COUNTRY Australia

CEO

URL global.vic.gov.au

E-mail Libby.oconnor@global.vic.gov.au

EXHIBIT CLASSIFICATION

- 1. 발기부전 치료 마이크로니들
- 2. 발기부전 치료 마이크로니들 콘돔
- 1. Erectile dysfunction treatment- Microneedle
- 2. Erectile dysfunction treatment- Microneedle condom

COMPANY & PRODUCT INTRODUCTION

인체구조의 특징과 마이크로니들이라는 새로운 개념의 약물전달체계를 융합한 혁신적 개념의 의료기기 개발, 연구, 생산을 위한 기업입니다.

UFU Health is a company focused on the development, research, and production of innovative medical devices that fuse the characteristics of human structure with the new concept of drug delivery system called Microneedle.

COMPANY & PRODUCT INTRODUCTION


As one of the world's leading life science clusters, Melbourne (located in the State of Victoria, Australia) is a highly sought-after destination by global companies.

The state boasts a low-risk, high-quality and competitive business environment. It has a rich legacy of commercial success, advanced manufacturing expertise and key R&D infrastructure, attracting and maintaining a talented and skilled workforce.

Victorian is Australia's epicentre of world-leading medical research. Supported by 16 major medical research institutes, 11 teaching hospitals and 9 universities, Victoria's researchers have been awarded more than 40 per cent of Australia's competitive medical research funding every year since 2000. Of Australia's top ten pharmaceutical companies, ranked by market capitalisation, six are based in Victoria.

Victoria's expertise in biotechnology, medical technologies and pharmaceuticals has been supported by a favourable regulatory and R&D environment, and consistently backed by strong Government investment over many decades. Our network of 22 international trade and investment offices works with Victorian and international partners to support the development and commercialisation of new breakthrough products and treatments.

SEOUL Biohub



COVID-19 SPECIAL PAVILION



VIVA INNOVATION

주식회사 비바이노베이션

COUNTRY Republic of Korea
CEO Park Han 박한
URL www.adoc.co.kr
E-mail jump@adoc.co.kr

VUNO

(주)뷰노

CEO Republic of Korea
Hyun-Jun Kim 김현준

URL www.vuno.co

E-mail jane.kim@vuno.co

EXHIBIT CLASSIFICATION

A.I 인공지능 질병 진단 및 병원과 병원비 비교 의료 플랫폼

Predict hospital expenses based on medical big data (statistical DB) analysis technology to eliminate disparity in medical information.

COMPANY & PRODUCT INTRODUCTION

- 1. 의료 빅데이터 분석 기술
- 2. 딥러닝 기반 인공지능 문진 알고리즘
- 3. 건강 정보 추천 알고리즘
- 1. Medical data analysis and statistics
- 2. Artificial Intelligence symptom check-up Algorithm
- 3. Recommendation algorithm based on Machine learning in health information

EXHIBIT CLASSIFICATION

뷰노메드 렁퀀트™, 뷰노메드 체스트 엑스레이™-코로나19 버전

VUNO $\mathsf{Med}^{@}$ -LungQuant™, VUNO $\mathsf{Med}^{@}$ -Chest X-ray™: COVID-19 Version

COMPANY & PRODUCT INTRODUCTION

뷰노는 의료분야에 인공지능 기술을 적용해 X-ray·CT·MRI 등 의료 영상 데이 터부터 생체신호까지 광범위한 의료데이터를 분석하고 진단을 돕는 의료 인공지능 솔루션 개발 기업이다. 2014년 설립 초부터 누적된 ▲제품 기획 ▲기술 개발 ▲인허가 ▲임상 검증 등 인공지능 의료기기 상용화 전주기에 대한 독보적인 경험과 업계 최정상급 딥러닝 기술력을 바탕으로 유수의 의료기관·대학·기업과 협력해 임상현장의 효율화를 돕는 다양한 진단 보조 솔루션을 개발하고 있다.

VUNO's Al solutions are reshaping the medical industry presenting a whole new level of experience to medical practitioners in their day-to-day workflow, enabling them to make diagnostic decisions faster and more accurately and to provide quality patient care. We are on a mission to "View the Invisible, Know the Unknown", and will never rest until we discover the invisible and unknown territories of medicine by navigating the ambiguity with the help of artificial intelligence.

Australian Trade and Investment Commission



K-Healthcare start-ups



WA Government WALSIH

WELLC

웰씨

COUNTRY Australia

CEO

URL www.mtpconnect.org.au

E-mail kate.brooks@mtpconnect.org.au

COUNTRY Republic of Korea

CEO Inkyung Park 박인경

URL www.wellc.k

E-mail cnear@naver.com

COMPANY & PRODUCT INTRODUCTION

The MTPConnect Western Australian (WA) Life Sciences Innovation Hub is an initiative of the Government of Western Australia to expand WA's already dynamic and innovative medtech, pharmaceutical (MTP), biotech and digital health sector. It is one of three intrinsically linked Western Australian innovation hubs - along with WA Data Science and WA AustCyber - that collaborate to accelerate State-wide economic growth and use WA's competitive assets to grow new industries.

Located in Perth and operated in partnership with MTPConnect and The University of Western Australia, the MTPConnect WA Life Sciences Innovation Hub has invaluable local, national and international networks across all levels of industry and government, and delivers targeted programs that connect the innovation community, build capacity and capability, attract investment, and foster commercialisation.

MTPConnect is a not-for-profit organisation that was formed in December 2015 as part of the Australian Government's Industry Growth Centre Initiative to achieve greater success in the translation of medical research, deliver business and jobs growth, and improve the health and wellbeing of Australian and international consumers.

The MTPConnect WA Life Sciences Innovation Hub is the gateway to Western Australia's leading Life Sciences innovation ecosystem, with world class research and clinical trial facilities, cancer research programs, regenerative medicine businesses and local therapeutics and medtech manufacturing capabilities. The ecosystem supports a growing entrepreneurial and startup scene that engages with WA's world-leading Industry 4.0 technologies and talent.

The hub's Director of Biomedical Innovation, Professor Kevin Pfleger, and Director of Stakeholder Engagement, Dr Kate Brooks, are ready to talk to innovators and business people across the world about Western Australia's commercialisation opportunities at Bio Korea 2020 or any other opportunity.

EXHIBIT CLASSIFICATION

레이저로 각막의 형태를 중심점 대칭으로 교정할 수 있는 각막절삭패턴 교정기술 Surgical program to achieve corneal correction

COMPANY & PRODUCT INTRODUCTION

각막교정기술-레이저로 각막의 형태를 중심점 대칭으로 교정할 수 있는 각막절 삭패턴을 제공.독립장치 또는 레이저에 탑재해 사용되도록 고안

This software provides a corneal cutting pattern that allows the shape of cornea to be corrected in central-point symmetrically with a laser. This software is designed to be used as an independent device or installed in the laser.

WELPEP

Hospital-based Business Innovation Center

Hospital-based Business Innovation Center

Wellysis

WELLPEP

㈜웰펩

(주)웰리시스

WELLYSIS

COUNTRY Republic of Korea

CEO 권영익, 김종민

URL www.cosbioteoch.co.kr

E-mail smykim2030@gmail.com

will94@naver.com

COUNTRY Republic of Korea

CEO Young-hyup Juhn 전영협

URL www.wellysis.com

E-mail jongwoo.kim@wellysis.com

EXHIBIT CLASSIFICATION

포포유 에센스 펩타이드 콤플렉스, 화장품 펩타이드

44U Essence Peptide 4 Complex cosmetic peptide

EXHIBIT CLASSIFICATION

S-Patch Cardio

S-Patch Cardio

COMPANY & PRODUCT INTRODUCTION

(주)웰펩은 독자적인 펩타이드 제조 전문 기업으로, 펩타이드 소재 개발 및 제조, 펩타이드 신약 개발 및 펩타이드 화장품 브랜드 444U "를 제조 및 판매하고 있습니다.

"44U"의 모든 제품에는 최적화된 펩타이드 4종의 comlex를 포함하며, 맑은 피부를 유지시켜주는 효과가 있습니다.

Wellpep Co., Ltd. is a company specialized in the manufacture of unique peptides, developing and manufacturing peptide materials, developing new peptide drugs, and manufacturing and selling the peptide cosmetics brand "44U".

All products of "44U" contain 4 optimized peptides of comlex and have the effect of maintaining clear skin.

COMPANY & PRODUCT INTRODUCTION

(주)웰리시스는의 S-Patch Cardio는 초경량 웨어러블 심전도 모니터링 디바이스 S-Patch를 활용한 심전도(ECG) 데이터 분석 솔루션입니다.

사용자는 11g의 초경량 웨어러블 디바이스를 장시간 편리하게 착용할 수 있고, 모바일 앱을 통해 정확한 증상기록을 할 수 있습니다. 의료진은 클라우드 기반 심전도 데이터 분석을 통해 신속한 운영서비스와 보다 정확한 진단지원을 받을 수 있습니다.

Wellysis Co., Ltd. is S-Patch Cardio provide 24/7 wearable technology to empower patients, physicians, and care managers to manage cardiovascular conditions, while providing payers, providers, and corporations with care planning and remote monitoring capabilities for effective population health management.

Wiregene

Korea Doctor Preneur

Wise & Wide Regeneration

SEOUL Biohub



Wiregene Co., Ltd.

㈜와이어젠

COUNTRY Republic of Korea

Jung Keun Hyun 현정근

URL www.wiregene.com

E-mail rhhyun@dankook.ac.kr

WonderBio Inc.

원더바이오 주식회사

COUNTRY Republic of Korea

Choi Hun 최훈

URL www.wonderbioinc.com

E-mail proactive123@naver.com

EXHIBIT CLASSIFICATION

- 1. MFDS(임상시험승인 계획 진행중)
- 2. 약물 리포지셔닝(연구개발 진행중)
- 3. 자기자극기 리포지셔닝(연구개발 진행중)
- 4. 신경자극기(연구개발 진행중)
- 1. MFDS(Clinical Test Approval Plan in progress)
- 2. Drugs repositioning(R&D in progress)
- 3. Magnetic Stimulator repositioning(R&D in progress)
- 4. Neurostimulator(R&D in progress)

EXHIBIT CLASSIFICATION

호기(呼氣,날숨) 분석을 통한 암·질병 조기 진단 솔루션

A Solution for Early Cancer Detection equipped with the Ultra-sensitive Bionano E-nose Sensor Technology

COMPANY & PRODUCT INTRODUCTION

세계 최초 세계 유일의 초민감도 바이오 나노 전자코 센서 기술로 암 조기 진단 솔루션을 개발하여 암 조기 진단의국 내외적 대중화 선도

To lead national and international popularization of early cancer diagnosis by developing a Solution for Early Cancer Detection equipped with the World's First and Only Ultra-sensitive Bionano E-nose Sensor Technology

COMPANY & PRODUCT INTRODUCTION

㈜와이어젠은 풍부한 기초 및 임상 경험을 토대로 신경재생용 신경도관 및 치료제를 개발하는 기업입니다. 말초신경 및 척수 손상환자 전문 재활의학과 임상 전문의로서 최적의 신경재생 효과를 가지는 다기능 신경도관과 신경도 관 구조체를 개발하고 있습니다.

Wiregene Co., Ltd. is a company that develops neural conduits and treatments for neuroregeneration based on extensive basic and clinical experiences.

As a clinical specialist in rehabilitation medicine specializing in peripheral nerve and spinal cord injury patients, we are developing multi-functional neural tube and neural tube structures with optimal neural regeneration effect.


Wonju Medical Industry Technovalley



COVID-19 SPECIAL PAVILION

㈜우영메디칼

WOOYOUNG MEDICAL



Wonju Medical Industry Technovalley

(재)원주의료기기테크노밸리

COUNTRY Republic of Korea

CEO 백종수

URL www.wmit.or.kr
E-mail phy@wmit.or.kr

COUNTRY Republic of Korea

CEO Lee, YoungGyu 이영규

URL www.wooyoungmed.com

TEL E-mail gad28@wooyoungmed.com

COMPANY & PRODUCT INTRODUCTION

(재)원주의료기기테크노밸리는 창업초기부터 글로벌 강소기업까지 체계적으로 지원하기 위해 수요자 맞춤형 기업지원체계를 구축하여 의료기기 개발 전 주기에 걸친 기업지원 서비스 역량을 보유하고 있습니다. 신기술 의료기기 선행기술에 대한 다각적 분석, 디자인, 기구 설계 및 시제품 제작과 국제표준규격에 부합하는 의료기기 안정성, 신뢰성 시험과 글로벌 시장 진출을 지원하는 등의 일련의 과정을 원스톱으로 지원함으로써 의료기 기산업의 글로벌 경쟁력을 향상시키고 있습니다.

Wonju Medical Industry Techno Valley' established customized 'MEDISTRY'provision system for companies with the intention of becoming 'Strong&Small'global companies throughout the cycle of developing medical device from each start-up.

The 'MEDISTRY' currently include comprehensive supports for multilateral analyses on proceding technologies, mechanical & instrumental design, pilot production, safety and reliability tests to secure conformity to international standards, and activities for making inroads to global market for corporations to have global competitiveness.

EXHIBIT CLASSIFICATION

Accumate 1200

COMPANY & PRODUCT INTRODUCTION

㈜우영메디칼은 Ambulatory Disposable Balloon Infuser 및 Ambulatory Infusion Pump를 전문적으로 연구, 개발, 생산 판매를 하고 있는 회사 입니다.

WOOYOUNG Medical has been medical device manufacturer specialized in production and selling of ambulatory disposable balloon infuser and Ambulatory Infusion pump.

COVID-19 SPECIAL PAVILION





WOSEM Co., Ltd.

㈜웃샘

COUNTRY Republic of Korea

CEO LEE, MYUNGSIK 이명식

URL www.wosem.co.kr

E-mail lsj@wosem.co.kr

WuXi AppTec

우시앱텍코리아

COUNTRY China

CEO Ge Li

URL www.wuxiapptec.com

E-mail yeojin_nam@wuxiapptec.com

EXHIBIT CLASSIFICATION

음압캐리어, 음압기

Negative pressure carrier, Negative pressure unt

COMPANY & PRODUCT INTRODUCTION

웃샘은 생물안전 분야의 의료기기 개발, 제조 및 엔지니어링을 수행하는 전 문기업으로서, 1999년 설립 이래 이 분야에서 관련 기술의 연구, 개발 및 사업 을 성공적으로 수행해 오고 있습니다.

특히 2015년 창궐하여 사회적 불안감을 조성했던 메르스 대응을 위한 "이동 형음압기"를 세계 최초 개발 및 관련기관에 납품하여 국가재난 위기를 극복 하는데 공헌하였고, 2018년 중소벤처기업부의 개발지원을 받아 "음압캐리어"를 국내 최초로 국산화에 성공 하였으며, 관련 특허, 의료기기 허가 및 조달 등록을 완료하였습니다.

Wosem is a specialized company that performs medical device development, manufacturing and engineering in the field of biosafety. Since its establishment in 1999, we have been successfully conducting research, development and business of related technologies in this field

In particular, we contributed to overcoming the national disaster crisis by supplying the world's first "mobile sound pressure suppressor" to respond to MERS in 2015 and supplying it to related organizations and in 2018, supported by the Small and Medium Business Administration's development support. Sound Pressure Carrier" was the first in Korea to succeed in localization, and completed the registration of related patents, medical device permits and procurement.

EXHIBIT CLASSIFICATION

우시앱텍은 임상연구, 의약품허가 및 의약품 연구개발의 전과정에 속하는 화합물합성, 화합물-생물분석, 프로세스 및 공정개발, API 생산, 약동-약력-약리학, 생물, 제제연구, 독성, 유전자 분석, 항체 및 생물 진단제제의 생산과 판매에 이르는 통합 서비스를 제공하고 있습니다.

"Integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services.

COMPANY & PRODUCT INTRODUCTION

우시앱텍은 제약, 바이오, 및 진단기술에 이르는 전반적인 healthcare 산업에 open-access 기술 플랫폼 서비스를 제공하는 회사로 2,2000여명의 직원과 6.5백만제곱피트의 연구-생산시설을 보유하고 있습니다. 기술혁신과 고객중심 서비스를 기본으로 의약품개발을 원하는 전세계 모든 연구자들에게 시간과 비용에서 가장 효과적인 솔루션을 제공하는 것이 우리의 목표입니다.

WuXi AppTec Group is a leading global pharmaceutical, medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer focused company, WuXi AppTec Group provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi AppTec Group's dream that "every drug can be made and every disease can be treated."

Korea Doctor Preneur



Korea Doctor Preneur



Xaimed Co., Ltd.

자이메드

COUNTRY Republic of Korea

CEO Sang Min Park 박상민

URL

E-mail xaimed.com@gmail.com

Y S Bio Co., Ltd.

㈜와이에스바이오

COUNTRY Republic of Korea

CEO Yoo soo Kim 김유수

URL www.dr-youth.com

E-mail info@ysbio.kr

EXHIBIT CLASSIFICATION

- 1. AI 안저영상 판독 시스템
- 1. Al Fundus image reading system

COMPANY & PRODUCT INTRODUCTION

자이메드㈜는 환자의 건강과 행복한 삶을 위해 인공지능 기술을 사용한 의료 용 판독시스템을 개발하는 벤처 기업입니다.

자체 보건 의료 데이터베이스와 연동되어 실시간 인공지능 판독 및 소견을 제공하도록 설계되어 의료진의 시간과 노력을 획기적으로 줄여 더욱 많은 환자의 도움이 되고자 합니다.

Xaimed Co, Inc. is a venture company that develops medical reading systems using artificial intelligence technology for the health and wellbeing of patients.

Our products are designed to provide real-time artificial intelligence readings and findings in conjunction with its own health and medical database. The company strives to reduce the time and effort of our medical staff to help more patients.

EXHIBIT CLASSIFICATION

- 1. MS힐링 (통증)
- 2. 로자올리바 (피부)
- 3. 닥터유스앱 (비만, 헬스케어)
- 1. MS Healing (Pain)
- 2. Rosaoliva (Skin)
- 3. Dr Youth App (Obesity, Healthcare)

COMPANY & PRODUCT INTRODUCTION

와이에스바이오는 서울대학교 재활의학 박사이자 미국 안티에이징의학 전문의(ABAARM) 김유수 대표가 2015년 4월 설립한 안티에이징 헬스케어 전문기업입니다. 2015년 더마코스메틱 브랜드 'Dr. YOUTH'를 시작으로 분당서울대병원과 함께 스마트 헬스케어 앱 '닥터유스 다이어트', 국내 최초 천연 통증완화제 'MS힐링'을 개발 출시하였습니다. 앞으로 제조와 IT기술을 융합한 미래 안티에이징 솔루션을 선보이는 기업이 될 것입니다.

YS Bio is a company founded in April 2015 by CEO Kim Yoo-soo of the U.S. anti-aging medical specialist (ABAARM). Dr Kim is a rehabilitation medicine doctor at Seoul National University and a doctor at the American Board of Anti-Aging.

Starting with Derma Cosmetics brand 'Dr. YOUTH' in 2015, the company has developed and released a smart healthcare app 'Doctor Youth Diet' and Korea's first natural pain reliever 'MS Healing' with Bundang Seoul National University Hospital.

We will aim to become a company that showcases future anti-aging solutions that combine manufacturing and IT technologies.

New Excellent Technology Exhibition



COVID-19 SPECIAL PAVILION

YD Diagnostics

영동제약

COUNTRY



YBSOFT Co., Ltd.

와이비소프트 주식회사

COUNTRY Republic of Korea

You Young Bae 유영배

URL www.ybsoft.kr E-mail

hj@ybsoft.kr

Ha Young Lee 이하영

URL www.yd-diagnostics.com

E-mail kimsa@yd-diagnostics.com

Republic of Korea

EXHIBIT CLASSIFICATION

세계최초 낙상방지 브레이크 솔루션

The world's first fall prevention brake solution

COMPANY & PRODUCT INTRODUCTION

당사가 개발한 낙상사고를 방지하는 브레이크 솔루션은 바퀴가 달린 사물들 은 모든 경우에 우선 정지되어 있으며 사용자가 이동하고자 할 때만 브레이 크가 풀려 움직이는 전세계 유일의 자동 안전 브레이크 시스템입니다.

The brake solution preventing fall down accidents developed by our company is the only automatic safety brake system in the world where heeled objects are first stopped in all cases and the brake is released and moved only when the user wants to move.

COMPANY & PRODUCT INTRODUCTION

영동제약은

- · 1966년 국내 최초로 설립된 체외진단용제품 전문 제조업체 입니다.
- · 매년 지속적으로 성장하고 있습니다.

기술력이 있는 회사입니다.

- · 자체 축적된 기술력과 노하우에 의한 지속적 품질개선으로 세계시장에서 품질경쟁력을 확보하고 있습니다.
- · 영동제약부설연구소에서는 세계 시장에서 수요가 큰 IVD제품을 지속적으 로 개발하고 있습니다.

세계화 경영을 하는 회사입니다.

· 품질 경쟁력으로 세계 100여개 국가에 판매망을 구축하고 있습니다. 또한 중국현지 공장과 태국 판매법인을 가동하고 있습니다.

YD Diagnostics

- · Established in 1966 as an IVD manufacturer.
- \cdot Annual revenue increased year to year.

IVD Products

- \cdot YD Diagnostics has developed new IVD products and persistently improved their quality by our own high technology and know-how.
- · R&D Center has been developing IVD products that have great demand worldwide.

Global business

- · Global business with competitive quality and world-wide sales network over 100 countries.
- · YD BioTech(Beijing)
- · YD Diagnostics(Thailand)Co., LTD

Healthcare Technology Licensing Office





Daejeon Technopark

Yeungnam University Creative Business Center

영남대학교 산학협력단

YJTECH. LTD

㈜와이제이테크

COUNTRY Republic of Korea

CEO Park, Yongwan 박용완

URL sansmbd.yu.ac.kr

E-mail jikim@ynu.ac.kr

COUNTRY Republic of Korea

Eunyoung Do 도은영

URL www.yjtech2017.com

E-mail olee286@hanmail.net

EXHIBIT CLASSIFICATION

의과분야(의예 및 의학), 제약분야, 생명공학분야 등

Medical (Pre-med, medicine), Pharmaceutical, Biotechnology, etc

EXHIBIT CLASSIFICATION

틀니살균세척기 / 오존수 세척장치(특허)

Denture disinfectant FreshDent / eco-friendly ozone water

COMPANY & PRODUCT INTRODUCTION

영남대학교 산학협력단은 영남대학교를 중심으로 산·학·연·관 클러스터를 구축하고 연구력 증진을 위한 종합서비스를 지원

Creative Business Center establishes industry-academy-researchgovernment clusters centering around Yeungnam University and provides comprehensive services to enhance research capabilities.

COMPANY & PRODUCT INTRODUCTION

FreshDent는 (주)와이제이테크의 특별한 기술로 생성된 친환경 오존수를 사용하여 살균 세척 합니다.

FreshDent disinfects and cleans with eco-friendly ozone water, created by YJ Tech's special technology.

Healthcare Technology Licensing Office





Yonsei University Health System

연세대학교 의료원

COUNTRY Republic of Korea

CEO Yoon, Do-Heum 윤도흠

URL www.yuhs.ac

E-mail asd21dsa@yuhs.ac

EXHIBIT CLASSIFICATION

암, 대사성 질환, 노인성 질환 등 의료 전반

Overall medical care for a variety of diseases including cancer, metabolic diseases and senile diseases

COMPANY & PRODUCT INTRODUCTION

연세의료원은 탁월한 의료역량과 인프라를 바탕으로 연구중심병원 지정 및 육성사업을 진행하고 있으며 연구 역량 강화와 기술 발굴, 사업화 노력을 지 속하고 있습니다. 또한, 산학협력 및 사업화 촉진에 매진함으로써 세계적인 의료기관으로 발돋움하고 있습니다.

Undertaking a variety of projects on designating and nurturing research-oriented hospitals with superior medical capabilities and infrastructure, Yonsei University Health System has been accelerating its effort to strengthen research capability, develop and discover new technology, and commercialize the research outcome. Furthermore, it is stretching out to be a global medical institution through the promotion of industry-academia cooperation and technology commercialization

Yonsei University Health System (Healthcare)

연세대학교 의료원 (헬스케어)

COUNTRY Republic of Korea

CEO 박은철

URL www.smartx.or.kr
E-mail smartx@yuhs.ac

EXHIBIT CLASSIFICATION

모바일 헬스케어 기술사업화 지원 프로그램

Mobile Healthcare Technology Commercialization Supporting Program

COMPANY & PRODUCT INTRODUCTION

과학기술정보통신부와 한국연구재단의 지원하에 설립된 모바일 헬스케어 기술사업화 지원센터는 모바일 헬스케어 가치창출 사업화 지원 의료기관-산업클러스터-지역사회 연계 플랫폼입니다..

Severance Mobile healthcare Technology Acceleration Center(SMART-X), established under the auspices of the Ministry of Science and ICT, and National Research Foundation of Korea, is a platform that connects medical institutions, industrial clusters, and communities to support commercialization of mobile healthcare value creation

GIMHAE INDUSTRY PROMOTION & BIO-MEDICAL FOUNDATION

✔ (주) 영메디칼
YOUNG MEDICAL CO..LTD.

Korea Innovative Pharmaceutical Company



YoungMedical Co., Ltd.

㈜영메디칼

COUNTRY Republic of Korea

CEO Youn Han Sung 윤한성

URL

E-mail 82jhpark01@gmail.com

YUHAN CORPORATION

유한양행

COUNTRY Republic of Korea

CEO Jung Hee Lee 이정희

URL www.yuhan.co.kr

E-mail josephine@yuhan.co.kr

EXHIBIT CLASSIFICATION

하이드로 콜로이드, 드레싱 Hydricolloid, Wound dressing

COMPANY & PRODUCT INTRODUCTION

창상 등의 상처 보호를 위한 제품 제조사

Manufacturer of dressing products for protecing wound

EXHIBIT CLASSIFICATION

 * P프레가발린서방정
 : 신경병증성 통증

 * P듀오웰정
 : 고혈압과 고지혈증

 * P로수암핀정
 : 고혈압과 고지혈증

* P로수메트서방정 : 당뇨병

* P뉴팩탄 : 신생아 호흡곤란증후군

 * P유크라정
 : 항생제

 * P알마겔현탁액
 : 제산제

 * P안티푸라민에스로션
 : 소염제

* P윌로겔더블액션현탁액 : 소화불량 및 속쓰림 개선 * P나자케어나잘스프레이 : 알레르기비염의 증상

* Pregabalin SR Tablet : Neuropathic pain

* Duowell Tablet : Treatment for hypertension and hyperlipidemia * Rosuampine Tablet : Treatment for hypertension and hyperlipidemia

* Rosumet SR Tablet : Antidiabetic

COMPANY & PRODUCT INTRODUCTION

1926년 유일한 박사가 유한양행을 창업한 이래 지난 90여년동안 국민건강을 위해 노력해 왔습니다. 우수한 의약품의 제조, 공급과 함께 다양한 사업에 진출하며 기업 가치의 향상과 지속성장을 위해 노력하고 있습니다. 그리고 끊임없는 연구개발을 통한 혁신적인 신약 개발로 글로벌 시장 진출에 박차를 가하고 있습니다.

Yuhan Corporation has increased the R&D investments since 2015 with a far-sighted vision of future growth. The results speak for themselves.



Korea Innovative Pharmaceutical Company

Yungjin Pharm.co., Ltd.



YUHAN KIMBERLY PROFESSIONAL

유한킴벌리

영진약품㈜

COUNTRY Republic of Korea

CEO CHOI GYU BOK 최규복

URL www.kr.kcprofessional.com

E-mail hcommunication@naver.com

COUNTRY Republic of Korea

CEO Chae Joon, Lee 이재준

URL www.yungjin.co.kr

E-mail nami0209@yungjin.co.kr

EXHIBIT CLASSIFICATION

클린룸 보호복, 글러브, 와이퍼

Cleanroom Apparel, Glove, Wiper

COMPANY & PRODUCT INTRODUCTION

더욱 건강하고, 더욱 안전하게, 더 나은 생산성 향상을 위하여!

유한킴벌리는 많은 사람들이 이용하는 다중이용시설에서 개개인의 안전하고 편안하게, 위생적인 생활을 할 수 있도록 다양한 제품을 공급하고 있습니다.

유한킴벌리는 산업, 생산설비 영역에서 킴테크* 브랜드로 대표되는 보호복 / 산업용 와이퍼 / 방진마스크 / 귀마개 / 보안경 / 안전화 등 개인보호구 / 안전 용품을 공급하여 작업자의 안전과 생산성 향상에 기여해 왔습니다.

유한킴벌리는 고객이 필요로 하는 건강·위생용품을 제공함으로써 가족과 사회가 보다 행복해 질 수 있도록 지속적으로 노력하겠습니다.

 $\label{the entropy decivity} Healthier, safer, and better productivity!$

Yuhan-Kimberly provides a variety of products to help individuals live a safe, comfortable, and hygienic life in multi-use facilities that many people use.

Yuhan-Kimberly has contributed to the safety and productivity of workers by supplying protective clothing / industrial wipers / dust masks / earplugs / safety glasses / safety shoes, which are represented by the KIMTECH* brand in the industrial and production facilities.

Yuhan-Kimberly will continue to make efforts to make families and society happier by providing the health and hygiene products that customers need."

EXHIBIT CLASSIFICATION

- * 세프카펜피복실: Cefcapene Pivoxil
- * 세프디토렌피복실 : Cefditoren Pivoxil
- * 세프메타좈: Cefmetazole
- * 세포티암: Cfotiam
- * 세프티족심: Ceftizoxime
- * 세프트리악손: Cefrtiaxone sodium
- * 세프타지딤: Ceftazidime sodium
- * 세프포독심: Cefpodoxime Proxetil
- * 세프디니르: Cefdinir
- * 리네졸린정: Linezolid
- * 메이세린주: Cefminox sodium hydrate
- * UK키트주: Cefmetazole sodium/ Cefotiam HCI/ Cefotetan sodium/ Cefoperazone sodium, Sulbactam sodium/ Ceftriaxone sodium/ Vancomycin/ Teicoplanin
- * 오파스트정: Limaprost alfadex
- * 오마론연질캡슐: Omega-3 acids ethyl esters 90
- * 칸데살탄: Candesartan Cilexetil
- * 데노간주: Propacetamol HCI
- * 록소프로펜: Loxoprofen sodium
- * 파이브로정: Pirfenidone
- * 판크론정: Dimethicone, hemicellulose, ox bile extract, pancreatin
- * 판프라졸정: Pantoprazole
- * 바로스콘더블액션현탁액: Sodium alginate, sodium bicarbonate, calcium carbonate
- * 타리민정: Bepotastine nicotinate
- * 하모닐란액: Protein, fat, carbohydrate, vitamin, mineral, fiber

COMPANY & PRODUCT INTRODUCTION

영진약품(주)은 1952년 설립 이래로 국가 경제발전과 국민보건 향상을 위하여 국내 제약업계의 선구자 역할을 해오고 있습니다. 그리고 KT&G그룹 계열사로서 우수한 의약품 생산 및 연구개발 노하우를 갖고 그룹 내 바이오/제약 사업부문의 중추적 역할을 하고 있으며, 신제품개발 및 수출확대를 통하여 글로벌 제약사로 성장해 나아가고 있습니다.

Yungjin Pharm. Co., Ltd. has been a pioneer i in the Korean pharmaceutical industry since its inception in 1952. In addition, as an affiliate of KT&G, we are playing the key role on Bio/Pharmaceutical business in the group with know-how about the manufacturing and R&D of medicines.





INVEST FAIR / JOB FAIR

Invest Fair · · · · · · · · · · · · · · · · · · ·	238
115	0.40



DATE May 18(Mon) ~ 23(Sat), 2020

POINT OF ACCESS www.biokorea.org

OVERVIEW

Pharmaceutical, Bio, and Healthcare companies that are researching and developing new drugs for global market entry and innovation introduce their excellent technology, management strategies and visions to investors.

A total of 24 bio and healthcare-related companies listed in Korean exchange markets such as KOSDAQ and KONEX. Those hoping to present their excellent technology will prepare IPO, and will participate in the online Investor Relations (IR).

We will engage in various exchanges as well as business partnerships with securities companies, asset managers and venture capital officials.

PROGRAM: Investor Relations

COVID-19 Special Session Celltrion | Solgent | SCM Lifescience | ImmuneMed

Stem Cell / Microbiome Biosolution | Genome & Company

Anticancer Drug Development HLB | ABL Bio | GC Cell

Healthcare & Medical Osstem Implant | i-Sens | Handok Kalos Medical | Jeios

Degenerative Neurodisease / Mediforum Pharm | TiumBio | ARIBIO | Neuroventi

Platform New Drug
Development

OliX Pharmaceuticals | SparkBioPharma | Inventage Lab | Ensol Biosciences

Artificial Intelligence / Healcerion | HUINNO

Bio New Drug Development Rznomics

Wearables

PROGRAM INFORMATION

5/18 Mon	Speaker & Agenda
10:20~10:45 A.M	Jae Chang Shin / President, Celltrion Current Status, Strategy, and Clinical Plan for the Development of Covid-19 Antibody Treatment
10:45~11:10 A.M	Jae-Hyung You / President, Solgent Covid-19 Diagnostic Kit Global Export and Related Industrial Growth Strategies and Challenges
11:10~11: 35 A.M	BG Rhee / CEO & President, SCM Lifescience Clinical Phase 2 a promotion plan for Corona-19 and Acute Respiratory Difficulty Syndrome (ARDS) by sepsis
11:35 A.M ~ Afternoon	Yoon-Won Kim / CEO & President, ImmuneMed Clinical results and outcomes for patients administered 'HzVSF' for the treatment of Covid-19-related severe pneumonia
1:30~1:55 P.M	Song Sun Chang / CEO & Chairman, Biosolution Global clinical strategies for cartilage cell therapies such as 'Cartilife' and strategies for developing immuno-cancer drugs using exosom
1:55~2:20 P.M	Ji Soo Bae / CEO & President, Genome & Company Strategies for Expansion of Microbiome Business and Development of Immunosuppressive Drugs Using GENIE Platform

5/19 Tue	Speaker & Agenda
10:20~10:45 A.M	Yang Gon Jin / Chairman, HLB Securing future value of HLB through mid- to long-term management strategy and collaborating with open innovation
10:45~11:10 A.M	Sang-Hoon Lee / CEO & President, ABL Bio ABL001 4Q clinical Trials 2a entry plan based on dual antibody platform and new drug development strategy using Grab body
11:10~11: 35 A.M	Duck-Joo Lee / CEO & President, GC Cell Strategies for commercialization after entering Phase 3 clinical trials for pancreatic cancer treatment by hepatic cancer treatment agent immuncell -LC
1:30~1:55 P.M	Tae-Kwan Eom / CEO & President, Osstem Implant Osstem Implant's Strategy for Global Entry and Its Rise to Total Dental Company
1:55~2:20 P.M	Hak Hyun Nam / Co-founder, i-Sens Mid- to long-term business strategy for developing continuous blood glucose meters (CGMS) and expanding strategies in the global market

PROGRAM INFORMATION

5/20 Wed	Speaker & Agenda
10:20~10:45 A.M	Jae-hyeong Park / CEO & President, Mediforum Pharm Vision Strategy to Achieve 150 billion Won in Sales in 2024 Development of long-term continuous injection type for dementia treatment using
10:45~11:10 A.M	Hun-Taek Kim / CEO & President, TiumBio Results of Phase 1 clinical trials for endometriosis treatment (TU2670), mid- to long-term clinical planning, global licensing out strategy
11:10~11: 35 A.M	Chan Young Shin / CEO & President, Neuroventi The direction of the U.S. FDA clinical 2 phase of the new drug candidate (AR 1001) for dementia treatment and the strategy of developing it as a treatment for virus complications using the candidate substance for the new drug for sepsis treatment.
11:35 A.M ~ Afternoon	Shin Chan Young / CEO & President, OliX Pharmaceuticals Development of autism treatment based on low molecular compounds, clinical strategies, and other new drug candidate materials
1:30~1:55 P.M	Dong-ki Lee / CEO & President, OliX Pharmaceuticals Global Clinical Phase II Strategies and Direction of New Drug Candidate Materials for hypertrophic scar Treatment Using RNA Interference Technology (Oligo Nucleic Acid Technology)
1:55~2:20 P.M	Seung Bum Park / CEO & President, SparkBioPharma Innovative new drug development strategy using pheno type-based platform and action mechanism using target protein identification technology

5/21 Thu	Speaker & Agenda
10:20~10:45 A.M	Jeong-won Ryu / CEO & President, Healcerion Strategies for entering the market for portable ultrasound diagnostic devices and strategies for developing ultrasound imaging artificial intelligence (AI) technology
10:45~11:10 A.M	Yeongjoon Gil / CEO & President, HUINNO Holter ECG Inspection Suggestions on the Global Market Size, Changes in U.S. Market Trends and Direction of Domestic Markets
1:30~1:55 P.M	Ju Hee Kim / CEO & President, Inventage Lab Development of Long Acting Injection based on innovative process
1:55~2:20 P.M	CEO & President, Ensol Biosciences Strategies to enter phase 3 clinical trials of degenerative disc treatment new drug candidate materials and develop treatments for triple-negative breast cancer (TNBC).

PROGRAM INFORMATION

5/22 Fri	Speaker & Agenda
10:20~10:45 A.M	Churl Joon Kim / CEO & President, Handok Kalos Medical Strategies for upgrading kidney neuroblocking hypertension devices (DENEX v 1.2, v.2.0) and upgrading catheterization and production through partnerships with global specialized R&D companies
10:45~11:10 A.M	Jeanhong Jeon / CEO & President, Jeios Building a business model that integrates healthcare and medical big data based on motion cores based on human dynamic characteristics (operation balance) analysis)
1:30~1:55 P.M	Seong-Wook Lee / CEO & President, Rznomics Strategies for the development of gene therapy for intractable diseases using RNA replacement enzyme platform and plans for global clinical entry in 2021



Job Fair



DATE May 18(Mon) ~ 23(Sat), 2020

POINT OF ACCESS

www.biokorea.org

OVERVIEW

The 2020 Health Industry Job Fair (BIO JOB FAIR 2020) is an event that offers various solutions to companies and job seekers in line with the government's policy of fostering the bio-health industry and job creation.

Celebrating its seventh anniversary this year, the event will provide companies in the health industry with opportunities to hire talented applicants and provide a wide range of employment information for job seekers.

In addition, we provide information on how to respond to blind recruitment, untact interviews, and artificial intelligence (Al) interviews, which have become a trend in employment.

About 30 pharmaceutical, bio and healthcare companies will participate in BIO JOB FAIR 2020 to hire new and experienced employees through online document screening in various jobs and fields.

PROGRAM

PROGRAM 1

A job talk concert series 1, 2 Deliver information on how to respond to working-level interviews and how to respond to non-face-to-face and artificial intelligence (AI) interviews, which have become a recent trend, to job seekers entering the job market.

PROGRAM 2

Academy of Entrepreneurship Provide human resources preparing for bio venture start-ups with information needed for start-ups, such as CEO stories, government support policies, and strategies to attract venture capital investment

PROGRAM 3

CEO Life Special Lecture "Follow Your Dream" It is a program that delivers dreams, passion, and hope to talented people who are preparing to get a job and start a business through storytelling, which is called the first generation of start-ups of Korea Kolmar Chairman Yoon Dong-han and Celltrion Chairman Seo Jung-jin.

PROGRAM 4 Bio Job Fair 2020

More than 30 bio and healthcare companies are recruiting people.



BIO KOREA Organizing Committee

T +82.1661.0810(0h!BIO) E biokorea@biokorea.org H www.biokorea.org